Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy

Information

  • Patent Grant
  • 11285127
  • Patent Number
    11,285,127
  • Date Filed
    Wednesday, June 10, 2020
    4 years ago
  • Date Issued
    Tuesday, March 29, 2022
    2 years ago
Abstract
In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof.
Description
BACKGROUND

Cardiovascular disease is one of the leading causes of death in the United States and most European countries. It is estimated that over 70 million people in the United States alone suffer from a cardiovascular disease or disorder including but not limited to high blood pressure, coronary heart disease, dyslipidemia, congestive heart failure and stroke.


SUMMARY

In various embodiments, the present invention provides pharmaceutical compositions and methods of using such compositions to treat and/or prevent cardiovascular-related diseases. In one embodiment, the subject is on concomitant statin therapy. In another embodiment, the subject on statin therapy has a baseline fasting serum triglyceride level of about 200 mg/dL to about 500 mg/dL.


In one embodiment, the invention provides a method of lowering triglycerides in a subject on statin therapy having baseline fasting triglycerides of about 200 mg/dl to about 500 mg/dl, the method comprising administering to the subject about 4 g of ethyl eicosapentaenoate per day.


In another embodiment, the invention provides a method of lowering triglycerides and LDL-C in a subject comprising, administering orally to a subject having fasting triglycerides of about 200 mg/dl to less than 500 mg/dl who is on stable statin therapy about 4 g per day of a pharmaceutical composition comprising at least about 90%, by weight, of all fatty acids (and/or derivatives thereof) present, ethyl eicosapentaenoate for a period of at least about 12 weeks.


In one embodiment, the invention provides a method of lowering triglycerides in a subject on stable statin therapy having baseline fasting triglycerides of about 200 mg/dl to about 500 mg/dl, the method comprising administering to the subject a pharmaceutical composition comprising polyunsaturated fatty acids, for example about 1 g to about 4 g of EPA per day, wherein upon administering the composition to the subject daily for a period of 12 weeks the subject exhibits at least 5% lower fasting triglycerides than a control subject maintained on stable statin therapy (optionally with placebo matching the EPA) without concomitant EPA for a period of 12 weeks wherein the control subject also has baseline fasting triglycerides of about 200 mg/dl to about 500 mg/dl. In another embodiment, upon administering the composition to the subject daily for a period of 12 weeks the subject exhibits no serum LDL-C increase, no statistically significant serum LDL-C increase, a serum LDL-C decrease, or the subject is statistically non-inferior to the control subjects (statin plus optional placebo) in regard to serum LDL-C elevation).


These and other embodiments of the present invention will be disclosed in further detail herein below.





BRIEF DESCRIPTION OF THE FIGURES


FIG. 1 shows the correlation of atherogenic lipoproteins with Apo B after 12 weeks of treatment with ethyl eicosapentaenoate.



FIG. 2A displays placebo-adjusted percent changes in FADI parameters compared to baseline in plasma for both 2 g/day and 4 g/day doses of ethyl eicosapentaenoate.



FIG. 2B displays placebo-adjusted percent changes in FADI parameters compared to baseline in red blood cells for both 2 g/day and 4 g/day doses of ethyl eicosapentaenoate.



FIG. 3 displays median percent change in fasting triglycerides from baseline to week 12 in a modified intent-to-treat (“MITT”) study population.



FIG. 4 displays median percent change from baseline for selected endpoints.



FIG. 5A displays percent change in fasting triglycerides plotted against percent change in EPA concentration in plasma from baseline to week 12 for the MITT study population.



FIG. 5B displays percent change in fasting triglycerides plotted against percent change in EPA concentration in red blood cells from baseline to week 12 for the MITT study population.



FIG. 6A displays a regression fit plot of atherogenic particle concentration to Apo B concentration at baseline for subjects assigned to placebo group (o) or to a treatment group (+).



FIG. 6B displays a regression fit plot of atherogenic particle concentration to Apo B concentration after 12 weeks of receiving placebo (o) or 4 g per day of a composition consistent with the present disclosure (+).



FIG. 6C displays a regression fit plot of total LDL particle concentration to Apo B concentration at baseline for subjects assigned to placebo group (o) or to a treatment group (+).



FIG. 6D displays a regression fit plot of total LDL particle concentration to Apo B concentration after 12 weeks of receiving placebo (o) or 4 g per day of a composition consistent with the present disclosure (+).





DETAILED DESCRIPTION

While the present invention is capable of being embodied in various forms, the description below of several embodiments is made with the understanding that the present disclosure is to be considered as an exemplification of the invention, and is not intended to limit the invention to the specific embodiments illustrated. Headings are provided for convenience only and are not to be construed to limit the invention in any manner. Embodiments illustrated under any heading may be combined with embodiments illustrated under any other heading.


The use of numerical values in the various quantitative values specified in this application, unless expressly indicated otherwise, are stated as approximations as though the minimum and maximum values within the stated ranges were both preceded by the word “about.” Also, the disclosure of ranges is intended as a continuous range including every value between the minimum and maximum values recited as well as any ranges that can be formed by such values. Also disclosed herein are any and all ratios (and ranges of any such ratios) that can be formed by dividing a disclosed numeric value into any other disclosed numeric value. Accordingly, the skilled person will appreciate that many such ratios, ranges, and ranges of ratios can be unambiguously derived from the numerical values presented herein and in all instances such ratios, ranges, and ranges of ratios represent various embodiments of the present invention.


In one embodiment, the invention provides a method for treatment and/or prevention of cardiovascular-related diseases. The term “cardiovascular-related disease” herein refers to any disease or disorder of the heart or blood vessels (i.e. arteries and veins) or any symptom thereof. Non-limiting examples of cardiovascular-related disease and disorders include hypertriglyceridemia, hypercholesterolemia, mixed dyslipidemia, coronary heart disease, vascular disease, stroke, atherosclerosis, arrhythmia, hypertension, myocardial infarction, and other cardiovascular events.


The term “treatment” in relation a given disease or disorder, includes, but is not limited to, inhibiting the disease or disorder, for example, arresting the development of the disease or disorder; relieving the disease or disorder, for example, causing regression of the disease or disorder; or relieving a condition caused by or resulting from the disease or disorder, for example, relieving, preventing or treating symptoms of the disease or disorder. The term “prevention” in relation to a given disease or disorder means: preventing the onset of disease development if none had occurred, preventing the disease or disorder from occurring in a subject that may be predisposed to the disorder or disease but has not yet been diagnosed as having the disorder or disease, and/or preventing further disease/disorder development if already present.


In one embodiment, the present invention provides a method of blood lipid therapy comprising administering to a subject or subject group in need thereof a pharmaceutical composition as described herein. In another embodiment, the subject or subject group has hypertriglyceridemia, hypercholesterolemia, mixed dyslipidemia and/or very high triglycerides.


In another embodiment, the subject or subject group being treated has a baseline triglyceride level (or mean or median baseline triglyceride level in the case of a subject group), fed or fasting, of about 200 mg/dl to about 500 mg/dl. In another embodiment, the subject or subject group has a baseline LDL-C level (or mean or median baseline LDL-C level), despite stable statin therapy, of about 40 mg/dl to about 115 or about 40 to about 100 mg/dl.


In one embodiment, the subject or subject group being treated in accordance with methods of the invention is on concomitant statin therapy, for example atorvastatin, rosuvastatin or simvastatin therapy (with or without ezetimibe). In another embodiment, the subject is on concomitant stable statin therapy at time of initiation of ultra-pure EPA therapy.


In another embodiment, the subject or subject group being treated in accordance with methods of the invention has a body mass index (BMI or mean BMI) of not more than about 45 kg/m2.


In one embodiment, the invention provides a method of lowering triglycerides in a subject on stable statin therapy having baseline fasting triglycerides of about 200 mg/dl to about 500 mg/dl, the method comprising administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of EPA (e.g. ultra-pure EPA), wherein upon administering the composition to the subject daily for a period of about 12 weeks the subject exhibits at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, or at least 75% lower fasting triglycerides than a control subject maintained on stable statin therapy (and optionally placebo matching the ultra-pure EPA) without concomitant ultra-pure EPA for a period of about 12 weeks, wherein the control subject also has baseline fasting triglycerides of about 200 mg/dl to about 500 mg/dl. The term “stable statin therapy” herein means that the subject, subject group, control subject or control subject group in question has been taking a stable daily dose of a statin (e.g. atorvastatin, rosuvastatin or simvastatin) for at least 4 weeks prior to the baseline fasting triglyceride measurement (the “qualifying period”). For example, a subject or control subject on stable statin therapy would receive a constant daily (i.e. the same dose each day) statin dose for at least 4 weeks immediately prior to baseline fasting triglyceride measurement. In one embodiment, the subject's and control subject's LDL-C is maintained between about 40 mg/dl and about 115 mg/dl or about 40 mg/dl to about 100 mg/dl during the qualifying period. The subject and control subject are then continued on their stable statin dose for the 12 week period post baseline.


In one embodiment, the statin is administered to the subject and the control subject in an amount of about 1 mg to about 500 mg, about 5 mg to about 200 mg, or about 10 mg to about 100 mg, for example about 1 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, or about 10 mg; about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 90 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, about 300 mg, about 325 mg, about 350 mg, about 375 mg, about 400 mg, about 425 mg, about 450 mg, about 475 mg, or about 500 mg. In another embodiment, the subject (and optionally the control subject) has a baseline LDL-C level, despite stable statin therapy, of about 40 mg/dl to about 115 mg/dl or about 40 mg/dl to about 100 mg/dl. In another embodiment, the subject and/or control subject has a body mass index (BMI; or mean BMI) of not more than about 45 kg/m2.


In another embodiment, the invention provides a method of lowering triglycerides in a subject group on stable statin therapy having mean baseline fasting triglycerides of about 200 mg/dl to about 500 mg/dl, the method comprising administering to members of the subject group a pharmaceutical composition comprising about 1 g to about 4 g of ultra-pure EPA per day, wherein upon administering the composition to the members of the subject group daily for a period of about 12 weeks the subject group exhibits at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75% lower mean fasting triglycerides than a control subject group maintained on stable statin therapy without concomitant ultra-pure EPA (optionally with matching placebo) for a period of about 12 weeks, wherein the control subject group also has mean baseline fasting triglycerides of about 200 mg/dl to about 500 mg/dl. In a related embodiment, the stable statin therapy will be sufficient such that the subject group has a mean LDL-C level about at least about 40 mg/dl and not more than about 100 mg/dl or about 40 mg/dl to about 100 mg/dl for the 4 weeks immediately prior to the baseline fasting triglyceride measurement.


In another embodiment, the invention provides a method of lowering triglycerides in subject group on stable statin therapy and having a mean baseline fasting triglyceride level of about 200 mg/dl to about 500 mg/dl, the method comprising administering to members of the subject group a pharmaceutical composition comprising about 1 g to about 4 g of ultra-pure EPA, wherein upon administering the composition to members of the subject group daily for a period of about 12 weeks the subject group exhibits: (a) at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75% lower mean fasting triglycerides by comparison with a control subject group maintained on stable statin therapy without concomitant ultra-pure EPA (optionally with matching placebo) for a period of about 12 weeks, and (b) no serum LDL-C increase, no statistically significant serum LDL-C increase, a serum LDL-C decrease, or the subject is statistically non-inferior to the control subjects (statin plus optional placebo) in regard to serum LDL-C elevation) no increase in mean serum LDL-C levels compared to baseline, wherein the control subject also has mean baseline fasting triglycerides of about 200 mg/dl to about 500 mg/dl.


In another embodiment, the invention provides a method of lowering triglycerides in subject on stable statin therapy and having mean baseline fasting triglyceride level of about 200 mg/dl to about 500 mg/dl, the method comprising administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of ultra-pure EPA, wherein upon administering the composition to the subject daily for a period of about 12 weeks the subject exhibits (a) at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, or at least 75% lower fasting triglycerides by comparison with a control subject maintained on stable statin therapy without concomitant ultra-pure EPA for a period of about 12 weeks and (b) no increase in serum LDL-C levels compared to baseline, wherein the control subject also has baseline fasting triglycerides of about 200 mg/dl to about 500 mg/dl.


In another embodiment, the invention provides a method of lowering triglycerides in subject group on stable statin therapy and having mean baseline fasting triglyceride level of about 200 mg/dl to about 500 mg/dl, the method comprising administering to members of the subject group a pharmaceutical composition comprising about 1 g to about 4 g of ultra-pure EPA, wherein upon administering the composition to the members of the subject group daily for a period of about 12 weeks the subject group exhibits: (a) at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75% lower mean fasting triglycerides and (b) at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45% or at least 50% lower mean serum LDL-C levels by comparison with a control subject group maintained on stable statin therapy without concomitant ultra-pure EPA (optionally with matching placebo) for a period of about 12 weeks, no serum LDL-C increase, no statistically significant serum LDL-C increase, no statistically significant serum LDL-C increase, a serum LDL-C decrease, or the subject group is statistically non-inferior to the control subject group (statin plus optional placebo) in regard to serum LDL-C elevation), wherein the control subject group also has mean baseline fasting triglycerides of about 200 mg/dl to about 500 mg/dl.


In another embodiment, the invention provides a method of lowering triglycerides in subject group on stable statin therapy and having mean baseline fasting triglyceride level of about 200 mg/dl to about 500 mg/dl, the method comprising administering to members of the subject group a pharmaceutical composition comprising about 1 g to about 4 g of ultra-pure EPA, wherein upon administering the composition to the members of the subject group daily for a period of about 12 weeks the subject group exhibits (a) at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75% lower mean fasting triglycerides and (b) at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45% or at least 50% lower mean serum LDL-C levels by comparison with a control subject group maintained on stable statin therapy without concomitant ultra-pure EPA (optionally with matching placebo) for a period of about 12 weeks, no serum LDL-C increase, no statistically significant serum LDL-C increase, no statistically significant serum LDL-C increase, a serum LDL-C decrease, or the subject group is statistically non-inferior to the control subject group (statin plus optional placebo) in regard to serum LDL-C elevation), wherein the control subject group also has mean baseline fasting triglycerides of about 200 mg/dl to about 500 mg/dl.


In another embodiment, the subject or subject group being treated in accordance with methods of the invention exhibits a fasting baseline absolute plasma level of free total fatty acid (or mean thereof) not greater than about 300 nmol/ml, not greater than about 250 nmol/ml, not greater than about 200 nmol/ml, not greater than about 150 nmol/ml, not greater than about 100 nmol/ml, or not greater than about 50 nmol/ml.


In another embodiment, the subject or subject group being treated in accordance with methods of the invention exhibits a fasting baseline absolute plasma level of free EPA (or mean thereof in the case of a subject group) not greater than about 0.70 nmol/ml, not greater than about 0.65 nmol/ml, not greater than about 0.60 nmol/ml, not greater than about 0.55 nmol/ml, not greater than about 0.50 nmol/ml, not greater than about 0.45 nmol/ml, or not greater than about 0.40 nmol/ml. In another embodiment, the subject or subject group being treated in accordance with methods of the invention exhibits a baseline fasting plasma level (or mean thereof) of free EPA, expressed as a percentage of total free fatty acid, of not more than about 3%, not more than about 2.5%, not more than about 2%, not more than about 1.5%, not more than about 1%, not more than about 0.75%, not more than about 0.5%, not more than about 0.25%, not more than about 0.2% or not more than about 0.15%. In one such embodiment, free plasma EPA and/or total fatty acid levels are determined prior to initiating therapy.


In another embodiment, the subject or subject group being treated in accordance with methods of the invention exhibits a fasting baseline absolute plasma level of free EPA (or mean thereof) not greater than about 1 nmol/ml, not greater than about 0.75 nmol/ml, not greater than about 0.50 nmol/ml, not greater than about 0.4 nmol/ml, not greater than about 0.35 nmol/ml, or not greater than about 0.30 nmol/ml.


In another embodiment, the subject or subject group being treated in accordance with methods of the invention exhibits a fasting baseline plasma, serum or red blood cell membrane EPA level not greater than about 150 μg/ml, not greater than about 125 μg/ml, not greater than about 100 μg/ml, not greater than about 95 μg/ml, not greater than about 75 μg/ml, not greater than about 60 μg/ml, not greater than about 50 μg/ml, not greater than about 40 μg/ml, not greater than about 30 μg/ml, or not greater than about 25 μg/ml.


In another embodiment, methods of the present invention comprise a step of measuring the subject's (or subject group's mean) baseline lipid profile prior to initiating therapy. In another embodiment, methods of the invention comprise the step of identifying a subject or subject group having one or more of the following: baseline non-HDL-C value (or mean) of about 200 mg/dl to about 400 mg/dl, for example at least about 210 mg/dl, at least about 220 mg/dl, at least about 230 mg/dl, at least about 240 mg/dl, at least about 250 mg/dl, at least about 260 mg/dl, at least about 270 mg/dl, at least about 280 mg/dl, at least about 290 mg/dl, or at least about 300 mg/dl; baseline total cholesterol value (or mean) of about 250 mg/dl to about 400 mg/dl, for example at least about 260 mg/dl, at least about 270 mg/dl, at least about 280 mg/dl or at least about 290 mg/dl; baseline vLDL-C value (or mean) of about 140 mg/dl to about 200 mg/dl, for example at least about 150 mg/dl, at least about 160 mg/dl, at least about 170 mg/dl, at least about 180 mg/dl or at least about 190 mg/dl; baseline HDL-C value (or mean) of about 10 to about 100 mg/dl, for example not more than about 90 mg/dl not, not more than about 80 mg/dl, not more than about 70 mg/dl, not more than about 60 mg/dl, not more than about 60 mg/dl, not more than about 50 mg/dl, not more than about 40 mg/dl, not more than about 35 mg/dl, not more than about 30 mg/dl, not more than about 25 mg/dl, not more than about 20 mg/dl, or not more than about 15 mg/dl; and/or baseline LDL-C value (or mean) of about 30 to about 300 mg/dl, for example not less than about 40 mg/dl, not less than about 50 mg/dl, not less than about 60 mg/dl, not less than about 70 mg/dl, not less than about 90 mg/dl or not less than about 90 mg/dl.


In a related embodiment, upon treatment in accordance with the present invention, for example over a period of about 1 to about 200 weeks, about 1 to about 100 weeks, about 1 to about 80 weeks, about 1 to about 50 weeks, about 1 to about 40 weeks, about 1 to about 20 weeks, about 1 to about 15 weeks, about 1 to about 12 weeks, about 1 to about 10 weeks, about 1 to about 5 weeks, about 1 to about 2 weeks or about 1 week, the subject or subject group exhibits one or more of the following outcomes:


(a) reduced triglyceride levels compared to baseline or placebo control (e.g. a subject on stable statin plus placebo matching the EPA treatment group);


(b) reduced Apo B levels compared to baseline or placebo control;


(c) a decrease or an increase in HDL-C levels compared to baseline or placebo control;


(d) no increase in LDL-C levels compared to baseline or placebo control;


(e) a reduction in LDL-C levels compared to baseline or placebo control;


(f) a reduction in non-HDL-C levels compared to baseline or placebo control;


(g) a reduction in VLDL-C levels compared to baseline or placebo control;


(h) an increase, no change, or a decrease in Apo A-1 levels compared to baseline or placebo control;


(i) an decrease, no change, or an increase in Apo B/Apo A-1 ratio compared to baseline or placebo control;


(j) no increase or a reduction in lipoprotein A levels compared to baseline or placebo control;


(k) a reduction in LDL particle number compared to baseline or placebo control;


(l) an increase in LDL size compared to baseline or placebo control;


(m) a reduction in remnant-like particle cholesterol (RLP-C) compared to baseline or placebo control;


(n) a reduction in oxidized LDL compared to baseline or placebo control;


(o) an increase, no change, or a reduction in fasting plasma glucose (FPG) compared to baseline or placebo control;


(p) an increase, no change, or a reduction in hemoglobin A1c (HbA1c) compared to baseline or placebo control;


(q) an increase, no change, or a reduction in homeostasis model insulin resistance (HOMA-IR) compared to baseline or placebo control;


(r) a reduction in lipoprotein associated phospholipase A2 (Lp-PLA2) compared to baseline or placebo control;


(s) a reduction in intracellular adhesion molecule-1 (IAM-1) compared to baseline or placebo control;


(t) an increase, no change, or a reduction in interleukin-6 (IL-6) compared to baseline or placebo control;


(u) an increase, no change, or a reduction in plasminogen activator inhibitor-1 (PAI-1) compared to baseline or placebo control;


(v) a reduction in high sensitivity C-reactive protein (hsCRP) compared to baseline or placebo control;


(w) an increase in serum or plasma EPA compared to baseline or placebo control;


(x) an increase in red blood cell membrane EPA compared to baseline or placebo control;


(y) a reduction or increase in one or more of serum and/or red blood cell content of docosahexaenoic acid (DHA), docosapentaenoic acid (DPA), arachidonic acid (AA), palmitic acid (PA), stearidonic acid (SA) or oleic acid (OA) compared to baseline or placebo control;


(z) a reduction in a fatty acid desaturation index (“FADI”) compared to baseline or placebo control;


(aa) a reduction in VLDL-TG compared to baseline or placebo control;


(bb) a reduction in total cholesterol compared to baseline or placebo control; and/or


(cc) an increase, no change, or a reduction in insulin compared to baseline or placebo control.


In one embodiment, methods of the present invention comprise measuring baseline levels of one or more markers set forth in (a)-(cc) above prior to dosing the subject or subject group. In another embodiment, the methods comprise administering a composition as disclosed herein to the subject after baseline levels of one or more markers set forth in (a)-(cc) are determined, and subsequently taking an additional measurement of said one or more markers.


In another embodiment, upon treatment with a composition of the present invention, for example over a period of about 1 to about 200 weeks, about 1 to about 100 weeks, about 1 to about 80 weeks, about 1 to about 50 weeks, about 1 to about 40 weeks, about 1 to about 20 weeks, about 1 to about 15 weeks, about 1 to about 12 weeks, about 1 to about 10 weeks, about 1 to about 5 weeks, about 1 to about 2 weeks or about 1 week, the subject or subject group exhibits any 2 or more of, any 3 or more of, any 4 or more of, any 5 or more of, any 6 or more of, any 7 or more of, any 8 or more of, any 9 or more of, any 10 or more of, any 11 or more of, any 12 or more of, any 13 or more of, any 14 or more of, any 15 or more of, any 16 or more of, any 17 or more of, any 18 or more of, any 19 or more of, any 20 or more of, any 21 or more of, any 22 or more of, any 23 or more of, any 24 or more of, any 25 or more of, any 26 or more of, any 27 or more of, any 28 or more of, or all 29 of outcomes (a)-(cc) described immediately above.


In another embodiment, upon treatment with a composition of the present invention, the subject or subject group exhibits one or more of the following outcomes:


(a) a reduction in triglyceride level of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55% or at least about 75% (actual % change or median % change) as compared to baseline or placebo control (e.g. a subject on statin and placebo matching the EPA treatment group);


(b) a less than 30% increase, less than 20% increase, less than 10% increase, less than 5% increase or no increase in non-HDL-C levels or a reduction in non-HDL-C levels of at least about 1%, at least about 3%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55% or at least about 75% (actual % change or median % change) as compared to baseline or placebo control;


(c) an reduction in HDL-C levels of no greater than about 10%, no greater than about 5%, no greater than about 4%, no greater than about 3%, no greater than about 2%, no greater than about 1%, substantially no change in HDL-C levels, no change in HDL-C levels, or an increase in HDL-C levels of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55% or at least about 75% (actual % change or median % change) as compared to baseline or placebo control;


(d) a less than 60% increase, a less than 50% increase, a less than 40% increase, a less than 30% increase, a less than 20% increase, a less than 10% increase, a less than 5% increase, a less than 4% increase, a less than 3% increase, a less than 2% increase, in LDL-C levels, no increase in LDL-C levels, or a reduction in LDL-C levels of at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 55% or at least about 75% (actual % change or median % change) as compared to baseline or placebo control;


(e) an increase in Apo B levels of no more than about 5%, no more than about 4%, no more than about 3%, no more than about 2%, no more than about 1%, or no increase in Apo B levels, or a decrease in Apo B levels of at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55% or at least about 75% (actual % change or median % change) as compared to baseline or placebo control;


(f) an increase in VLDL-C levels of no more than about 5%, no more than about 4%, no more than about 3%, no more than about 2%, no more than about 1%, no increase in VLDL-C levels, or a reduction in VLDL-C levels of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 100% (actual % change or median % change) compared to baseline or placebo control;


(g) an increase in Apo A-1 levels of at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 100%, substantially no change in Apo A-1 levels, no change in Apo A-1 levels, or a reduction in Apo A-1 levels of no greater than about 1%, no greater than about 2%, no greater than about 3%, no greater than about 4%, no greater than about 5%, no greater than about 6%, no greater than about 7%, no greater than about 8%, no greater than about 9%, or no greater than about 10% (actual % change or median % change) compared to baseline or placebo control;


(h) an increase in Apo B/Apo A-1 ratio of no more than about 5%, no more than about 4%, no more than about 3%, no more than about 2%, no more than about 1%, or no more than about 0.5%, no substantial change in in Apo B/Apo A-1 ratio, no change in in Apo B/Apo A-1 ratio, or an decrease in Apo B/Apo A-1 ratio of at least about 0.5%, at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 100% (actual % change or median % change) compared to baseline or placebo control;


(i) an increase in lipoprotein (a) levels of no more than about 5%, no more than about 4%, no more than about 3%, no more than about 2%, no more than about 1%, no more than about 0.5%, no substantial change in lipoprotein (a) levels, no change in lipoprotein (a) levels, or a reduction in lipoprotein (a) levels of at least about 0.5%, at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 100% (actual % change or median % change) compared to baseline or placebo control;


(j) an increase in LDL particle number of no more than about 5%, no more than about 4%, no more than about 3%, no more than about 2%, or no more than about 1%, no substantial change in LDL particle number, no change in LDL particle number, or a reduction in mean LDL particle number of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 100% (actual % change or median % change) compared to baseline or placebo control;


(k) an increase in mean LDL particle size of at least about0.5%, at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 100% (actual % change or median % change) compared to baseline or placebo control;


(l) a reduction in remnant-like particle cholesterol (RLP-C) of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 100% (actual % change or median % change) compared to baseline or placebo control;


(m) an increase in oxidized LDL of no more than about 5%, no more than about 4%, no more than about 3%, no more than about 2%, or no more than about 1%, no substantial change in oxidized LDL, no change in LDL, or a reduction in oxidized LDL of at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 100% (actual % change or median % change) compared to baseline or placebo control;


(n) an increase in fasting plasma glucose (FPG) of no more than about 10%, no more than about 9%, no more than about 8%, no more than about 7%, no more than about 6%, no more than about 5%, no more than about 4%, no more than about 3%, no more than about 2%, or no more than about 1%, substantially no change, no statistically significant change, or a reduction in fasting plasma glucose (FPG) of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 100% (actual % change or median % change) compared to baseline or placebo control;


(o) an increase in hemoglobin A1c d(HbA1c) of no more than about 2%, no more than about 1%, or no more than about 0.5%, substantially no change, no statistically significant change, a reduction in hemoglobin A1c (HbA1c) of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, or at least about 50% (actual % change or median % change) compared to baseline or placebo control;


(p) an increase in homeostasis model index insulin resistance (HOMA-IR) of no more than about 5%, no more than about 4%, no more than about 3%, no more than about 2%, no more than about 1%, or no more than about 0.5%, no substantial change in HOMA-IR, no change in HOMA-IR, or a reduction in HOMA-IR of at least about 0.1%, at least about 0.5%, at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 100% (actual % change or median % change) compared to baseline or placebo control;


(q) a reduction in lipoprotein associated phospholipase A2 (Lp-PLA2) of at least about 1%, at least about 2%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 100% (actual % change or median % change) compared to baseline or placebo control;


(r) an increase in intracellular adhesion molecule-1 (ICAM-1) of no more than about 5%, no more than about 4%, no more than about 3%, no more than about 2%, or no more than about 1%, no substantial change in ICAM-1, no change in ICAM-1, or a reduction in ICAM-1 of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 100% (actual % change or median % change) compared to baseline or placebo control;


(s) an increase in interleukin-6 (IL-6) of no more than about 5%, no more than about 4%, no more than about 3%, no more than about 2%, no more than about 1%, or no more than about 0.5%, no substantial change in IL-6, no change in IL-6, or a reduction in IL-6 of at least about 0.1%, at least about 1%, at least about 2%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 100% (actual % change or median % change) compared to baseline or placebo control;


(t) an increase in plasminogen activator inhibitor-1 (PAI-1) of no more than about 15%, no more than about 10%, no more than about 5%, or no more than about 1%, no substantial change in PAI-1, no change in PAI-1, or a reduction in PAI-1 of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 100% (actual % change or median % change) compared to baseline or placebo control;


(u) an increase in high sensitivity C-reactive protein (hsCRP) of no more than about 15%, no more than about 10%, no more than about 5%, or no more than about 1%, no substantial change in hsCRP, no change in hsCRP, or a reduction in hsCRP of at least about1%, at least about 2%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 100% (actual % change or median % change) compared to baseline or placebo control;


(v) an increase in serum, plasma and/or RBC EPA of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 100%, at least about 200% or at least about 400% (actual % change or median % change) compared to baseline or placebo control;


(w) an increase in serum phospholipid and/or red blood cell membrane EPA of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, or at least about 50%, at least about 100%, at least about 200%, or at least about 400% (actual % change or median % change) compared to baseline or placebo control;


(x) a reduction or increase in one or more of serum phospholipid and/or red blood cell DHA, DPA, AA, PA and/or OA of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55% or at least about 75% (actual % change or median % change) compared to baseline or placebo control;


(y) a reduction in total cholesterol of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55% or at least about 75% (actual % change or median % change) compared to baseline or placebo control;


(z) a reduction in a fatty acid desaturation index (“FADI”) of at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 11%, at least about 12%, at least about 13%, at least about 14%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or greater than about 95% (actual % change or median % change) compared to baseline or placebo control;


(aa) a reduction in VLDL-TG of at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, or at least about 50% (actual % change or median % change) compared to baseline or placebo control;


(bb) an increase in total cholesterol of no more than about 5%, no more than about 4%, no more than about 3%, no more than about 2%, or no more than about 1%, no substantial change in total cholesterol, no change in total cholesterol, or a reduction in total cholesterol of at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 11%, at least about 12%, at least about 13%, at least about 14%, at least about 15%, or at least about 20% (actual % change or median % change) compared to baseline or placebo control; and/or


(cc) an increase in insulin of no more than about 5%, no more than about 4%, no more than about 3%, no more than about 2%, no more than about 1%, or no more than about 0.5%, no substantial change in insulin, no change in insulin, or a decrease in insulin of at least about 0.1%, at least about 0.5%, at least about 1%, at least about 2%, at least about 3%, at least about 4%, or at least about 5% (actual % change or median % change) compared to baseline or placebo control.


In one embodiment, methods of the present invention comprise measuring baseline levels of one or more markers set forth in (a)-(cc) prior to dosing the subject or subject group. In another embodiment, the methods comprise administering a composition as disclosed herein to the subject after baseline levels of one or more markers set forth in (a)-(cc) are determined, and subsequently taking a second measurement of the one or more markers as measured at baseline for comparison thereto.


In another embodiment, upon treatment with a composition of the present invention, for example over a period of about 1 to about 200 weeks, about 1 to about 100 weeks, about 1 to about 80 weeks, about 1 to about 50 weeks, about 1 to about 40 weeks, about 1 to about 20 weeks, about 1 to about 15 weeks, about 1 to about 12 weeks, about 1 to about 10 weeks, about 1 to about 5 weeks, about 1 to about 2 weeks or about 1 week, the subject or subject group exhibits any 2 or more of, any 3 or more of, any 4 or more of, any 5 or more of, any 6 or more of, any 7 or more of, any 8 or more of, any 9 or more of, any 10 or more of, any 11 or more of, any 12 or more of, any 13 or more of, any 14 or more of, any 15 or more of, any 16 or more of, any 17 or more of, any 18 or more of, any 19 or more of, any 20 or more of, any 21 or more of, any 22 or more of, any 23 or more of, any 24 or more of, any 25 or more of, any 26 or more of, any 27 or more of, any 28 or more of, or all 29 of outcomes (a)-(cc) described immediately above.


Parameters (a)-(z) can be measured in accordance with any clinically acceptable methodology. For example, triglycerides, total cholesterol, HDL-C and fasting blood sugar can be sample from serum and analyzed using standard photometry techniques. VLDL-TG, LDL-C and VLDL-C can be calculated or determined using serum lipoprotein fractionation by preparative ultracentrifugation and subsequent quantitative analysis by refractometry or by analytic ultracentrifugal methodology. Apo A1, Apo B and hsCRP can be determined from serum using standard nephelometry techniques. Lipoprotein (a) can be determined from serum using standard turbidimetric immunoassay techniques. LDL particle number and particle size can be determined using nuclear magnetic resonance (NMR) spectrometry. Remnants lipoproteins and LDL-phospholipase A2 can be determined from EDTA plasma or serum and serum, respectively, using enzymatic immunoseparation techniques. Oxidized LDL, intercellular adhesion molecule-1 and interleukin-2 levels can be determined from serum using standard enzyme immunoassay techniques. These techniques are described in detail in standard textbooks, for example Tietz Fundamentals of Clinical Chemistry, 6th Ed. (Burtis, Ashwood and Borter Eds.), WB Saunders Company.


In one embodiment, subjects fast for up to 12 hours prior to blood sample collection, for example about 10 hours.


In another embodiment, the subject being treated is in the highest risk category of Adult Treatment Panel (ATP) III Classification of LDL, Total, and HDL Cholesterol (mg/dL) (e.g. CHD or CHD Risk Equivalents (10-year risk >20%)). In another embodiment, the subject is in the ATP III Multiple (2+) risk factor category.


In one embodiment, the invention provides a method of lowering triglycerides in a subject in the highest risk category of Adult Treatment Panel (ATP) III Classification of LDL, Total, and HDL Cholesterol (mg/dL) (e.g. CHD or CHD Risk Equivalents (10-year risk >20%)). In another embodiment, the subject is in the ATP III Multiple (2+) risk factor category. In another embodiment, the method includes a step of identifying a subject in the ATP III Multiple (2+) risk factor category prior to administering ultra-pure E-EPA to the subject.


In another embodiment, the present invention provides a method of treating or preventing primary hypercholesterolemia and/or mixed dyslipidemia (Fredrickson Types IIa and Ilb) in a patient in need thereof, comprising administering to the patient one or more compositions as disclosed herein. In a related embodiment, the present invention provides a method of reducing triglyceride levels in a subject or subjects when treatment with a statin or niacin extended-release monotherapy is considered inadequate (Frederickson type IV hyperlipidemia).


In another embodiment, the present invention provides a method of treating or preventing risk of recurrent nonfatal myocardial infarction in a patient with a history of myocardial infarction, comprising administering to the patient one or more compositions as disclosed herein.


In another embodiment, the present invention provides a method of slowing progression of or promoting regression of atherosclerotic disease in a patient in need thereof, comprising administering to a subject in need thereof one or more compositions as disclosed herein.


In another embodiment, the present invention provides a method of treating or preventing very high serum triglyceride levels (e.g. Types IV and V hyperlipidemia) in a patient in need thereof, comprising administering to the patient one or more compositions as disclosed herein.


In another embodiment, the present invention provides a method of lowering triglycerides and a fatty acid desaturation index (“FADI”) in a subject on statin therapy having baseline fasting triglycerides of about 200 mg/dl to about 500 mg/dl, the method comprising administering to the subject about 4 capsules per day, each capsule comprising about 1 g of ethyl eicosapentaenoate. In some embodiments, the subject has a baseline LDL-C level of about 40 mg/dl to about 115 mg/dl. In some embodiments, the method effects a reduction in serum LDL-C. In some embodiments, the method effects at least a 5% reduction in fasting triglycerides and a reduction in LDL-C. In some embodiments, the method effects at least a 5%, at least a 10%, or at least a 15% reduction in LDL-C. In some embodiments, the method effects at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 11%, at least about 12%, at least about 13%, at least about 14%, at least about 15%, at least about 16%, at least about 17%, at least about 18%, at least about 19%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or greater than about 95% reduction in the FADI (e.g., a ratio of palmitoleic acid to palmitic acid and/or a ratio of oleic acid to stearic acid). In some embodiments, the method effects a reduction in Apolipoprotein B, total cholesterol, and lipoprotein associated phospholipase A2. In some embodiments, the subject is on stable statin therapy (e.g., atorvastatin therapy, rosuvastatin therapy, or simvastatin therapy). In some embodiments, the subject has a baseline body mass index not greater than 45 kg/m′.


In another embodiment, the present invention provides a method of lowering triglycerides, LDL-C and a fatty acid desaturation index (“FADI”) in a subject comprising, administering orally to a subject having fasting triglycerides of about 200 mg/dl to less than 500 mg/dl who is on stable statin therapy about 4 g per day of a pharmaceutical composition comprising at least about 90%, by weight, of all fatty acids (and/or derivatives thereof) present, ethyl eicosapentaenoate for a period of at least about 12 weeks. In some embodiments, the method effects a reduction in fasting triglycerides and fasting LDL-C in the subject compared to fasting triglycerides and fasting LDL-C in a second subject on stable statin therapy who has not received the pharmaceutical composition. In some embodiments, the method effects a reduction in fasting non-HDL-C compared to fasting non-HDL-C in the second subject. In some embodiments, the method effects a reduction in fasting VLDL-C compared to fasting VLDL-C in the second subject. In some embodiments, the method effects a reduction in fasting Apolipoprotein B compared to fasting Apolipoprotein B in the second subject. In some embodiments, the method effects a reduction in fasting total cholesterol compared to fasting total cholesterol in the second subject. In some embodiments, the method effects at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 11%, at least about 12%, at least about 13%, at least about 14%, at least about 15%, at least about 16%, at least about 17%, at least about 18%, at least about 19%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or greater than about 95% reduction in the FADI (e.g., a ratio of palmitoleic acid to palmitic acid and/or a ratio of oleic acid to stearic acid).


In one embodiment, a composition of the invention is administered to a subject in an amount sufficient to provide a daily dose of EPA of about 1 mg to about 10,000 mg, 25 about 5000 mg, about 50 to about 3000 mg, about 75 mg to about 2500 mg, or about 100 mg to about 1000 mg, for example about 75 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, about 300 mg, about 325 mg, about 350 mg, about 375 mg, about 400 mg, about 425 mg, about 450 mg, about 475 mg, about 500 mg, about 525 mg, about 550 mg, about 575 mg, about 600 mg, about 625 mg, about 650 mg, about 675 mg, about 700 mg, about 725 mg, about 750 mg, about 775 mg, about 800 mg, about 825 mg, about 850 mg, about 875 mg, about 900 mg, about 925 mg, about 950 mg, about 975 mg, about 1000 mg, about 1025 mg, about 1050 mg, about 1075 mg, about 1100 mg, about 1025 mg, about 1050 mg, about 1075 mg, about 1200 mg, about 1225 mg, about 1250 mg, about 1275 mg, about 1300 mg, about 1325 mg, about 1350 mg, about 1375 mg, about 1400 mg, about 1425 mg, about 1450 mg, about 1475 mg, about 1500 mg, about 1525 mg, about 1550 mg, about 1575 mg, about 1600 mg, about 1625 mg, about 1650 mg, about 1675 mg, about 1700 mg, about 1725 mg, about 1750 mg, about 1775 mg, about 1800 mg, about 1825 mg, about 1850 mg, about 1875 mg, about 1900 mg, about 1925 mg, about 1950 mg, about 1975 mg, about 2000 mg, about 2025 mg, about 2050 mg, about 2075 mg, about 2100 mg, about 2125 mg, about 2150 mg, about 2175 mg, about 2200 mg, about 2225 mg, about 2250 mg, about 2275 mg, about 2300 mg, about 2325 mg, about 2350 mg, about 2375 mg, about 2400 mg, about 2425 mg, about 2450 mg, about 2475 mg, about 2500 mg, about 2525 mg, about 2550 mg, about 2575 mg, about 2600 mg, about 2625 mg, about 2650 mg, about 2675 mg, about 2700 mg, about 2725 mg, about 2750 mg, about 2775 mg, about 2800 mg, about 2825 mg, about 2850 mg, about 2875 mg, about 2900 mg, about 2925 mg, about 2950 mg, about 2975 mg, about 3000 mg, about 3025 mg, about 3050 mg, about 3075 mg, about 3100 mg, about 3125 mg, about 3150 mg, about 3175 mg, about 3200 mg, about 3225 mg, about 3250 mg, about 3275 mg, about 3300 mg, about 3325 mg, about 3350 mg, about 3375 mg, about 3400 mg, about 3425 mg, about 3450 mg, about 3475 mg, about 3500 mg, about 3525 mg, about 3550 mg, about 3575 mg, about 3600 mg, about 3625 mg, about 3650 mg, about 3675 mg, about 3700 mg, about 3725 mg, about 3750 mg, about 3775 mg, about 3800 mg, about 3825 mg, about 3850 mg, about 3875 mg, about 3900 mg, about 3925 mg, about 3950 mg, about 3975 mg, about 4000 mg, about 4025 mg, about 4050 mg, about 4075 mg, about 4100 mg, about 4125 mg, about 4150 mg, about 4175 mg, about 4200 mg, about 4225 mg, about 4250 mg, about 4275 mg, about 4300 mg, about 4325 mg, about 4350 mg, about 4375 mg, about 4400 mg, about 4425 mg, about 4450 mg, about 4475 mg, about 4500 mg, about 4525 mg, about 4550 mg, about 4575 mg, about 4600 mg, about 4625 mg, about 4650 mg, about 4675 mg, about 4700 mg, about 4725 mg, about 4750 mg, about 4775 mg, about 4800 mg, about 4825 mg, about 4850 mg, about 4875 mg, about 4900 mg, about 4925 mg, about 4950 mg, about 4975 mg, about 5000 mg, about 5025 mg, about 5050 mg, about 5075 mg, about 5100 mg, about 5125 mg, about 5150 mg, about 5175 mg, about 5200 mg, about 5225 mg, about 5250 mg, about 5275 mg, about 5300 mg, about 5325 mg, about 5350 mg, about 5375 mg, about 5400 mg, about 5425 mg, about 5450 mg, about 5475 mg, about 5500 mg, about 5525 mg, about 5550 mg, about 5575 mg, about 5600 mg, about 5625 mg, about 5650 mg, about 5675 mg, about 5700 mg, about 5725 mg, about 5750 mg, about 5775 mg, about 5800 mg, about 5825 mg, about 5850 mg, about 5875 mg, about 5900 mg, about 5925 mg, about 5950 mg, about 5975 mg, about 6000 mg, about 6025 mg, about 6050 mg, about 6075 mg, about 6100 mg, about 6125 mg, about 6150 mg, about 6175 mg, about 6200 mg, about 6225 mg, about 6250 mg, about 6275 mg, about 6300 mg, about 6325 mg, about 6350 mg, about 6375 mg, about 6400 mg, about 6425 mg, about 6450 mg, about 6475 mg, about 6500 mg, about 6525 mg, about 6550 mg, about 6575 mg, about 6600 mg, about 6625 mg, about 6650 mg, about 6675 mg, about 6700 mg, about 6725 mg, about 6750 mg, about 6775 mg, about 6800 mg, about 6825 mg, about 6850 mg, about 6875 mg, about 6900 mg, about 6925 mg, about 6950 mg, about 6975 mg, about 7000 mg, about 7025 mg, about 7050 mg, about 7075 mg, about 7100 mg, about 7125 mg, about 7150 mg, about 7175 mg, about 7200 mg, about 7225 mg, about 7250 mg, about 7275 mg, about 7300 mg, about 7325 mg, about 7350 mg, about 7375 mg, about 7400 mg, about 7425 mg, about 7450 mg, about 7475 mg, about 7500 mg, about 7525 mg, about 7550 mg, about 7575 mg, about 7600 mg, about 7625 mg, about 7650 mg, about 7675 mg, about 7700 mg, about 7725 mg, about 7750 mg, about 7775 mg, about 7800 mg, about 7825 mg, about 7850 mg, about 7875 mg, about 7900 mg, about 7925 mg, about 7950 mg, about 7975 mg, about 8000 mg, about 8025 mg, about 8050 mg, about 8075 mg, about 8100 mg, about 8125 mg, about 8150 mg, about 8175 mg, about 8200 mg, about 8225 mg, about 8250 mg, about 8275 mg, about 8300 mg, about 8325 mg, about 8350 mg, about 8375 mg, about 8400 mg, about 8425 mg, about 8450 mg, about 8475 mg, about 8500 mg, about 8525 mg, about 8550 mg, about 8575 mg, about 8600 mg, about 8625 mg, about 8650 mg, about 8675 mg, about 8700 mg, about 8725 mg, about 8750 mg, about 8775 mg, about 8800 mg, about 8825 mg, about 8850 mg, about 8875 mg, about 8900 mg, about 8925 mg, about 8950 mg, about 8975 mg, about 9000 mg, about 9025 mg, about 9050 mg, about 9075 mg, about 9100 mg, about 9125 mg, about 9150 mg, about 9175 mg, about 9200 mg, about 9225 mg, about 9250 mg, about 9275 mg, about 9300 mg, about 9325 mg, about 9350 mg, about 9375 mg, about 9400 mg, about 9425 mg, about 9450 mg, about 9475 mg, about 9500 mg, about 9525 mg, about 9550 mg, about 9575 mg, about 9600 mg, about 9625 mg, about 9650 mg, about 9675 mg, about 9700 mg, about 9725 mg, about 9750 mg, about 9775 mg, about 9800 mg, about 9825 mg, about 9850 mg, about 9875 mg, about 9900 mg, about 9925 mg, about 9950 mg, about 9975 mg, or about 10,000 mg.


In another embodiment, any of the methods disclosed herein are used in treatment of a subject or subjects that consume a traditional Western diet. In one embodiment, the methods of the invention include a step of identifying a subject as a Western diet consumer or prudent diet consumer and then treating the subject if the subject is deemed a Western diet consumer. The term “Western diet” herein refers generally to a typical diet consisting of, by percentage of total calories, about 45% to about 50% carbohydrate, about 35% to about 40% fat, and about 10% to about 15% protein. A Western diet may alternately or additionally be characterized by relatively high intakes of red and processed meats, sweets, refined grains, and desserts, for example more than 50%, more than 60% or more or 70% of total calories come from these sources.


In another embodiment, any of the methods disclosed herein are used in treatment of a subject or subjects that consume less than (actual or average) about 150 g, less than about 125 g, less than about 100 g, less than about 75 g, less than about 50 g, less than about 45 g, less than about 40 g, less than about 35 g, less than about 30 g, less than about 25 g, less than about 20 g or less than about 15 g of fish per day.


In another embodiment, any of the methods disclosed herein are used in treatment of a subject or subjects that consume less than (actual or average) about 10 g, less than about 9 g, less than about 8 g, less than about 7 g, less than about 6 g, less than about 5 g, less than about 4 g, less than about 3 g, less than about 2 g per day of omega-3 fatty acids from dietary sources.


In another embodiment, any of the methods disclosed herein are used in treatment of a subject or subjects that consume less than (actual or average) about 2.5 g, less than about 2 g, less than about 1.5 g, less than about 1 g, less than about 0.5 g, less than about 0.25 g, or less than about 0.2 g per day of EPA and DHA (combined) from dietary sources.


In one embodiment, compositions useful in various embodiments of the invention comprise a polyunsaturated fatty acid as an active ingredient. In another embodiment, such compositions comprise EPA as an active ingredient. The term “EPA” as used herein refers to eicosapentaenoic acid (e.g. eicosa-5,8,11,14,17-pentaenoic acid) and/or a pharmaceutically acceptable ester, derivative, conjugate or salt thereof, or mixtures of any of the foregoing.


In one embodiment, the EPA comprises all-cis eicosa-5,8,11,14,17-pentaenoic acid. In another embodiment, the EPA is in the form of an eicosapentaenoic acid ester. In another embodiment, the EPA comprises a C1-C5 alkyl ester of EPA. In another embodiment, the EPA comprises eicosapentaenoic acid ethyl ester, eicosapentaenoic acid methyl ester, eicosapentaenoic acid propyl ester, or eicosapentaenoic acid butyl ester. In still another embodiment, the EPA comprises all-cis eicosa-5,8,11,14,17-pentaenoic acid ethyl ester.


In still other embodiments, the EPA comprises ethyl-EPA, lithium EPA, mono, di- or triglyceride EPA or any other ester or salt of EPA, or the free acid form of EPA. The EPA may also be in the form of a 2-substituted derivative or other derivative which slows down its rate of oxidation but does not otherwise change its biological action to any substantial degree.


The term “pharmaceutically acceptable” in the present context means that the substance in question does not produce unacceptable toxicity to the subject or interaction with other components of the composition.


In one embodiment, EPA present in a composition suitable for use according to the invention comprises ultra-pure EPA. The term “ultra-pure” as used herein with respect to EPA refers to a composition comprising at least 96%, by weight, of all fatty acids (and/or derivatives thereof) present, EPA (as the term “EPA” is defined and exemplified herein). Ultra-pure EPA can comprise even higher purity EPA, for example at least 97%, at least 98%, or at least 99%, by weight, of all fatty acids (and/or derivatives thereof) present, EPA, wherein the EPA is any form of EPA as set forth herein. Ultra-pure EPA can further be defined (e.g. impurity profile) by any of the description of EPA provided herein.


In some embodiments, EPA is present in a composition in an amount of about 50 mg to about 5000 mg, about 75 mg to about 2500 mg, or about 100 mg to about 1000 mg, for example about 75 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, about 300 mg, about 325 mg, about 350 mg, about 375 mg, about 400 mg, about 425 mg, about 450 mg, about 475 mg, about 500 mg, about 525 mg, about 550 mg, about 575 mg, about 600 mg, about 625 mg, about 650 mg, about 675 mg, about 700 mg, about 725 mg, about 750 mg, about 775 mg, about 800 mg, about 825 mg, about 850 mg, about 875 mg, about 900 mg, about 925 mg, about 950 mg, about 975 mg, about 1000 mg, about 1025 mg, about 1050 mg, about 1075 mg, about 1100 mg, about 1025 mg, about 1050 mg, about 1075 mg, about 1200 mg, about 1225 mg, about 1250 mg, about 1275 mg, about 1300 mg, about 1325 mg, about 1350 mg, about 1375 mg, about 1400 mg, about 1425 mg, about 1450 mg, about 1475 mg, about 1500 mg, about 1525 mg, about 1550 mg, about 1575 mg, about 1600 mg, about 1625 mg, about 1650 mg, about 1675 mg, about 1700 mg, about 1725 mg, about 1750 mg, about 1775 mg, about 1800 mg, about 1825 mg, about 1850 mg, about 1875 mg, about 1900 mg, about 1925 mg, about 1950 mg, about 1975 mg, about 2000 mg, about 2025 mg, about 2050 mg, about 2075 mg, about 2100 mg, about 2125 mg, about 2150 mg, about 2175 mg, about 2200 mg, about 2225 mg, about 2250 mg, about 2275 mg, about 2300 mg, about 2325 mg, about 2350 mg, about 2375 mg, about 2400 mg, about 2425 mg, about 2450 mg, about 2475 mg, about 2500 mg, about 2525 mg, about 2550 mg, about 2575 mg, about 2600 mg, about 2625 mg, about 2650 mg, about 2675 mg, about 2700 mg, about 2725 mg, about 2750 mg, about 2775 mg, about 2800 mg, about 2825 mg, about 2850 mg, about 2875 mg, about 2900 mg, about 2925 mg, about 2950 mg, about 2975 mg, about 3000 mg, about 3025 mg, about 3050 mg, about 3075 mg, about 3100 mg, about 3125 mg, about 3150 mg, about 3175 mg, about 3200 mg, about 3225 mg, about 3250 mg, about 3275 mg, about 3300 mg, about 3325 mg, about 3350 mg, about 3375 mg, about 3400 mg, about 3425 mg, about 3450 mg, about 3475 mg, about 3500 mg, about 3525 mg, about 3550 mg, about 3575 mg, about 3600 mg, about 3625 mg, about 3650 mg, about 3675 mg, about 3700 mg, about 3725 mg, about 3750 mg, about 3775 mg, about 3800 mg, about 3825 mg, about 3850 mg, about 3875 mg, about 3900 mg, about 3925 mg, about 3950 mg, about 3975 mg, about 4000 mg, about 4025 mg, about 4050 mg, about 4075 mg, about 4100 mg, about 4125 mg, about 4150 mg, about 4175 mg, about 4200 mg, about 4225 mg, about 4250 mg, about 4275 mg, about 4300 mg, about 4325 mg, about 4350 mg, about 4375 mg, about 4400 mg, about 4425 mg, about 4450 mg, about 4475 mg, about 4500 mg, about 4525 mg, about 4550 mg, about 4575 mg, about 4600 mg, about 4625 mg, about 4650 mg, about 4675 mg, about 4700 mg, about 4725 mg, about 4750 mg, about 4775 mg, about 4800 mg, about 4825 mg, about 4850 mg, about 4875 mg, about 4900 mg, about 4925 mg, about 4950 mg, about 4975 mg, or about 5000 mg.


In various embodiments, one or more antioxidants can be present in the EPA (e.g. E-EPA or ultra pure E-EPA). Non-limiting examples of suitable antioxidants include tocopherol, lecithin, citric acid and/or ascorbic acid. One or more antioxidants, if desired, are typically present in the EPA in an amount of about 0.01% to about 0.1%, by weight, or about 0.025% to about 0.05%, by weight.


In one embodiment, a composition of the invention contains not more than about 10%, not more than about 9%, not more than about 8%, not more than about 7%, not more than about 6%, not more than about 5%, not more than about 4%, not more than about 3%, not more than about 2%, not more than about 1%, or not more than about 0.5%, by weight, of all fatty acids (and/or derivatives thereof) present, docosahexaenoic acid or derivative thereof such as E-DHA, if any. In another embodiment, a composition of the invention contains substantially no docosahexaenoic acid or derivative thereof such as E-DHA. In still another embodiment, a composition of the invention contains no docosahexaenoic acid or E-DHA.


In another embodiment, EPA represents at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, at least about 98%, at least about 99%, or 100%, by weight, of all fatty acids (and/or derivatives thereof) present in a composition useful in accordance with the invention.


In another embodiment, a composition of the invention contains less than 30%, less than 20%, less than 10%, less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1%, less than 0.5% or less than 0.25%, by weight of the total composition or by weight of the total fatty acid content (including or excluding derivatives of fatty acids), of any fatty acid other than EPA, or derivative thereof. Illustrative examples of a “fatty acid other than EPA” include linolenic acid (LA) or derivative thereof such as ethyl-linolenic acid, arachidonic acid (AA) or derivative thereof such as ethyl-AA, docosahexaenoic acid (DHA) or derivative thereof such as ethyl-DHA, alpha-linolenic acid (ALA) or derivative thereof such as ethyl-ALA, stearadonic acid (STA) or derivative thereof such as ethyl-SA, eicosatrienoic acid (ETA) or derivative thereof such as ethyl-ETA and/or docosapentaenoic acid (DPA) or derivative thereof such as ethyl-DPA.


In another embodiment, a composition of the invention has one or more of the following features: (a) eicosapentaenoic acid ethyl ester represents at least 96%, at least 97%, or at least 98%, by weight, of all fatty acids (and/or derivatives thereof) present in the composition; (b) the composition contains not more than 4%, not more than 3%, or not more than 2%, by weight, of all fatty acids (and/or derivatives thereof) present, of fatty acids other than eicosapentaenoic acid ethyl ester; (c) the composition contains not more than 0.6%, 0.5%, 0.4% or 0.3%, by weight, of all fatty acids (and/or derivatives thereof) present, of any individual fatty acid other than eicosapentaenoic acid ethyl ester; (d) the composition has a refractive index (20° C.) of about 1 to about 2, about 1.2 to about 1.8 or about 1.4 to about 1.5; (e) the composition has a specific gravity (20° C.) of about 0.8 to about 1.0, about 0.85 to about 0.95 or about 0.9 to about 0.92; (f) the composition contains not more than 20 ppm, 15 ppm or 10 ppm heavy metals, (g) the composition contains not more than 5 ppm, 4 ppm, 3 ppm, or 2 ppm arsenic, and/or (h) the composition has a peroxide value not more than 5, 4, 3, or 2 Meq/kg.


In another embodiment, a composition useful in accordance with the invention comprises, consists essentially of or consists of at least 95%, by weight, of all fatty acids (and/or derivatives thereof) present, ethyl eicosapentaenoate (EPA-E), about 0.2% to about 0.5%, by weight, of all fatty acids (and/or derivatives thereof) present, ethyl octadecatetraenoate (ODTA-E), about 0.05% to about 0.25%, by weight, of all fatty acids (and/or derivatives thereof) present, ethyl nonadecapentaenoate (NDPA-E), about 0.2% to about 0.45%, by weight, of all fatty acids (and/or derivatives thereof) present, ethyl arachidonate (AA-E), about 0.3% to about 0.5%, by weight, of all fatty acids (and/or derivatives thereof) present, ethyl eicosatetraenoate (ETA-E), and about 0.05% to about 0.32%, by weight, of all fatty acids (and/or derivatives thereof) present, ethyl heneicosapentaenoate (HPA-E). In another embodiment, the composition is present in a capsule shell. In still another embodiment, the capsule shell contains no chemically modified gelatin.


In another embodiment, compositions useful in accordance with the invention comprise, consist essentially of, or consist of at least 95%, 96% or 97%, by weight, of all fatty acids (and/or derivatives thereof) present, ethyl eicosapentaenoate, about 0.2% to about 0.5%, by weight, of all fatty acids (and/or derivatives thereof) present, ethyl octadecatetraenoate, about 0.05% to about 0.25%, by weight, of all fatty acids (and/or derivatives thereof) present, ethyl nonadecapentaenoate, about 0.2% to about 0.45%, by weight, of all fatty acids (and/or derivatives thereof) present, ethyl arachidonate, about 0.3% to about 0.5%, by weight, of all fatty acids (and/or derivatives thereof) present, ethyl eicosatetraenoate, and about 0.05% to about 0.32%, by weight, of all fatty acids (and/or derivatives thereof) present, ethyl heneicosapentaenoate. Optionally, the composition contains not more than about 0.06%, about 0.05%, or about 0.04%, by weight, of all fatty acids (and/or derivatives thereof) present, DHA or derivative thereof such as ethyl-DHA. In one embodiment the composition contains substantially no or no amount of DHA or derivative thereof such as ethyl-DHA. The composition further optionally comprises one or more antioxidants (e.g. tocopherol) in an amount of not more than about 0.5% or not more than 0.05%. In another embodiment, the composition comprises about 0.05% to about 0.4%, for example about 0.2% by weight tocopherol. In another embodiment, about 500 mg to about 1 g of the composition is provided in a capsule shell. In another embodiment, the capsule shell contains no chemically modified gelatin.


In another embodiment, compositions useful in accordance with the invention comprise, consist essentially of, or consist of at least 96%, by weight, of all fatty acids (and/or derivatives thereof) present, ethyl eicosapentaenoate, about 0.22% to about 0.4%, by weight, of all fatty acids (and/or derivatives thereof) present, ethyl octadecatetraenoate, about 0.075% to about 0.20%, by weight, of all fatty acids (and/or derivatives thereof) present, ethyl nonadecapentaenoate, about 0.25% to about 0.40%, by weight, of all fatty acids (and/or derivatives thereof) present, ethyl arachidonate, about 0.3% to about 0.4%, by weight, of all fatty acids (and/or derivatives thereof) present, ethyl eicosatetraenoate and about 0.075% to about 0.25%, by weight, of all fatty acids (and/or derivatives thereof) present, ethyl heneicosapentaenoate. Optionally, the composition contains not more than about 0.06%, about 0.05%, or about 0.04%, by weight, of all fatty acids (and/or derivatives thereof) present, DHA or derivative thereof such as ethyl-DHA. In one embodiment the composition contains substantially no or no amount of DHA or derivative thereof such as ethyl-DHA. The composition further optionally comprises one or more antioxidants (e.g. tocopherol) in an amount of not more than about 0.5% or not more than 0.05%. In another embodiment, the composition comprises about 0.05% to about 0.4%, for example about 0.2% by weight tocopherol. In another embodiment, the invention provides a dosage form comprising about 500 mg to about 1 g of the foregoing composition in a capsule shell. In one embodiment, the dosage form is a gel- or liquid-containing capsule and is packaged in blister packages of about 1 to about 20 capsules per sheet.


In another embodiment, compositions useful in accordance with the invention comprise, consist essentially of or consist of at least 96%, 97% or 98%, by weight, of all fatty acids (and/or derivatives thereof) present, ethyl eicosapentaenoate, about 0.25% to about 0.38%, by weight, of all fatty acids (and/or derivatives thereof) present, ethyl octadecatetraenoate, about 0.10% to about 0.15%, by weight, of all fatty acids (and/or derivatives thereof) present, ethyl nonadecapentaenoate, about 0.25% to about 0.35%, by weight, of all fatty acids (and/or derivatives thereof) present, ethyl arachidonate, about 0.31% to about 0.38% by weight ethyl eicosatetraenoate, and about 0.08% to about 0.20%, by weight, of all fatty acids (and/or derivatives thereof) present, ethyl heneicosapentaenoate. Optionally, the composition contains not more than about 0.06%, about 0.05%, or about 0.04%, by weight, of all fatty acids (and/or derivatives thereof) present, DHA or derivative thereof such as ethyl-DHA. In one embodiment the composition contains substantially no or no amount of DHA or derivative thereof such as ethyl-DHA. The composition further optionally comprises one or more antioxidants (e.g. tocopherol) in an amount of not more than about 0.5% or not more than 0.05%. In another embodiment, the composition comprises about 0.05% to about 0.4%, for example about 0.2% by weight tocopherol. In another embodiment, the invention provides a dosage form comprising about 500 mg to about 1 g of the foregoing composition in a capsule shell. In another embodiment, the capsule shell contains no chemically modified gelatin.


In another embodiment, a composition as described herein is administered to a subject once or twice per day. In another embodiment, 1, 2, 3 or 4 capsules, each containing about 1 g of a composition as described herein, are administered to a subject daily. In another embodiment, 1 or 2 capsules, each containing about 1 g of a composition as described herein, are administered to the subject in the morning, for example between about 5 am and about 11 am, and 1 or 2 capsules, each containing about 1 g of a composition as described herein, are administered to the subject in the evening, for example between about 5 pm and about 11 pm.


In one embodiment, a subject being treated in accordance with methods of the invention is not on fibrate or nitrate therapy.


In another embodiment, compositions useful in accordance with methods of the invention are orally deliverable. The terms “orally deliverable” or “oral administration” herein include any form of delivery of a therapeutic agent or a composition thereof to a subject wherein the agent or composition is placed in the mouth of the subject, whether or not the agent or composition is swallowed. Thus “oral administration” includes buccal and sublingual as well as esophageal administration. In one embodiment, the composition is present in a capsule, for example a soft gelatin capsule.


A composition for use in accordance with the invention can be formulated as one or more dosage units. The terms “dose unit” and “dosage unit” herein refer to a portion of a pharmaceutical composition that contains an amount of a therapeutic agent suitable for a single administration to provide a therapeutic effect. Such dosage units may be administered one to a plurality (i.e. 1 to about 10, 1 to 8, 1 to 6, 1 to 4 or 1 to 2) of times per day, or as many times as needed to elicit a therapeutic response.


In another embodiment, the invention provides use of any composition described herein for treating moderate to severe hypertriglyceridemia in a subject in need thereof, comprising: providing a subject having a fasting baseline triglyceride level of about 500 mg/dl to about 1500 mg/dl and administering to the subject a pharmaceutical composition as described herein. In one embodiment, the composition comprises about 1 g to about 4 g of eicosapentaenoic acid ethyl ester, wherein the composition contains substantially no docosahexaenoic acid.


EXAMPLES
Example 1. Safety and Efficacy of Ultra-Pure EPA

A multi-center, placebo-controlled, randomized, double-blind, 12-week study was performed to evaluate the efficacy and safety of >96% E-EPA in patients with fasting triglyceride levels >200 mg/dl and <500 mg/dl despite statin therapy (the mean of two qualifying entry values needed to be >185 mg/dl and at least one of the values needed to be >200 mg/dl). The primary objective of the study was to determine the efficacy of >96% E-EPA 2 g daily and 4 g daily, compared to placebo, in lowering fasting TG levels in patients with high risk for cardiovascular disease and with fasting TG levels 200 mg/dl and <500 mg/dl, despite treatment to LDL-C goal on statin therapy.


The secondary objectives of this study were the following:

    • 1. To determine the safety and tolerability of >96% E-EPA 2 g daily and 4 g daily;
    • 2. To determine the effect of >96% E-EPA on lipid and apolipoprotein profiles including total cholesterol (TC), non-high-density lipoprotein cholesterol (non-HDL-C), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), and very high density lipoprotein cholesterol (VHDL-C);
    • 3. To determine the effect of >96% E-EPA on lipoprotein associated phospholipase A2 (Lp-PLA2) from baseline to week 12;
    • 4. To determine the effect of >96% E-EPA on low-density lipoprotein (LDL) particle number and size;
    • 5. To determine the effect of >96% E-EPA on oxidized LDL;
    • 6. To determine the effect of >96% E-EPA on fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c);
    • 7. To determine the effect of >96% E-EPA on insulin resistance;
    • 8. To determine the effect of >96% E-EPA on high-sensitivity C-reactive protein (hsCRP);
    • 9. To determine the effects of >96% E-EPA 2 g daily and 4 g daily on the incorporation of fatty acids into red blood cell membranes and into plasma phospholipids;
    • 10. To explore the relationship between baseline fasting TG levels and the reduction in fasting TG levels; and
    • 11. To explore the relationship between changes of fatty acid concentrations in plasma and red blood cell membranes, and the reduction in fasting TG levels.


The population for this study was men and women >18 years of age with a body mass index ≤45 kg/m2 with fasting TG levels greater than or equal to 200 mg/dl and less than 500 mg/dl and on a stable does of statin therapy (with or without ezetimibe). The statin was atorvostatin, rosuvastatin or simvastatin. The dose of statin must have been stable for ≥4 weeks prior to the LDL-C/TG baseline qualifying measurement for randomization. The statin dose was optimized such that the patients are at their LDL-C goal at the LDL-C/TG baseline qualifying measurements. The same statin at the same dose was continued until the study ended.


Patients taking any additional non-statin, lipid-altering medications (niacin >200 mg/day, fibrates, fish oil, other products containing omega-3 fatty acids, or other herbal products or dietary supplements with potential lipid-altering effects), either alone or in combination with statin therapy (with or without ezetimibe), must have been able to safely discontinue non-statin, lipid-altering therapy at screening.


Patients at high risk for CVD, i.e., patients with clinical coronary heart disease (CHD) or clinical CHD risk equivalents (10-year risk >20%) as defined in the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) Guidelines were eligible to participate in this study. Those included patients with any of the following criteria: (1) Known CVD, either clinical coronary heart disease (CHD), symptomatic carotid artery disease (CAD), peripheral artery disease (PAD) or abdominal aortic aneurism; or (2) Diabetes Mellitus (Type 1 or 2).


Approximately 702 patients were randomized at approximately 80 centers in the U.S. The study was a 18- to 20-week, Phase 3, multi-center study consisting of 2 study periods: (1) A 6- to 8-week screening period that included a diet and lifestyle stabilization, a non-statin lipid-altering treatment washout, and an LDL-C and TG qualifying period and (2) A 12-week, double-blind, randomized, placebo-controlled treatment period.


During the screening period and double-blind treatment period, all visits were within ±3 days of the scheduled time. All patients continued to take the statin product (with or without ezetimibe) at the same dose they were taking at screening throughout their participation in the study.


The 6- to 8-week screening period included a diet and lifestyle stabilization, a non-statin lipid-altering treatment washout, and an LDL-C and TG qualifying period. The screening visit (Visit 1) occurred for all patients at either 6 weeks (for patients on stable statin therapy [with or without ezetimibe] at screening) or 8 weeks (for patients who will require washout of their current non-statin lipid-altering therapy at screening) before randomization, as follows:

    • Patients who did not require a washout: The screening visit occurred at Visit 1 (Week −6). Eligible patients entered a 4-week diet and lifestyle stabilization period. At the screening visit, all patients received counseling regarding the importance of the National Cholesterol Education Program (NCEP) Therapeutic Lifestyle Changes (TLC) diet and received basic instructions on how to follow this diet.
    • Patients who required a washout: The screening visit occurred at Visit 1 (Week −8). Eligible patients began a 6-week washout period at the screening visit (i.e. 6 weeks washout before the first LDL-C/TG qualifying visit). Patients received counseling regarding the NCEP TLC diet and received basic instructions on how to follow this diet. Site personnel contacted patients who did not qualify for participation based on screening laboratory test results to instruct them to resume their prior lipid-altering medications.


At the end of the 4-week diet and lifestyle stabilization period or the 6-week diet and stabilization and washout period, eligible patients entered the 2-week LDL-C and TG qualifying period and had their fasting LDL-C and TG levels measured at Visit 2 (Week −2) and Visit 3 (Week −1). Eligible patients must have had an average fasting LDL-C level ≥40 mg/dL and <100 mg/dL and an average fasting TG level 200 mg/dL and <500 mg/dL to enter the 12-week double-blind treatment period. The LDL-C and TG levels for qualification were based on the average (arithmetic mean) of the Visit 2 (Week −2) and Visit 3 (Week −1) values. If a patient's average LDL-C and/or TG levels from Visit 2 and Visit 3 fell outside the required range for entry into the study, an additional fasting lipid profile was collected 1 week later at Visit 3.1. If a third sample was collected at Visit 3.1, entry into the study was based on the average (arithmetic mean) of the values from Visit 3 and Visit 3.1.


After confirmation of qualifying fasting LDL-C and TG values, eligible patients entered a 12-week, randomized, double-blind treatment period. At Visit 4 (Week 0), patients were randomly assigned to 1 of the following treatment groups:

    • >96% E-EPA 2 g daily,
    • >96% E-EPA 4 g daily, or
    • Placebo.


226 to 234 patients per treatment group were randomized in this study. Stratification was by type of statin (atorvastatin, rosuvastatin or simvastatin), the presence of diabetes, and gender.


During the double-blind treatment period, patients returned to the site at Visit 5 (Week 4), Visit 6 (Week 11), and Visit 7 (Week 12) for efficacy and safety evaluations.


Eligible patients were randomly assigned at Visit 4 (Week 0) to receive orally >96% E-EPA 2 g daily, >96% E-EPA 4 g daily, or placebo.


>96% E-EPA was provided in 1 g liquid-filled, oblong, gelatin capsules. The matching placebo capsule was filled with light liquid paraffin and contained 0 g of >96% E-EPA. >96% E-EPA capsules were to be taken with food (i.e. with or at the end of a meal).


During the double-blind treatment period, patients were to take 2 capsules (>96% E-EPA or matching placebo) in the morning and 2 capsules in the evening for a total of 4 capsules per day.

    • Patients in the >96% E-EPA 2 g/day treatment group received 1>96% E-EPA 1 g capsule and 1 matching placebo capsule in the morning and in the evening.
    • Patients in the >96% E-EPA 4 g/day treatment group received 2>96% E-EPA 1 g capsules in the morning and evening.


Patients in the placebo group received 2 matching placebo capsules in the morning and evening.


The primary efficacy variable for the double-blind treatment period was percent change in TG from baseline to Week 12 endpoint. The secondary efficacy variables for the double-blind treatment period included the following:

    • Percent changes in total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), LDL-C, calculated non-HDL-C, and very low-density lipoprotein cholesterol (VLDL-C) from baseline to Week 12 endpoint;
    • Percent change in very low-density lipoprotein TG from baseline to Week 12;
    • Percent changes in apolipoprotein A-I (Apo A-1), apolipoprotein B (Apo B), and Apo A-1/Apo B ratio from baseline to Week 12;
    • Percent changes in lipoprotein(a) from baseline to Week 12;
    • Percent changes in LDL particle number and size, measured by nuclear magnetic resonance, from baseline to Week 12;
    • Percent change in remnant-like particle cholesterol from baseline to Week 12;
    • Percent change in oxidized LDL from baseline to Week 12;
    • Changes in FPG and HbA1c from baseline to Week 12;
    • Change in insulin resistance, as assessed by the homeostasis model index insulin resistance, from baseline to Week 12;
    • Percent change in lipoprotein associated phospholipase A2 (Lp-PLA2) from baseline to Week 12;
    • Change in intracellular adhesion molecule-1 from baseline to Week 12;
    • Change in interleukin-2 from baseline to Week 12;
    • Change in plasminogen activator inhibitor-1 from baseline to Week 12. Note: this parameter will only be collected at sites with proper storage conditions;
    • Change in hsCRP from baseline to Week 12; and
    • Change in plasma concentration and red blood cell membrane content of fatty acid from baseline to Week 12 including EPA, docosapentaenoic acid (DPA), docosahexaenoic acid (DHA), arachidonic acid (AA), dihomo-γ-linolenic acid (DGLA), the ratio of EPA/AA, ratio of oleic acid/stearic acid (OA/SA), and the ratio of total omega-3 acids over total omega-6 acids.


Safety assessments included adverse events, clinical laboratory measurements (chemistry, hematology, and urinalysis), 12-lead electrocardiograms (ECGs), vital signs, and physical examinations.


For TG, TC, HDL-C, LDL-C, calculated non-HDL-C, and VLDL-C, baseline was defined as the average of Visit 4 (Week 0) and the preceding lipid qualifying visit (either Visit 3 [Week −1] or if it occurs, Visit 3.1) measurements. Baseline for all other efficacy parameters was the Visit 4 (Week 0) measurement.


For TG, TC, HDL-C, LDL-C, calculated non-HDL-C, and VLDL-C, Week 12 endpoint was defined as the average of Visit 6 (Week 11) and Visit 7 (Week 12) measurements.


Week 12 endpoint for all other efficacy parameters were the Visit 7 (Week 12) measurement.


The primary efficacy analysis was performed using a 2-way analysis of covariance (ANCOVA) model with treatment as a factor and baseline TG value as a covariate. The least-squares mean, standard error, and 2-tailed 95% confidence interval for each treatment group and for each comparison were estimated. The same 2-way ANCOVA model was used for the analysis of secondary efficacy variables.


The primary analysis was repeated for the per-protocol population to confirm the robustness of the results for the intent-to-treat population.


Non-inferiority tests for percent change from baseline in LDL-C were performed between >96% E-EPA doses and placebo using a non-inferiority margin of 6% and a significant level at 0.05.


For the following key secondary efficacy parameters, treatment groups were compared using Dunnett's test to control the Type 1 error rate: TC, LDL-C, HDL-C, non-HDL-C, VLDL-C, Lp-PLA2, and Apo B. For the remaining secondary efficacy parameters, Dunnett's test was be used and the ANCOVA output were considered descriptive.


The evaluation of safety was based primarily on the frequency of adverse events, clinical laboratory assessments, vital signs, and 12-lead ECGs. The primary efficacy variable is the percent change in fasting TG levels from baseline to Week 12. A sample size of 194 completed patients per treatment group provided 90.6% power to detect a difference of 15% between >96% E-EPA and placebo in percent change from baseline in fasting TG levels, assuming a standard deviation of 45% in TG measurements and a significance level of p<0.05.


Previous data on fasting LDL-C show a difference in percent change from baseline of 2.2%, with a standard deviation of 15%, between study drug and placebo. A sample size of 194 completed patients per treatment group provided 80% power to demonstrate non-inferiority (p<0.05, one-sided) of the LDL-C response between >96% E-EPA 4 g daily and placebo, within a 6% margin. To accommodate a 10% drop-out rate from randomization to completion of the double-blind treatment period, a total of 648 randomized patients was planned (216 patients per treatment group); 702 subjects were randomized, as further described below.


Results


Of the 702 randomized subjects, 687 were in the intent-to-treat (“ITT”) population as follows:

    • Ultra-pure EPA, 4 g/day: 226 subjects
    • Ultra-pure EPA, 2 g/day: 234 subjects
    • Placebo: 227 subjects


Lipids were extracted from plasma and red blood cell (“RBC”) suspensions and converted into fatty acid methyl esters for analysis using a standard validated gas chromatography/flame ionization detection method. Fatty acid parameters were compared between EPA treatment groups and placebo using an ANCOVA model with treatment, gender, type of statin therapy, and presence of diabetes as factors, and the baseline parameter value as a covariate. LSMs, SEs, and 2-tailed 95% confidence intervals for each treatment group and for each comparison were determined.


Baseline characteristics of the three ITT groups were comparable, with 61.4% of the ITT subjects being male, 96.3% being white, having a mean age of 61.4 years, a weight of 95.7 kg and a BMI of 32.9 kg/m2. ITT subjects with incomplete fatty acid data at baseline and/or at 12 weeks were excluded from the analyses described below.


As shown in Table 1 below, administration of 4 g per day of ethyl eicosapentaenoate (e.g., in a composition according to the present disclosure) reduced median concentrations of total VLDL by 12.2% over baseline when adjusted for placebo (P<0.001). Similarly, median concentrations of total LDL were reduced by 7.7% over baseline when adjusted for placebo (P<0.01). Median concentrations of total HDL were also reduced, by 7.4% over baseline when adjusted for placebo (P<0.0001). In addition, median concentrations of small LDL particles were reduced by 13.5% over baseline when adjusted for placebo control (P<0.0001).









TABLE 1







Placebo-Adjusted Effects of 4 g/day Ethyl Eicosapentaenoate


on Select Lipid Parameters Relative to Baseline.











Parameter
% Change
P















VLDL
−12.2%
<0.001



LDL
−7.7%
<0.01



HDL
−7.4%
<0.0001



Small LDL
−13.5%
<0.0001










Additional lipoprotein particle concentration data for 4 g/day and 2 g/day ethyl eicosapentaenoate groups is shown in Table 2.









TABLE 2







Median Change from Baseline to Study End in Lipoprotein Particle Concentrations












IPE 4 g/day (n = 216)
IPE 2 g/day (n = 222)
Placebo (n = 211)
Median Change From Baseline





















Change


Change


Change







from


from


from
IPE 4 g/day
IPE 2 g/day




End of
Baseline

End of
Baseline

End of
Baseline
vs Placebo
vs Placebo



Baseline
Treatment
%
Baseline
Treatment
%
Baseline
Treatment
%
%, P
%, P





















Total VLDL,
116.7
110.0
−2.5
113.4
122.4
12.0
111.2
122.0
7.9
−12.2
1.8


nmol/L
(66.6)
(78.0)
(41.8)
(53.5)
(66.2)
(56.1)
(50.6)
(60.0)
(40.1)
0.0002
0.6102


Large VLDL,
12.9
7.7
−41.9
12.1
10.0
−19.7
12.9
14.1
6.0
−46.4
−24.2


mmol/L
(10.7)
(7.6)
(57.2)
(8.3)
(9.9)
(72.5)
(9.7)
(13.2)
(101.1)
<0.0001
<0.0001


Medium VLDL,
54.8
49.7
−6.9
52.6
59.6
7.9
53.3
58.8
9.2
−12.1
2.6


nmol/L
(37.2)
(41.8)
(59.3)
(33.4)
(39.0)
(69.6)
(29.9)
(36.1)
(56.3)
0.0068
0.5998


Small VLDL,
43.9
46.8
8.3
43.1
49.6
22.1
41.4
45.3
8.5
2.8
16.5


nmol/L
(36.8)
(39.9)
(81.8)
(34.8)
(41.3)
(96.3)
(32.8)
(37.4)
(70.0)
0.6321
0.0058


Total LDL,
1131
1191
3.8
1171
1215
4.7
1152
1287
11.9
−7.7
−7.5


nmol/L
(369.5)
(512.0)
(31.8)
(349.0)
(355.0)
(29.2)
(353.0)
(456.0)
(31.6)
0.0017
0.0013


IDL, nmol/L
51.5
63.0
23.7
45.0
63.5
10.5
55.0
55.0
0.0
10.0
8.6



(81.5
(94.0)
(173.7)
(94.0)
(122.0)
(200.7)
(88.0)
(102.0)
(194.8)
0.3051
0.3602


Large LDL,
113.5
172.5
55.2
128.0
202.0
47.7
113.0
166.0
30.6
34.2
26.5


nmol/L
(198.5)
(226.0)
(241.0)
(190.0)
(242.0)
(207.2)
(215.0)
(271.0)
(200.4)
0.0076
0.0336


SmallLDL,
894.0
902.5
−1.1
944.0
920.5
−4.3
902.0
978.0
11.0
−13.5
−14.7


nmol/L
(266.5)
(387.5)
(36.1)
(310.0)
(313.0)
(32.0)
(323.0)
(387.0)
(39.0)
<0.0001
<0.0001


Total HDL,
34.3
32.6
−4.0
34.3
34.7
0.7
34.8
35.5
4.7
−7.4
−3.1


μmol/L
(8.9)
(8.2)
(16.4)
(8.3)
(7.2)
(14.9)
(10.1)
(9.3)
(16.2)
<0.0001
0.0150


Large HDL,
2.5
1.9
−21.6
2.5
2.4
−4.0
2.8
2.9
9.1
−31.0
−13.5


μmol/L
(1.8)
(2.0)
(58.1)
(2.0)
(2.3)
(63.3)
(2.0)
(2.3)
(50.4)
<0.0001
0.0017


Medium HDL,
6.7
6.9
4.2
7.0
7.2
2.9
7.8
8.3
8.6
−6.5
−4.5


μmol/L
(6.0)
(4.8)
(69.4)
(5.6)
(5.2)
(93.8)
(5.6)
(7.3)
(81.8)
0.2245
0.4359


Small HDL,
24.2
23.1
−3.9
24.0
23.8
−0.6
23.0
24.0
1.6
−2.8
−0.2


μmol/L
(6.4)
(6.7)
(21.9)
(6.7)
(6.4)
(24.8)
(8.1)
(7.4)
(25.4)
0.1267
0.9028





Data are presented as median (IQR) for end point values.


Median placebo-adjusted percent changes are Hodges-Lehmann medians.






These data show that 4 g/day ethyl eicosapentaenoate significantly reduced median concentrations of total, large, and medium VLDL particles; total and small LDL particles; and total and large HDL particles. In addition, 4 g/day of ethyl eicosapentaenoate increased the concentration of large LDL particles compared to placebo.


As shown in FIG. 1, atherogenic lipoprotein particle (i.e., total VLDL and total LDL particles) concentrations correlated well with Apo B (N=649; R2=0.64; P<0.0001) at week 12. The shaded band corresponds to confidence limits of the mean, which is shown as a dark line.


Median changes in lipoprotein particle size from baseline are shown in Table 3 below for 4 g/day ethyl eicosapentaenoate, 2 g/day ethyl eicosapentaenoate, and placebo, along with placebo-adjusted median percent changes from baseline for both 4 g/day and 2 g/day ethyl-EPA dosages. Data is presents as median (IQR) for end point values, and as Hodges-Lehmann medians for placebo-adjusted percent changes.









TABLE 3







Median Change from Baseline to Study End in Lipoprotein Particle Sizes



























Placebo-Adjusted












Median Change












4 g/day E-EPA (n = 216)
2 g/day E-EPA (n = 222)
Placebo (n = 211)
from Baseline



















Baseline
End
% Δ
Baseline
End
% Δ
Baseline
End
% Δ
4 g/d, %, P
2 g/d, %, P





















VLDL, nm
56.3
51.2
−8.1
55.9
53.2
−5.0
56.5
55.9
−0.6
−7.7
−4.8


(IQR)
(8.3)
(8.4)
(13.7)
(8.7)
(9.2)
(14.1)
(10.0)
(11.3)
(14.3)
<0.0001
<0.0001


LDL*, nm
19.8
20.0
+0.5
19.8
20.0
+0.5
19.8
19.9
0.0
+0.5
+0.5


(IQR)
(0.5)
(0.6)
(2.5)
(0.5)
(0.6)
(2.5)
(0.6)
(0.5)
(2.5)
0.0031
0.0007


HDL, nm
8.7
8.6
−1.1
8.6
8.6
0.0
8.7
8.7
0.0
−1.2
0.0


(IQR)
(0.3)
(0.2)
(3.5)
(0.5)
(0.5)
(2.4)
(0.3)
(0.4)
(3.5)
0.0014
0.4171





*Patient numbers (n) for LDL data only were 215, 221, and 211 for IPE 4 g/day, IPE 2 g/day and placebo, respectively.






These data show that 4 g/day of ethyl eicosapentaenoate significantly reduced median VLDL and HDL particle sizes, with a modest but significant increase in LDL particle size compared to placebo.


As shown in Table 4 below, administration of 4 g per day of ethyl eicosapentaenoate (e.g., in a composition according to the present disclosure) significantly reduced median percent changes from baseline compared to placebo for both the FADI-16 ratio and the FADI-18 ratio.









TABLE 4







Placebo-Adjusted Effects of 4 g/day Ethyl


Eicosapentaenoate on FADI Ratios.










Plasma
RBCs












Parameter
Definition
% Change
P
% Change
P















FADI-16
Palmitoleic
−6.8%
<0.01
−15.7%
<0.0001



acid/Palmitic



acid



(C16:1/C16:0)


FADI-18
Oleic acid/
−9.8%
<0.001
−3.1%
<0.01



Stearic Acid



(C18:1/C18:0)









Corresponding FIG. 2 shows percent change in FADI parameters compared to placebo in both plasma (FIG. 2A) and in red blood cells (FIG. 2B). Data are placebo-adjusted least square means values.


Endpoint data for subjects who were randomized and took at least one dose of any study drug, had baseline laboratory efficacy measurement, and had at least one valid post-randomization laboratory efficacy measurement of any type is summarized below.


Endpoint data for a subset of the study population (a modified intent-to-treat group referred to herein as the “MITT” group) were also analyzed. The MITT group included 687 individuals, each of which took at least one dose of study drug, had a baseline laboratory efficacy measurement, and had at least one post-randomization laboratory efficacy measurement.


The baseline characteristics of the MITT subgroup were similar to those of the ITT population. The majority of subjects in the MITT population did not have coronary heart disease. A summary of the MITT subjects' diabetes and cardiovascular disease is shown in Table 5 below:









TABLE 5







Summary of diabetes and cardiovascular disease-MITT.












Placebo
2 g/day
4 g/day
Total















n, total
227
234
226
687














History of diabetes and CVD*
52
(22.9%)
49
(20.9%)
42
(18.6%)
143 (20.8%)


History of diabetes; no CVD
113
(49.8%)
122
(52.1%)
123
(54.4%)
358 (52.1%)


No history of diabetes
62
(27.3%)
63
(26.9%)
61
(27.0%)
186 (27.1%)





*CVD defined as history of any of the following: MI, unstable angina, stable angina, angioplasty, bypass surgery, clinically significant myocardial ischemia, peripheral arterial disease, abdominal aortic aneurysm, TIA, stroke of carotid origin, or obstruction of carotid artery (>50%).






A summary of selected concomitant medications is shown in Table 6.









TABLE 6







Selected Concomitant medications-MITT.











Placebo
AMR101 2 g/d
AMR101 4 g/d



N = 233
N = 236
N = 233



n (%)
n (%)
n (%)

















HMG-CoA reductase
233
(100.0)
236
(100.0)
232
(99.6)


inhibitors


Anti-hypertensive
190
(81.5)
200
(84.7)
199
(85.4)


agents


Anti-platelet agent
141
(60.5)
135
(57.2)
138
(59.2)


(excluding heparin)


Aspirin
135
(57.9)
130
(55.1)
133
(57.1)


Clopidogrel
26
(11.2)
20
(8.5)
18
(7.7)












Asasantin
2
(0.9)
0
1
(0.4)











Cilostazol
1
(0.4)
0
0













Anti-diabetic agents
139
(59.7)
138
(58.5)
141
(60.5)





Concomitant medications were defined as those used during the double-blind treatment period.


1. In addition, 41 patients were on an HMG-CoA reductase inhibitor in combination with another medication.


2. Patient 0.57-061 (in the AMR101 4 g group) was not on a statin at randomization and did not inform site personnel until Visit 5 (Week 4) that he had stopped taking his statin 1 week prior to randomization. Patient 057-061 continued in the study; however, because the patient was not on a statin at the time baseline lipid measurements were drawn at Visit 4 (Week 0), the statin was not restarted following Visit 5.






A summary of statin use by MITT subjects (by intensity of therapy at randomization) is shown in Table 7.









TABLE 7







Statin use at randomization (by intensity)-MITT.











Placebo
AMR101 2 g/d
AMR101 4 g/d



N = 227
N = 234
N = 226



n (%)
n (%)
n (%)

















Lower intensity
14
(6.2)
15
(6.4)
16
(7.1)


Simvastatin 5 mg
4
(1.8)
4
(1.7)
2
(0.9)











Simvastatin 5 mg +
0
1
(0.4)
0


eze*













Simvastatin 10 mg
10
(4.4)
10
(4.3)
13
(5.8)











Simvastatin 15 mg
0
0
1
(0.4)













Medium intensity
140
(61.7)
147
(62.8)
141
(62.4)


Atorvastatin 10 mg
10
(4.4)
8
(3.4)
9
(4.0)


Atorvastatin 20 mg
14
(6.2)
18
(7.7)
15
(6.6)


Rosuvastatin 5 mg
9
(4.0)
7
(3.0)
8
(3.5)











Rosuvastatin 5 mg +
1
(0.4)
0
0


eze













Rosuvastatin 10 mg
21
(9.3)
28
(12.0)
19
(8.4)












Rosuvastatin 10 mg +
1
(0.4)
0
1
(0.4)


eze












Simvastatin 10 mg +
0
3
(1.3)
1
(0.4)


eze













Simvastatin 20 mg
31
(13.7)
32
(13.7)
31
(13.7)


Simvastatin 20 mg +
5
(2.2)
3
(1.3)
4
(1.8)


eze


Simvastatin 40 mg
47
(20.7)
48
(20.5)
53
(23.5)











Simvastatin 60 mg
1
(0.4)
0
0













Higher intensity
73
(32.2)
72
(30.8)
69
(30.5)


Atorvastatin 40 mg
16
(7.0)
9
(3.8)
12
(5.3)












Atorvastatin 40 mg +
1
(0.4)
2
(0.9)
0


eze











Atorvastatin 60 mg
0
1
(0.4)
0













Atorvastatin 80 mg
4
(1.8)
4
(1.7)
4
(1.8)












Atorvastatin 80 mg +
0
1
(0.4)
1
(0.4)


eze













Rosuvastatin 20 mg
20
(8.8)
15
(6.4)
21
(9.3)











Rosuvastatin 20 mg +
0
2
(0.9)
0


eze













Rosuvastatin 40 mg
2
(0.9)
3
(1.3)
5
(2.2)











Rosuvastatin 40 mg +
0
2
(0.9)
0


eze













Simvastatin 40 mg +
10
(4.4)
10
(4.3)
6
(2.7)


eze












Simvastatin 80 mg +
0
4
(1.7)
2
(0.9)


eze





*Note:


Ezetimibe includes patients on 5 mg or 10 mg






A summary of subjects' statin use before and during the study is shown in Table 8.









TABLE 8







Statin use-MITT.









Category












Placebo
AMR101 2 g/d
AMR101 4 g/d
Total



N = 227
N = 234
N = 226
N = 687



n (%)
n (%)
n (%)
n (%)



















Patients taking a statin prior
203
(89.4)
212
(90.6)
205
(90.7)
620
(90.2)


to screening


Continued statin after screening
190
(83.7)
198
(84.6)
194
(85.8)
582
(84.7)


Continued dose
187
(82.4)
194
(82.9)
190
(84.1)
571
(83.1)


Changed dose
3
(1.3)
4
(1.7)
4
(1.8)
11
(1.6)


Changed statin after screening
13
(5.7)
14
(6.0)
11
(4.9)
38
(5.5)


Patients not taking a statin
24
(10.6)
22
(9.4)
21
(9.3)
67
(9.8)


prior to screening









As shown in Table 9 below, subjects in the MITT group receiving 4 g/day of study drug experienced a 17.5% median reduction in triglycerides compared to baseline, while MITT subjects receiving 2 g/day of study drug reduced median triglycerides by 2.6% compared to baseline. Placebo subjects' median triglycerides increased by 5.9% over baseline.









TABLE 9







Change in Fasting Triglycerides from Baseline to Week 12—MITT.














Baseline [2]
Week 12 EP
Percent change from Baseline
Difference from placebo
















Treatment +
n
Median
[3] Median
Median


Estimated




Statin
[1]
(IQR)
(IQR)
(IQR)
(Q1, Q3)
p-value
median
95% CI
p-value



















Placebo
227
259.0 (81.0)
269.5 (149.5)
  5.9 (44.9)
(−13.5, 31.3)
0.0002





AMR101
234
254.0 (92.5)
244.3 (117.0)
 −5.6 (34.5)
(−21.1, 13.4)
0.1111
−10.1
(−15.7, −4.5) 
0.0005


2 g/d











AMR101
226
264.8 (93.0)
220.8 (92.0) 
−17.5 (31.0)
(−30.5, 0.5) 
<0.0001
−21.5
(−26.7, −16.2)
<0.0001


4 g/d














1. Only patients with non-missing baseline and Week 12 endpoint values were included.


2. Baseline was defined as the average of Visit 4 (Week 0) and the preceding lipid qualifying visit (either Visit 3 [Week −1] or if it occurred, Visit 3.1) measurements. If the measurement at 1 visit was missing, the other visit was used. If the measurements at both visits were missing, the last valid measurement prior to dosing with study drug was used as the baseline value.


3. The Week 12 endpoint was defined as the average of Visit 6 (Week 11) and Visit 7 (Week 12) measurements. If the measurement at 1 visit was missing, the other visit was used. If the measurements at both visits were missing, the last valid post-baseline measurement during the double-blind treatment period was used as the endpoint measurement.


CI = confidence interval;


EP = endpoint;


IQR = interquartile range;


Q1 = first quartile;


Q3 = third quartile






Data for individual MITT subjects corresponding to Table 9 is shown in a box-and-whisker plot in FIG. 3.


Table 10 shows the percentage of subjects achieving triglyceride treatment goal (less than 150 mg/dL) at Week 12.









TABLE 10







Percentage of Subjects Achieving Triglyceride Goal at Week 12.











Placebo
2 g/day
4 g/day
















Total n
227
234
226



Achieved TG Goal
13
9
16



Percentage Achieving
5.7%
3.8%
7.1%



TG Goal










Table 11 shows changes in lipid parameters by statin type in the MITT group.









TABLE 11





Changes in Lipid Parameters by Statin Type—MITT




















Pbo + statin
AMR 101 2 g + statin
























EOT
Median




Median


p





BL [2]
[3]
% chg




% chg

Diff
value




n
Median
Median
from
p from
n
BL
EOT
from
p from
from
from


Parameter
Statin
[1]
(IQR)
(IQR
BL
BL
[1]
[2]
[3]
BL
BL
pbo
pbo [4]





TG
Atorva
45
247
266.0
7.8
 0.1729
43
235.0
245.0
−0.5
 0.5764
−2.4
 0.6642





(71.0)
(142.5)



(89.0)
(125.0)







Simva
128
262.0
274.5
6.0
 0.0016
134
256.5
241.3
−8.8
 0.0176
−14.3
 0.0004





(97.8)
(148.3)



(102.0)
(133.0)







Rosuva
54
258.8
268.3
−0.6
 0.1437
57
258.0
252.5
−5.8
 0.9656
−5.7
 0.2512





(69.0)
(147.0)



(93.5)
(99.0)






LDL-C
Atorva
45
85.0
88.0
6.8
 0.1239
43
82.0
88.0
4.9
 0.0264
1.1
 0.8477





(24.0)
(32.0)



(21.0)
(29.0)







Simva
127
83.0
88.0
8.6
 0.0003
133
85.0
88.0
1.8
 0.0954
−4.8
 0.0844





(30.0)
(31.0)



(25.0)
(25.0)







Rosuva
54
81.0
89.5
10.5
 0.0016
57
78.0
87.0
4.3
 0.0365
−4.2
 0.3482





(28.0)
(30.0)



(25.)
(34.0)






Non-
Atorva
45
132.0
141.0
4.2
 0.0139
42
128.0
135.0
10.5
<0.0001
2.0
 0.7259


HDL-


(30.0)
(39.0)



(37.0)
(46.0)






C
Simva
128
128.0
135.0
9.2
<0.0001
134
128.0
133.5
0.0
 0.0862
−6.8
 0.0067





(37.5)
(45.0)



(34.0)
(41.0)







Rosuva
54
126.0
145
12.8
<0.0001
57
125.0
133.0
2.7
 0.0659
−9.0
 0.0481





(25.0)
(40.0)



(30.0)
(44.0)
















AMR 101 4 g + statin






















Median











% chg

Diff
p value





n
BL
EOT
from
p from
from
from



Parameter
Statin
[1]
[2]
[3]
BL
BL
pbo
pbo [4]






TG
Atorva
41
281.5
216.0
−23.9
<0.0001
−28.4
<0.0001






(59.0)
(82.5)








Simva
131
262.0
228.0
−14.7
<0.0001
−18.8
<0.001 






(106.0)
(114.5)








Rosuva
54
250.8
204.0
−20.5
 0.0001
−23.4
<0.0001






(85.5)
(77.0)







LDL-C
Atorva
40
78.5
82.5
9.0
 0.0358
2.5
 0.6188






(24.5)
(29.5)








Simva
131
82.0
83.0
1.5
 0.2468
−5.4
 0.0539






(24.0)
(27.0)








Rosuva
54
85.0
82.5
−3.8
 0.3532
−14.8
 0.0033






(33.0)
(40.0)







Non-
Atorva
41
131.0
122.0
−6.3
 0.0936
−13.5
 0.0071



HDL-


(30.0)
(32.0)







C
Simva
131
128.0
125.0
−4.3
 0.3514
−11.1
<0.0001






(35.0)
(38.0)








Rosuva
54
128.5
118.0
−5.5
 0.0240
−20.0
<0.0001






(28.0)
(42.0)





The median differences between the treatment groups were estimated with the Hodges-Lehmann method.


1. Only patients with both baseline and Week 12 endpoint values are included.


2. Baseline for TG was defined as the average of the measurements at Visit 4 (Week 0) and the preceding lipid qualifying visit (either Visit 3 [Week-1] or if it occurred, Visit 3.1) measurements. If the measurement at 1 visit was missing, the other visit measurement was used. If the measurements at both visits were missing, the last valid measurement prior to dosing with study drug was used as the baseline value. Baseline for other parameters were defined as the Visit 4 (Week 0) measurement. If missing, the last valid


measurement prior to dosing with study drug was used.


3. For TG: the Week 12 endpoint was defined as the average of measurements at Visit 6 (Week 11) and Visit 7 (Week 12). If the measurement at 1 visit was missing, the other visit measurement was used. If the measurements at both visits were missing, the last valid post-baseline measurement during the double-blind treatment period was used as the endpoint measurement. For other lipid parameters, the Week 12 endpoint was defined as the Visit 7 (Week 12) measurement.


If missing, the LOCF method was used.


4. P-value is from the Wilcoxon rank-sum test.


BL = Baseline;


pbo = placebo;


EOT = end of treatment (Week 12 endpoint);


IQR = interquartile range;


LOCF = last observation carried forward;


Q1 = first quartile;


Q3 = third quartile.






Table 12 shows changes in lipid parameters by statin regimen intensity in the MITT group.









TABLE 12





Changes in Lipid Parameters by Statin Regimen Intensity—MITT.




















Pbo + statin
AMR 101 2 g + statin
























EOT
Median




Median


p





BL [2]
[3]
% chg




% chg
p
Diff
value



Statin
n
Median
Median
from
p from
n

EOT
from
from
from
from


Parameter
Potency
[1]
(IQR)
(IQR
BL
BL
[1]
BL [2]
[3]
BL
BL
pbo
pbo [4]





TG
Low
14
315.0
304.5
19.4
 0.9515
15
256.0
208.5
−18.8
 0.6387
−13.8
 0.6784





(148.5)
(158.5)



(64.0)
(162.0)







Medium
140
257.3
268.3
4.6
 0.0047
148
253.8
248.0
−5.3
 0.3500
−8.7
 0.0139





(83.5)
(131.3)



(83.0
(116.0)







High
73
257.5
266.0
6.5
 0.0210
71
256.5
239.5
−5.8
 0.2668
−11.7
 0.0200





(76.5)
(160.0)



(103.5)
(115.0)






LDL-
Low
14
101.5
98.0
−4.4
 0.2661
15
91.0
95.0
0.9
 0.6788
7.1
 0.4450


C


(35.0)
(41.0)



(30.0)
(20.0)







Medium
140
83.0
91.5
9.9
<0.0001
147
82.0
85.0
2.4
 0.0168
−5.9
 0.0231





(26.0)
(34.0)



(23.0)
(25.0)







High
72
83.0
84.0
8.3
 0.0133
71
83.0
91.0
3.1
 0.0205
−1.7
 0.6410





(27.0)
(26.0)



(26.0)
(35.0)






Non-
Low
14
150
152
1.5
 0.7609
15
139
135
−2.2
 0.5614
3.3
 0.7107


HDL-


(50.0)
(45.0)′



(20.0)
(28.0)






C
Medium
140
128
140
10.5
<0.0001
148
127
133
1.7
 0.0094
−7.1
 0.0031





(35.0)
(43.0)



(36.0)
(40.0)







High
73
126
134
12.3
<0.0001
71
128
142
5.4
 0.0030
−3.5
 0.3266





(27.0)
(41.0)



(31.0)
(47.0)




















AMR 101 4 g + statin






















Median











% chg

Diff
p value




Statin
n
BL
EOT
from
p from
from
from



Parameter
Potency
[1]
[2]
[3]
BL
BL
pbo
pbo [4]






TG
Low
16
267.8
256.8
0.5
 0.6387
−13.1
 0.5467






(87.0)
(131.5)








Medium
141
269.0
221.0
−15.8
<0.0001
−20.1
<0.0001






(96.5)
(91.0)








High
69
254.5
214.5
−20.2
<0.0001
−26.0
<0.0001






(92.5)
(87.0)







LDL-
Low
16
78.5
84.5
7.8
 0.0934
12.4
 0.0483



C


(14.5)
(20.0)








Medium
140
85.0
84.0
−2.2
 0.9545
−10.0
 0.0006






(28.0)
(35.0)








High
69
79.0
82.0
5.4
 0.1139
−2.9
 0.4910






(22.0)
(29.0)







Non-
Low
16
128
131
−1.4
 0.5282
2.4
 0.6326



HDL-


(24.0)
(37.0)







C
Medium
141
129
124
−4.3
 0.0618
−13.9
<0.0001






(35.0)
(40.0)








High
69
128
118
−6.3
 0.0212
−15.8
<0.0001






(31.0)
(38.0)





The median differences between the treatment groups were estimated with the Hodges-Lehmann method.


Low intensity was defined as simvastatin 5-10 mg; medium intensity was defined as rosuvastatin 5-10 mg, atorvastatin 10-20 mg, simvastatin 20-40 mg, or simvastatin 10-20 mg + ezetimibe 5-10 mg;


High intensity was defined as rosuvastatin 20-40 mg, atorvastatin 40-80 mg, simvastatin 80 mg, or simvastatin 40-80 mg +ezetimibe 5-10 mg.


1. Only patients with both baseline and Week 12 endpoint values are included.


2. Baseline for TG was defined as the average of the measurements at Visit 4 (Week 0) and the preceding lipid qualifying visit (either Visit 3 [Week-1] or if it occurred, Visit 3.1) measurements. If the measurement at 1 visit was missing, the other visit measurement was used.


If the measurements at both visits were missing, the last valid measurement prior to dosing with study drug was used as the baseline value. Baseline for other parameters were defined as the Visit 4 (Week 0) measurement.


If missing, the last valid measurement prior to dosing with study drug was used.


3. For TG: the Week 12 endpoint was defined as the average of measurements at Visit 6 (Week 11) and Visit 7 (Week 12). If the measurement at 1 visit was missing, the other visit measurement was used.


If the measurements at both visits were missing, the last valid post-baseline measurement during the double-blind treatment period was used as the endpoint measurement.


For other lipid parameters, the Week 12 endpoint was defined as the Visit 7 (Week 12) measurement.


If missing, the LOCF method was used.


4. P-value is from the Wilcoxon rank-sum test.


BL = Baseline;


pbo = placebo;


EOT = end of treatment (Week 12 endpoint);


IQR = interquartile range;


LOCF = last observation carried forward;


Q1 = first quartile;


Q3 = third quartile.






Table 13 shows changes in lipid parameters by TG tertile in the MITT group.









TABLE 13





Changes in Lipid Parameters by TG Tertile—MITT.




















Pbo + statin
AMR 101 2 g + statin
























EOT
Median




Median


p



Baseline

BL [2]
[3]
% chg




% chg
p
Diff
value



TG
n
Median
Median
from
p from
n
BL
EOT
from
from
from
from


Parameter
tertile
[1]
(IQR)
(IQR
BL
BL
[1]
[2]
[3]
BL
BL
pbo
pbo [4]





TG
Lowest
72
203.8
214.5
7.9
 0.0055
84
205.8
207.8
0.7
 0.1560
−4.1
 0.3694





(31.5)
(71.5)



(33.0)
(74.5)







Middle
80
257.8
263.5
3.3
 0.3629
76
257.0
228.3
−13.0
 0.0092
−9.9
 0.0324





(30.3)
(112.3)



(30.5)
(83.5)







Highest
75
340.5
380.5
5.2
 0.0039
74
348.5
320.3
−8.7
 0.0914
−16.9
 0.0043





(94.0)
(165.5)



(75.0)
(119.0)






LDL-
Lowest
72
85.5
95.0
9.2
 0.0002
84
84.5
92.0
3.1
 0.0656
−5.7
 0.0889


C


(23.5)
(28.0)



(28.0)
(32.0)







Middle
80
86.5
90.0
7.3
 0.0012
76
82.0
86.5
3.1
 0.0161
−2.6
 0.4097





(27.0)
(26.5)



(25.0)
(23.5)







Highest
74
80.0
80.0
9.2
 0.0821
73
81.0
85.0
1.7
 0.1876
−2.0
 0.6672





(33.0)
(37.0)



(24.0)
(26.0)






Non-
Lowest
72
117
134
12.1
<0.0001
84
121
129
6.9
 0.0001
−4.2
 0.1926


HDL-


(23.0)
(32.0)



(32.0)
(38.0)






C
Middle
80
132
138
6.0
 0.0004
76
129
132
−1.2
 0.7214
−7.0
 0.0169





(26.0)
(36.0)



(30.0)
(35.0)







Highest
75
140
149
12.2
<0.0001
74
140
150
3.0
 0.0183
−5.0
 0.2151





(48.0)
(60.0)



(44.0)
(51.0)




















AMR 101 4 g + statin






















Median







Baseline



% chg

Diff
p value




TG
n
BL
EOT
from
p from
from
from



Parameter
tertile
[1]
[2]
[3]
BL
BL
pbo
pbo [4]






TG
Lowest
68
207.8
183.5
−10.9
 0.1127
−14.4
 0.0020






(28.0)
(67.5)








Middle
81
261.5
205.0
−19.3
<0.0001
−17.9
<0.0001






(26.0)
(74.5)








Highest
77
346.5
260.0
−21.8
<0.0001
−31.1
<0.0001






(75.5)
(110.5)







LDL-
Lowest
68
82.5
83.0
−3.9
 0.3336
−12.2
 0.0007



C


(25.0)
(30.5)








Middle
80
81.5
82.5
2.1
 0.3260
−5.8
 0.1345






(29.5)
(34.0)








Highest
77
82.0
83.0
4.8
 0.0289
0
 0.9970






(25.0)
(24.0)







Non-
Lowest
68
116
118
−2.0
 0.4390
−13.8
<0.0001



HDL-


(26.0)
(31.0)







C
Middle
81
127
124
−4.0
 0.5345
−9.5
 0.0039






(31.0)
(42.0)








Highest
77
142
130
−6.9
 0.0030
−17.6
<0.0001






(36.0)
(48.0)





The median differences between the treatment groups were estimated with the Hodges-Lehmann method.


Baseline TG tertiles were <230.5 mg/dL, 230.5 to <289.5 mg/dL, and ≥289.5 mg/dL.


1. Only patients with both baseline and Week 12 endpoint values are included.


2. Baseline for TG was defined as the average of the measurements at Visit 4 (Week 0) and the preceding lipid qualifying visit (either Visit 3 [Week-1] or if it occurred, Visit 3.1) measurements. If the measurement at 1 visit was missing, the other visit measurement was used. If the measurements at both visits were missing, the last valid measurement prior to dosing with study drug was used as the baseline value. Baseline for other parameters were defined as the Visit 4 (Week 0) measurement.


If missing, the last valid measurement prior to dosing with study drug was used.


3. For TG: the Week 12 endpoint was defined as the average of measurements at Visit 6 (Week 11) and Visit 7 (Week 12).


If the measurement at 1 visit was missing, the other visit measurement was used. If the measurements at both visits were missing, the last valid post-baseline measurement during the double-blind treatment period was used as the endpoint measurement.


For other lipid parameters, the Week 12 endpoint was defined as the Visit 7 (Week 12) measurement.


If missing, the LOCF method was used.


4. P-value is from the Wilcoxon rank-sum test.


BL= Baseline;


pbo = placebo;


EOT = end of treatment (Week 12 endpoint);


IQR = interquaitile range;


LOCF = last observation carried forward;


Q1 = first quartile;


Q3 = third quartile.






Table 14 shows changes in lipid parameters by non-statin washout status in the MITT group.









TABLE 14





Changes in Lipid Parameters by Non-Statin Washout Status—MITT.




















Pbo + statin
AMR 101 2 g + statin





















Non-


EOT
Median




Median


p



statin

BL [2]
[3]
% chg




% chg

Diff
value



Washout
n
Median
Median
from
p from
n
BL
EOT
from
p from
from
from


Parameter
(Yes/No)
[1]
(IQR)
(IQR
BL
BL
[1]
[2]
[3]
BL
BL
pbo
pbo [4]





TG
Yes
100
258.3
267.5
3.9
 0.0075
109
262.5
249.5
−4.2
 0.4771
−9.5
 0.0292


(mg/dL)


(81.8)
(175.5)



(95.5)
(120.5)







No
127
259.0
272.0
6.2
 0.0105
125
247.5
229.0
−7.9
 0.1416
−10.7
 0.0060





(85.5)
(131.5)



(87.0)
(114.5)






LDL-C
Yes
100
82.0
84.5
9.5
 0.0002
109
82.0
85.0
2.2
 0.1289
−6.3
 0.0423


(mg/dL)


(27.5)
(27.5)



(24.0)
(23.0)







No
126
85.0
90.0
7.3
 0.0007
124
84.0
91.5
3.5
 0.0024
−1.2
 0.6549





(25.0)
(35.0)



(26.0)
(32.5)






Non-HDL-
Yes
100
124
136
10.7
<0.0001
109
127
133
0.0
 0.0239
−6.9
 0.0345


C (mg/dL)


(31.0)
(40.0)



(30.0)
(38.0)







No
127
129
140
9.6
<0.0001
125
129
135
3.8
 0.0020
−4.6
 0.0847





(35.0)
(44.0)



(35.0)
(44.0)
















AMR 101 4 g + statin


















Non-



Median


p value




statin



% chg

Diff
from




Washout
n
BL
EOT
from
p from
from
pbo



Parameter
(Yes/No)
[1]
[2]
[3]
BL
BL
pbo
[4]






TG
Yes
92
269.3
220.8
−17.7
<0.0001
−22.4
<0.0001



(mg/dL)


(92.8)
(80.8)








No
134
263.0
220.0
−16.7
<0.0001
−20.8
<0.0001






(90.5)
(100.0)







LDL-C
Yes
91
82.0
80.0
−1.4
 0.4932
−7.5
 0.0428



(mg/dL)


(28.0)
(33.0)








No
134
82.0
83.5
2.5
 0.2283
−5.1
 0.0692






(25.0)
(30.0)







Non-HDL-
Yes
92
129
124
−5.4
 0.0900
−14.4
<0.0001



C (mg/dL)


(35.0)
(36.0)








No
134
128
122
−4.9
 0.0522
−4.8
<0.0001






(32.0)
(42.0)





The median differences between the treatment groups were estimated with the Hodges-Lehmann method.


1. Only patients with both baseline and Week 12 endpoint values are included.


2. Baseline for TG was defined as the average of the measurements at Visit 4 (Week 0) and the preceding lipid qualifying visit (either Visit 3 [Week-1] or if it occurred, Visit 3.1) measurements. If the measurement at 1 visit was missing, the other visit measurement was used.


If the measurements at both visits were missing, the last valid measurement prior to dosing with study drug was used as the baseline value.


Baseline for other parameters were defined as the Visit 4 (Week 0) measurement.


If missing, the last valid measurement prior to dosing with study drug was used.


3. For TG: the Week 12 endpoint was defined as the average of measurements at Visit 6 (Week 11) and Visit 7 (Week 12).


If the measurement at 1 visit was missing, the other visit measurement was used.


If the measurements at both visits were missing, the last valid post-baseline measurement during the double-blind treatment period was used as the endpoint measurement.


For other lipid parameters, the Week 12 endpoint was defined as the Visit 7 (Week 12) measurement.


If missing, the LOCF method was used.


4. P-value is from the Wilcoxon rank-sum test.


BL= Baseline;


pbo = placebo;


EOT = end of treatment (Week 12 endpoint);


IQR = interquartile range;


LOCF = last observation carried forward;


Q1 = first quartile;


Q3 = third quartile.






Table 15 shows changes in lipid parameters by diabetes status in the MITT group.









TABLE 15





Changes in Lipid Parameters by Diabetes Status—MITT.




















Pbo + statin
AMR 101 2 g + statin
























EOT
Median




Median


p





BL [2]
[3]
% chg




% chg
p
Diff
value



Diabetes
n
Median
Median
from
p from
n
BL
EOT
from
from
from
from


Parameter
(Yes/No)
[1]
(IQR)
(IQR)
BL
BL
[1]
[2]
[3]
BL
BL
pbo
pbo [4]





TG
Yes
165
259.0
275.5
6.2
 0.0002
171
253.5
244.0
−1.5
 0.7846
−9.8
 0.0074


(mg/dL)


(78.0)
(153.5)



(87.0)
(116.5)







No
62
258.8
258.5
4.3
 0.3134
63
256.5
245.0
−12.1
 0.0075
−10.8
 0.0261





(123.5)
(138.0)



(96.0)
(121.5)






LDL-C
Yes
164
84.0
87.5
8.8
<0.0001
170
82.0
87.0
2.2
 0.0063
−3.8
 0.1482


(mg/dL)


(25.5)
(31.0)



(24.0)
(26.0)







No
62
85.5
90.0
8.5
 0.0060
63
83.0
88.0
2.6
 0.0674
−3.1
 0.3161





(33.0)
(31.0)



(29.0)
(35.0)






Non-HDL-
Yes
165
128
136
10.7
<0.0001
171
125
135
5.1
<0.0001
−4.4
 0.0723


C (mg/dL)


(34.0)
(44.0)



(33.0)
(41.0)







No
62
129
143
8.3
 0.0001
63
135
133
−0.7
 0.7421
−8.6
 0.0108





(33.0)
(36.0)



(31.0)
(42.0)




















AMR 101 4 g + statin






















Median


p








% chg

Diff
value




Diabetes
n

EOT
from
p from
from
from



Parameter
(Yes/No)
[1]
BL [2]
[3]
BL
BL
pbo
pbo [4]






TG
Yes
165
262.0
216.5
−18.7
<0.0001
−23.2
<0.0001



(mg/dL)


(92.0)
(88.0)








No
61
271.5
234.5
−15.0
<0.0001
−16.8
 0.0005






(114.5)
(90.0)







LDL-C
Yes
165
81.0
83.0
2.0
 0.2403
−6.3
 0.0227



(mg/dL)


(26.0)
(29.0)








No
60
83.0
83.5
1.4
 0.4317
−5.3
 0.1402






(23.0)
(37.0)







Non-HDL-
Yes
165
128
121
−5.5
 0.0317
−14.4
<0.0001



C (mg/dL)


(35.0)
(40.0)








No
61
131
126
−0.9
 0.3032
−11.3′
 0.0003






(38.0)
(38.0)












The median differences between the treatment groups were estimated with the Hodges-Lehmann method.


1. Only patients with both baseline and Week 12 endpoint values are included.


2. Baseline for TG was defined as the average of the measurements at Visit 4 (Week 0) and the preceding lipid qualifying visit (either Visit 3 [Week-1] or if it occurred, Visit 3.1) measurements.


If the measurement at 1 visit was missing, the other visit measurement was used. If the measurements at both visits were missing, the last valid measurement prior to dosing with study drug was used as the baseline value.


Baseline for other parameters were defined as the Visit 4 (Week 0) measurement. If missing, the last valid measurement prior to dosing with study drug was used.


3. For TG: the Week 12 endpoint was defined as the average of measurements at Visit 6 (Week 11) and Visit 7 (Week 12).


If the measurement at 1 visit was missing, the other visit measurement was used.


If the measurements at both visits were missing, the last valid post-baseline measurement during the double-blind treatment period was used as the endpoint measurement.


For other lipid parameters, the Week 12 endpoint was defined as the Visit 7 (Week 12) measurement.


If missing, the LOCF method was used.


4. P-value is from the Wilcoxon rank-sum test.


BL = Baseline;


pbo = placebo;


EOT = end of treatment (Week 12 endpoint);


IQR = interquartile range;


LOCF = last observation carried forward;


Q1 = first quartile;


Q3 = third quartile.






Table 16 shows lipid changes in placebo-treated subjects in various clinical trials in the MITT group.









TABLE 16







Lipid changes in placebo-treated subjects in various clinical trials—MITT.
























Back-

Central











Study/


ground

tend-











Active


statin
Lead-in
ency
Duration










drug
Population
Placebo
therapy
period
measure
of PBO
n
TG
LDLc
nHDLc
TC
HDLc
VLDLc
apo B










Very high TG population (≥500 mg/dL)





















MARINE
TG 500-2000
Mineral
25% on
4 to 6 wks
Median
12 wks
75
+9.7
−3.0
+7.8
+7.7
0.0
+13.7
+4.3


Icosapent
mg/dL
oil
statin

% CFB











Ethyl1
















Harris
TG 500-2000
Corn oil
No
6 wks
Median
6-
42
+6.7
−4.8
−3.6
−1.7
0.0
−0.9
NR


Pownall
mg/dL



% CFB
16 wks










pooled
















analysis/
















Omega 3 acid
















Ethyl Esters2,3
















Goldberg4/
TG 500-1500
Yes
No
6 to 12
Mean
8 wks
44
+7.2
−4.2
NR
+0.4
+5.0
+11.0
NR


Fenofibrate
mg/dL


weeks
% CFB
















High TG population (200-500 mg/dL)





















ANCHOR
TG 200-499
Mineral
Simva
6 to 8 wks
Median
12 wks
227
+5.9
+8.8
+9.8
+9.1
+4.8
+15.0
+7.1


Icosapent
mg/dL
oil
Atorva
Stopped all
% CFB











Ethyl5


Rosuva
lipid meds















+/−
except















Eze
statin












COMBOS/
TG 200-499
Corn oil
Simva
8 wks
Median
 8 wks
132
−6.3
−2.8
−2.2
−1.7
−1.2
−7.2
−1.9


Omega 3
mg/dL

40 mg
stopped
% CFB











Ethyl



all lipid












Esters6



meds start
















simva 40












Goldberg7/
TG 350-499
Yes
No
6 to 12
Mean
 8 wks
28
−0.5
+12.0
NR
+2.8
+4.0
+5.8
NR



mg/dL


weeks
% CFB











Simvastatin8
Type IV
Yes
No
4 weeks
Median
  6 weeks
74
−9
+1
+1
+2
+3
−7
NR



LDL-C < 160



% CFB












   TG > 200















Atorvastatin9
Type IV
Yes
No
Yes
Median
NR
12
−12.4
+3.6
−2.8
−2.3
+3.8
−1.0
NR






duration not
% CFB















specified












Rosuvastatin10
Primary htg
Yes
No
6 week
Median
 6 wks
26
+0.8
+4.5
+1.7
+1.2
−2.9
+2.1
−0.2







% CFB











Niacin ER11
Primary
Yes
No
Not
Mean
16 wks
73
+12
+1
NR
+2
+2
NR
+1



hyperlipidemia


specified
% CFB












and mixed
















dyslipidemia















FIRST/
Mixed
Yes
Atorva
2 to 10
Mean
24 mos
329
−2*
+2*
*0
NR
+3*
NR
NR


Fenofibric
dyslipidemia

up to
weeks
% CFB


Median








acid12
   TG ≥ 150

40 mg




% CFB









HDL-C ≤ 45
















 M or ≤ 55
















FLDL-C ≤ 100





NR: not reported;


% CFB: percent change from baseline;


*Results at 13 week timepoint acid on carotid



1Bays HE et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, placebo-controlled, Randomized, double-blind, 12-week study with an open-label Extension MARINE. Am J Cardiol. 2001; 108 (5): 682-90.




2Pownall HJ et al. Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis 1999; 143: 285-97.




3Harris WS et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk 1997; 4(5-6): 385-91.




4Goldberg AC et al. Fenofibrate for the treatment of type IV and type V hyperlipoproteinemias: a double-blind, placebo-controlled multicenter US study. Clin Ther. 1989; 11 (1): 69-83.




5Ballantyne CM et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am j Cardiol. 2012; 110 (7): 984-92.




6Davidson MH et al. COMBination of prescriptionOmega-3 with Simvastatin (COMBOS) Investigators. Efficacy and tolerability of adding prescription omega-3 fatty acids 4g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week randomized, double-blind, placebo-controlled study. Clin Ther. 2007; 29 (7); 1354-67.




7Goldberg AC et al. Fenofibrate for the treatment of type IV and type V hyperlipoproteinemias: a double-blind, placebo-controlled multicenter US study. Clin Ther. 1989; 11 (1): 69-83.




8Zocor (simvastatin) Prescribing Information, 2012. Merck Sharp & Dohme Ltd.




9Lipitor (atorvastatin calcium) Prescribing information, 2013. Pfizer Inc.




10Crestor (rosuvastatin calcium) Prescribing information, 2013. AstraZeneca




11NIASPAN (niacin extended-release) Prescribing information, 2013. AbbVie LTD.




12Davidson MH et al. Results from the fenofibric intima-media thickness in subjects with Type Ilb dyslipidemia with residual risk in addition to atorvastatin (FIRST) trial. J Am Col Cardiol. 2013; 61(10-2): E1434.







Table 17 shows percent change from baseline and difference from placebo for secondary endpoints in the MITT group.









TABLE 17







Percent change from baseline and difference from placebo for secondary endpoints—MITT.












Treatment

Baseline
Week 12
Percent change from Baseline
Difference from placebo
















+
n
[2] Median
EP [3]
Median


Estimated

Adjusted


Statin
[1]
(IQR)
Median (IQR)
(IQR)
(Q1, Q3)
p-value
median
95% CI
p-value [4 ]










LDL-C (mg/dL)
















Placebo
226
 84.0 (27.0)
88.5 (31.0)
8.8 (31.0)
 (−7.8, 23.2)
<0.0001





AMR101 2 g/d
234
 82.0 (24.0)
87.0 (27.0)
2.4 (26.1)
 (−8.3, 17.7)
 0.0010
−3.6
(−7.9, 0.5)
0.0867


AMR101 4 g/d
225
 82.0 (25.0)
83.0 (31.0)
1.5 (26.6)
(−11.6, 15.0)
 0.1733
−6.2
(−10.5, −1.7)
0.0067







Non-HDL-C (mg/dL)
















Placebo
227
128.0 (34.0)
138.0 (43.0) 
9.8 (27.6)
 (−3.5, 24.1)
<0.0001





AMR101 2 g/d
234
128.0 (33.0)
134.0 (41.0) 
2.4 (26.1)
 (−7.0, 19.0)
 0.0001
−5.5
 (−9.4, −1.7)
0.0140


AMR101 4 g/d
226
128.0 (32.0)
122.0 (39.0) 
−5.0 (21.3) 
(−13.5, 7.8) 
 0.0106
−13.6
(−17.2, −9.9)
0.0001







Apo B (mg/dL)
















Placebo
219
 91.0 (24.0)
98.0 (25.0)
7.1 (23.2)
 (−4.7, 18.6)
<0.0001





AMR101 2 g/d
227
 91.0 (22.0)
95.0 (24.0)
1.6 (20.7)
 (−6.4, 14.3)
 0.0001
−3.8
 (−6.9, −0.7)
0.0170


AMR101 4 g/d
217
 93.0 (23.0)
90.0 (25.0)
−2.2 (16.4) 
(−10.2, 6.2) 
 0.0759
−9.3
(−12.3, −6.1)
0.0001







VLDL-C (mg/dL)
















Placebo
226
 42.0 (21.0)
49.0 (28.0)
15.0 (58.8)
(−10.9, 47.8)
<0.0001





AMR101 2 g/d
233
 43.0 (21.0)
44.0 (25.0)
 1.6 (54.6)
(−20.0, 34.5)
 0.0287
−10.5
(−18.3, −2.5) 
0.0170


AMR101 4 g/d
225
 44.0 (21.0)
38.0 (22.0)
−12.1 (47.9) 
(−31.3, 16.7)
 0.0043
−24.4
(−31.9, −17.0)
0.0001







Lp-PLA2 (ng/mL)
















Placebo
213
185.0 (58.0)
200.0 (71.0) 
 6.7 (24.0)
 (−6.4, 17.6)
<0.0001





AMR101 2 g/d
224
190.0 (55.5)
183.5 (57.5) 
−1.8 (23.1)
(−12.7, 10.4)
 0.2686
−8.0
(−11.6, −4.5) 
0.0004


AMR101 4 g/d
217
180.0 (56.0)
160.0 (57.0) 
−12.8 (18.5) 
(−22.1, −3.6)
<0.0001
−19.0
(−22.2, −15.7)
0.0001





1. Only patients with non-missing baseline and Week 12 endpoint values were included.


2. Baseline was defined as the Visit 4 (Week 0) measurement. If missing, the last valid measurement prior to dosing with study drug was used.


3. The Week 12 endpoint was defined as the Visit 7 (Week 12) measurement. If missing, the LOCF method was used.


4. The adjusted p-value was obtained from applying Hommel's multiple comparison procedure to the p-value from the treatment comparison between the AMR101 4g or 2g with placebo with exception of LDL-C


CI = confidence interval;


EP = endpoint;


IQR = interquartile range;


Q1 = first quartile;


Q3 = third quartile






Table 18 shows percent change from baseline and difference from placebo for lipid exploratory endpoints in the MITT group.









TABLE 18







Percent Change from Baseline and Difference from Placebo for Lipid Exploratory Endpoints—MITT Population.














Baseline
Week 12 EP
Percent change from Baseline
Difference from placebo
















Treatment +
n
[2] Median
[3] Median
Median


Estimated




Statin
[1]
(IQR)
(IQR)
(IQR)
(Q1, Q3)
p-value
median
95% CI
p-value










Total cholesterol (mg/dL)
















Placebo
227
168.0 (38.0)
181.0 (46.0)
  9.1 (20.8)
 (−1.4, 19.4)
<0.0001





AMR101 2 g/d
234
169.0 (34.0)
175.0 (44.0)
  2.1 (19.6)
 (−4.4, 15.2)
<0.0001
−4.8
(−7.8, −1.8) 
 0.0019


AMR101 4 g/d
226
167.0 (38.0)
162.0 (38.0)
 −3.2 (16.8)
(−11.3, 5.5) 
 0.0023
−12.0
(−14.9, −9.2)  
<0.0001







HDL-C (mg/dL)
















Placebo
227
 39.0 (12.0)
 40.0 (14.0)
  4.8 (22.0)
 (−7.7, 14.3)
<0.0001





AMR101 2 g/d
234
 38.0 (13.0)
 38.0 (11.0)
    0 (19.5)
 (−7.7, 11.8)
 0.0164
−2.2
(−4.9, 0.5)  
 0.1265


AMR101 4 g/d
226
 37.0 (12.0)
 37.0 (13.0)
 −1.0 (18.2)
(−8.7, 9.5)
 0.8474
−4.5
(−7.4, −1.8) 
 0.0013







VLDL-TG (mg/dL)
















Placebo
226
183.0 (94.0)
 196.0 (136.0)
  8.9 (63.8)
(−19.3, 44.5)
<0.0001





AMR101 2 g/d
233
185.0 (86.0)
168.0 (98.0)
 −2.1 (48.9)
(−26.3, 22.6)
 0.8897
−11.3
(−19.4, −3.4)  
 0.0049


AMR101 4 g/d
225
190.0 (99.0)
147.0 (88.0)
−19.2 (46.2)
(−39.2, 7.0) 
<0.0001
−26.5
(−33.9, −19.0) 
<0.0001







Apo A1 (mg/dL)
















Placebo
219
140.0 (35.0)
145.0 (34.0)
  3.6 (14.9)
 (−2.1, 12.1)
<0.0001





AMR101 2 g/d
227
140.0 (26.0)
141.0 (26.0)
  2.0 (13.0)
(−4.0, 9.0)
 0.0007
−1.7
(−3.7, 0.3) 
 0.0943


AMR101 4 g/d
217
141.0 (31.0)
137.0 (29.0)
 −2.9 (12.6)
(−9.6, 3.1)
<0.0001
−6.9
(−8.9, −4.9) 
<0.0001







Apo B/Apo A1 ratio
















Placebo
219
 0.7 (0.2)
 0.7 (0.2)
  2.4 (21.7)
 (−7.8, 13.9)
 0.0028





AMR101 2 g/d
227
 0.7 (0.2)
 0.7 (0.2)
  0.1 (18.3)
 (−7.9, 10.4)
 0.2523
−2.0
(−5.0, 0.9) 
 0.1886


AMR101 4 g/d
217
 0.7 (0.2)
 0.7 (0.2)
 −0.7 (20.3)
 (−8.1, 12.2)
 0.4097
−2.4
(−5.4, 0.8) 
 0.1333







Lp (a) (mg/dL)
















Placebo
 83
 12.0 (31.0)
 12.0 (37.0)
  0.0 (35.0)
 (−8.3, 26.7)
 0.0452





AMR101 2 g/d
 83
 11.0 (33.0)
 12.0 (33.0)
  0.0 (24.9)
 (−2.5, 22.4)
 0.0011
0.0
(−2.5, 8.3) 
 0.5466


AMR101 4 g/d
 81
  7.0 (33.0)
  9.0 (31.0)
  0.0 (10.0)
(−6.5, 3.4)
 0.4722
0.0
(−8.3, 0.0) 
 0.3626







RLP-C (mg/dL)
















Placebo
 86
14.0 (7.0)
13.0 (9.0)
  8.0 (66.9)
(−29.4, 37.5)
 0.1316





AMR101 2 g/d
 84
15.0 (7.0)
11.0 (7.0)
−11.1 (40.0)
(−30.0, 10.0)
 0.0124
−16.7
(−30.0, 10.0) 
 0.0153


AMR101 4 g/d
 82
13.5 (6.0)
10.0 (6.0)
−24.0 (45.5)
(−45.5, 0.0) 
 0.0002
−25.8
(−39.9, −12.4)
 0.0001







Oxidized LDL (U/L)
















Placebo
 84
 51.8 (16.8)
 59.7 (18.1)
 11.6 (28.1)
 (−4.0, 24.1)
<0.0001





AMR101 2 g/d
 75
 54.0 (17.8)
 55.8 (22.8)
 2.6 (18.3)
 (−4.5, 13.8)
 0.0245
−5.8
(−11.9, 0.9) 
 0.0946


AMR101 4 g/d
 78
 54.0 (14.6)
 51.4 (17.5)
 −4.8 (19.6)
(−11.5, 8.1) 
 0.0610
−13.3
(−19.3, −7.5) 
<0.0001





1. Only patients with non-missing baseline and Week 12 endpoint values were included.


2. Baseline was defined as the Visit 4 (Week 0) measurement. If missing, the last valid measurement prior to dosing with study drug was used.


3. The Week 12 endpoint was defined as the Visit 7 (Week 12) measurement. If missing, the LOCF method was used.


CI = confidence interval;


EP = endpoint;


IQR = interquartile range;


Q1 = first quartile;


Q3 = third quartile






Table 19 shows change from baseline and difference from placebo for LDL Particle Concentration and Size in the MITT group.









TABLE 19







Change from Baseline and Difference from Placebo for LDL Particle Concentration and Size—MITT Population.














Baseline
Week 12
Percent change from Baseline
Difference from placebo
















Treatment +
n
[2] Median
EP [3 ]
Median


Estimated




Statin
[1]
(IQR)
Median (IQR)
(IQR)
(Q1, Q3)
p-value
median
95% CI
p-value










LDL Particle Concentration (nmol/L)
















Placebo
211
1152.0 (353.0)
1287.0 (456.0)
11.9 (31.6)
 ( −3.0, 28.6)
<0.0001





AMR101 2g/d
222
1170.5 (349.0)
1215.0 (355.0)
 4.7 (29.2)
( −10.3, 18.9)
 0.0008
−7.5
( −12.1, −2.9)
0.0013


AMR101 4g/d
216
1130.5 (369.5)
1190.5 (512.0)
 3.8 (31.8)
( −11.0, 20.8)
 0.0016
−7.7
( −12.3, −2.8)
0.0017







LDL Particle Size (nm)
















Placebo
211
19.8 (0.6)
19.9 (0.5)
0.0 (2.5)
( −1.0, 1.5)
 0.3037





AMR101 2g/d
221
19.8 (0.5)
20.0 (0.6)
0.5 (2.5)
( −0.5, 2.0)
<0.0001
0.5
(0.5, 1.0)
0.0007


AMR101 4g/d
215
19.8 (0.5)
20.0 (0.6)
0.5 (2.5)
( −0.5, 2.0)
<0.0001
0.5
(0.0, 1.0)
0.0031





1. Only patients with non-missing baseline and Week 12 endpoint values were included.


2. Baseline was defined as the Visit 4 (Week 0) measurement. If missing, the last valid measurement prior to dosing with study drug was used.


3. The Week 12 endpoint was defined as the Visit 7 (Week 12) measurement. If missing, the LOCF method was used.


CI = confidence interval;


EP = endpoint;


IQR = interquartile range;


Q1 = first quartile;


Q3 = third quartile






Table 20 shows change from baseline and difference from placebo for glucose metabolism exploratory endpoints in the MITT group.









TABLE 20







Change from baseline and difference from placebo for glucose metabolism exploratory endpoints—MITT.














Baseline
Week 12
Percent change from Baseline
Difference from placebo
















Treatment +
n
[2] Median
EP [3]
Median


Estimated




Statin
[1]
(IQR)
Median (IQR)
(IQR)
(Q1, Q3)
p-value
median
95% CI
p-value










Fasting plasma glucose (mg/dL)
















Placebo
219
128.9 (35.2)
133.7 (38.5) 
4.2 (2.1) 
 (0.0, 8.4)
 0.0032





AMR101 2 g/d
226
134.8 (42.6)
138.0 (44.9) 
3.6 (2.1) 
(−0.5, 7.7)
 0.0042
−0.6 (3.0) 
(−6.5, 5.3) 
0.8408


AMR101 4 g/d
217
133.1 (37.0)
141.9 (51.1) 
8.9 (2.1) 
  (4.7, 13.1)
 0.0007
4.7 (3.0)
(−1.2, 10.6)
0.1200







HbAlc (%)
















Placebo
218
 6.5 (0.9)
6.7 (1.1)
0.2 (0.04)
 (0.1, 0.2)
<0.0001





AMR101 2 g/d
228
 6.7 (1.1)
6.8 (1.2)
0.2 (0.04)
 (0.1, 0.2)
<0.0001
−0.0 (0.05)
(−0.1, 0.1) 
0.9392


AMR101 4 g/d
220
 6.6 (0.9)
6.9 (1.1)
0.3 (0.04)
 (0.2, 0.3)
<0.0001
 0.1 (0.05)
(−0.0, 0.3) 
0.0899







Insulin (μIU/mL)
















Placebo
215
 23.0 (33.1)
20.1 (17.5)
−1.2 (0.9)  
(−2.9, 0.6)
 0.1568





AMR101 2 g/d
217
 18.6 (11.5)
18.6 (11.0)
−1.2 (0.9)  
(−3.0, 0.5)
 0.5685
−0.1 (1.3) 
(−2.6, 2.4) 
0.9567


AMR101 4 g/d
215
 19.6 (16.0)
19.0 (16.2)
−1.1 (0.9)  
(−2.9, 0.6)
 0.9601
0.0 (1.3)
(−2.5, 2.5) 
0.9874







HOMA-IR
















Placebo
215
  8.1 (16.4)
6.9 (6.9)
−0.4 (0.4)  
(−1.2, 0.3)
 0.4806





AMR101 2 g/d
217
 6.4 (4.8)
6.4 (4.5)
−0.6 (0.4)  
(−1.3, 0.2)
 0.4192
−0.1 (0.5) 
(−1.2, 0.9) 
0.8022


AMR101 4 g/d
213
 6.8 (7.0)
6.9 (6.7)
−0.1 (0.4)  
(−0.8, 0.7)
 0.2462
0.3 (0.6)
(−0.7, 1.4) 
0.5225





1. Only patients with non-missing baseline and Week 12 endpoint values were included.


2. Baseline was defined as the Visit 4 (Week 0) measurement. If missing, the last valid measurement prior to dosing with study drug was used.


3. The Week 12 endpoint was defined as the Visit 7 (Week 12) measurement. If missing, the LOCF method was used.


LS means, SE, CI, and p-values are from linear contrasts of an ANCOVA model of change from baseline to Week 12 EP with treatment as a factor and baseline value as a covariate.


CI = confidence interval;


EP = endpoint;


SE = standard error;


SD = standard deviation






Table 21 shows change from baseline and difference from placebo for inflammatory biomarkers in the MITT group.









TABLE 21







Change from Baseline and Difference from Placebo for Inflammatory Biomarkers—MITT.
















Percent change from Baseline
Difference from placebo





















Baseline
Week 12








Treatment +
n
[2] Median
EP [3]
Median


Estimated




Statin
[1]
(IQR)
Median (IQR)
(IQR)
(Q1, Q3)
p-value
median
95% CI
p-value










ICAM-1 (ng/mL)
















Placebo
83
269.0 (122.0)
257.0 (131.0)
9.0 (31.0)
 (−6.0, 25.0)
 0.0085





AMR101 2g/d
74
267.0 (97.0) 
268.5 (89.0) 
1.5 (37.0)
(−15.0, 22.0)
 0.3718
−6.0
(−15.0, 3.0) 
0.2086


AMR101 4 g/d
78
273.0 (96.0) 
270.0 (110.0)
2.5 (40.0)
(−18.0, 22.0)
 0.4487
−6.0
(−16.0, 4.0)
0.1910







IL-6 (pg/mL)
















Placebo
83
3.2 (3.2)
2.9 (3.0)
0.1 (1.8) 
(−0.8, 0.9)
 0.6566





AMR101 2 g/d
74
2.4 (2.0)
2.7 (2.3)
0.2 (1.3) 
(−0.4, 0.9)
 0.1344
0.1
(−0.3, 0.6)
0.5979


AMR101 4 g/d
78
2.7 (2.6)
2.6 (2.1)
0.1 (1.8) 
(−1.0, 0.8)
 0.9920
−0.1
(−0.6, 0.4)
0.7608







PAI-1 (ng/mL)
















Placebo
54
72.2 (62.0)
86.4 (60.7)
−1.7 (73.3) 
(−29.1, 44.2)
 0.8618





AMR101 2 g/d
50
28.1 (58.1)
90.3 (67.4)
14.6 (38.8) 
 (−8.7, 30.1)
 0.0551
12.1
 (−9.1, 29.4)
0.2631


AMR101 4 g/d
55
84.7 (73.5)
85.6 (86.3)
−3.1 (45.2) 
(−24.2, 21.0)
 0.9967
0.6
(−16.7, 17.8)
0.9420










hsCRP (mg/L) [4]


















Baseline
Week 12
Median %







Treatment +
n
[2] Median
EP [3]
Chg from


Estimated




Statin
[1]
(IQR)
Median (IQR)
BL
(Q1, Q3)
p-value
median
95% CI
p-value





Placebo
219
2.2 (4.0)
2.6 (4.7)
17.1 (108.0)
(−26.5, 81.5)
<0.0001





AMR101 2 g/d
227
1.9 (2.9)
2.5 (3.4)
10.3 (88.6) 
(−24.3, 64.3)
<0.0001
−6.8
(−20.0, 6.0) 
0.2889


AMR101 4 g/d
217
2.2 (2.7)
2.0 (3.0)
−2.4 (62.8) 
(−29.4, 33.3)
 0.5544
−22.0
(−34.1, −9.4)
0.0005





1. Only patients with non-missing baseline and Week 12 endpoint values were included.


2. Baseline was defined as the Visit 4 (Week 0) measurement. If missing, the last valid measurement prior to dosing with study drug was used.


3. The Week 12 endpoint was defined as the Visit 7 (Week 12) measurement. If missing, the LOCF method was used.


4. Post-hoc analysis of hsCRP based on median percent change from baseline p-values are from Wilcoxon rank-sum test. When hsCRP = <0.2, 0.1 was imputed for the analysis.


CI = confidence interval;


EP = endpoint;


IQR = interquartile range;


Q1 = first quartile;


Q3 = third quartile






Table 22 shows changes in EPA concentration from baseline to week 12 in the MITT group.









TABLE 22







Changes in EPA Concentration from Baseline to Week 12—MITT.











Placebo
AMR101 2g
AMR101 4g





















Baseline
Week 12
LS Mean

Baseline
Week 12
LS Mean

Baseline
Week 12
LS Mean




[2]
Endpoint
Change (SE)

[3]
Endpoint
Change (SE)

[3]
Endpoint
Change (SE)



n
Mean
[3] Mean
[4] From
n
Mean
[4] Mean
[5] From
n
Mean
[4] Mean
[5] From


Parameter
[1]
(SD)
(SD)
Baseline
[1]
(SD)
(SD)
Baseline
[2]
(SD)
(SD)
Baseline





Plasma EPA
81
28.1
30.6
8.1
73
28.1
123.8
100.5
71
28.1
182.6
159.5


concentration

(28.01)
(27.90)
(6.59)

(13.71)
(67.82)
(6.83)

(18.79)
(71.73)
(6.95)


(μg/mL)














RBC EPA
79
11.2
9.9
0.4
71
10.9
43.7
34.6
69
11.6
72.7
62.8


concentration

(6.64)
(5.70)
(2.38)

(5.21)
(16.84)
(2.48)

(5.56)
(31.49)
(2.55)


(μg/mL)

















Outliers were identified within each treatment group as percent change values <Q1 − 11.5*IQR or >Q3 + 1.5*IQR.


Patients with outliers were excluded from the analysis.


When LLOQ was <10.0, 5 μg/mL was imputed for analysis.


When LLOQ was <5.00, 2.5 μg/mL was imputed for analysis.


1. Only patients with non-missing baseline and Week 12 endpoint values were included.


2. Baseline was defined as the Visit 4 (Week 0) measurement. If missing, the last valid measurement prior to dosing with study drug was used.


3. The Week 12 endpoint was defined as the Visit 7 (Week 12) measurement. If missing, the LOCF method was used.


4. Least-squares means and SEs were from linear contrasts of an ANCOVA model of change from baseline to Week 12 endpoint, with treatment, gender, type of stain, and presence of diabetes as factors and baseline value as a covariate.


ANCOVA = analysis of covariance;


EPA = eicosapentaenoic acid;


IQR = interquartile range;


LLOQ = lower limit of quantitation;


LOCF = last observation carried forward;


LS = least squares;


Q1 = first quartile;


Q3 = third quartile;


RBC = red blood cell;


SD = standard deviation;


SE = standard error.






These data demonstrate that administration of 4 g per day of ethyl eicosapentaenoate for 12 weeks resulted in atherogenic particle concentrations that correlate with Apo B and, compared with placebo and relative to baseline, reduce key atherogenic lipoprotein particle concentrations and produce potentially beneficial reductions in FADI in statin-treated subjects at high atherosclerotic coronary heart disease risk.


Example 2. Effects of High Purity Ethyl-EPA on Lipoprotein Particle Concentration and Size

The reductions in lipoprotein particle concentration and size for all randomized subjects in the populations of Example 1 who had a baseline triglyceride primary efficacy end point measurement, received at least one dose of the ethyl EPA study drug or placebo, and had at least one post-randomization efficacy measurement were studied.


As shown in Table 23, this subset of subjects had similar baseline triglycerides, LDL-C, non-HDL-C, HDL-C and Apo-B levels to the ITT population of Example 1. Subjects in this subset who received 4 g/day of >96% ethyl-EPA of Example 1 (“IPE”) experienced similar significant reductions in triglycerides, LDL-C, non-HDL-C, HDL-C and Apo-B versus placebo at 12 weeks that the larger ITT population of Example 1 experienced in the same time period.









TABLE 23







Median Changes in Selected Lipid End Points After


12 Weeks—Patients with Lipoprotein Data.













Median





Change



IPE 4 g/day
Placebo
From



(n = 216)
(n = 211)
Baseline














Lipid


Change

End of
Change
IPE 4 g/day


End Point

End of
From


From
vs Placebo,


(mg/dL)
Baseline
Treatment
Baseline, %
Baseline
Treatment
Baseline, %
%, P

















TG
264.8
219.3
−17.5
258.0
267.5
4.8
−21.1



(90.3)
(91.3)
(30.4)
(80.5)
(141.0)
(43.6)
<0.0001


LDL-C*  
82.0
83.0
2.1
84.0
88.0
7.7
−5.2



(24.0)
(31.0)
(27.0)
(27.0)
(31.0)
(31.2)
0.0225


Non-HDL-C
128.0
122.0
−5.1
128.0
136.0
9.8
−13.5



(32.5)
(37.0)
(21.4)
(34.0)
(42.0)
(27.2)
<0.0001


HDL-C   
38.0
36.5
−2.2
39.0
40.0
5.2
−5.0



(12.0)
(13.0)
(18.5)
(12.0)
(14.0)
(22.0)
0.0005


Apo-B   
92.5
90.0
−2.2
92.0
98.0
7.0
−8.8



(23.5)
(25.5)
(16.5)
(25.0)
(25.0)
(23.0)
<0.0001





Data are presented as median (interquartile range) for end point values.


Median percent changes versus placebo are Hodges-Lehmann medians.


Apo-B, apolipoprotein B;


HDL-C, high-density lipoprotein cholesterol;


IPE, icosapent ethyl;


LDL-C, low-density lipoprotein cholesterol;


TG, triglycerides.


*n = 210 for placebo.






As shown in Table 24, subjects receiving 4 g/day of the >96% ethyl-EPA composition for 12 weeks also had significantly reduced concentrations of total VLDL particles, large VLDL particles, medium VLDL particles, total LDL particles, small LDL particles, total HDL particles and large HDL particles compared to placebo. The treated subjects also had significantly increased large LDL particle concentration compared to placebo after 12 weeks. Treated subjects also had significantly reduced VLDL particle size, significantly reduced HDL particle size, and slightly increased LDL particle size compared to placebo after 12 weeks.









TABLE 24







Median Changes in Lipoprotein Particle Concentration and Size After 12 Weeks-


Patients with Lipoprotein Data.













Median





Change



IPE 4 g/day
Placebo
From



(n = 216)
(n = 211)
Baseline

















Change


Change
IPE 4 g/day




End of
From

End of
From
vs Placebo,



Baseline
Treatment
Baseline, %
Baseline
Treatment
Baseline, %
%, P










Lipoprotein Particle Concentration














Total VLDL,
116.7
110.0
−2.5
111.2
122.0
7.9
−12.2


nmol/L
(66.6)
(78.0)
(41.8)
(50.6)
(60.0)
(40.1)
0.0002


Large
12.9
7.7
−41.9
12.9
14.1
6.0
−46.4


VLDL,
(10.7)
(7.6)
(57.2)
(9.7)
(13.2)
(101.1)
<0.0001


nmol/L









Medium
54.8
49.7
−6.9
53.3
58.8
9.2
−12.1


VLDL,
(37.2)
(41.8)
(59.3)
(29.9)
(36.1)
(56.3)
0.0068


nmol/L









Small
43.9
46.8
8.3
41.4
45.3
8.5
2.8


VLDL,
(36.8)
(39.9)
(81.8)
(32.8)
(37.4)
(70.0)
0.6321


nmol/L









Total LDL,
1131
1191
3.8
1152
1287
11.9
−7.7


nmol/L
(369.5)
(512.0)
(31.8)
(353.0)
(456.0)
(31.6)
0.0017


IDL,
51.5
63.0
23.7
55.0
55.0
0.0
10.0


nmol/L
(81.5)
(94.0)
(173.7)
(88.0)
(102.0)
(194.8)
0.3051


Large LDL,
113.5
172.5
55.2
113.0
166.0
30.6
34.2


nmol/L
(198.5)
(226.0)
(241.0)
(215.0)
(271.0)
(200.4)
0.0076


Small LDL,
894.0
902.5
−1.1
902.0
978.0
11.0
−13.5


nmol/L
(266.5)
(387.5)
(36.1)
(323.0)
(387.0)
(39.0)
<0.0001


Total HDL,
34.3
32.6
−4.0
34.8
35.5
4.7
−7.4


μmon/L
(8.9)
(8.2)
(16.4)
(10.1)
(9.3)
(16.2)
<0.0001


Large HDL,
2.5
1.9
−21.6
2.8
2.9
9.1
−31.0


μmon
(1.8)
(2.0)
(58.1)
(2.0)
(2.3)
(50.4)
<0.0001


Medium
6.7
6.9
4.2
7.8
8.3
8.6
−6.5


HDL,
(6.0)
(4.8)
(69.4)
(5.6)
(7.3)
(81.8)
0.2245


μmon/L









Small HDL,
24.2
23.1
−3.9
23.0
24.0
1.6
−2.8


μmon/L
(6.4)
(6.7)
(21.9)
(8.1)
(7.4)
(25.4)
0.1267







Lipoprotein Particle Size














VLDL,
56.3
51.2
−8.1
56.5
55.9
−0.6
−7.7


nm
(8.3)
(8.4)
(13.7)
(10.0)
(11.3)
(14.3)
<0.0001


LDL,*
19.8
20.0
0.5
19.8
19.9
0.0
0.5


nm
(0.5)
(0.6)
(2.5)
(0.6)
(0.5)
(2.5)
0.0031


HDL,
8.7
8.6
−1.1
8.7
8.7
0.0
−1.2


nm
(0.3)
(0.2)
(3.5)
(0.3)
(0.4)
(3.5)
0.0014





Data are presented as median (interquartile range) for end point values.


Median percent changes versus placebo are Hodges-Lehmann medians.


Diameter as follows: large VLDL (>60 nm);


medium VLDL (42-60 nm);


small VLDL (29-42 nm);


IDL (23-29 nm);


large LDL (20.5-23.0 nm);


small LDL (18.0-20.5 nm);


large HDL (9.4-14.0 nm);


medium HDL (8.2-9.4 nm); and


small HDL (7.3-8.2 nm).


HDL, high-density lipoprotein;


IDL, intermediate-density lipoprotein;


IPE, icosapent ethyl;


LDL, low-density lipoprotein;


VLDL, very-low-density lipoprotein.


*n = 215 for IPE 4 g/day.






Atherogenic particle concentration (e.g., concentration of all VLDL and LDL particles) correlated well with ApoB concentrations at both baseline (FIG. 6A) and after 12 weeks (FIG. 6B). Similarly, total LDL particle concentrations correlated strongly with ApoB concentrations at both baseline (FIG. 6C) and after 12 weeks (FIG. 6D).

Claims
  • 1. A method of lowering triglycerides and high sensitivity C-reactive protein (“hsCRP”) in a subject on statin therapy having baseline fasting triglycerides of about 200 mg/dl to less than 500 mg/dl and a baseline fasting Apolipoprotein B (“Apo B”) level of about 217 mg/dl or about 227 mg/dl, the method comprising determining a baseline fasting triglyceride level, a baseline fasting Apo B level, and a baseline hsCRP level associated with the subject; and thereafter administering to the subject about 2 grams or about 4 grams per day of ethyl eicosapentaenoate.
  • 2. The method of claim 1 further comprising determining a baseline fasting low-density lipoprotein cholesterol (“LDL-C”) level associated with the subject before the administering, wherein an LDL-C level associated with the subject after the administering is not increased compared to the baseline fasting LDL-C level.
  • 3. The method of claim 1, wherein the subject is administered about 2 grams per day of ethyl eicosapentaenoate, and wherein the triglycerides are lowered by about 10% compared to a second subject who has received statin therapy but not the ethyl eicosapentaenoate.
  • 4. The method of claim 2, wherein the subject is administered about 2 grams per day of ethyl eicosapentaenoate, and wherein the triglycerides are lowered by about 10% compared to a second subject who has received statin therapy but not the ethyl eicosapentaenoate.
  • 5. The method of claim 1, wherein the subject is administered about 4 grams per day of ethyl eicosapentaenoate, and wherein the triglycerides are lowered by about 21% compared to a second subject who has received statin therapy but not the ethyl eicosapentaenoate.
  • 6. The method of claim 2, wherein the subject is administered about 4 grams per day of ethyl eicosapentaenoate, and wherein the triglycerides are lowered by about 21% compared to a second subject who has received statin therapy but not the ethyl eicosapentaenoate.
  • 7. The method of claim 1, wherein after the administering an Apo B level associated with the subject is lower than the baseline fasting Apo B level compared to a second subject who has received statin therapy but not the ethyl eicosapentaenoate.
  • 8. The method of claim 1 further comprising determining a baseline fasting very low-density lipoprotein cholesterol (“VLDL-C”) level associated with the subject, wherein after the administering an VLDL-C level associated with the subject is lower than the baseline fasting VLDL-C level compared to a second subject who has received statin therapy but not the ethyl eicosapentaenoate.
  • 9. The method of claim 1 further comprising determining a baseline fasting lipoprotein associated phospholipase A2 (“LP-PLA2”) level associated with the subject, wherein after the administering an LP-PLA2 level associated with the subject is lower than the baseline fasting LP-PLA2 level compared to a second subject who has received statin therapy but not the ethyl eicosapentaenoate.
  • 10. The method of claim 1 further comprising determining baseline fasting levels of LDL-C, Apo B, VLDL-C and Lp-PLA2 associated with the subject, wherein after the administering levels of LDL-C, Apo B, VLDL-C and Lp-PLA2 associated with the subject are lower than the baseline fasting levels compared to a second subject who has received statin therapy but not the ethyl eicosapentaenoate.
  • 11. The method of claim 10, wherein the subject receives about 2 grams of ethyl eicosapentaenoate per day.
  • 12. The method of claim 10, wherein the subject receives about 4 grams of ethyl eicosapentaenoate per day.
  • 13. The method of claim 2, wherein the subject has a baseline fasting LDL-C level of about 82 mg/dl.
  • 14. The method of claim 8, wherein the subject has a baseline fasting VLDL-C level of about 225 mg/dl or about 233 mg/dl.
  • 15. The method of claim 9, wherein the subject has a baseline fasting Lp-PLA2 level of about 217 mg/dl or about 224 mg/dl.
  • 16. The method of claim 10, wherein the subject has: a baseline fasting LDL-C level of about 82 mg/dl;a baseline fasting Apo B level of about 217 mg/dl or about 227 mg/dl;a baseline fasting VLDL-C level of about 225 mg/dl or about 233 mg/dl; anda baseline fasting Lp-PLA2 level of about 217 mg/dl or about 224 mg/dl.
  • 17. The method of claim 1, wherein the subject is administered about 4 grams per day of ethyl eicosapentaenoate, and wherein a hsCRP level associated with the subject after the administering is lower than the baseline hsCRP level compared to a second subject who has received statin therapy but not the ethyl eicosapentaenoate.
PRIORITY CLAIM

This application is a continuation of U.S. patent application Ser. No. 16/384,230 filed Apr. 15, 2019, which is a continuation of U.S. patent application Ser. No. 15/411,500 filed Jan. 20, 2017 (now U.S. Pat. No. 10,292,959), which is a continuation of U.S. patent application Ser. No. 14/496,429 filed Sep. 25, 2014 (now U.S. Pat. No. 9,585,859), which claims priority to U.S. Provisional Patent Application Ser. No. 61/889,315, filed Oct. 10, 2013, the entire contents of each of which are incorporated herein by reference and relied upon.

US Referenced Citations (525)
Number Name Date Kind
4377526 Fujita et al. Mar 1983 A
4526902 Rubin Jul 1985 A
4920098 Cotter et al. Apr 1990 A
4935243 Borkan et al. Jun 1990 A
5013443 Higashidate et al. May 1991 A
5116871 Horrobin et al. May 1992 A
5178873 Horrobin et al. Jan 1993 A
5198468 Horrobin Mar 1993 A
5215630 Hata et al. Jun 1993 A
5252333 Horrobin Oct 1993 A
5343389 Otvos Aug 1994 A
5385929 Bjorge et al. Jan 1995 A
5457130 Tisdale et al. Oct 1995 A
5502077 Breivik et al. Mar 1996 A
5567730 Miyashita et al. Oct 1996 A
5589508 Schlotzer et al. Dec 1996 A
5603959 Horrobin et al. Feb 1997 A
5604119 Haraldsson et al. Feb 1997 A
5618558 Horrobin et al. Apr 1997 A
5656667 Breivik et al. Aug 1997 A
5698594 Breivik et al. Dec 1997 A
5760081 Leaf et al. Jun 1998 A
5763496 Holland Jun 1998 A
5776978 Bruzzese Jul 1998 A
5792795 Buser et al. Aug 1998 A
5837731 Vaddadi Nov 1998 A
5840944 Furihata et al. Nov 1998 A
5886037 Klor et al. Mar 1999 A
5888541 Horrobin et al. Mar 1999 A
5948818 Buser et al. Sep 1999 A
6011049 Whitcomb Jan 2000 A
6025008 Akahoshi Feb 2000 A
6069168 Horrobin et al. May 2000 A
6193999 Gennadios Feb 2001 B1
6207699 Rothman Mar 2001 B1
6284268 Mishra et al. Sep 2001 B1
6313330 Kiyohara et al. Nov 2001 B1
6326031 Hsia et al. Dec 2001 B1
6326355 Abbruzzese et al. Dec 2001 B1
6331568 Horrobin Dec 2001 B1
6362236 Aviram Mar 2002 B1
6368621 Engel et al. Apr 2002 B1
6383482 Gorsek May 2002 B1
6384077 Peet et al. May 2002 B1
6440961 Lohray et al. Aug 2002 B1
6479544 Horrobin Nov 2002 B1
6482421 Weidner Nov 2002 B2
6531150 Sunohara et al. Mar 2003 B1
6555700 Horrobin et al. Apr 2003 B1
6596766 Igarashi et al. Jul 2003 B1
6620821 Robl Sep 2003 B2
6689812 Peet Feb 2004 B2
6846942 Rubin Jan 2005 B2
7022713 Aoki et al. Apr 2006 B2
7112609 Hermelin et al. Sep 2006 B2
7119118 Peet Oct 2006 B2
7179491 Mag Feb 2007 B1
7205329 Chien et al. Apr 2007 B2
7405302 Hutchinson et al. Jul 2008 B2
7498359 Yokoyama et al. Mar 2009 B2
7511131 Crooke et al. Mar 2009 B2
7598227 Crooke et al. Oct 2009 B2
7642287 Guzman Jan 2010 B2
7776881 Aoki et al. Aug 2010 B2
8188146 Peet et al. May 2012 B2
8293727 Manku et al. Oct 2012 B2
8293728 Manku et al. Oct 2012 B2
8298554 Manku Oct 2012 B2
8314086 Manku et al. Nov 2012 B2
8318715 Manku et al. Nov 2012 B2
8324195 Manku et al. Dec 2012 B2
8357677 Manku et al. Jan 2013 B1
8367652 Manku et al. Feb 2013 B2
8377920 Manku et al. Feb 2013 B2
8410086 Osterloh et al. Apr 2013 B2
8431560 Manku et al. Apr 2013 B1
8440650 Manku et al. May 2013 B1
8455472 Osterloh et al. Jun 2013 B2
8518929 Manku et al. Aug 2013 B2
8524698 Manku et al. Sep 2013 B2
8546372 Manku et al. Oct 2013 B2
8551521 Manku et al. Oct 2013 B2
8563608 Manku et al. Oct 2013 B2
8617593 Manku et al. Dec 2013 B2
8617594 Manku et al. Dec 2013 B2
8618168 Fujii et al. Dec 2013 B2
8623406 Manku et al. Jan 2014 B2
8642077 Manku et al. Feb 2014 B2
8660662 Manku et al. Mar 2014 B2
8669245 Osterloh et al. Mar 2014 B2
8680144 Osterloh et al. Mar 2014 B2
8691871 Osterloh et al. Apr 2014 B2
8703185 Manku et al. Apr 2014 B2
8709475 Manku et al. Apr 2014 B2
8802718 Yokoyama et al. Aug 2014 B2
8853256 Yokoyama et al. Oct 2014 B2
8906964 Bobotas et al. Dec 2014 B2
9006285 Ohnishi Apr 2015 B2
9060981 Sato et al. Jun 2015 B2
9138415 Manku et al. Sep 2015 B2
9452121 Manku et al. Sep 2016 B2
9452150 Ueshima et al. Sep 2016 B2
9585859 Osterloh Mar 2017 B2
9603826 Soni Mar 2017 B2
9610272 Soni Apr 2017 B2
9623001 Soni Apr 2017 B2
9693984 Soni Jul 2017 B2
9693985 Soni Jul 2017 B2
9693986 Soni Jul 2017 B2
9700537 Yokoyama et al. Jul 2017 B2
9855237 Osterloh et al. Jan 2018 B2
9918954 Soni Mar 2018 B2
10058521 Bobotas et al. Aug 2018 B2
10166209 Manku et al. Jan 2019 B2
10220013 Osterloh et al. Mar 2019 B2
10265290 Manku et al. Apr 2019 B2
10278935 Soni May 2019 B2
10292959 Osterloh May 2019 B2
10441593 Loumaye et al. Oct 2019 B2
10555925 Soni Feb 2020 B1
10557856 Singbartl et al. Feb 2020 B2
10568861 Soni Feb 2020 B1
10576054 Soni Mar 2020 B1
10722485 Osterloh Jul 2020 B2
20010035125 Talieh et al. Nov 2001 A1
20020016312 Seed et al. Feb 2002 A1
20020025983 Horrobin Feb 2002 A1
20020035125 Shear Mar 2002 A1
20020052394 Mason May 2002 A1
20020054871 Huang May 2002 A1
20020055529 Bisgaier et al. May 2002 A1
20020055539 Bockow et al. May 2002 A1
20020077361 Peet et al. Jun 2002 A1
20020137082 Lewandrowski et al. Sep 2002 A1
20020169209 Horrobin Nov 2002 A1
20020177602 Piper Nov 2002 A1
20020183389 Peet Dec 2002 A1
20020193439 Peet et al. Dec 2002 A1
20020198177 Horrobin et al. Dec 2002 A1
20030100610 Shibuya May 2003 A1
20030104048 Patel et al. Jun 2003 A1
20030161918 Kendrick et al. Aug 2003 A1
20030166614 Harrison Sep 2003 A1
20030232385 Breit et al. Dec 2003 A1
20040009208 Edson Jan 2004 A1
20040018248 Bendich Jan 2004 A1
20040048919 Dreon et al. Mar 2004 A1
20040062847 Koiki et al. Apr 2004 A1
20040077723 Granata Apr 2004 A1
20040106591 Pacioretty et al. Jun 2004 A1
20040121000 Bowe et al. Jun 2004 A1
20040162348 Peet et al. Aug 2004 A1
20040204356 Guenzler-Pukall Oct 2004 A1
20040258645 Trejo et al. Dec 2004 A1
20050042214 Gershwin et al. Feb 2005 A1
20050137253 Phinney et al. Jun 2005 A1
20050147665 Horrobin et al. Jul 2005 A1
20050187292 Aoki et al. Aug 2005 A1
20050215625 Nesselroad Sep 2005 A9
20050244367 Hui et al. Nov 2005 A1
20050272095 Wang Dec 2005 A1
20060034815 Guzman et al. Feb 2006 A1
20060051418 Cowen et al. Mar 2006 A1
20060088502 Sata et al. Apr 2006 A1
20060111437 Aoki et al. May 2006 A1
20060134178 Doisaki et al. Jun 2006 A1
20060134206 Iyer et al. Jun 2006 A1
20060135607 Kobayashi et al. Jun 2006 A1
20060135610 Bortz et al. Jun 2006 A1
20060141022 Kawamura et al. Jun 2006 A1
20060142390 Manku et al. Jun 2006 A1
20060172012 Finley et al. Aug 2006 A1
20060189682 Payne et al. Aug 2006 A1
20060211749 Bobotas et al. Sep 2006 A1
20060211761 Kumar et al. Sep 2006 A1
20060211762 Rongen Sep 2006 A1
20060211763 Fawzy et al. Sep 2006 A1
20060217356 Wright et al. Sep 2006 A1
20060223838 Jiang et al. Oct 2006 A1
20060252833 Peet et al. Nov 2006 A1
20070021504 Yokoyama et al. Jan 2007 A1
20070060532 Junien et al. Mar 2007 A1
20070098787 Kakiuchi May 2007 A1
20070104779 Rongen et al. May 2007 A1
20070105793 Hendrix May 2007 A1
20070105954 Puri May 2007 A1
20070141138 Feuerstein et al. Jun 2007 A1
20070167520 Bruzzese Jul 2007 A1
20070185198 Yokoyama et al. Aug 2007 A1
20070191467 Rongen et al. Aug 2007 A1
20070202159 Mathur et al. Aug 2007 A1
20070212411 Fawzy et al. Sep 2007 A1
20070219271 Mittmann et al. Sep 2007 A1
20070265340 Shalwitz et al. Nov 2007 A1
20070269507 Sachetto et al. Nov 2007 A1
20070292501 Udell Dec 2007 A1
20080020018 Moodley et al. Jan 2008 A1
20080057115 Okamoto Mar 2008 A1
20080085911 Rongen et al. Apr 2008 A1
20080089876 Cavazza Apr 2008 A1
20080113046 Gardette May 2008 A1
20080125490 Svensson et al. May 2008 A1
20080139604 Fitzpatrick et al. Jun 2008 A1
20080185198 Jones Aug 2008 A1
20080200453 Cincotta Aug 2008 A1
20080200547 Peet et al. Aug 2008 A1
20080200707 Shimano et al. Aug 2008 A1
20080214531 Saxena et al. Sep 2008 A1
20080299187 Opheim et al. Dec 2008 A1
20080306154 Svensson et al. Dec 2008 A1
20080319077 Suzuki et al. Dec 2008 A1
20090012167 Rongen et al. Jan 2009 A1
20090018125 Mittmann et al. Jan 2009 A1
20090042979 Guzman et al. Feb 2009 A1
20090054329 Willemsen et al. Feb 2009 A1
20090105340 Yokoyama Apr 2009 A1
20090148543 Theoharides Jun 2009 A1
20090156675 Yokoyama et al. Jun 2009 A1
20090182049 Opheim Jul 2009 A1
20090227602 Griffin et al. Sep 2009 A1
20090233843 Marin Sep 2009 A1
20090239927 Bobotas et al. Sep 2009 A1
20090304784 Mane et al. Dec 2009 A1
20090311322 Dlugatch et al. Dec 2009 A1
20100021555 Geiringer et al. Jan 2010 A1
20100063018 Pellicciari et al. Mar 2010 A1
20100069492 Geiringen et al. Mar 2010 A1
20100113506 Kawano et al. May 2010 A1
20100113811 Yadav et al. May 2010 A1
20100119598 Yoshinari et al. May 2010 A1
20100130608 Ryan et al. May 2010 A1
20100160261 Fortin Jun 2010 A1
20100233280 Driscoll Sep 2010 A1
20100254951 Shido et al. Oct 2010 A1
20100278879 Manku Nov 2010 A1
20100285121 Uchiyama et al. Nov 2010 A1
20100298379 Jacobsen Nov 2010 A1
20100305205 Yokoyama et al. Dec 2010 A1
20100311834 Manku et al. Dec 2010 A1
20110034555 Osterloh et al. Feb 2011 A1
20110065793 Peet et al. Mar 2011 A1
20110071176 Rowe Mar 2011 A1
20110082119 Yano Apr 2011 A1
20110092592 Yano Apr 2011 A1
20110105510 Ishikawa May 2011 A1
20110130458 Breivik et al. Jun 2011 A1
20110178105 Gillies et al. Jul 2011 A1
20110195061 Minatelli Aug 2011 A1
20110218243 Rowe Sep 2011 A1
20110223158 Sacks et al. Sep 2011 A1
20110236476 Manku Sep 2011 A1
20110268811 Minatelli et al. Nov 2011 A1
20110288171 Manku et al. Nov 2011 A1
20120035105 Geho et al. Feb 2012 A1
20120035262 Osterloh et al. Feb 2012 A1
20120039997 Manku et al. Feb 2012 A1
20120046251 Schaefer et al. Feb 2012 A1
20120093922 Manku et al. Apr 2012 A1
20120093924 Manku et al. Apr 2012 A1
20120100208 Manku Apr 2012 A1
20120108659 Manku et al. May 2012 A1
20120108660 Manku et al. May 2012 A1
20120108663 Manku et al. May 2012 A1
20120121698 Manku et al. May 2012 A1
20120156285 Manku et al. Jun 2012 A1
20120157530 Manku et al. Jun 2012 A1
20120157531 Osterloh et al. Jun 2012 A1
20120172432 Manku et al. Jul 2012 A1
20120184595 Macdonald et al. Jul 2012 A1
20120195963 Peet et al. Aug 2012 A1
20120207800 Abu-Baker Aug 2012 A1
20120214771 Sampalis Aug 2012 A1
20120225120 Manku et al. Sep 2012 A1
20120232145 Osterloh et al. Sep 2012 A1
20120237594 Manku et al. Sep 2012 A1
20120245121 Lopez Pedrosa et al. Sep 2012 A1
20120264824 Mizuguchi et al. Oct 2012 A1
20120295976 Yokoyama Nov 2012 A1
20120302589 Manku et al. Nov 2012 A1
20120329852 Yokoyama Dec 2012 A1
20130004566 Manku et al. Jan 2013 A1
20130004567 Manku et al. Jan 2013 A1
20130004568 Manku et al. Jan 2013 A1
20130004572 Manku et al. Jan 2013 A1
20130005757 Osterloh et al. Jan 2013 A1
20130005809 Manku et al. Jan 2013 A1
20130011471 Manku et al. Jan 2013 A1
20130011472 Manku et al. Jan 2013 A1
20130012580 Osterloh et al. Jan 2013 A1
20130017256 Manku et al. Jan 2013 A1
20130065956 Yokoyama Mar 2013 A1
20130079409 Manku et al. Mar 2013 A1
20130090383 Manku et al. Apr 2013 A1
20130095178 Manku Apr 2013 A1
20130095179 Davidson et al. Apr 2013 A1
20130096197 Manku Apr 2013 A1
20130102674 Manku Apr 2013 A1
20130115284 Fujii et al. May 2013 A1
20130131170 Manku May 2013 A1
20130156852 Manku et al. Jun 2013 A1
20130158120 Manku et al. Jun 2013 A1
20130164375 Manku et al. Jun 2013 A1
20130165513 Manku et al. Jun 2013 A1
20130171249 Manku et al. Jul 2013 A1
20130171250 Manku et al. Jul 2013 A1
20130171251 Manku et al. Jul 2013 A1
20130172413 Manku Jul 2013 A1
20130189355 Manku et al. Jul 2013 A1
20130195972 Manku et al. Aug 2013 A1
20130252989 Manku et al. Sep 2013 A1
20130252990 Manku et al. Sep 2013 A1
20130253030 Osterloh et al. Sep 2013 A1
20130253031 Osterloh et al. Sep 2013 A1
20130260403 Button et al. Oct 2013 A1
20130261180 Gillies et al. Oct 2013 A1
20130281534 Osterloh et al. Oct 2013 A1
20130295173 Machielse et al. Nov 2013 A1
20130303614 Kanehiro et al. Nov 2013 A1
20130324607 Mason Dec 2013 A1
20130331447 Manku et al. Dec 2013 A1
20140004183 Soni et al. Jan 2014 A1
20140005264 Soni et al. Jan 2014 A1
20140005265 Soni et al. Jan 2014 A1
20140017306 Manku Jan 2014 A1
20140057981 Fujii Feb 2014 A1
20140073692 Peet Mar 2014 A1
20140080850 Mason Mar 2014 A1
20140080909 Manku Mar 2014 A1
20140088194 Manku Mar 2014 A1
20140094520 Bobotas et al. Apr 2014 A1
20140107199 Fawzy et al. Apr 2014 A1
20140127289 Osterloh et al. May 2014 A1
20140128453 Mullick et al. May 2014 A1
20140128464 Rowe May 2014 A1
20140142127 Almarsson May 2014 A1
20140154310 Osterloh et al. Jun 2014 A1
20140155455 Osterloh et al. Jun 2014 A1
20140155481 Osterloh et al. Jun 2014 A1
20140186438 Manku et al. Jul 2014 A1
20140187633 Manku et al. Jul 2014 A1
20140213648 Manku et al. Jul 2014 A1
20140221358 Zakrzewski Aug 2014 A1
20140221452 Zakrzewski Aug 2014 A1
20140221486 Manku et al. Aug 2014 A1
20140221676 Braeckman et al. Aug 2014 A1
20140234410 Moodley et al. Aug 2014 A1
20140235716 Manku et al. Aug 2014 A1
20140243389 Zakrzewski Aug 2014 A1
20140249200 Braeckman et al. Sep 2014 A1
20140249214 Braeckman et al. Sep 2014 A1
20140249220 Braeckman et al. Sep 2014 A1
20140249225 Mason Sep 2014 A1
20140256809 Zakrzewski Sep 2014 A1
20140271841 Grandolfi Sep 2014 A1
20140271907 Zakrzewski Sep 2014 A1
20140275252 Zakrzewski Sep 2014 A1
20140275253 Zakrzewski Sep 2014 A1
20140322314 Fawzy et al. Oct 2014 A1
20140357717 Braeckman et al. Dec 2014 A1
20140364459 Zakrzewski Dec 2014 A1
20150045431 Zakrzewski Feb 2015 A1
20150051143 Harada et al. Feb 2015 A1
20150051282 Zakrzewski Feb 2015 A1
20150065572 Zakrzewski Mar 2015 A1
20150073050 Zakrzewski Mar 2015 A1
20150141510 Kiyohara et al. May 2015 A1
20150157592 Soni Jun 2015 A1
20150157593 Braeckman et al. Jun 2015 A1
20150164850 Osterloh et al. Jun 2015 A1
20150190361 Osterloh et al. Jul 2015 A1
20150216831 Manku et al. Aug 2015 A1
20150250754 Ohta Sep 2015 A1
20150250756 Mason Sep 2015 A1
20150250757 Soni Sep 2015 A1
20150258051 Manku et al. Sep 2015 A1
20150265566 Osterloh et al. Sep 2015 A1
20150265574 Rowe Sep 2015 A1
20150272917 Manku et al. Oct 2015 A1
20150283074 Fujii Oct 2015 A1
20150290154 Roberts et al. Oct 2015 A1
20150335607 Rowe Nov 2015 A1
20150359775 Osterloh et al. Dec 2015 A1
20160045444 Kim et al. Feb 2016 A1
20160058729 Manku et al. Mar 2016 A1
20160120837 Manku et al. May 2016 A1
20160143875 Zakrzewski May 2016 A1
20160151319 Kimura Jun 2016 A1
20160158184 Ito Jun 2016 A1
20160213636 Manku et al. Jul 2016 A1
20160213639 Suzuki et al. Jul 2016 A1
20160220522 Osterloh et al. Aug 2016 A1
20160287546 Osterloh et al. Oct 2016 A1
20170014366 Osterloh et al. Jan 2017 A1
20170035722 Soni Feb 2017 A1
20170056361 Soni Mar 2017 A1
20170079946 Ohta Mar 2017 A1
20170087111 Mason Mar 2017 A1
20170100363 Zakrzewski Apr 2017 A9
20170119721 Zakrzewski May 2017 A1
20170119722 Manku et al. May 2017 A1
20170119723 Soni May 2017 A1
20170119724 Fujii May 2017 A1
20170128402 Manku et al. May 2017 A1
20170128405 Osterloh et al. May 2017 A1
20170128406 Rowe May 2017 A1
20170136055 Zakrzewski May 2017 A1
20170143656 Soni May 2017 A1
20170143657 Braeckman et al. May 2017 A1
20170143658 Soni May 2017 A1
20170151202 Mason Jun 2017 A1
20170151206 Yokoyama Jun 2017 A1
20170217943 Lairson Aug 2017 A1
20170258753 Soni Sep 2017 A1
20170258754 Soni Sep 2017 A1
20170258755 Soni Sep 2017 A1
20170273928 Yokoyama Sep 2017 A1
20170304249 Abu-Baker Oct 2017 A1
20170333377 Mason Nov 2017 A1
20170348268 Kimura Dec 2017 A1
20170348273 Ito Dec 2017 A1
20170368184 Ito Dec 2017 A1
20180015038 Ito Jan 2018 A1
20180015071 Braeckman et al. Jan 2018 A1
20180028480 Mason Feb 2018 A1
20180028505 Oshima Feb 2018 A1
20180042880 Osterloh et al. Feb 2018 A1
20180042883 Manku et al. Feb 2018 A1
20180064676 Zakrzewski Mar 2018 A1
20180085334 Soni Mar 2018 A1
20180153846 Soni Jun 2018 A1
20180185320 Manku et al. Jul 2018 A1
20180280334 Manku Oct 2018 A1
20180289657 Soni Oct 2018 A1
20180289658 Soni Oct 2018 A1
20180289659 Soni Oct 2018 A1
20180333383 Philip Nov 2018 A1
20190038590 Manku Feb 2019 A1
20190054054 Mason Feb 2019 A1
20190054058 Thero Feb 2019 A1
20190060308 Mason Feb 2019 A1
20190070141 Osterloh Mar 2019 A1
20190076388 Soni Mar 2019 A1
20190076389 Soni Mar 2019 A1
20190076390 Manku Mar 2019 A1
20190083444 Manku Mar 2019 A1
20190083445 Soni Mar 2019 A1
20190099422 Grandolfi Apr 2019 A1
20190175535 Mason Jun 2019 A1
20190175537 Osterloh Jun 2019 A1
20190175538 Osterloh Jun 2019 A1
20190183829 Osterloh Jun 2019 A1
20190183831 Osterloh Jun 2019 A1
20190183840 Braeckman Jun 2019 A1
20190192472 Soni Jun 2019 A1
20190201364 Manku Jul 2019 A1
20190209506 Mason Jul 2019 A1
20190240182 Osterloh Aug 2019 A1
20190240183 Manku Aug 2019 A1
20190269642 Philip Sep 2019 A1
20190274991 Osterloh Sep 2019 A1
20190275057 Philip Sep 2019 A1
20190282533 Osterloh Sep 2019 A1
20190316122 Zakrzewski Oct 2019 A1
20190321323 Soni Oct 2019 A1
20190343788 Soni Nov 2019 A1
20190358185 Mason Nov 2019 A1
20200000759 Manku Jan 2020 A1
20200061011 Mason Feb 2020 A1
20200061012 Manku et al. Feb 2020 A1
20200069632 Soni Mar 2020 A1
20200078329 Soni Mar 2020 A1
20200093777 Soni Mar 2020 A1
20200093778 Soni Mar 2020 A1
20200093790 Rowe Mar 2020 A1
20200108041 Braeckman et al. Apr 2020 A1
20200113862 Manku et al. Apr 2020 A1
20200113864 Soni Apr 2020 A1
20200121628 Osterloh et al. Apr 2020 A1
20200121630 Osterloh et al. Apr 2020 A1
20200138768 Soni May 2020 A1
20200163925 Soni May 2020 A1
20200188343 Osterloh Jun 2020 A1
20200188344 Osterloh Jun 2020 A1
20200197350 Manku Jun 2020 A1
20200215017 Manku Jul 2020 A1
20200237699 Mason Jul 2020 A1
20200237700 Mason Jul 2020 A1
20200246300 Manku et al. Aug 2020 A1
20200261391 Soni Aug 2020 A1
20200268702 Braeckman et al. Aug 2020 A1
20200289450 Mason Sep 2020 A1
20200297681 Rowe Sep 2020 A1
20200297682 Osterloh Sep 2020 A1
20200297683 Manku Sep 2020 A1
20200316006 Manku Oct 2020 A1
20200338035 Soni Oct 2020 A1
20200360330 Rowe Nov 2020 A1
20200397735 Osterloh et al. Dec 2020 A1
20200405675 Manku et al. Dec 2020 A1
20200405677 Osterloh et al. Dec 2020 A1
20210000779 Osterloh et al. Jan 2021 A1
20210046036 Manku Feb 2021 A1
20210046037 Osterloh et al. Feb 2021 A1
20210069142 Manku et al. Mar 2021 A1
20210069145 Braeckman et al. Mar 2021 A1
20210085629 Mason Mar 2021 A1
20210100764 Osterloh et al. Apr 2021 A1
20210100765 Osterloh et al. Apr 2021 A1
20210100768 Soni Apr 2021 A1
20210108202 Zakrzewski Apr 2021 A1
20210113509 Osterloh et al. Apr 2021 A1
20210113510 Manku et al. Apr 2021 A1
20210113513 Osterloh et al. Apr 2021 A1
20210128582 Manku et al. May 2021 A1
20210137872 Philip May 2021 A1
20210137873 Soni May 2021 A1
20210137879 Soni May 2021 A1
20210144786 Zakrzewski May 2021 A1
20210145787 Manku et al. May 2021 A1
20210154164 Soni May 2021 A1
20210205255 Osterloh et al. Jul 2021 A1
20210206710 Osterloh et al. Jul 2021 A1
20210212974 Osterloh et al. Jul 2021 A1
20210212975 Manku et al. Jul 2021 A1
20210251941 Manku et al. Aug 2021 A1
Foreign Referenced Citations (148)
Number Date Country
2628305 May 2007 CA
2653787 Dec 2007 CA
2675836 Jul 2008 CA
2724983 Nov 2009 CA
2772378 Dec 2010 CA
101252837 Aug 2008 CN
0273708 Jul 1988 EP
0277747 Aug 1988 EP
0302482 Feb 1989 EP
0347509 Dec 1989 EP
0460917 Dec 1991 EP
0606012 Jul 1994 EP
0610506 Aug 1994 EP
0641562 Mar 1995 EP
0843972 May 1998 EP
1125914 Aug 2001 EP
1157692 Nov 2001 EP
1296670 Apr 2003 EP
1549299 Dec 2003 EP
1743644 Jan 2007 EP
1782801 May 2007 EP
1790339 May 2007 EP
1834639 Sep 2007 EP
1946755 Jul 2008 EP
1982710 Oct 2008 EP
2022495 Feb 2009 EP
2395991 Aug 2010 EP
2308493 Apr 2011 EP
2343066 Jul 2011 EP
2433630 Mar 2012 EP
2719382 Apr 2014 EP
2792746 Oct 2014 EP
2635263 Feb 1990 FR
2148713 Jun 1985 GB
2221843 Feb 1990 GB
2229363 Sep 1990 GB
9901809.5 Jan 1999 GB
2480146 Nov 2011 GB
55227 Dec 1982 IL
61035356 Feb 1986 JP
04182426 Jun 1992 JP
H0692847 Apr 1994 JP
08040981 Feb 1996 JP
09059206 Mar 1997 JP
H10139662 May 1998 JP
2001139981 May 2001 JP
2003306690 Oct 2003 JP
2007238598 Sep 2007 JP
2008050367 Mar 2008 JP
10-2006-0109988 Oct 2006 KR
10-2007-0058460 Jun 2007 KR
2281764 Aug 2006 RU
2290185 Dec 2006 RU
2302248 Jul 2007 RU
2402326 Oct 2010 RU
WO1990004391 May 1990 WO
WO1992021335 Dec 1992 WO
WO1994010125 May 1994 WO
WO1994028891 Dec 1994 WO
WO1995024459 Sep 1995 WO
WO1996036329 Nov 1996 WO
WO1997039759 Oct 1997 WO
WO1998016216 Apr 1998 WO
WO1999026583 Jun 1999 WO
WO1999029316 Jun 1999 WO
WO2000044361 Aug 2000 WO
WO2000051573 Sep 2000 WO
WO2001015552 Mar 2001 WO
WO2002002105 Jan 2002 WO
WO2002058793 Aug 2002 WO
WO2002089787 Nov 2002 WO
WO2002096408 Dec 2002 WO
WO2003068216 Aug 2003 WO
WO2003092673 Nov 2003 WO
WO2004050913 Jun 2004 WO
WO2004064716 Aug 2004 WO
WO2004078166 Sep 2004 WO
WO2004082402 Sep 2004 WO
WO2005060954 Jul 2005 WO
WO2005065652 Jul 2005 WO
WO2005079797 Sep 2005 WO
WO2005079853 Sep 2005 WO
WO2005102301 Nov 2005 WO
WO2005123060 Dec 2005 WO
WO2005123061 Dec 2005 WO
WO2006017627 Feb 2006 WO
WO2006029577 Mar 2006 WO
WO2006062748 Jun 2006 WO
WO2006096806 Sep 2006 WO
WO2007011886 Jan 2007 WO
WO2007016256 Feb 2007 WO
WO2007017240 Feb 2007 WO
WO2007073176 Jun 2007 WO
WO2007075841 Jul 2007 WO
WO2007091338 Aug 2007 WO
WO2007103557 Sep 2007 WO
WO2007128801 Nov 2007 WO
WO2007142118 Dec 2007 WO
WO2008004900 Jan 2008 WO
WO2008045465 Apr 2008 WO
WO2008088415 Jul 2008 WO
WO2008106787 Sep 2008 WO
WO2008115529 Sep 2008 WO
WO2008145170 Dec 2008 WO
WO2009004999 Jan 2009 WO
WO2009085386 Jul 2009 WO
WO2009085388 Jul 2009 WO
WO2010028067 Mar 2010 WO
WO2010093634 Aug 2010 WO
WO2010103402 Sep 2010 WO
WO2010119319 Oct 2010 WO
WO2010127099 Nov 2010 WO
WO2010127103 Nov 2010 WO
WO2010134614 Nov 2010 WO
WO2010147994 Dec 2010 WO
WO2011028689 Mar 2011 WO
WO2011038122 Mar 2011 WO
WO2011047259 Apr 2011 WO
WO2011085211 Jul 2011 WO
WO2011109724 Sep 2011 WO
WO2012032414 Mar 2012 WO
WO2012074930 Jun 2012 WO
WO2012128587 Sep 2012 WO
WO2013070735 May 2013 WO
WO2013103958 Jul 2013 WO
WO2013136277 Sep 2013 WO
WO2013148136 Oct 2013 WO
WO2014004861 Jan 2014 WO
WO2014004993 Jan 2014 WO
WO2014005013 Jan 2014 WO
WO2014057522 Apr 2014 WO
WO2014074552 May 2014 WO
WO2014130200 Aug 2014 WO
WO2014134466 Sep 2014 WO
WO2014142364 Sep 2014 WO
WO2014143469 Sep 2014 WO
WO2014143523 Sep 2014 WO
WO2014205310 Dec 2014 WO
WO2015021141 Feb 2015 WO
WO2015066512 May 2015 WO
WO2015195662 Dec 2015 WO
WO2016140949 Sep 2016 WO
WO2018213663 Nov 2018 WO
WO2020037153 Feb 2020 WO
WO2020065402 Apr 2020 WO
WO2020068163 Apr 2020 WO
WO2020168251 Aug 2020 WO
WO2021097120 May 2021 WO
Non-Patent Literature Citations (1113)
Entry
A study of AMR101 to evaluate its ability to reduce cardiovascular events in high risk patients with hypertriglyceridemia and on statin (REDUCE-IT). Available at: http://clinicaltrials.gov/show/NCT01492361. (3 pages).
Aarsetoey H, Gurndt H, Nygaard O. The Role of Long-Chained Marine N-3 Polyunsaturated Fatty Acids in Cardiovascular Disease. Cardiol Res Pract. 2012. Epub Dec. 13, 2012.
Aarsland, et al., “On the Effect of Peroximsomal beta-Oxidation and Carnitine Palmitoyltransferase Activity by Eicosapentaenoic Aid in Live and Heart of Rats.” Lipids, 25:546-548, (Sep. 1990).
Aas, V., et al., “Eicosapentaenoic acid (20:5 n-3) increases fatty acid and glucose uptake in cultured human skeletal muscle cells.” Journal of Lipid Research, 47:366-374 (Feb. 2006).
Abbey, M., et al., “Effect of fish oil on lipoproteins, lecithin:cholesterol acyltransferase, and lipidtransfer protein activity in humans.” Arterioscler. Thromb. Vasc. Biol. 10:85-94 (Jan./Feb. 1990).
Abela GS, Aziz K. “Cholesterol crystals cause mechanical damage to biological membranes: a proposed mechanism of plaque rupture and erosion leading to arterial thrombosis.” Clin. Cardiol. (Sep. 2005);28(9):413-420.
Abelo A, Andersson TB, Antonsson M, et al. “Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes.” Drug Metab. Dispos. Aug. 28, 2000 (8): 966-72.
Ackman et al., “The ‘Basic’ Fatty Acid Composition of Atlantic Fish Oils: Potential Similarties Useful for Enrichment of Polyunsaturated Fatty Acids by Urea Complexation,” JAOCS, vol. 65, 1:136-138 (Jan. 1988).
Adan, Y, et al., “Effects of docosahexaenoic and eicosapentaenoic acid on lipid metabolism, eicosanoid production, platelet aggregation and atherosclerosis.” Biosci. Biotechnol. Biochem. 63(1), 111-119 (Jan. 1999).
Adan, Y., et al., “Concentration of serum lipids and aortic lesion size in female and male apo E-deficient mice fed docosahexaenoic acid.” Biosci. Biotechnol. Biochem. 63(2):309-313 (Feb. 1999).
Adorini et al., “Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis,” Drug Discover Today, 14(17-18):988-997 (Sep. 2012)(available online May 28, 2012).
Agren JJ, Vaisanen S, Hanninen O, et al. “Hemostatic factors and platelet aggregation after a fish-enriched diet or fish oil or docosahexaenoic acid supplementation.” Prostaglandins Leukot Essent Fatty Acids (Oct. 1997) 57 (4-5): 419-21.
Agren, J.J., et al., “Fatty acid composition of erythrocyte, platelet, and serum lipids in strict vegans.” Lipids 30:365-369 (Apr. 1995).
Agren, J.J., et al., “Fish diet, fish oil and docosahexaenoic acid rich oil lower fasting and postprandial plasma lipid levels.” Eur J Clin Nutr., 50:765-771. (Nov. 1996).
Aguilar-Salinas et al., “High Prevalence of Low HDL Cholesterol Concentrations and Mixed Hyperlipidemia in a Mexican Nationwide Survey,” J Lipid Res., (Aug. 2001), 42:1298-1307.
Ai M, Otokozawa S, Asztalos BF, Ito Y, Nakajima K, White CC, Cuppies LA, Wilson PW, Schaefer EJ. “Small dense LDL cholesterol and coronary heart disease: results from the Framingham Offspring Study.” Clin. Chem. (Jun. 2010);56(6):967-976.
Ait-Said, et al., “Inhibition by eicosapentaenoic acid of IL-1β-induced PGHS-2 expression in human microvascular endothelial cells: involvement of lipoxygenase-derived metabolites and p38 MAPK pathway.” Biohimicia et Biophysica Acta, 1631:66-85 (Feb. 2003).
Albert CM, Campos H, Stampfer MJ, et al. Blood Levels of Long-Chain n-3 Fatty Acids and the Risk of Sudden Death. N Engl J Med 346(15):1113-1138, Apr. 2002.
Alberti K, et. al. Harmonizing the Metabolic Syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 120:1640-1645; Oct. 20, 2009.
Alderman, J.D., et al., “Effect of a modified, well-tolerated niacin regimen on serum total cholesterol, high density lipoprotein cholesterol and the cholesterol to high density lipoprotein ratio,” Am. J. Cardio, 64: 725-729.A (Oct. 1989).
Alessandri, J-M., et al., “Estradiol favors the formation of eicosapentaenoic acid (20:5n-3) and n-3 docosapentaenoic acid (22:5n-3) from alpha-linolenic acid (18:3n-3) in SH-SY5Y neuroblastoma cells.” Lipids 43:19-28 (Jan. 2008).
Allard et al. “Nutritional assessment and hepatic fatty acid composition in non-alcoholic fatty liver disease (NAFLD): a cross-sectional study.” J Hepatol. Feb. 2008;48(2):300-7.
Allred, C., et al., “PPARγ1 as a molecular target of eicosapentaenoic acid in human colon cancer (HT-29) cells.” J. Nutr. 138:250-256 (Feb. 2008).
Almeida et al., “Effect of nebicapone on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.” Eur J Clin Pharmacol. (Oct. 2008);64(10):961-6.
Amarin Appoints Medpace as CRO for Two Phase 3 Cardiovascular Trials, published Oct. 19, 2009 (2 pages).
Amarin Corporation Announces First Patients Enrolled in Two Phase 3 Clinical Trials Assessing AMR101 for the Treatment of Cardiovascular Disease [online], Amarin Corporation, Jan. 11, 2010 [retrieved Apr. 27, 2011], Retrieved from Internet: <http://inestor.amarincorp.com/releasedetail.cfm?ReleaseID=504380> (2 pages).
Amarin Corporation, Annual Report, Jun. 24, 2010,submitted in 3 parts: Part I: Cover and pp. 1-39 (81 pages); Part II: pp. 40 through F-10 (81 pages); Part III: pp. F11-F51 (83 pages)) (245 pages total).
Amarin Corporation, Executive Informational Overview, “Neurological Disease-Focused Biopharmaceutical Opportunity,” SEC filing dated Oct. 11, 2005 (99 pages).
Amarin Corporation, Globe Newswire press release, “Reduce-It™ Cardiovascular Outcomes Study of Vascepa® (icosapent ethyl) Capsules Met Primary Endpoint,” Sep. 24, 2018 (4 pages).
Amarin Corporation, press release (Jan. 18, 2008)(1 page).
Amarin Presentation “Next Generation Lipid Modification in Cardiovascular Disease,” (Aug. 2011)(27 pages).
Amarin Presentation “Next Generation Lipid Modification in Cardiovascular Disease,” (Mar. 2010)(25 pages).
Amarin Proceeding to Phase 3 with AMR101 for Hypertriglyceridemia, published Jul. 23, 2008 (1 page).
Amarin, Next Generation Lipid Modification in Cardiovascular Disease, Investor Meetings, Nov. 2010, (http://files.shareholder.com/downloads/AMRN/0x0x417754/AA72705F-1D67-4E1D-A989-5805E5CF0244/Investor_Presentation_2010_Nov_10.pdf, accessed Jan. 6, 2015.
Amarin's Vascepa® Briefing Document for the Endocrinologic and Metabolic Drugs Advisory Committee Meeting dated Oct. 16, 2013, (117 pages).
American Heart Association. Heart Disease and Stroke Statistics—2010 Update. Dallas, Texas: American Heart Association; 2010.
Anand RG, Alkadri M, Lavie CJ, Milani RV. The Role of Fish Oil in Arrhythmia Prevention. J Cardioplin Rehabil Preven., Mar./Apr. 2008; 28:92-98.
Anber V, Griffin BA, McConnell M, Packard CJ, Shepherd J. Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. Atherosclerosis. Aug. 1996;124(2):261-271.
Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction—executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 50:652-726, Aug. 14, 2007.
Anderson TJ, Gregoire J, Hegele RA, et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can. J. Cardiol. Feb. 2013;29:151-167.
Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N. Engl. J. Med. Feb. 1995;332:488-493.
Anderson, “Lipoprotein-Associated Phospholipase A2: An Independent Predictor of Coronary Artery Disease Events in Primary and Secondary Prevention,” 101 Am. J. Cardiology 23F-33F (Jun. 2008).
Ando, M., et al., “Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients.” J. Am. Soc. Nephrol., 10:2177-2184 (Oct. 1999).
Ando, Y., et al., “Positional distribution of highly unsaturated fatty acids in triacyl-sn-glycerols of Artemia Nauplii enriched with docosahexaenoic acid ethyl ester.” Lipids 36:733-740 (Jul. 2001).
Andrade, SE. et al., “Discontinuation of antihyperlipidaemicdrugs_ do rates reported in clinical trials reflect rates in primary care settings?” New Eng. J. Med. 332: 1125-1131. (Apr. 1995).
Andrews HE, Bruckdorfer KR, Dunn RC, Jacobs M. Low-density lipoproteins inhibit endotheliumdependent relaxation in rabbit aorta. Nature. May 1987;327:237-239.
Angerer et al., “n-3 Polyunsaturated Fatty Acids and the Cardiovascular System”, Current Opinion in Lipidology, 11(1):57-63, (Feb. 2000).
Anil, Eliz, “The Impact of EPA and DHA on Blood Lipids and Lipoprotein Metabolism: Influence of ApoE Genotype”, Proceedings of the Nutrition Society, 66:60-68, (Feb. 2007).
Annex to Rule 161 Response dated Apr. 16, 2012 (4 pages).
Antman E, Anbe D, Armstrong P, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction—executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). J Am Coll Cardiol 44:671-719, Aug. 4, 2004.
Aoki T et al. “Experience of the use of ethyl eicosapentaenoic acid preparation (Epadel) in patients with arteriosclerosis obliterans complicated with diabetes mellitus. A study of the long-term effects on glycemic control and blood lipids,” Rinsho to Kenkyu; 70:625-631. (1993) (with English translation).
Appendix A to Defendants' Invalidity Contentions, 3:14-CV-02550-MLC-DEA (D.N.J.), 478 pages (Dec. 5, 2014).
Appleton, Katherine M., et al., “Effects of n-3 long-chain polyunsaturated fatty acids on depressed mood: systematic review of published trials”, Am. J. Clin. Nutr., 84(6):1308-1316, (Dec. 2006).
Arca et al., “Treating statin-intolerant patients,” Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 4:155-156 (Apr. 28, 2011).
Armaganijan L, Lopes RD, Healey JS, Piccini JP, Nair GN, Morillo CA. Do Omega-3 fatty acids prevent atrial fibrillation after open heart surgery? A meta-analysis of randomized controlled trials. Clinics. 2011 (accepted for publication Jul. 19, 2011); 66(11):1923-1928.
Arrol, S. et al., “The effects of fatty acids on apolipoprotein B secretion by human hepatoma cells (HEP G2),” Atherosclerosis 150:255-264. (Jun. 2000).
Arshad, A., et al., “Sudden cardiac death and the role of medical therapy.” Progress in Cardiovascular Diseases, vol. 50, No. 6, 420-438, (May/Jun. 2008).
Arterburn, L., et al., “Distribution, interconversion, and dose response of n-3 fatty acids in humans.” Am J Clin Nutr., 83:1467S-76S (Jun. 2006).
Asahara, EPA Products What is the Clinical Significance of Epadel? Obesity and Diabetes 10(6):903-905 (2011) (with English translation).
Asano, M., et al., “Eicosapentaenoic acid inhibits vasopressin-activated Ca2q influx and cell proliferation in rat aortic smooth muscle cell lines.” European Journal of Pharmacology 379:199-209 (Aug. 1999).
Asano, M., et al., “Inhibitory effects of ω-3 polyunsaturated fatty acids on receptor-mediated non-selective cation currents in rat A7r5 vascular smooth muscle cells.” British Journal of Pharmacology 120:1367-1375, (Apr. 1997).
ASCEND Study Collaborative Group. Effects of n-3 fatty acid supplements in diabetes mellitus. N Engl J Med, 379(16):1540-1550 (publication date Oct. 18, 2018; epublication date Aug. 26, 2018).
Ascenta Health “Fish Oil as Triglycerides vs. Ethyl Esters: Why this Matters.” (2015)(14 pages).
Astarita et al., “Targeted lipidomics strategies for oxygenated metabolites of polyunsaturated fatty acids,” Biochim Biophys Acta, 1851(4):456-468 (Apr. 2015).
Atorvastatin Package Leaflet, Reg. No. LSR-005205/08, Sep. 30, 2016 [retrieved Sep. 30, 2016] retrieved from Internet: academ-clinic.ru/drugs/atorvastatin (6 pages).
ATP III guidelines, NIH publication No. 01-3305 (2001).(6 pages).
Attie AD, et al., “Relationship between stearoyl-CoA desaturase activity and plasma trigylcerides in human and mouse hypertriglyceridemia,” J. Lipid Res. 2002;43:1899-907.
Ault, “Prescription omega-3 fatty acid formulation approved,” OB.GYN.News, (Jan. 15, 2005).
Aung T, Halsey J, Kromhout D, et al. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: Meta-analysis of 10 trials involving 77917 individuals. JAMA Cardiol 3:225-34 (publication date Mar. 1, 2018; epublication date Jan. 31, 2018).
Avandia [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2011.(45 pages).
Avery et al., “Upper Gastrointestinal System,” Integrating Therapeutic and Complementary Nutrition, Edited by Mary Marian, CRC Press (2006)(14 pages).
Aviram M, Rosenblat M, Bisgaier CL, Newton RS. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis. Jun. 1998; 138(2):271-280.
Ayton, et al., “A pilot open case series of Ethyl-EPA supplementation in the treatment of anorexia nervosa,” Prostaglandins, Leukotrienes and Essential Fatty Acids 71, pp. 205-209. (Oct. 2004).
Ayton, et al., “Rapid improvement of severe anorexia nervosa during treatment with ethyl-eicosapentaenoate and micronutrients,” European Psychiatry 19, pp. 317-319. (Aug. 2004).
Baigent, C., et al., “Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.” Lancet; 366:1267-1278. (Oct. 2005).
Baldwin RM, Ohlsson S, Pedersen RS, et al. Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. Br. J. Clin. Pharmacol. May 2008 65 (5): 767-74.
Baldwin SJ, Clarke SE, Chenery RJ. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br. J. Clin. Pharmacol. Sep. 1999;48:424-432.
Balfour et al., “Rosiglitazone,” Drugs, 57(6):921-930 (Jun. 1999).
Balk, E.M., et al., “Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis.” 189:19-30. (Nov. 2006).
Ballantyne CM, Bays HE, Kastelein JJ, et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR 101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol Oct. 2012 110 (7): 984-92.
Ballantyne et al., “Abstract 15071: AMR101 Lowers Triglycerides, Atherogenic Lipoprotein, Phospholipase A2, and High-sensitivity C-reactive Protein Levels in Patients with High Triglycerides and on Background Statin Therapy (the ANCHOR Study),” Circulation, Lippincott Williams and Wilkins, vol. 124, No. 21, Suppl., Nov. 22, 2011.
Ballantyne et al., “Effects of icosapent ethyl on lipoprotein particle concentration and the fatty acid desaturation index in statiotreated patients with persistent high triglycerides (the ANCHOR study).” Journ. Clin. Lipidology, 2013, 7(3):270-271.
Ballantyne et al., Influence of low-high density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S, Circulation, 104:3046-3051. (Dec. 2001).
Bang HO, Dyerberg J. “Plasma lipids and Lipoproteins in Greenlandic west coast Eskimos” Acta Med Scand, 192:85-94. (Jul./Aug. 1972).
Banga, A., et al., “Adiponectin translation is increased by the PPARγ agonists pioglitazone and ω-3 fatty acids.” Am J Physiol Endocrinol Metab 296:480-489 (Mar. 2009).
Bangham et al., “Diffusion of univalent ions across the lamellae of swolloen phospholipids.” J. Mol. Biol. (Aug. 1965) 13(1):238-252.
Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM, “Fasting Compared With Nonfasting Triglycerides and Risk of Cardiovascular Events in Women,” JAMA, 298:309-316 (Jul. 2007).
Barter et al., “Effectiveness of Combined Statin Plus Omega-3 Fatty Acid Therapy for Mixed Dyslipidemia.” Am. J. Cardiol. 102(8):1040-1045 (Oct. 15, 2008).
Basu, A., et al., “Dietary Factors That Promote or Retard Inflammation.” Arterioscler. Thromb. Vasc. Biol. 26:995-1001 (May 2006).
Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes. Apr. 1991;40(4):405-412.
Bays HE et al., “Prescription omega 3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications,” Expert Rev Cardiovasc Ther., 6:391-409. (Mar. 2008).
Bays HE, Ballantyne CM, Braeckman RA, Stirtan WG, Soni PN. Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the Marine and Anchor studies. Am. J. Cardiovasc. Drugs. Feb. 2013;13(1):37-46.
Bays HE, Braeckman RA, Ballantyne CM, et al. Icosapent ethyl, a pure EPA omega-3 fatty acid: Effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the Marine study). J. Clin. Lipidol. Nov./Dec. 2012;6:565-572.
Bays HE, Safety considerations with omega-3 fatty acid therapy. Am. J. Cardiol. Mar. 2007 99 (6A): 35C-43C.
Bays, H., Clinical Overview of Omacor: A Concentrated Formulation of Omega-3 Polyunsaturated Fatty Acids, Am J Cardiol.; 98[suppl]:71i-76i (Aug. 2006).
Bays, H., “Rationale for Prescription Omega-3-Acid Ethyl Ester Therapy for Hypertriglyceridemia: A Primer for Clinicians,” Drugs of Today, 44(3); 205-246. (Mar. 2008).
Bays, H.E., Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients With Very High Triglyceride Levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [Marine] Trial) Am J Cardiol;108:682-690. (Sep. 2011).
Bays, H.E., et al., “Long-term up to 24-month efficacy and safety of concomitant prescription omega-3-acid ethyl esters and simvastatin in hypertriglyceridemic patients.” CurrMed Res Opin.; 26:907-915. (Apr. 2010).
Beal, M.F., Annals of Neurology, vol. 38, No. 3, “Aging, Energy, and Oxidative Stress in Neurodegenerative Diseases”, pp. 357-366, (Sep. 1995).
Beaumont et al., Design of Ester Prodrugs to Enhance Oral Absorption of Poorly Permeable Compounds: Challenges to the Discovery Scientist, Current Drug and Metabolism. (Dec. 2003) 4:461-485.
Becker LB, Aufderheide TP, Geocadin RG, Callaway CW, Lazar RM, Donnino MW, Nadkarni VM, Abella BS, Adrie C, Berg RA, Merchant RM, O'Connor RE, Meltzer DO, Holm MB, Longstreth WT, Halperin HR. AHA Consensus Statement: Primary Outcomes for Resuscitation Science Studies: A Consensus Statement From the American Heart Association. Circulation 2011; CIR. 0b013e3182340239 published online before print Oct. 2011, doi: 10.1161/CIR.0b013e3182340239.
Belarbi et al., “A process for high yield and scaleable recovery of high purity eicosapentaenoic acid esters from microalgae and fish oil,” Enzyme and Microbail Technology 26:516-529 (Apr. 2000).
Belger et al., “Assessment of prefrontal activation by infrequent visual targets and non-target noval stimuli in schisophrenia: a function MRI study,” Presented at the 9th Biennial winter workshop on schizophrenia, Davos, Switzerland, Feb. 7-13, 1998, Abstract in Schizophrenia Research. vol. 29. No. 1/02, Jan. 1998.
Belikov, Pharmaceutical Chemistry in Two Parts, 1/General Pharmaceutical Chemistry 43-47 (1993) (with English translation)(9 pages).
Belmaker et al., “Addition of Omega-3 Fatty Acid to Maintenance Medication Treatment for Recurrent Unipolar Depressive Disorder,” Am. J. Psychiatry, 159:477-479 (Mar. 2002).
Belmaker, et al., “Omega-3 Eicosapentaenoic Acid in Bipolar Depression: Report of a Small Open-Label Study,” J Clin Psychiatry; 66:726-729. (Jun. 2005).
Bender NK, Kraynak MA, Chiquette E, et al. Effects of marine fish oils on the anticoagulation status of patients receiving chronic warfarin therapy. J. Thromb. Thrombolysis Jul. 1998 5 (3): 257-61.
Bénistant, C., et al., “Docosapentaenoic acid (22:5, n-3): metabolism and effect on prostacyclin production in endothelial cells.” Prostaglandins, Leukotrienes and Essential Fatty Acids, 55(4):287-292, (Oct. 1996).
Benn et al., Improving Prediction of Ischemic Cardiovascular Disease in the General Population Using Apolipoprotein B: The Copenhagen City Heart Study, 27 Arteriosclerosis, Thrombosis, & Ascular Biology 661 (Mar. 2007).
Bennett et al., “Treatment of IgA nephropathy with eicosapentanoic acid (EPA): a two-year prospective trial [Abstract Only].” Clin. Nephrol. 31(3):128-131 (Mar. 1989).
Berge, R.K., et al., “In contrast with docosahexaenoic acid, eicosapentaenoic acid and hypolipidaemic derivatives decrease hepatic synthesis and secretion of triacylglycerol by decreased diacylglycerol acyltransferase activity and stimulation of fatty acid oxidation.” Biochem J.; 343(Pt 1):191-197. (Oct. 1999).
Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hypertriglyceridemia: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. Sep. 2012 97 (9): 2969-89.
Berliner JA, Watson AD. A role for oxidized phospholipids in atherosclerosis. N. Engl. J. Med. Jul. 2005;353(1):9-11.
Bertelsen M, Anggard EE, Carrier MJ. Oxidative stress impairs insulin internalization in endothelial cells in vitro. Diabetologia. May 2001;44(5):605-613.
Betteridge, D.J., “Diabetic dyslipidaemia: past, present and future.” Practical Diabetes Int, 21(2): 78-85. (Mar. 2004).
Bhatt DL, Eagle KA, Ohman EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA 304(12):1350-7 (publication date Sep. 22, 2010; epublication date Aug. 30, 2010).
Bhatt DL, Fox KAA, Hacke W, et al; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 354(16):1706-1717 (publication date Apr. 20, 2006; epublication date Mar. 12, 2006).
Bhatt DL, Hulot JS, Moliterno DJ, Harrington RA. Antiplatelet and anticoagulation therapy for acute coronary syndromes. Circ Res 114(12):1929-43 (publication date Jun. 6, 2014).
Bhatt DL, Steg PG, Brinton EA, et al. Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-lntervention Trial. Clin Cardiol 40:138-48 (publication date Mar. 2017; epublication date Mar. 15, 2017).
Bhatt DL, Steg PG, Ohman EM, et al; Reach Registry Investigators. International prevalence, recognition and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 295(2):180-189 (publication date Jan. 11, 2006).
Bhatt et al., “Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertiglyceridemia,” N. Eng. J. Med., Nov. 10, 2018 (epub ahead of print)(12 pages)(downloaded from nejm.org on Nov. 13, 2018 at https://www.nejm.org/doi/full/10.1056/NEJMoa1812792).
Bild et at., “Multi-Ethnic Study of Atherosclerosis: objectives and design,” Am J Epidemiol 156(9):871-81 (Nov. 1, 2002).
Black et al., “Effect of intravenous eicosapentaenoic acid on cerebral blood flow, edema, and brain prostaglandins in ischemic gerbils”, Prostaglandins, 28(4), pp. 545-546. cited by other. (Oct. 1984).
Blankenhorn D.H. et al., “Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts.” JAMA 257: 3233-3240. (Jun. 1987).
Block, R. C., et al., “EPA and DHA in blood cell membranes from acute coronary syndrome patients and controls.” Atherosclerosis, 197(2):821-828 (Apr. 2008).
Blumenthal, Advanced Studies in Medicine, 2:148-157 (2002).
Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, IJ McBride R, Teo K, Weintraub W. and the Aim-High Investigators, “Niacin in patients with low hdl cholesterol levels receiving intensive statin therapy,” N. Engl. J. Med. Dec. 2011;365:2255-2267.
Bonaa, KH et al., Docosahexaenoic and Eicosapentaenoic acids in plasma phospholipids are divergently associated with high density lipoprotein in humans, Arterioscler. Thromb. Vasc. Biol.;12;675-681 (Jun. 1992).
Bonnet et al., “Comparative Effects of 10-mg Versus 80-mg Atorvastatin on High-Sensitivity C-Reactive Protein in Patients with Stable Coronary Artery Disease: Results of the CAP (Comparative Atorvastatin Pleiotropic Effects) Study,” Clinical Therapeutics. 30(12):2298-2313 (Dec. 2008).
Borchman D, Lamba OP, Salmassi S, Lou M, Yappert MC. The dual effect of oxidation on lipid bilayer structure. Lipids. Apr. 1992;27(4):261-265.
Bordin et al., “Effects offish oil supplementation on apolipoprotein B100 production and lipoprotein metabolism in normolipidaemic males,” Eur. J. Clin. Nutr. 52: 104-9 (Feb. 1998).
Borow et al., “Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis,” Atherosclerosis, 242(1):357-66 (Sep. 2015).
Borthwick et al., “The effects of an omega-3 ethyl ester concentrate on blood lipid concentrations in pateitns with hyperlipidemia,” Clin. Drug Investig. (1998) 15(5): 397-404.
Bossaller C, Habib GB, Yamamoto H, Williams C, Wells S, Henry PD. Impaired muscarinic endothelium-dependent relaxation and cyclic guanosine 5′-monophosphate formation in atherosclerotic human coronary artery and rabbit aorta. J. Clin. Invest. Jan. 1987;79:170-174.
Bousserouel, S., et al., “Different effects of n-6 and n-3 polyunsaturated fatty acids on the activation of rat smooth muscle cells by interleukin-1beta.” J. Lipid Res. 44:601-611 (Mar. 2003).
Bousserouel, S., et al., “Modulation of cyclin D1 and early growth response factor-1 gene expression in interleukin-1beta-treated rat smooth muscle cells by n-6 and n-3 polyunsaturated fatty acids.” Eur. J. Biochem. 271:4462-4473 (Nov. 2004).
Brady, L., et al., Increased n-6 polyunsaturated fatty acids do not attenuate the effects of long-chain n-3 polyunsaturated fatty acids on insulin sensitivity or triacylglycerol reduction in Indian Asians. Am J Clin Nutr 79:983-91 (Jun. 2004).
Braeckman et al., “Abstract 18549: Effects of AMR101, a Pure Eicosapentaenoic Omega-3 Fatty Acid, on the Fatty Acid Profile in Plasma and Red Blood Cells in Statin-Treated Patients with Persistent High Triglycerides—Results from the Anchor study,” Circulation 126(21S):A15071 (Nov. 20, 2012)(2 pages).
Braeckman et al., “Effect of Concomitant Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Pharmacokinetics of Atorvastatin,” Clinical Drug Investigation. (Jan. 2015) (3)45-51.
Braeckman RA, Manku MS, Bays HE, Stirtan WG, Soni PN. Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the Marine study). Prostaglandins Leukot Essent Fatty Acids. Sep. 2013;89(4):195-201.
Braeckman RA, Stirtan WG, Soni PN. Pharmacokinetics of eicosapentaenoic acid in plasma and red blood cells after multiple oral dosing with AMR101 (ethyleicosapentaenoic acid) in healthy subjects [abstract]. Presented at: Congress of the International Society for the Study of Fatty Acids and Lipids, Vancouver, Canada, May 26-30, 2012.
Braeckman RA, Stirtan WG, Soni PN. Pharmacokinetics of eicosapentaenoic acid in plasma and red blood cells after multiple oral dosing with icosapent ethyl in healthy subjects. Clin. Pharmacol. Drug Dev. Mar. 2014 (epub Oct. 22, 2013); 3:101-108.
Braunersreuther V, Steffens S, Arnaud C, Pelli G, Burger F, Proudfoot A, Mach F. A novel rantes antagonist prevents progression of established atherosclerotic lesions in mice. Arterioscler. Thromb. Vasc. Biol. Jun. 2008;28:1090-1096.
Breslow, J., “n-3 Fatty acids and cardiovascular disease.” Am J Clin Nutr., 83:1477S-82S (Jun. 2006).
Brinton EA, Ballantyne CM, Bays HE, Kastelein JJ, Braeckman RA, Soni PN. Effects of AMR101 on lipid and inflammatory parameters in patients with diabetes mellitus-2 and residual elevated triglycerides (200-500 mg/dl) on statin therapy at LDL-C goal: the Anchor study.[abstract629-P] Diabetes. 2012;61(suppl 1):A159-A160.
Brinton et al., “Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the Anchor study,” Cardiovasc. Diabetol. Jul. 9, 2013;12:100. doi: 10.1186/1475-2840-12-100.
Brossard, N., et al., “Retroconversion and metabolism of [13C]22:6n-3 in humans and rats after intake of a single dose of [13C]22:6n-3-3-triacyylglycerols.” Am. J. Clin. Nutr. 64:577-86 (Oct. 1996).
Brouwer, I.A., et al., “Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators.” JAMA. 295(22):2613-2619 (Jun. 2006).
Brovkovych V, Dobrucki LW, Brovkovych S, Dobrucki I, Do Nascimento CA, Burewicz A, Malinski T. Nitric oxide release from normal and dysfunctional endothelium. J. Physiol. Pharmacol. Dec. 1999;50:575-586.
Brown et al., Simvastatin and Niacin, Antioxidant Vitamins, or the Combination for the Prevention of Coronary Disease, N Engl J Med, vol. 345, No. 22, 1583-1592 (Nov. 29, 2001).
Brown, A. J., et al., “Administration of n-3 Fatty Acids in the Diets of Rats or Directly to Hepatocyte Cultures Results in Different Effects on Hepatocellular ApoB Metabolism and Secretion.” Arterioscler. Thromb. Vasc. Biol. 19:106-114 (Jan. 1999).
Brown, A. J., et al., “Persistent changes in the fatty acid composition of erythrocyte membranes after moderate intake of n-3 polyunsaturated fatty acids: study design and implications.” Am.J. Clin. Nutri. 54:668-73(Oct. 1991).
Brown, G., et al., “Regression of coronary artery-disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein,” B., N. Engl. J. Med. 323:1289-1298. (Nov. 1990).
Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. Dec. 2001; 414(6865):813-820.
Bryhn, M., et al., “The bioavailability and pharmacodynamics of different concentrations of omega-3 acid ethyl esters.” Prostaglandins, Leukotrienes and Essential Fatty Acids 75:19-24 (Jul. 2006).
Budavari, S., Editor, “The Merck Index”, Merck & Co., Inc., p. 725 item 4511 and p. 279 and item 2417 (1989).
Budoff, “Triglycerides and Triglyceride-Rich Lipoproteins in the Causal Pathway of Cardiovascular Disease,” Am. J. Cardiol., 118(1):138-45 (Jul. 1, 2016).
Bunting et al. “Depression in Parkinson's Disease”. J Neurosci Nurs.; 23(3):158-164. (Abstract Only) (Jun. 1991).
Burdge, G.C., et al., “Eicosapentaenoic and docosapentaenoic acids are the principal products of a-linolenic acid metabolism in young men.” British Journal of Nutrition 88:355-363 (Oct. 2002).
Burdge, G.C., et al., “Lack of effect of meal fatty acid composition on postprandial lipid, glucose and insulin responses in men and women aged 50-65 years consuming their habitual diets.” British Journal of Nutrition, 96:489-500 (Sep. 2006).
Burdge, G.C., et al., “The effect of altering the 20:5n-3 and 22:6n-3 content of a meal on the postprandial incorporation of n-3 polyunsaturated fatty acids into plasma triacylglycerol and non-esterified fatty acids in humans.” Prostaglandins, Leukotrienes and Essential Fatty Acids 77:59-65 (Jul. 2007).
Burr ML, Sweetham PM, Fehily AM. Diet and reinfarction. Eur Heart J 15:1152-1153, Aug. 1994.
Burr, M. L., et al., “Effects of changes in fat, fish and fibre intakes on death and myocardial reinfarction: Diet and reinfarction trial.” The Lancet, 2(8666):757-61 (Sep. 1989).
Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care. 2007;30: 162-172.
Calabresi, L., et al., “Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses.” Atherosclerosis 148:387-396 (Feb. 2000).
Calder PC. Omega-3 Fatty Acids and Inflammatory Processes. Nutrients 2(3):355-374, Mar. 2010 (epub Mar. 18, 2010).
Calder PC. The role of marine omega-3 (n-3) fatty acids in inflammatory processes, atherosclerosis and plaque stability. Mol. Nutr. Food Res. Jul. 2012;56(7):1073-1080.
Campos, H., et al., “Lowdensity lipoprotein size, pravastatin treatment, and coronary events.” JAMA, 286:1468-1474 (Sep. 2001).
Canner P.L. et al., “Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin,” J. Am. Coll. Cardiol. 8. 1245-1255. (Dec. 1986).
Cannon CP, Blazing MA, Giugliano RP, et al; Improve-IT Investigators. “Ezetimibe added to statin therapy after acute coronary syndromes.” N Engl J Med. 372:2387-2397. (Jun. 18, 2015/epub Jun. 3, 2015).
Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350(15):1495-1504 (publication date Apr. 8, 2004; epublication date Mar. 8, 2004).
Cao H, Wang X, Huang H, Ying SZ, Guy W, Wang T, Huang CX. Omega-3 Fatty Acids in the Prevention of Atrial Fibrillation Recurrences after Cardioversion: A Meta-analysis of Randomized Controlled Trials. Intern. Med. 2012 (epub Sep. 15, 2012); 51:2503-2508.
Cao, et al., “Cloning, Expression, and Chromosomal Locatlization . . . ”, Genomics, 49:327-331, (Apr. 15, 1998).
Cao, J., et al., “Incorporation and Clearance of Omega-3 Fatty Acids in Erythrocyte Membranes and Plasma Phospholipids.” Clinical Chemistry 52(12):2265-2272 (Dec. 2006).
Capuzzi, DM et al., “Efficacy and safety of an extended-release niacin (Niaspan): a long-term study.” Am. J. Cardiol. 82: 74U-81U. (Dec. 17, 1998).
Carlson, L.A. & Rosenhamer G., “Reduction of mortaility in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid.” Acta Med. Scand. 223, 405-418 (1988).
Carlson, L.A., “Nicotinic acid: the broad spectrum lipid drug. A 50th Anniversary review”, J. Int. Med., 258:94-114, (Aug. 2005).
Carrero et al., “Intake of Fish Oil, Oleic Acid, Folic Acid, and Vitamins B-6 and E for 1 Year Decreases Plasma C-Reactive Protein and Reduces Coronary Heart Disease Risk Factors in Male Patients in a Cardiac Rehabilitation Program”, pp. 384-390 (Feb. 2007).
Carrero, J.J. et al. “Efectos cardiovasculares de los acidos grasos omega-3 y alternativas para incrementar su ingesta,” Nutricion Hospitalaria. (2005) (1) 63-69 [with English abstract].
Carroll, D. N., et al., “Evidence for the Cardioprotective Effects of Omega-3 Fatty Acids.” Ann Pharmacother., 36:1950-6 (Dec. 2002).
Carulli et al., “Chenodeoxycholic acid and ursodeoxycholic acid effects in endogenous hypertriglyceridemias. A controlled double-blind trial.” J. Clin. Pharmacol., 21(10):436-42 (Oct. 1981).
Caughey GE, Mantzioris E, Gibson RA, Cleland LG, James MJ. The effect on human tumor necrosis factor α and interleukin 1β production of diets enriched in n-3 fatty acids from vegetable oil or fish oil. Am J Clin Nutr. Jan. 1996;63:116-122.
Cavender MA, Steg PG, Smith SC, et al; Reach Registry Investigators. Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the reduction of atherothrombosis for continued health (Reach) registry. Circulation. 132(10):923-931 (publication date Sep. 8, 2015; epublication date Jul. 7, 2015).
Cawood AL, Ding R, Napper FL, et al. Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. Atherosclerosis. Sep. 2010 (epub May 20, 2010); 212:252-259.
Cazzola, R., et al., “Age- and dose-dependent effects of an eicosapentaenoic acid-rich oil on cardiovascular risk factors in healthy male subjects.” Atherosclerosis 193:159-167 (Jul. 2007).
Ceci et al., “The effects of oral 5-hydroxytryptophan administration on feeding behavior in obese adult female subjects,” J Neural. Transm (1989) 76(2):109-117.
Cefali, E.A., et al., “Aspirin reduces cutaneous flushing after administration of an optimised extended-release niacin formulation”, Int. J. Clin. Pharmacol. & Ther., 45(2):78-88, (Feb. 2007).
Center for Drug Evaluation and Research. Application No. 21-853, 21654s016, (Omacor). Statistical Review and Evaluation: Clinical Studies, Omacor (omega-3 acid ethyl ester) Capsules, 4 grams/day; 2007. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021853s000;%20021654s016_StatR.pdf. (Accessed Jan. 26, 2012) (156 pages).
Center for Drug Evaluation and Research. Approval Package for Application No. 202057Orig1s000. Review—Vascepa (formerly AMR101), 373 pages (Jul. 26, 2012)(in two parts).
Center for Drug Evaluation and Research. Approval Package for: 21-654 (Omacor/Lovaza). Statistical Review; 2004. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-654_Omacor_AdminCorres_P1.pdf. Accessed Jan. 26, 2012. (54 pages).
Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler. Thromb. Vasc. Biol. (May 2004);24(5):816-823.
Chait A, Brazg RL, Tribble DL, Krauss RM. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am. J. Med. (Apr. 1993);94(4):350-356.
Chan et al., “Effect of Atorvastatin and Fish Oil on Plasma High-Sensitivity C-Reactive Protein Concentrations in Individuals with Visceral Obesity”, Clin. Chem., vol. 48, pp. 877-883 (2002).
Chan et al., Factorial Study of the Effects of Atorvastatin and Fish Oil on Dyslipidaemia in Visceral Obesity, 32 Euro. J. Clinical Investigation. 32(6):429-36 (Jun. 2002).
Chan, D.C., et al., “Randomized controlled trial of the effect of n-3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity.” Am J Clin Nutr 77:300-7 (2003).
Chang CL, Seo T, Du CB, Accili D, Deckelbaum RJ. n-3 Fatty Acids Decrease Arterial Low-Density Lipoprotein Cholesterol Delivery and Lipoprotein Lipase Levels in Insulin-Resistant Mice. Arterioscler Thromb Vasc Biol. Dec. 2010 (epub Oct. 7, 2010);30(12):2510-2517.
Chapman, M.J., et al., “Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.” EurHeart J., 31(2):149-164 (Jan. 2010).
Chatterjee SN, Agarwal S. Liposomes as membrane model for study of lipid peroxidation. Free Radic. Biol. Med. 1988;4(1):51-72.
Chemical Book, Eicosapentaenoic acid ethyl ester, copyright 2010, printed Jun. 16, 2011 from www.chemicalbook.com. (2010).
Chen, H., et al., “Eicosapentanoic acid inhibits hypoxia-reoxygenation-induced injury by attenuating upregulation of MMP-1 in adult rat myocytes.” Cardiovascular Research 59:7-13 (Jul. 2003).
Chen, H., et al., “EPA and DHA attenuate ox-LDL-induced expression of adhesion molecules in human coronary artery endothelial cells via protein kinase B pathway.” Journal of Molecular and Cellular Cardiology 35:769-775 (Jul. 2003).
Chen, I.S., et al., “In vitro clearance of chylomicron triglycerides containing (ω-3) eicosapentaenoate.” Atherosclerosis, 65:193-198 (1987).
Cheng et al., “Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induces vasodilation in mice and humans,” PNAS 103(17):6682-7 (Apr. 25, 2006).
Childs, M.T., et al., “Divergent lipoprotein Responses to Fish Oils With Various Ratios of Eicosapentaenoic Acid and Docasahexaenoic Acid”, American Society for Clinical Nutrition, 52:632-9, (Oct. 1990).
Christensen, J. H., et al., “Effect offish oil on heart rate variability in survivors of myocardial infarction: a double blind randomised controlled trial.” BMJ, 312:677-678 (Mar. 16, 1996).
Christensen, M.S., et al., “Intestinal absorption and lymphatic transport of eicosapentaenoic (EPA), docosahexaenoic (DHA), and decanoic acids: dependence on intramolecular triacyiglycerol structure.” Am J Clin Nutr 61:56-61 (Jan. 1995).
Citizen Petition, Pronova BioPharma Norge AS, Docket No. FDA-2009-P-0398-0001 (Aug. 4, 2009), at ii (Appendix), available at www.regulations.gov.
Classification of Hyperlipidaemias and Hyperlipoproteinaemias, Bulletin of the World Health Organization, 43(6): 891-915 (1970).
Cleland, L.G., et al., “A Biomarker of n-3 compliance in patients taking fish oil for rheumatoid arthritis.” Lipids 38:419-424 (Apr. 2003).
Clinical Trial NCT01047501, Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (>200 and <500 mg/dL) (Anchor), ClinicalTrials.gov [database online], U.S. National Institute of Health, Jan. 2010 [retrieved Apr. 27, 2011], Retrieved from Internet: <http://clinicaltrials.gov/ct2/show/NCT01047501> (3 pages).
Cohen AW, Combs TP, Scherer PE, Lisanti MP. Role of caveolin and caveolae in insulin signaling and diabetes. American journal of physiology. Endocrinology and metabolism. (Dec. 2003);285(6):E1151-1160.
Cohen, J.D., et al., “30-year trends in serum lipids among United States adults: results from the National Health and Nutrition Examination Surveys II, III, and 1999-2006.” Am J Cardiol., 106:969-975. (Dec. 15, 2010).
Cole et al., “Challenges and opportunities in the encapsulation of liquid and semi-solid formulations into capsules for oral administration,” Advanced Drug Delivery Reviews, vol. 60, No. 6, pp. 747-756. (Mar. 17, 2007).
Colhoun, H. M., et al., “Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.” Lancet 364: 685-9 (Aug. 21-24, 2004).
Collins, N., et al., “Differences between Dietary Supplement and Prescription Drug Omega-3 Fatty Acid Formulations: A Legislative and Regulatory Perspective.” Journal of the American College of Nutrition, 27 (6):659-666 (Dec. 2008).
Committee Roster for the Oct. 16, 2013 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee, 2 pages. (2013).
Conklin, S. M., et al., “Serum ω-3 fatty acids are associated with variation in mood, personality and behavior in hypercholesterolemic community volunteers.” Psychiatry Research 152: 1-10 (Jul. 30, 2007).
Connor et al, “Are Fish Oils Beneficial in the Prevention and Treatment of Coronary Artery Disease?”, Am J Clin Nutr vol. 66, No. 4, Jan. 1, 1997, pp. 1020S-1031S, XP002502041.
Connor et al., “Seminars in thrombosis and hemostasis,” 14:271-284. (1988).
Connor, W.E., “Importance of n-3 Fatty Acids in Health and Disease”, Am. J. Clin. Nutr., 71(1(S)):171S-175S, (Jan. 2000).
Conquer, J.A., et al., “Effect of supplementation with different doses of DHA on the levels of circulating DHA as non-esterified fatty acid in subjects of Asian Indian background. J Lipid Res.” 39:286-292. (Feb. 1998).
Conquer, J.A., et al., “Supplementation with an algae source of docosahexaenoic acid increases (n-3) fatty acid status and alters selected risk factors for heart disease in vegetarian subjects.” J Nutr., 126: 3032-3039. (Dec. 1996).
Contacos et al. Effect of pravastatin and omega-3 fatty acids on plasma lipids and lipoproteins in patients with combined hyperlipidemia, pp. 1755-1762 (Dec. 1993).
Coronary Artery Bypass Grafting, NIH, published online Feb. 23, 2012 (12 pages).
Costanzo S, di Niro V, Castelnuovo AD, et al. Prevention of postoperative atrial fibrillation in open heart surgery patients by preoperative supplementation of n-3 polyunsaturated fatty acids: An updated meta-analysis. Periop Manga. Apr. 12, 2013; epub.
Coumadin [package insert], Princeton, NJ: Bristol-Myers Squibb; 2011. (10 pages).
Cox PJ, Ryan DA, Hollis FJ, et al. Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metab. Dispos. Jul. 2000;28:772-780.
Creager MA, Gallagher SJ, Girerd XJ, Coleman SM, Dzau VJ, Cooke JP. L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J. Clin. Invest. Oct. 1992;90:1248-1253.
Crevel et al., “Allergenicity of Refined Vegetable Oils,” Food and Chemical Toxicology, 38, pp. 385-393 (Apr. 2000).
Criqui, M., “Triglycerides and Coronary Heart Disease Revisited (Again),” vol. 147 No. 6, pp. 425-427 (Sep. 18, 2007).
Cromwell et al., “LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study—Implications for LDL Management,” Journal of Lipidololgy. (Dec. 2007) 1, 583-592.
Crowe, F. L., et al., “Serum phospholipid n-3 long-chain polyunsaturated fatty acids and physical and mental health in a population-based survey of New Zealand adolescents and adults.” Am J Clin Nutr 86:1278-85 (Nov. 2007).
Cruz et al., “The metabolic syndrome in children and adolescents,” Curr. Diab. Rep., vol. 4(1):53-62 (Feb. 2004).
Culhane et al., “Rosuvastatin for the treatment of hypercholesterolemia,” Pharmacotherapy, 25(7):990-1000 (Jul. 2005).
Daggy, B., et al., Dietary fish oil decreases VLDL production rates. Biochimica et Biophysics Acta 920: 293-300 (Aug. 15, 1987).
Dall et al., “Clinical utility of low-density lipoprotein particle measurement in management of cardiovascular disease: a case report,” Research Reports in Clin. Cardiol., vol. 2, pp. 57-62 (2011).
Daniel et al., “The Effect of Elevated Triglycerides on the Onset and Progression of Coronary Artery Disease: A Retrospective Chart Review,” Cholesterol, vol. 2015, Article ID 292935, 5 pages (epub Nov. 4, 2015).
Das, U.N., Essential fatty acids as possible mediators of the actions of statins. Prostaglandins, Leukotrienes and Essential FattyAcids 65(1):37-40, (Jul. 2001).
Davidson MH, Ballantyne CM, Jacobson TA, et al. Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. J. Clin. Lipidol. Sep./Oct. 2011;5:338-367.
Davidson MH, et al., Effects of prescription omega-3-acid ethyl esters on lipo protein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A2 mass in statin-treated subjects with hypertrigylceridemia, J.Clin. Lipid., vol. 3(5), pp. 332-340 (Oct. 2009).
Davidson MH, Rosenson RS, Maki KC, Nicholls SJ, Ballantyne CM, Mazzone T, Carlson DM, Williams LA, Kelly MT, Camp HS, Lele A, Stolzenbach JC. Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: Randomized, placebo-controlled study (first). Arterioscler. Thromb. Vasc. Biol. Jun. 2014;34:1298-1306.
Davidson MH, Stein EA, Bays HE et al. “Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study,” Clin Ther., 29:1354-1367. (Jul. 26, 2007).
Davidson MH., “Mechanisms for the hypotriglyceridemic effect of marine omega 3 fatty acids.” Am J Cardiol 98(4A):27i-33i. (Aug. 21, 2006).
Davidson, M.H., et al., “Effects of docosahexaenoic acid on serum lipoproteins in patients with combined hyperlipidemia: a randomized, doubleblind, placebo-controlled trial.” J Am Coll Nutr., 16:236-243. (Jun. 1997).
Davies et al., “Rapid separation of LDL subclasses by iodixanol gradient ultracentrifugation,” Clin. Chem., 49(11):1865-72. (Nov. 2003).
Davies-Tuck et al., “Total cholesterol and triglycerides are associated with development of new bone marrow lesions in asymptomatic middle-aged women—a prospective cohort study,” Arthritis Research & Therapy. (published online Dec. 4, 2009) pp. 1-7.
De Caterina, R, et al., “Control of Endothelial Leukocyte Adhesion Molecules by Fatty Acids.” Lipids, vol. 31:S57-S63 (1996).
De Caterina, R., et al., “The Omega-3 fatty acid docosahexaenoate reduces cytokine-induced expression of proatherogenic and proinflammatory proteins in human endothelial cells.” Arterioscler. Thromb. Vasc. Biol. 14:1829-1836 (1994).
De Graaf J, Hak-Lemmers HL, Hectors MP, Demacker PN, Hendriks JC, Stalenhoef AF. Enhanced V susceptibility to in vitro oxidation of the dense low density lipoprotein subtraction in healthy subjects. Arterioscler. Thromb. 1991;11(2):298-306.
De Morais et al., “Evaluation of lipid extraction and fatty acid composition of human plasma,” Rev. Bras. Hematol. Hemoter. 32(6):439-443 (2010).
Deckelbaum,, R. J., et al., “Conclusions and recommendations from the symposium, Beyond Cholesterol: Prevention and Treatment of Coronary Heart Disease with n-3 Fatty Acids.” Am J Clin Nutr 87:2010S-12S (2008).
Defendants' Invalidity Contentions, 3:14-CV-02550-MLC-DEA (D.N.J.), 520 pages (Dec. 5, 2014).
Defendants' Joint Invalidity Contentions, 3:14-CV-02550-MLC-TJB (D.N.J.), 901 pages (Dec. 5, 2014).
DeMets DL, Lan KK. Interim Analysis: the Alpha Spending Function Approach. Stat Med., Jul. 15-30, 1994; 13(13-14):1341-52.
Dewailly, E., et al., “n-3 Fatty acids and cardiovascular disease risk factors among the Inuit of Nunavik.” Am J Clin Nutr 74:464-73 (2001).
Dewey FE, Gusarova V, O'Dushlaine C, et al. Supplement to: Inactivating variants in ANGPTL4 and risk of coronary artery disease. N Engl J Med. DOI: 10.1056/NEJMoa1510926; Mar. 24, 2016 (epub Mar. 2, 2016).
Di Spirito, M., Morelli, G., Doyle, R.T., Johnson, J. & McKenney, J. Effect of omega-3-acid ethyl esters on steady-state plasma pharmacokinetics of atorvastatin in healthy adults. Expert Opin. Pharmacother. 9, 2939-2945 (2008).
Diagnostic and Statistical Manual of Mental Disorders, 4.Ed. Text revision, published by the American Psychiatric Assoc., pp. 154-163 and 369-381 (2000).
Diagnostic and Statistical Manual of Mental Disorders, 4.sup.th Ed., published by the American Psychiatric Assoc., pp. 285-286, (1994).
Dijan, P., et al., Proc. Natl. Acad. Sci., vol. 93, “Codon repeats in genes associated with human diseases: Fewer repeats in the genes of nonhuman primates and nucleotide substitutions concentrated at the sites of reiteration,” pp. 417-421, (Jan. 9, 1996).
Dijk, J. M., et al., “Carotid intima-media thickness and the risk of new vascular events in patients with manifest atherosclerotic disease: the Smart study.” European Heart Journal 27:1971-1978 (2006).
Din et al., “Omega 3 fatty acids and cardiovascular disease—fishing for a natural treatment,” BMJ, vol. 327, No. 7430, pp. 30-35 (Jan. 3, 2004).
Djousse L, Akinkuolie AO, Wu JHY, Ding EL, Gaziano JM. Fish consumption, omega-3 fatty acids and risk of heart failure: A meta-analysis. Clin Nutr. Dec. 2012 (epub Jun. 6, 2012); 31:846-853.
Do R, Stitziel NO, Won HH, et. al. Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature. Feb. 5, 2015 (epub Dec. 10, 2014); 518(7537):102-106.
Do R, Wilier CJ, Schmidt EM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet Nov. 2013 (Oct. 6, 2013); 45(11):1345-52.
Dodin, S., et al., “Flaxseed on cardiovascular disease markers in healthy menopausal women: a randomized, double-blind, placebo-controlled trial.” Nutrition 24:23-30 (2008).
Doi M, Nosaka K, Miyoshi T, et al. Early eicosapentaenoic acid treatment after percutaneous coronary intervention reduced acute inflammatory responses and ventricular arrhythmias in patients with acute myocardial infarction: A randomized controlled study. Int J Cardiol., 176(3):577-82 (publication date Oct. 20, 2014; epublication date Aug. 19, 2014).
Dolecek, “Epidemiological Evidence of Relationships Between Dietary Polyunsaturated Farry Acids and Morality in the Multiple Risk Factor Intervention Trial”, Society of Experimental Biology and Medicine, 200(2):177-182, (1991).
Draft Agenda for the Oct. 16, 2013 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee, 2 pages.
Draft Meeting Roster for the Oct. 16, 2013 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee, 2 pages.
Draft Questions for the Oct. 16, 2013 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee, 1 page.
Drexler H, Zeiher AM, Meinzer K, Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by I-arginine. Lancet. 1991;338:1546-1550.
Dullenmeijer, C., et al., “n-3 Fatty acid proportions in plasma and cognitive performance in older adults.” Am J Clin Nutr 86:1479-85 (2007).
Duncan, R. E., et al., “Regulation of HMG-CoA reductase in MCF-7 cells by genistein, EPA, and DHA, alone and in combination with mevastatin.” Cancer Letters 224:221-228 (2005).
Durrington PN et al. “An omega 3 poly unsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persistent Hypertriglyceridemia,” Heart, 85:544-48 (2001).
Dwyer, J. H., et al., “Arachidonate 5-Lipoxygenase Promoter Genotype, Dietary Arachidonic Acid, and Atherosclerosis.” N. Engl. J. Med., 350:1 (2004).
Dyerberg, J., et al., “Marine Oils and Thrombogenesis.” Prog. Lipid Res. 21:255-269 (1982).
Egert, S., et al., “Dietary alpha-linolenic acid, EPA, and DHA have differential effects on LDL fatty acid composition but similar effects on serum lipid profiles in normolipidemic humans.” J Nutr., 139:861-868 (2009).
Ehara S, Ueda M, Naruko T, Haze K, Itoh A, Otsuka M, Komatsu R, Matsuo T, Itabe H, Takano T, Tsukamoto Y, Yoshiyama M, Takeuchi K, Yoshikawa J, Becker AE. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation. 2001;103(15):1955-1960.
Eilat-Adar et al. “Association of Intentional Changes in Body Weight with Coronary Heart Disease Event Rates in Overweight Subjects who have an Additional Coronary Risk Factor,” Amer. Journ. Epidemiol.161(4)pp. 352-358 (Sep. 9, 2004).
Eisenberg S, Bilheimer DW, Levy RI, Lindgren FT. “On the metabolic conversion of human plasma very low density lipoprotein to low density lipoprotein,” Biochim Biophys Acta, 326:361-77 (1973).
Eisenberg S, Rachmilewitz D. “Metabolism of rat plasma very low density lipoprotein. I. Fate in circulation of the whole lipoprotein,” Biochim Biophys Acta, 326:378-90 (1973).
El-Serag HB, Graham DY, Satia JA, et al. Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. Am. J. Gastroenterol. Jun. 2005 100 (6): 1243-50.
Elam, M.B., et al., “Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease study: a randomized trial”, The ADMIT [Arterial Disease Multiple Intervention Trial] JAMA, 284:1263-1270, (2000).
El-Saadani M, Esterbauer H, El-Sayed M, Gober M, Nassar AY, Jurgens G. A spectrophotometric assay for lipid peroxides in serum lipoproteins using commercially available reagent. J. Lipid Res. 1989;30:627-630.
El-Sohemy, A., et al., “Regulation of Mevalonate Synthesis in Low Density Lipoprotein Receptor Knockout Mice Fed n-3 or n-6 Polyunsaturated Fatty Acids.” Lipids, 34 (10): 1037-43 (1999).
Emsley et al., “Randomized, Placebo-Controlled Study of Ethyl-Eicosapentaenoic Acid as Supplemental Treatment in Schizophrenia,” Am. J. Psychiatry, 159:1596-1598 (2002).
Endo et al., “The Effects of Dietary Fatty Acids on Serum Lipids and Plasma Prostaglandin Levels in the Treatment of Obesity,” Japanese Journal of Pediatric Gastroenterology and Nutrition 7(1):67-72 (Apr. 15, 1993) (with English translation)(22 pages).
ENews—JAX, “Cholesterol Crystals Induce Atherosclerosis-Associated Inflammation in Mice,” 1-4 (Jun. 14, 2010)(4 pages).
Engler, et al., “Docosahexaenoic acid restores endothelial function in children with hyperlipidemia: results from the EARLY Study.” International Journal of Clinical Pharmacology and Therapeutics, vol. 42—No. 12-2004 (672-679). (2004).
Engler, M.B., et al., “Mechanisms of vasorelaxation induced by eicosapentaenoic acid (20:5n-3) in WKY rat aorta.” British Journal of Pharmacology 131:1793-1799 (2000).
Engler, M.M., et al., “The effects of a diet rich in docosahexaenoic acid on organ and vascular fatty acid composition in spontaneously hypertensive rats.” Prostaglandins, Leukotrienes and Essential Fatty Acids 61(5):289-295 (1999).
Ennis JL, Cromwell WC. Clinical utility of low-density lipoprotein particles and apolipoprotein B in patients with cardiovascular risk. J. Fam. Pract. 2013;62:1-8.
Epadel—PubChem CID 9831415, Retrieved on Apr. 9, 2014 [Retrieved from Internet] <URL:http://pubchem.ncbi.nlm.nih.gov/compound/9831415> (19 pages).
Epadel 1990 and JELIS Study (4 pages).
Epadel Capsules 300, Japan Pharmaceutical Reference 369-371 (2nd ed.) (1991). (5 pages).
Epadel drug information brochure (2000), certified English translation(36 pages).
Epadel Package Insert 2007 (with Translation)(6 pages).
Epadel Summary of Product Characteristics (SPC), Mochida Pharmaceutical Co., Ltd. Tokyo, Japan, Oct. 2013.
Epadel® [Complete prescribing information]. Update (Version 5). Tokyo, Japan: Mochida Pharmaceutical; Jan. 2007 (9 pages).
Epanova® (omega-3-carboxylic acids) capsules, for oral use, Prescribing information, 5 pgs., AstraZeneca Pharmaceuticals LP, (Revised: Mar. 2017)(5 pages).
Eritsland J, Arnesen H, Gronseth K, et al. Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency. Am. J. Cardiol. Jan. 1996 77 (1): 31-6.
Eritsland J, Arnesen H, Seljeflot I, et al. Long-term effects of n-3 polyunsaturated fatty acids on haemostatic variables and bleeding episodes in patients with coronary artery disease. Blood Coagul. Fibrinolysis Feb. 1995 6 (1): 17-22.
Errata to the FDA Briefing Document Endocrinologic and Metabolic Drug Advisory Committee Meeting Oct. 16, 2013, 1 page.
Esposito, “Effect of a Mediterranean-Style Diet on Endothelial Dysfunction and Markers ofVascular Inflammation in the Metabolic Syndrome: A Randomized Trial”, Journal of the American Medical Association, 2004, 292(12), 1440-1446.
Essentialis Inc. press release, “Essentialis Meets Primary Endpoint in Phase 2b Trial of DCCR for Treatement of Hypertriglyceridemia and is Granted Extensive Patent Coverage in the US,” PR Newswire (May 17, 2009)( 2 pages).
Exhibit A to Defendants' Joint Invalidity Contentions, 3:14-CV-02550-MLC-TJB (D.N.J.), 48 pages (Dec. 5, 2014).
Exhibit B to Defendants' Joint Invalidity Contentions, 3:14-CV-02550-MLC-TJB (D.N.J.), 6 pages (Dec. 5, 2014).
Exhibit C to Defendants' Joint Invalidity Contentions, 3:14-CV-02550-MLC-TJB (D.N.J.), 14 pages (Dec. 5, 2014).
Exhibit D to Defendants' Joint Invalidity Contentions, 3:14-CV-02550-MLC-TJB (D.N.J.), 19 pages (Dec. 5, 2014).
Exhibit E to Defendants' Joint Invalidity Contentions, 3:14-CV-02550-MLC-TJB (D.N.J.), 6 pages (Dec. 5, 2014).
Exhibit F to Defendants' Joint Invalidity Contentions, 3:14-CV-02550-MLC-TJB (D.N.J.), 10 pages (Dec. 5, 2014).
Exhibit G to Defendants' Joint Invalidity Contentions, 3:14-CV-02550-MLC-TJB (D.N.J.), 21 pages (Dec. 5, 2014).
Exhibit H to Defendants' Joint Invalidity Contentions, 3:14-CV-02550-MLC-TJB (D.N.J.), 10 pages (Dec. 5, 2014).
Exhibit I to Defendants' Joint Invalidity Contentions, 3:14-CV-02550-MLC-TJB (D.N.J.), 14 pages (Dec. 5, 2014).
Exhibit J to Defendants' Joint Invalidity Contentions, 3:14-CV-02550-MLC-TJB (D.N.J.), 13 pages (Dec. 5, 2014).
Exhibit K to Defendants' Joint Invalidity Contentions, 3:14-CV-02550-MLC-TJB (D.N.J.), 5 pages (Dec. 5, 2014).
Exhibit L to Defendants' Joint Invalidity Contentions, 3:14-CV-02550-MLC-TJB (D.N.J.), 5 pages (Dec. 5, 2014).
Exhibit M to Defendants' Joint Invalidity Contentions, 3:14-CV-02550-MLC-TJB (D.N.J.), 7 pages (Dec. 5, 2014).
Exhibit N to Defendants' Joint Invalidity Contentions, 3:14-CV-02550-MLC-TJB (D.N.J.), 15 pages (Dec. 5, 2014).
Exhibit O to Defendants' Joint Invalidity Contentions, 3:14-CV-02550-MLC-TJB (D.N.J.), 6 pages (Dec. 5, 2014).
Exhibit P to Defendants' Joint Invalidity Contentions, 3:14-CV-02550-MLC-TJB (D.N.J.), 17 pages (Dec. 5, 2014).
Exhibit Q to Defendants' Joint Invalidity Contentions, 3:14-CV-02550-MLC-TJB (D.N.J.), 64 pages (Dec. 5, 2014).
Faggin, E., et al., “Fish Oil Supplementation Prevents Neointima Formation in Nonhypercholesterolemic Balloon-Injured Rabbit Carotid Artery by Reducing Medial and Adventitial Cell Activation.” Arterioscler. Thromb. Vasc. Biol., 20:152-163 (2000).
FDA Briefing Document, Endocrinologic and Metaboloic Drugs Advisory Committee Meeting, dated Oct. 16, 2013, available publicly at least as of Oct. 16, 2013, 115 pages.
FDA News Release, “FDA approves new orphan drug Kynamro to treat inherited cholesterol disorder,” U.S. Food and Drug Administration, Protecting and Promoting Your Health (Jan. 29, 2013)(2 pages).
Fer, M., et al., “Metabolism of eicosapentaenoic and docosahexaenoic acids by recombinant human cytochromes P450.” Archives of Biochemistry and Biophysics 471:116-125 (2008).
Ferns, G., et al., “Investigation and management of hypertriglyceridaemia.” J. Clin. Pathol. 61:1174-1183 (2008).
Feron O, Dessy C, Desager JP, Balligand JL. Hydroxy-methylgluataryl-coenzyme a reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation. 2001;103:113-118.
Final Agenda for the Oct. 16, 2013 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee, 2 pages.
Final Meeting Roster for the Oct. 16, 2013 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee, 2 pages.
Final Questions for the Oct. 16, 2013 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee, 1 page.
Finnen et al., “Purification and characterisation of phospholipase A2 from human epidermis,”, Biochemical Society Trans,19(2):91S, 1991.
Fischer, R., et al., “Dietary n-3 polyunsaturated fatty acids and direct renin inhibition improve electrical remodeling in a model of high human renin hypertension.” Hypertension 51:540-546 (2008).
Fisher et al., Journal of Biological Chemistry (2001) 276(3) 27855-27863.
Flaten, H., et al., “Fish-oil concentrate: effects on variables related to cardiovascular disease.” Am. J. Clin. Nutr. 52:300-306 (1990).
Food and Drug Administration (FDA), (2005) NIASPAN niacin extended release tablets.
Food and Drug Administration (FDA), (2005) Tablets ZOCOR® (Simvastatin).
Ford, E.S. et al., “Hypertriglyceridemia and Its Pharmacologic Treatment Among US Adults.” Arch, Intern. Med., 169(6): 572-78 (2009).
Fraker TD, Fihn SD. Writing on behalf of the 2002 Chronic Stable Angina Writing Committee. 2007 chronic angina focused update of the ACC/AHA guidelines for the management of patients with chronic stable angina. A Report of the ACC/AHA Task Force on Practice Guidelines. Circulation 50:2264-2274, Dec. 4, 2007.
Frangou et al., “Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study,” British Journ. Psychiatry, 188, 46-50 (2006).
Frey R, Muck W, Kirschbaum N, et al. Riociguat (BAY 63-2521) and warfarin: a pharmacodynamic and pharmacokinetic interaction study. J. Clin. Pharmacol. Jul. 2011 51 (7): 1051-60.
Frick, MH, et al., “Helsinki Heart Study. Primary prevention trial with gemfibrozil in middle-aged men with dyslipidaemia. Safety of treatment, changes in risk factors and incidence of coronary heart disease”, N. Eng. J. Med., 317:1237-1245, (1987).
Friedewald, W.T., et al., “Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.” Clin Chem.,18:499-502 (1972).
Friedman, A. N., et al., “Fish Consumption and Omega-3 Fatty Acid Status and Determinants in Long-Term Hemodialysis.” Amer. J. Kidney Diseases, 47(6):1064-1071 (2006).
Frøyland et al., “Chronic administration of eicosapentaenoic acid and docosahexaenoic acid as ethyl esters reduced plasma cholesterol and changed the fatty acid composition in rat blood and organs.” Lipids 31(2):169-78 (Feb. 1996).
Frøyland, L., et al., “Hypotriacylglycerolemic component of fish oil.” Prostaglandins, Leukotrienes and Essential Fatty Acids 57 (4 & 5):387-388 (1997).
Furuta T, Shirai N, Sugimoto M, et al. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab. Pharmacokinet Jun. 20, 2005 (3): 153-67.
Futata et al., “Effect of Eicosapentaenoic Acid (EPA) Formulation on Glucose Metabolism in Non-Insulin Dependent Diabetic Patients,” Journal of Clinical and Experimental Medicine 169(8):889-890 (May 21, 1994)(English translation, 4 pages).
Galan P, Kesse-Guyot E, Czernichow S, et al. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. Br Med J. Nov. 29, 2010;341:c6273.
Galeano NF, Al-Haideri M, Keyserman F, Rumsey SC, Deckelbaum RJ. Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites: a potential mechanism for increased atherogenicity. J. Lipid Res. 1998;39(6):1263-1273.
Gallagher et al., “Germline BRCA Mutations Denote a Clinicopathalogic Subset of Prostate Cancer,” Amer. Assoc. Cancer Res. Clin Cancer Res., 16(7):2115-21 (Apr. 1, 2010).
Ganda OP, Bhatt DL, Mason RP, Miller M, Boden WE. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. J Am Coll Cardiol 72(3):330-43 (publication date Jul. 17, 2018).
Garber AJ, Abrahamson MJ, Barzilay JI, et al. American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement. Endocr. Pract. 2013;19(suppl 2):1-48.
Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA. 1996;276(11):875-881.
Garg, R., et al., “Niacin treatment increases plasma homocyst(e)ine levels”, Am. Heart. J., 138:1082-1087, (1999).
Garnett, “Interactions with Hydroxymethylglutaryl-coenzyme A reductase inhibitors,” Am J Health-Sys Pharm vol. 52, 1639-1645, (Aug. 1, 1995).
Geleijnse JM, Giltay EJ, Grobbee DE, Donders ART, Kok FJ. Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J Hypertens. Aug. 2002;20(8):1493-1499.
Genest, JJ, et al., “Familial lipoprotein disorders in patients with premature coronary artery disease”, 85:2025-2033, (1992).
Geppert, et al. “Microalgal docosahexaenoic acid decreases plasma triacylglycerol in normolipidaemic vegetarians: a randomized trial.” British Journal of Nutrition, 95, 779-786. (2006).
Gillet L, Roger S, Bougnoux P, Le Guennec JY, Besson P. Beneficial effects of omega-3 long-chain fatty acids in breast cancer and cardiovascular diseases: voltage-gated sodium channels as a common feature? Biochimi. Jan. 2011 (epub Feb. 16, 2010); 93:4-6.
Gillies, et al. “Effect of a Novel Eicosapentaenoic Acid-Rich Oil on Serum Cholesterol in Man,” DuPont 2010.
Ginsberg HN, Elam MB, Lovato LC, Crouse JR, 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC, Jr., Cushman WC, Simons-Morton DG, Byington RP. Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med. Apr. 29, 2010;362:1563-1574.
Ginsberg HN. “Hypertriglyceridemia: new insights and new approaches to pharmacologic therapy,” Am J Cardiol, 87:1174-1180 (2001).
Girotti A W. Lipid hydroperoxide generation, turnover, and effector action in biological systems. J. Lipid Res. 1998;39(8):1529-1542.
GISSI-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. Oct. 4, 2008 (epub Aug. 29, 2008); 372(9645):1223-1230.
GISSI-Prevenzione Investigators, “Dietary Supplementation with n-3 Polyunsaturated Fatty Acids and Vitamin E after Myocardial Infarction: Results of the GISSI-Prevenzione Trial”, The Lancet, 354:447-455, (Aug. 7, 1999).
Glod, “Recent Advances in the Pharmacotherapy of Major Depression”, Arch. Psychiatr. Nurs., 10(6):355-364 (Dec. 1996).
Goff DC, Lloyd-Jones DM, Bennett G, et al. ACC/AHA Prevention Guideline: 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. Jun. 24, 2014 (epub Nov. 12, 2013); 129:S74-S75.
Goldberg, A C: “Combination therapy of dyslipidemia,” Current Treatment Options in Cardiovascular Medicine 200708 GB, vol. 9, No. 4, pp. 249-258 (2007).
Goodman & Gilman (Robert W. Mahley & Thomas P. Bersot) Drug Therapy for Hypercholesterolemia and Dyslipidemia, in Goodman & Gilman's The Pharmacological Basis fo Therapeutics 971 (Hardman et al., eds 10th ed. 2001)(32 pages).
Gordon, DJ. et al., High density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation. 79: 8-15. (1989).
Gorriz JL et al., “Rhabdomyolysis and Acute Renal Failure Associated with Gemfibrozil Therapy,” Nephron 74(2): 437-438 (1996).
Gorriz, JL, “Rhabdomyolysis and Acute Renal Failure Associated with Bezafibrate Treatment,” Nephrol Dial Transplant 10(12):2371-2372 (1995).
Gosai, P. et al. Effect of omega-3-acid ethyl esters on the steady-state plasma pharmacokinetics of rosuvastatin in healthy adults. Expert Opin. Pharmacother. 9, 2947-2953 (2008).
Goto, Y., et al., “Clinical Pharmacological Trial of Ethyl Icosapentate (MND-21)—Dose Finding Study.” Journal of Clinical Therapeutic & Medicines 8:1293-309 (1992).
Gould, A.L., et al., “Cholesterol reduction yields clinical benefit: impact of statin trials.” Circulation, 97:946-952 (1998).
Greenblatt DJ, von Moltke LL. Interaction of warfarin with drugs, natural substances, and foods. J. Clin. Pharmacol. Feb. 2005 45 (2): 127-32.
Grenyer, Brin F.S., et al., “Fish Oil Supplementation in the Treatment of Major Depression: A Randomised Double-Blind Placebo-Controlled Trial”, Progress in Neuro-Psychopharmacology & Biological Psychiatry, 31:1393-1396, (2007).
Griffin, M.D., et al., “Effects of altering the ratio of dietary n-6 to n-3 fatty acids on insulin sensitivity, lipoprotein size, and postprandial lipemia in men and postmenopausal women aged 45-70 y: the OPTILIP Study.” Am J Clin Nutr 84:1290-8 (2006).
Grimsgaard et al., “Effects of Highly Purified Eicosapentaenoic Acid and Docosahexaenoic Acid on Hemodynamics in Humans” American Society for Clinical Nutrition, 68:52-9, (1998).
Grimsgaard, Kaare H. Bonaa, John-Bjarne Hansen, and Arne Nordoy, “Highly purified eicosapentaenoic acid and docosahexaenoic acid in humans have similar triacylglycerol-lowering effects but divergent effects on serum fatty acids” Am J Clin Nutr, 66:649-659, (1997).
Grundy S.M et al., Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial. Arch. Intern. Med. 162: 1568-1576 (2002).
Grundy SM, et al. Implications of Recent Clinical Trials for the National Cholesterol Education Prgram Adult Treatment Panel III Guidelines, Circulation. 2004; 110:227-39.
Grundy, Scott M., “Low-Density Lipoprotein, Non-High-Density Lipoprotein, and Apolipoprotein B as Targets of Lipid-Lowering Therapy” Circulation. 106:2526-2529 (2002).
Guallar, E., et al., “Omega-3 fatty acids in adipose tissue and risk of myocardial infarction—The EURAMIC study.” Arterioscler. Thromb. Vasc. Biol., 19:1111-1118 (1999).
Guillot, et al., “Increasing intakes of the long-chain omega-3 docosahexaenoic acid: effects on platelet functions and redox status in healthy men,” The FASEV Journal, vol. 23, pp. 2909-2916 (2009).
Guizy, M., et al., “ω-3 and ω-6 Polyunsaturated fatty acids block HERG channels.” Am J Physiol Cell Physiol 289:C1251-C1260 (2005).
Gyarmathy, M., “Selection from the industrial manufacturing. 5th part: Gelatine capsules. 5/2 part: Soft gelatine capsules,” Gyogyszereszet, vol. 38, No. 2, pp. 105-109 (1994) (with English summary).
Hakonarson, H., et al., “Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction—a randomized trial.” JAMA, 293(8):2245-56 (May 11, 2005).
Hall, W. L., et al., “A high-fat meal enriched with eicosapentaenoic acid reduces postprandial arterial stiffness measured by digital volume pulse analysis in healthy men.” J. Nutr. 138: 287-291 (Feb. 2008).
Hamazaki et al., “Docosahexaenoic Acid-Rich Fish Oil Does Not Affect Serum Lipid Concentrations of Normolipidemic Young Adults”, American Institute of Nutrition, 126(11):2784-2789, Nov. 1996.
Hamazaki et al., “Effects of fish oil rich in eicosapentaenoic acid on serum lipid in hyperlipidemic hemodialysis patients,” Kidney Int'l., 26:81-84 (Jul. 1984).
Hamazaki et al., “Effects of Orally Administered Ethyl Ester of Eicosapentaenoic Acid (EPA: C20:5, omega-3) On PG12-Like Substance Production by Rat Aorta” Prostaglandins, vol. 23 No. 4, pp. 557-567 (Apr. 1982).
Hamazaki T. et al., “Reduction of microalbuminuria in diabetics by Eicosapentaenoic acid ethyl ester” Lipids. 25 (9):542-5 (Sep. 1990).
Hampel H, Abraham NS, El-Se rag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann. Intern. Med. Aug. 2005 143 (3): 199-211.
Han, J. J., et al., “Enhancement of both reaction yield and rate of synthesis of structured triacylglycerol containing eicosapentaenoic acid under vacuum with water activity control.” Lipids 34:989-995 (Sep. 1999).
Hanasaki, K., et al., “Potent modification of low density lipoprotein by group X secretory phospholipase A2 is linked to macrophage foam cell formation.” J. Biol. Chem. 277(32):29116-24 (Aug. 9, 2002).
Haney, E.M., et al., “Screening for lipid disorders in children and adolescents; Systematic evidence review for the U.S. Preventive Services Task Force (evidence synthesis).” No. 47. Rockville, MD: Agency for Healthcare Research and Quality, US Department of Health and Human Services; AHRQ Publication No. 07-0598-EF-1; Jul. 2007. Available at: http://www.uspreventiveservicestaskforce.org/uspstf07/chlipid/chlipidsyn.pdf. (Accessed Mar. 23, 2011)(573 pages).
Hannah, J., et al., “Effect of dietary fatty acids on LDL binding.” Ann N Y Acad Sci., 683:178-182 (Jun. 14, 1993).
Hansen et al., “Comparative effects of prolonged intake of highly purified fish oils as ethyl ester or triglyceride on lipids, haemostasis and platelet function in normolipaemic men.” Eur. J. Clin. Nutr. 47(7):497-507 (Jul. 1993).
Hansen, J.B., et al., “Effects of highly purified eicosapentaenoic acid and docosahexaenoic acid on fatty acid absorption, incorporation into serum phospholipids and postprandial triglyeridemia.” Lipids 33:131-38 (Feb. 1998).
Harada-Shiba et al., Journal of Clinical and Experimental Medicine, Jun. 30, 2007, vol. 221, No. 13, pp. 1068-1073 (with English translation).
Harris WS. International recommendations for consumption of long-chain omega-3 fatty acids. J Cardiovasc Med (Hagerstown) 8(suppl 1):S50-S52, Sep. 2007.
Harris, “n-3 Fatty acids and lipoproteins: a comparison of results from human and animal studies,” Lipids 31, 243-252 (Mar. 1996).
Harris, W. S. et al. “Safety and efficacy of Omacor in severe hypertriglyceridemia,” Journal of Cardiovascular Risk, 4:385-391 (Oct.-Dec. 1997).
Harris, W. S., “Fish oils and plasma lipid and lipoprotein metabolism in humans: a critical review.” J Lipid Res. 30:785-807 (Jun. 1989).
Harris, W. S., “The omega-3 index as a risk factor for coronary heart disease.” Am J Clin Nutr 87:1997S-2002S (Jun. 2008).
Harris, W. S., et al., “n-3 Fatty acids and urinary excretion of nitric oxide metabolites in humans.” Am. J. Clin. Nutr., 65:459-64 (Feb. 1997).
Harris, W. S., et al., “Influence of n-3 fatty acid supplementation on the endogenous activities of plasma lipases.” Am. J. Clin. Nutr. 66:254-60 (Aug. 1997).
Harris, W.S., “Expert opinion: omega-3 fatty acids and bleeding-cause for concern?” The American Journal of Cardiology 99(6A): 45C-46C (Mar. 19, 2007).
Harris, W.S., “n-3 Fatty acids and human lipoprotein metabolism: an update.” Lipids 34:S257-S258 (1999).
Harris, W.S., “n-3 Fatty acids and serum lipoproteins: human studies.” Am J Clin Nutr 65:1645S-54S (1997).
Harris, W.S., “Omega-3 fatty acids in cardiac biopsies from heart transplantation patients.” Circulation 110;1645-1649 (Sep. 21, 2004).
Harris, W.S., et al., “Comparison of the effects of fish and fish-oil capsules on the n-3 fatty acid content of blood cells and plasma phospholipids.” Am J Clin Nutr 86:1621-5 (Dec. 2007).
Harris, W.S., et al., “Omega-3 fatty acids and coronary heart disease risk: Clinical and mechanistic perspectives.” Atherosclerosis 197:12-24 (Mar. 2008)(epub Dec. 26, 2007).
Harris, W.S., et al., “Stearidonic acid increases the red blood cell and heart eicosapentaenoic acid content in dogs.” Lipids 42:325-333 (Apr. 2007)(epub Mar. 9, 2007).
Harris, W.S., et al., “Tissue n-3 and n-6 fatty acids and risk for coronary heart disease events.” Atherosclerosis 193:1-10 (Jul. 2007)(epub May 15, 2007).
Hartweg, J., et al., “Potential impact of omega-3 treatment on cardiovascular disease in type 2 diabetes.” Curr Opin Lipidol., 20:30-38 (Feb. 2009).
Hata et al, Geriatric Medicine, 30 (5), 799-852, 1992 (with English introduction).
Hawthorne, et al., “High dose eicosapentaenoic acid ethyl ester: effects on lipids and neutrophil leukotriene production in normal volunteers.” Br. J. Clin. Pharmac., vol. 30, 187-194 (Aug. 1990).
Hayashi et al., Decreases in Plasma Lipid Content and Thrombotic Activity by Ethyl Icosapentate Purified from Fish Oiles, Current Therapeutic Research, vol. 56, No. 1, pp. 24-31 (1995).
Herbette L, Marquardt J, Scarpa A, Blasie JK. A direct analysis of lamellar x-ray diffraction from hydrated oriented multilayers of fully functional sarcoplasmic reticulum. Biophys. J. Nov. 1977;20(2):245-272.
Hibbeln, J. R., et al., “Healthy intakes of n-3 and n-6 fatty acids: estimations considering worldwide diversity.” Am J Clin Nutr. 83:1483S-93S (Jun. 2006).
Higashihara et al. “Effects of Eicosapentaenoic Acid on Biochemical Failure after Radical Prostatectomy for Prostate Cancer,” in vivo 24:561-566 (Jul./Aug. 2010).
Hilpert, K.F., et al., “Postprandial effect of n-3 polyunsaturated fatty acids on apolipoprotein B-containing lipoproteins and vascular reactivity in type 2 diabetes.” Am J Clin Nutr 85:369-76 (Feb. 2007).
Hirafuji, M., et al., “Docosahexaenoic acid potentiates interleukin-1beta induction of nitric oxide synthase through mechanism involving p44/42 MAPK activation in rat vascular smooth muscle cells.” British Journal of Pharmacology 136:613-619 (Jun. 2002).
Hirai, A., et al., “The effects of the oral administration of fish oil concentrate on the release and the metabolism of [14C ] arachidonic acid and [14C ] eicosapentaenoic acid by human platelets”, Thromb. Res., 28:285-298, (Nov. 1, 1982).
Hirano T, Ito Y, Koba S, Toyoda M, Ikejiri A, Saegusa H, Yamazaki J, Yoshino G. Clinical significance of small dense low-density lipoprotein cholesterol levels determined by the simple precipitation method. Arterioscler. Thromb. Vase. Biol. Mar. 2004;24(3):558-563.(epub Jan. 15, 2004).
Hirano, R., et al., “Regulation by long-chain fatty acids of the expression of cholesteryl ester transfer protein in HepG2 cells.” Lipids, 36:401-406 (Apr. 2001).
Hofacer R, et al., Omega-3 fatty acid deficiency increases stearoyl-CoA desaturase expression and activity indices in rat liver: Positive association with non-fasting plasma triglyceride levels, Prostaglandins Leukot. Essent. Fatty Acids. Jan./Feb. 2012;86:71-7. (epub Nov. 1, 2011).
Hoffman, “Atherosclerosis: Prevention through the Ages,” WebMD, https://www.webmed.com/heart/features/atherosclerosis-prevention-through-ages#1, (Dec. 4, 2007).
Hohenester, “Primary Biliary Cirrhosis,” Semin Immunopathol. 31L:283-307, 285 (Sep. 2009)(epub Jul. 15, 2009).
Holmeide, A. K., et al., “Oxidative degradation of eicosapentaenoic acid into polyunsaturated aldehydes.” Tetrahedron 59:7157-7162 (2003).
Holub, B.J., PhD, “Fish Oils and Cardiovascular Disease”, Canadian Medical Association Journal, 141(10):1063 (Nov. 15, 1989).
Holvoet P, Kritchevsky SB, Tracy RP, Mertens A, Rubin SM, Butler J, Goodpaster B, Harris TB. The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in wellfunctioning elderly people in the health, aging, and body composition cohort. Diabetes. Apr. 2004;53(4):1068-1073.
Hom et al., “Soft Gelatin Capsules II: Oxygen Permeability Study of Capsule Shells,” J Pharm Sci. (May 1975) 64(5):851-857.
Hombeck, M., et al., “Biosynthesis of the algal pheromone fucoserratene by the freshwater diatom Asterionella formosa (Bacillariophyceae).” Tetrahedron 54:11033-11042 (1998).
Hong KN, Fuster V, Rosenson RS, Rosendorff C, Bhatt DL. How low to go with glucose, cholesterol, and blood pressure in primary prevention of CVD. J Am Coll Cardiol 70(17):2171-85 (publication date Oct. 24, 2017; epublication date Oct. 16, 2017).
Hoogeveen EK, Geleijnse JM, Kromhout D, et al. No effect of n-3 fatty acids supplementation on NT-proBNP after myocardial infarction: the Alpha Omega Trial. Eur J Prev Cardiol. May 2015;22:648-55.
Horrobin, D.F. The Phospholipid Concept of Psychiatric Disorders and its Relationship to the Neurodevelopmental Concept of Schizophrenia. In M. Peet (ed.) Phospholipid Spectrum Disorder in Psychiatry pp. 1-19 (1999).
Hoskins et al., “Combination use of statins and omega-3 fatty acids: an emerging therapy for combined hyperlipidemia,” Abstract, 1(5): 579-591(13) (2006).
Howe, P.R.C., et al., “Equal antithrombotic and triglyceride-lowering effectiveness of eicosapentaenoic acid-rich and docosahexaenoic acid-rich fish oil supplements.” Lipids 34:S307-S308 (1999).
HPs2-thrive Collaborative Group, “randomized placebo-controlled trial in 25 673 high-risk patients of er niacin/laroprant: Trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment.” Eur. Heart J. May 2013;34:1279-1291.
HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. Jul. 17, 2014; 371(3):203-12.
Hruska MW, Amico JA, Langaee TY, Ferrell RE, Fitzgerald SM, Frye RF. The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects. Br. J. Clin. Pharmacol. Jan. 2005;59:70-79.
Hughes et al., “Fish oil produces an atherogenic lipid profile in hypertensive men,” Atherosclerosis, 84, pp. 229-237 (Oct. 1990).
Hulthe J, Hulten LM, Fagerberg B. Low adipocyte-derived plasma protein adiponectin CJ concentrations are associated with the metabolic syndrome and small dense low-density lipoprotein particles: atherosclerosis and insulin resistance study. Metab. Clin. Exp. Dec. 2003;52(12):1612-1614.
Huntington's Diesase Drug Works—The DHA Dilemma http://hddrugworks.org/index2.php?option=com_content&task=view&id=185&pop=1&pa . . . Printed on Aug. 22, 2008.(2 pages).
Ignarro LJ, Buga GM, Wood KS, Byrnes RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc. Natl. Acad. Sci. USA. Dec. 1987;84:9265-9269.
Illingworth, DR, et al., “Comparative effects of lovastatin and niacin in primary hypercholesterolemia: A prospective trial”, Arch. Int. Med., 154:1586-1595, (Jul. 25, 1994).
Inoue, I., et al., “Expression of peroxisome proliferator-activated receptor α (PPARα) in primary cultures of human vascular endothelial cells.” Biochem. Biophys. Res. Comm., 246, 370-374 (May 19, 1998).
Inzucchi et al., “Diagnosis of Diabetes,” New Engl. Journ of Med., 367(6):541-550 (Aug. 9, 2012).
Ishida, Y., et al., “α-Lipoic Acid and Insulin Autoimmune Syndrome.” Diabeters Care, 30(9): 2240-41 (Sep. 2007).
Isley, et al., “Pilot study of combined therapy with ω-3 fatty acids and niacin in atherogenic dyslipidemia,” Journal of Clinical Lipidology, 1, 211-217 (Jul. 2007).
Itoh et al., “Increased adiponectin secretion by highly purified eicosapentaenoic acid in rodent models of obesity and human obses subjects,” Arterioscler. Thromb. Vasc. Biol., pp. 1918-1925 (together with online Supplements 1-15) (Sep. 2007)(epub Jun. 14, 2007).
Ivanova et al., “Small Dense Low-Density Lipoprotein as Biomarker for Atherosclerotic Diseases,” May 9, 2017, Oxidative Medicine and Cellular Longevity (2017), 10 pp.
Jacob RF, Mason RP. Lipid peroxidation induces cholesterol domain formation in model membranes. J. Biol. Chem. Nov. 25, 2005;280(47):39380-39387.(epub Sep. 28, 2005).
Jacob RF, Walter MF, Self-Medlin Y, Mason RP. Atorvastatin active metabolite inhibits oxidative modification of small dense low-density lipoprotein. J. Cardiovasc. Pharmacol. Aug. 2013;62(2):160-166.
Jacobson et al. “Hypertriglyceridemia and Cardiovascular Risk Reduction”, Clinical Therapeutics, vol. 29 pp. 763-777 (May 2007).
Jacobson TA. Opening a new lipid “apo-thecary”: incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk. Mayo Clin. Proc. Aug. 2011;86:762-780.
Jacobson, T. Secondary Prevention of Coronary Artery Disease with Omega-3 Fatty Acids. Am J Cardiol; 98 [suppl]: 61i-70i (Aug. 21, 2006).
Jacobson, T.A., “Role of n-3 fatty acids in the treatment of hypertriglyceridemia and cardiovascular disease.” Am J Clin Nutr 87:1981S-90S (Jun. 2008).
Jacobson, T.A., et al., “Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: A review.” J. Clin. Lipidology, vol. 6, pp. 5-18 (Jan./Feb. 2012).
Jakus V, Rietbrock N. Advanced glycation end-products and the progress of diabetic vascular complications. Physiol. Res. 2004;53(2): 131-142.
Jenner, “Presymptomatic Detection of Parkinson's Disease”. J Neural Transm Suppl., 40:23-36. (Abstract only) (1993).
Jialal I, Devaraj S. Antioxidants and atherosclerosis: Don't throw out the baby with the bath water. Circulation. Feb. 25, 2003;107:926-928.
Jialal, I., “Editorial: Remnant lipoproteins: measurement and clinical significance.” Clinical Chemistry 48(2):217-219 (Feb. 2002).
Jinno Y, Nakakuki M, Kawano H, Notsu T, Mizuguchi K, Imada K. Eicosapentaenoic acid administration attenuates the pro-inflammatory properties of VLDL by decreasing its susceptibility to lipoprotein lipase in macrophages. Atheroscler.Dec. 2011;219:566-572.(epub Oct. 4, 2011).
Jong et al., “Role of ApoCs in Lipoprotein Metabolism: Function Differences Between ApoC1, ApoC2, and ApoC3,” Arteriosclerosis, Thrombosis and Vascular Biology. (Mar. 1999) 19(3):472-484.
Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjærg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. Jul. 3, 2014; 371(1):32-41 (epub Jun. 18, 2014).
Journal of Practical Pharmacy, “Hyperlipidemia Drug,” 58(4):1303-1324 (2007) (with English abstract).
Journal of the Japan Diabetes Society, “The Relationship Between Postprandial ApoB48 Increase and Insulin Resistance in Type-2 Diabetes,” 55(Suppl. 1):S310 (Apr. 2012) (with English Translation)(2 pages).
Journal of the Japanese Diabetes Society, “A Case of Familial Combined Hyperlipidemia Associated with Obesity, Type 2 Diabetes Mellitus and Severe Hypertriglyceridemia,” 51(3), pp. 233-237 (Mar. 30, 2008) (with English abstract).
Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 375 (9729):1875-1884, May 29, 2010 (epub May 10, 2010).
Jung, U.J., et al., “n-3 Fatty acids and cardiovascular disease: mechanisms underlying beneficial effects.” Am J Clin Nutr 87: 2003S-9S (Jun. 2008).
Kamanna et al., “Mechanism of Action of Niacin,” The American Journal of Cardiology (Apr. 17, 2008), 101(8), S20-S26.
Kamido et al., Lipid Composition of Platelets from Patients with Atherosclerosis:Effect of Purified Eicosapentaenoic Acid Ethyl Ester Administration, Oct. 1988, Lipids, 23, pp. 917-923 [Abstract only] (7 pages).
Kaminski WE, Jendraschak E, Kiefl R, et al. Dietary omega-3 fatty acids lower levels of platelet-derived growth factor mRNA in human mononuclear cells. Blood Apr. 1993. 81(7): 1871-9.
Kanayasu, T., et al., “Eicosapentaenoic acid inhibits tube formation of vascular endothelial cells in vitro.” Lipids 26:271-276 (Apr. 1991).
Kastelein et al., Omega-3 Free Fatty Acids for the Treatment of Severe Hypertriglyceridemia: The EpanoVa for Lowering Very High Triglycerides (EVOLVE) Trial, J. Clin. Lipidol. (JACL 597) Jan./Feb. 2014 (epub Oct. 14, 2013).
Katan, M. B., et al., “Kinetics of the incorporation of dietary fatty acids into serum cholesteryl esters, erythrocyte membranes, and adipose tissue: an 18-month controlled study.” J. Lipid Res. 38: 2012-2022 (Oct. 1997).
Katayama et al., Effect of long-term administration of ethyl eicosapentate (EPA-E) on local cerebral blood flow and glucose utilization in stroke-prone spontaneously hypertensive rats (SHRSP), Brain Research, vol. 761, pp. 300-305 (Dec. 31, 1997).
Katayama et al., “Efficacy and Safety of Ethyl Icosapentate (Epadel) Given for a Long Term Against Hyperlipidemia,” Prog. Med., 21:457-467 (2001) (with English translation).
Kato, T., et al., “Palmitate impairs and eicosapentaenoate restores insulin secretion through regulation of SREBP-1c in pancreatic islets.” Diabetes, 57(9):2382-2392 (2008) (published online May 5, 2008.).
Kawamura et al., “Effects of 4 weeks' intake of polyunsaturated fatty acid ethylester rich in eicosapentaenoic acid (ethylester) on plasma lipids, plasma and platelet phsopholipid fatty acid composition and platelet aggregation; a double blind study,” Nihon Naika Gakkai Zasshi, 72(1):18-24 (Jan. 10, 1983).
Kawano, H., et al., “Changes in aspects such as the collagenous fiber density and foam cell size of atherosclerotic lesions composed of foam cells, smooth muscle cells and fibrous components in rabbits caused by all-cis 5, 8, 11, 14, 17-icosapentaenoic acid,” J. Atheroscler. Thromb., 9:170-177, (2002).
Kawashima, H., et al., “Oral Administration of Dihomo-γ-Linolenic Acid Prevents Development of Atopic Dermatitis in NC/Nga Mice.” Lipids 43:37-43 (Jan. 2008)(epub Nov. 6, 2007).
Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesaniemi Y A, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the Field study): Randomised controlled trial. Lancet. Nov. 26, 2005;366:1849-1861.
Kelley, D. S., et al., “Docosahexaenoic Acid Supplementation Decreases Remnant-Like Particle-Cholesterol and Increases the (n-3) Index in Hypertriglyceridemic Men.” J. Nutr. 138: 30-35 (Jan. 2008).
Kelley, et al., “Docosahexaenoic acid supplementation improves fasting and postprandial lip profiles in hypertriglyceridemic men.” The American Journal of Clinical Nutrition, 86: 324-333 (Aug. 2007).
Kellner-Weibel G, Yancey PG, Jerome WG, Walser T, Mason RP, Phillips MC, Rothblat GH. Crystallization of free cholesterol in model macrophage foam cells. Arterioscler. Thromb. Vasc. Biol. Aug. 1999;19(8):1891-1898.
Kendall BJ, Macdonald GA, Hayward NK, et al. The risk of Barrett's esophagus associated with abdominal obesity in males and females. Int. J. Cancer May 2013 132 (9): 2192-9.
Kerr, S., Brosnan MJ, Mcintyre M, Reid JL, Dominiczak AF, Hamilton CA. Superoxide anion production is increased in a model of genetic hypertension role of the endothelium. Hypertension. Jun. 1999;33:1353-1358.
Kew, S., et al., “Effects of oils rich in eicosapentaenoic and docosahexaenoic acids on immune cell composition and function in healthy humans.” Am J Clin Nutr 79:674-81 (Apr. 2004).
Kholodov et al., “Clinical Pharmacokinetics,” M. Medicine. (1985) pp. 89-98, 134-138, 160, 378-380 [with English Summary](27 pages).
Khoueiry G, Rafeh NA, Sullivan E, et al. Do omega-3 polyunsaturated fatty acids reduce risk of sudden cardiac death and ventricular arrhythmias? A meta-analysis of randomized trials. Heart and Lung. Jul./Aug. 2013;42:251-256. (epub May 25, 2013).
Kim F, Tysseling KA, Rice J, Gallis B, Haji L, Giachelli CM, Raines EW, Corson MA, Schwartz MW. Activation of IKKbeta by glucose is necessary and sufficient to impair insulin signaling and nitric oxide production in endothelial cells. J. Mol. Cell. Cardiol. Aug. 2005;39(2):327-334.
Kim KA, Park PW, Kim HK, Ha JM, Park JY. Effect of quercetin on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in healthy subjects. J. Clin. Pharmacol. Aug. 2005;45:941-946.
Kimura, F., et al., “Long-term supplementation of docosahexaenoic acid-rich, eicosapentaenoic acid-free microalgal oil in n-3 fatty acid-deficient rat pups.” Biosci. Biotechnol. Biochem., 72(2):608-610 (Feb. 2008).
Kinoshita, “Anti-hyperlipidemic agents,” Nihon Rinsho, 60(5):968-74 (May 2002) (with English Abstract)(11 pages).
Kinsella, J.E., et al., “Dietary n-3 polyunsaturated fatty acids and amelioration of cardiovascular disease: possible mechanisms.” Am J Clin Nutr 52:1-28 (Jul. 1990).
Kitada, 9th Diabetes Drug and Drug Related Seminar Diabetes Q&A, Kanazawa Medical University, Diabetes and Endocrine Internal Medicine (http://plaza.umin.ac.jp/iby/etcdata/yakuyaku110410.pdf)(Apr. 10, 2011) (with English translation)(105 pages).
Klempfner R, Erez A, Sagit BZ, et al. Elevated triglyceride level is independently associated with increased all-cause mortality in patients with established coronary heart disease: Twenty-two-year follow-up of the Bezafibrate Infarction Prevention Study and Registry. Circ Cardiovasc Qual Outcomes 9(2):100-8 (publication date Mar. 8, 2016).
Knapp HR. Dietary fatty acids in human thrombosis and hemostasis. Am. J. Clin. Nutr. May 1997 65 (5 Suppl): 1687S-98S.
Knopp, R.H., et al., “Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin”, Metabolism, 34:642-650, (Jul. 1985).
Koba S, Hirano T, Ito Y, Tsunoda F, Yokota Y, Ban Y, Iso Y, Suzuki H, Katagiri T. Significance of small dense low-density lipoprotein-cholesterol concentrations in relation to the severity of coronary heart diseases. Atherosclerosis. Nov. 2006;189(1):206-214. (epub Jan. 18, 2006).
Kohno, M., et al., “Inhibition by Eicosapentaenoic Acid of Oxidized-LDL- and Lysophosphatidylcholine-Induced Human Coronary Artery Smooth Muscle Cell Production of Endothelin.” J. Vasc. Res. 38:379-388 (Jul./Aug. 2001).
Kojda G, Harrison DG. Interactions between no and reactive oxygen species: Pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc. Res. Aug. 15, 1999;43:562-571.
Kojima, T, et al., “Long-term administration of highly purified eicosapentaenoic acid provides improvement of psoriasis.” Dermatologica, 182:225-230 (1991).
Koroshetz, W.J. Huntington's Disease. In Samuels, M. (ed.) Office Practice of Neurology, pp. 654-661 (1996).
Kosonen, O., et al., “Inhibition by nitric oxide-releasing compounds of E-selectin expression in and neutrophil adhesion to human endothelial cells.” European Journal of Pharmacology 394:149-156 (Apr. 7, 2000).
Koyama et al., Plaque Reduction and Stabilization Observed in Borderline Diabetes Using Coronary CT Angiogram During Administration of Purified Eicosapentaenoic Acid (EPA) Ther. Res. 31(2):219-225 (Feb. 2010) (with English translation)(20 pages).
Krauss RM. Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Curr. Opin. Lipidol. Oct. 1994;5(5):339-349.
Kris-Etherton, et al., “Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Disease” Circulation, 106:2747-2757 (Nov. 19, 2002)(epub Jan. 28, 2003).
Kris-Etherton, P. M., et al., “Omega-3 Fatty Acids and Cardiovascular Disease—New Recommendations From the American Heart Association.” Arterioscler Thromb Vasc Biol. 23:151-152 (Feb. 1, 2003).
Krzynowek et al., “Purification of Omega-3 Fatty Acids from Fish Oils Using HPLC: An Overview,” National Marine Fisheries—Proceedings of the first joint conference of the Tropical and Subtropical Fisheries Technological Soceity of the Americas with the Atlantic Fisheries Technological Society, pp. 74-77 (1988).
Ku, K., et al., “Beneficial Effects of to-3 Fatty Acid Treatment on the Recovery of Cardiac Function After Cold Storage of Hyperlipidemic Rats.” Metabolism, 48(10):123-1209 (Oct. 1999).
Kunimoto M, Inoue K, Nojima S. Effect of ferrous ion and ascorbate-induced lipid peroxidation on liposomal membranes. Biochem. Biophys.Acta. Aug. 6, 1981;646(1):169-178.
Kurabayashi, T., et al., “Eicosapentaenoic acid effect on hyperlipidemia in menopausal Japanese women. The Niigata Epadel Study Group” Obstet Gynecol 96:521-8 (Oct. 2000).
Labor Diagnostik Karlsruhe, “Target Values of Lipid Metabolism [Recommendation for lipid plasma levels in Germany],” (exact publication date unknown; circa 2006) (with English abstract)(4 pages).
Lada et al., “Associations of Low Density Lipoprotein Particle Compositions with Atherogenicity,” Curr. Opin. Lipidol. (Feb. 2004) 15(1):19-24.
Lai, E., et al., “Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1”, Clin. Pharm. & Ther., 81:849-857, (Jun. 2007/epub Mar. 28, 2007).
Laidlaw, M., et al., “Effects of supplementation with fish oil-derived n-3 fatty acids and γ-linolenic acid on circulating plasma lipids and fatty acid profiles in women.” Am J Clin Nutr 77:37-42 (Jan. 2003).
Laird et al., “Relationship of early hyperglcemia to mortality in trauma patients,” J. Trauma, 56(5):1058-1062 (May 2004).
Lamb RE, Goldstein BJ. Modulating an Oxidative-Inflammatory Cascade: Potential New Treatment Strategy for Improving Glucose Metabolism, Insulin Resistance, and Vascular Function. Int. J. Clin. Pract. Jul. 2008(epub May 16, 2008); 62(7): 1087-1095.
Lamharzi N, Renard CB, Kramer F, Pennathur S, Heinecke JW, Chait A, Bomfeldt KE. Hyperlipidemia in concert with hyperglycemia stimulates the proliferation of macrophages in atherosclerotic lesions: potential role of glucose-oxidized LDL. Diabetes. Dec. 2004;53(12):3217-3225.
Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, Mitch WE, Harrison DG. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J. Clin. Invest., Apr. 2003;111:1201-1209.
LaRosa JC. Understanding risk in hypercholesterolemia. Clin Cardiol 26(Suppl 1):3-6, Jan. 2003.
Larsen, L.N., et al., “Heneicosapentaenoate (21:5n-3): Its incorporation into lipids and its effects on arachidonic acid and eicosanoid Synthesis.” Lipids 32:707-714 (Jul. 1997).
Laufs et al., “Upregulation of endothelial nitric oxide synthase by hmg coa reductase inhibitors,” Circulation (Mar. 31, 1998) 97:1129-1135.
Law TK, Yan AT, Gupta A, et al. Primary prevention of cardiovascular disease: global cardiovascular risk assessment and management in clinical practice. Eur Heart J Qual Care Clin Outcomes. 1(1):31-36 (publication date Jul. 2, 2015; epublication date Jul. 1, 2015).
Law, M.R., et al., “Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis.” Br Med J., 326:1423-1427 (Jun. 28, 2003).
Lawson et al., “Human absorption of fish oil fatty acids as triacylglycerols, free acids or ethyl esters,” Biochemical and Biophysical Research Communications 152(1):328-335 (Apr. 15, 1988).
Leaf A, Albert CM, Josephson M, et al. for the Fatty Acid Antiarrhythmia Trial Investigators. Prevention of Fatal Arrhythmias in High-Risk Subjects by Fish Oil n-3 Fatty Acid Intake. Circ. Nov. 1, 2005;112:2762-2768.
Leaf A, Kang JX. Prevention of cardiac sudden death by N-3 fatty acids: a review of the evidence. J Intern Med 240:5-12, Jul. 1996.
Leaf, “Hypertriglyceridemia: A Guide to Assessment and Treatment,” Hospital Physician 17-23 (Sep. 2008).
Leaf, A., “Historical overview of n3 fatty acids and coronary heart disease.” Am J Clin Nutr 87:1978S-80S. (Jun. 2008).
Lee and G.Y.H. Lip, “The Role of Omega-3 Fatty Acids in the Secondary Prevention of Cardiovascular Disease”, Q J Med, 96:465-480, (Jul. 2003).
Lee C, Sigari F, Segrado T, Horkko S, Hama S, Subbaiah PV, Miwa M, Navab M, Witztum JL, Reaven PD. All ApoB-containing lipoproteins induce monocyte chemotaxis and adhesion when minimally modified. Modulation of lipoprotein bioactivity by platelet-activating factor acetylhydrolase. Arterioscler. Thromb. Vase. Biol., Jun. 1999; 19(6): 1437-1446.
Lee, J.H., et al., “Omega-3 fatty acids for cardioprotection.” Mayo Clin Proc., 83(3):324-332 (Mar. 2008).
Leigh-Firbank et al., “Eicosapentaenoic acid and docosahexanoic acid from fish oils: differential associations with lipid responses,” Br. J. Nutr. 87:435-445 (May 2002).
Lemaitre, R.N., et al., “n-3 Polyunsaturated fatty acids, fatal ischemic heart disease, and nonfatal myocardial infarction in older adults: the Cardiovascular Health Study.” Am J Clin Nutr 77:319-25 (Feb. 2003).
Leonard, Brian E., “Neurological Aspects”, Fundamentals of Psychopharmacology,186-187, (1997).
Leucht, S., et al., Schizophrenia Research, vol. 35, “Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials”, pp. 51-68, (Jan. 4, 1999).
Levey A, at. al. A New Equation to Estimate Glomerular Filtration Rate. Ann Intern Med. 150:604-612; May 5, 2009.
Li, D., et al., “Effect of dietary a-linolenic acid on thrombotic risk factors in vegetarian men.” Am J Clin Nutr 69:872-82 (May 1999).
Li, H., et al., “EPA and DHA reduce LPS-induced inflammation responses in HK-2 cells: Evidence for a PPAR-γ-dependent mechanism.” Kidney Int'l. 67:867-74 (Mar. 2005).
Libby P. Triglycerides on the rise: should we swap seats on the seesaw? Eur Heart J. 36(13):774-776 (publication date Apr. 1, 2015; epublication date Dec. 29, 2014).
Libby, “Inflammation and atherosclerosis,” Nature (Dec. 2002) 420(6917):868-874.
Lichtman et al., “Depression and Coronary Heart Disease, Recommendations for Screening, Referral and Treatment,” AHA Science Advisory, Circulation 118:1768-1775 (Sep. 29, 2008).
Lien, E.L., “Toxicology and safety of DHA.” Prostaglandins Leukot Essent Fatty Acids., 81:125-132 (2009).
Lin, Pao-Yen, M.D., et al., “A Meta-Analytic Review of Double-Blind, Placebo-Controlled Trials of Antidepressant Efficacy of Omega-3 Fatty Acids”, Psychiatry, 1056-1061 (Jul. 2007).
Lin, Y., et al., “Differential effects of eicosapentaenoic acid on glycerolipid and apolipoprotein B metabolism in primary human hepatocytes compared to HepG2 cells and primary rat hepatocytes.” Biochimica et Biophysica Acta 1256:88-96 (Apr. 28, 1995).
Lindsey, S., et al., “Low density lipoprotein from humans supplemented with n-3 fatty acids depresses both LDL receptor activity and LDLr mRNA abundance in HepG2 cells.” J Lipid Res., 33:647-658 (Mar. 1992).
Lipitor [package insert]. New York, NY: Parke-Davis (2012). (22 pages).
Lipitor [product information] Dublin, Ireland: Pfizer Inc. (2007).(18 pages).
Liu et al., “Effects of stable fish oil and simvastatin on plasma lipoproteins in patients with hyperlipidemia,” Nutrion Res. , vol. 23, pp. 1027-1034 (Aug. 2003).
Liu X, et al., Stearoyl CoA Desaturase 1: Role in Cellular Inflammation and Stress, Adv. Nutr. Jan. 2011 (Jan. 10, 2011); 2:15-22.
Lohmussaar, E., et al., “ALOX5AP Gene and the PDE4D Gene in a Central European Population of Stroke Patients.” Stroke, 36:731-736 (Apr. 2005)(epub Feb. 24, 2005).
Lovaza (omega-3-acid ethyl esters) Capsules, Prescribing information, GlaxoSmithKline (Nov. 2008).(9 pages).
Lovaza [package insert]. Research Triangle Park, NC: GlaxoSmithKline (2012). (14 pages).
Lovaza Side Effects, web archived webpage, archived from Drugs.com website on (Jul. 31, 2010), Retrieved from URL <https://web.archive.org/web/20100731021902/https://www.drugs.com/sfx/lovaza-side-effects.html> (4 pages)(Jul. 2010).
Lovaza TM (omega-3-acid ethyl esters) Capsules, Aug. 2007 (Aug. 1, 2007)m oaget 1-2, XP055589332.
Lovaza United States Prescribing Information, GlaxoSmithKline. Research Triangle Park, USA, May 2014.
Lovaza, (omega-3-acid ethyl esters) Capsules, Prescribing information Smith Kline Beechum (Jul. 2009).(17 pages).
Lovaza, GlaxoSmithKline, Lovaza Prescribing Information, Jun. 2008 [retrieved from Internet Jun. 6, 2012 <https://web.archive.org/web/20090206170311/http://us.gsk.com/products/assets/us_lovaza.pdf>]; Table 3, p. 1, section entitled ‘Description;’ p. 3, section entitled ‘Very High Triglycerides: Monotherapy;’ p. 4 section entitled ‘Indications and Usage’ and ‘Information for Patients.’ (12 pages).
Lovaza® (omega-3-acid ethyl esters) Capsules, Prescribing information, GlaxoSmithKline, (Dec. 2010)(12 pages).
Lovaza®, Physicians' Desk Reference 2699-2701 (62d ed., 2008).(4 pages).
Lovegrove et al., “Moderate fish-oil supplementation reverses low-platelet, long chain n-3 polyunsaturated fatty acid status and reduced plasma triacylglycerol concentrations in British Indo-Asians,” Am. J. Clin. Nutr., 79:974-982 (Jun. 2004).
Lu, G., et al., “Omega-3 fatty acids alter lipoprotein subtraction distributions and the in vitro conversion of very low density lipoproteins to lowdensity lipoproteins.” J Nutr Biochem., 10:151-158 (Mar. 1999).
Lucas, M., et al., “Ethyl-eicosapentaenoic acid for the treatment of psychological distress and depressive symptoms in middle-aged women: a double-blind, placebo-controlled, randomized clinical trial.” Am J Clin Nutr 89:641-51 (Feb. 2009)(epub Dec. 30, 2008).
Luria, MH, “Effect of low-dose niacin on high-density lipoprotein cholesterol and total cholesterol/high density lipoprotein cholesterol ratio”, Arch. Int. Med., 148:2493-2495, (Nov. 1998).
Lvovich V, Scheeline A. Amperometric sensors for simultaneous superoxide and hydrogen peroxide detection. Anal. Chern. Feb. 1, 1997;69:454-462.
Madhavi et al., “Effect of n-6 and n-3 fatty acids on the survival of vincristine sensitive and resistant human cervical carcinoma cells in vitro”, Cancer Letters, vol. 84. No. 1, pp. 31-41 (Aug. 29, 1994).
Madsen, L., et al., “Eicosapentaenoic and Docosahexaenoic Acid Affect Mitochondrial and Peroxisomal Fatty Acid Oxidation in Relation to Substrate Preference.” Lipids 34:951-963 (Sep. 1999).
Mak IT, Weglicki WB. Antioxidant properties of calcium channel blocking drugs. Methods Enzymol. 1994;234:620-630.
Maki et al., “Effects of Adding Prescription Omega-3 Acid Ethyl Esters to Simvastatin (20 mg/day) on Lipids and Lipoprotein Particles in Men and Women with Mixed Dyslipidemia,” Am. J. Cardiol., 102:429-433 (Aug. 15, 2008)(Epub May 22, 2008).
Maki, K.C., et al., “Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to simvastatin therapy.” Am J Cardiol., 105:1409-1412 (May 15, 2010)(epub Mar. 30, 2010).
Maki, PhD, et al., “Lipid Responses to a Dietary Docosahexaenoic Acid Supplement in Men and Women with Below Average Levels of High Density Lipoprotein Cholesterol.” Journal of the American College of Nutrition, vol. 24, No. 3, 189-199 (Jun. 2005).
Malinowski et al., “Elevation of Low-Density Lipoprotein Cholesterol Concentration with Over-the-Counter Fish Oil Supplementation.” Annals of Pharmacotherapy 41:1296-1300 (Jul./Aug. 2007).
Malinski T, Taha Z. Nitric oxide release from a single cell measured in situ by a porphyrinic-based microsensor. Nature. Aug. 20, 1992;358:676-678.
Mallat, Z., et al., “Apoptosis in the vasculature: mechanisms and functional importance.” British Journal of Pharmacology 130:947-962 (Jul. 2000).
Mallat, Z., et al., “Protective role of interleukin-10 in atherosclerosis.” Circ. Res. 85:e17-e24 (Oct. 15, 1999).
Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 85:37-45, Jan. 1992.
Marangell, Lauren B., M.D., et al., “A Double-Blind, Placebo-Controlled Stury of the Omega-3 Fatty Acid Docosahexaenoic Acid in the Treatment of Major Depression”, Am. J. Psychiatry, 160(5):996-998, (May 2003).
Marchioli R, Barzi F, Bomba E, et al, GISSI-Prevenzione Investigators. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Soprawivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation. 105(16):1897-1903, Apr. 23, 2002.
Marckmann, P., “Fishing for heart protection.” Am J Clin Nutr, 78:1-2 (Jul. 2003).
Marcoux et al., “Plasma remnant-like particle lipid and apolipoprotein levels in normolipidemic and hyperlipidemic subjects,” Atherosclerosis, vol. 139, pp. 161-171 (Jul. 1998).
Marder, “An Approach to Treatment Resistance in Schizophrenia,” British Journ. Psychiatry, 37:19-22 (1999).
Margolis, Simeon “What is Hyperlipidemia?” (http:www.healthcommunities.com/highcholesterol/whatishyperlipidemia.shtml, accessed Oct. 20, 2015, published Aug. 25, 2011)(4 pages).
Martin SS, Blaha MJ, Elshazly MB, et al. Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. JAMA. Nov. 20, 2013;310:2061-8.
Martinez-Gonzalez J, Raposo B, Rodriguez C, Badimon L. 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition prevents endothelial no synthase downregulation by atherogenic levels of native ldls: Balance between transcriptional and posttranscriptional regulation. Arterioscler. Thromb. Vasc. Biol. May 2001;21:804-809.
Martinez-Gonzalez, Jose et al., “Estatinas y acidos grasos omega-3. Disminucion de la mortalidad cardiovascular dependiente e independiente de la reduccion de la colesterolemia,” (2006) Rev Esp Cardiol Suppl., 6(D):20D-30D [with English abstract].
Martin-Jadraque, R. et al., Effectiveness of low dose crystalline nicotinic acid in men with low density lipoprotein cholesterol levels. Arch. Int. Med. 156: 1081-1088. (May 27, 1996).
Martz, “Moving Upstream in Huntington's,” Science-Business eXchange, 2 pgs., Oct. 2008.
Mason et al., “Comparative lipid antioxidant effects of omega-3 fatty acids in combination with HMG-CoA reductase inhibitors,” Journ. Clin. Lipidology (May/Jun. 2011) 5(3):201.
Mason et al., “Direct evidence for cholesterol crystalline domains in biological membranes: role in human pathobiology,” Biochimica et Biophysica Acta 198-207 (Mar. 10, 2003).
Mason et al., “Eicosapentaenoic Acid (EPA) inhibits the formation of membrane cholesterol crystalline domains by a potent antioxidant mechanism,” Journ. Clin. Lipid., 7(3): 272-273 (May/Jun. 2013) [Abstract only].
Mason et al., “Eicosapentaenoic acid inhibits glucose-induced membrane cholesterol crystalline domain formation through a potent antioxidant mechanism,” Biochim. Biophy. Acta., 1848(2):502-9, (Feb. 2015).
Mason et al., “Eicosapentaenoic Acid Inhibits Oxidation of ApoB-containing Lipoprotein Particles of Different Size In Vitro When Administered Alone or in Combination With Atorvastatin Active Metabolite Compared With Other Triglyceride-lowering Agents,” J. Cardiovasc. Pharmacol., 68(1):33-40 (Jul. 2016).
Mason et al., “Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes,” Biochim. Biophy. Acta., 1858(12):3131-3140 (Dec. 2016).
Mason RP, Gonye GE, Chester DW, Herbette LG. Partitioning and location of Bay K 8644, 1,4-dihydropyridine calcium channel agonist, in model and biological membranes. Biophys. J. Apr. 1989;55(4):769-778.
Mason RP, Jacob RF, Kubant R, Walter MF, Bellamine A, Jacoby A, Mizuno Y, Malinski T. Effect of enhanced glycemic control with saxagliptin on endothelial nitric oxide release and CD40 levels in obese rats. J. Atheroscler. Thromb. Epub Jun. 13, 2011;18:774-783.
Mason RP, Jacob RF. Membrane microdomains and vascular biology: Emerging role in atherogenesis. Circulation. May 6, 2003; 107:2270-2273.
Mason RP, Kalinowski L, Jacob RF, Jacoby AM, Malinski T. Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black americans. Circulation. Dec. 13, 2005 (epub Dec. 5, 2005); 112:3795-3801.
Mason RP, Kubant R, Heeba G, Jacob RF, Day CA, Medlin YS, Funovics P, Malinski T. Synergistic effect of amlodipine and atorvastatin in reversing ldl-induced endothelial dysfunction. Pharm. Res. Aug. 2008 (epub 2007 Dec. 2018); 25:1798-1806.
Mason RP, Walter MF, Day CA, Jacob RF. Active metabolite of atorvastatin inhibits membrane cholesterol domain formation by an antioxidant mechanism. J. Biol. Chem. Apr. 7, 2006 (epub Feb. 7, 2006) ;281(14):9337-9345.
Mason RP, Walter MF, Day CA, Jacob RF. Intermolecular differences for HMG-CoA reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. Am. J Cardiol. Sep. 5, 2005;96(5A):11F-23F.
Mason RP, Walter MF, Jacob RF. Effects of hmg-coa reductase inhibitors on endothelial function: Role of microdomains and oxidative stress. Circulation. Jun. 1, 2004;109:II34-II41.
Mason RP, Walter MF, Mason PE. Effect of oxidative stress on membrane structure: Small angle x-ray diffraction analysis. Free Radic. Biol. Med. 1997;23(3):419-425.
Mason RP. Molecular basis of differences among statins and a comparison with antioxidant vitamins. Am. J. Cardiol. Dec. 4, 2006 (epub Oct. 10, 2006); 98:34P-41P.
Mataki et al., “Effect of Eicosapentaenoic Acid in Combination with HMG-CoA Reductase Inhibitor on Lipid Metabolism,” Int. Med. J. 5(1):35-36 (Mar. 1998).
Mater, M.K., et al., “Arachidonic acid inhibits lipogenic gene expression in 3T3-L1 adipocytes through a prostanoid pathway.” J. Lipid Res. 39:1327-1334 (Jul. 1998).
Matsumoto, M., et al., “Orally administered eicosapentaenoic acid reduces and stabilizes atherosclerotic lesions in ApoE-deficient mice.” Atherosclerosis, 197(2):524-533 (Apr. 2008/epub Sep. 4, 2007).
Matsuzaki et al., “Incremental Effects of Eicosapentaenoic Acid on Cardiovascular Events in Statin-Treated Patients with Coronary Artery Disease,” Circ. J. 73:1283-1290 (Jul. 2009/epub May 8, 2009).
Matsuzawa, Y., et al., “Effect of Long-Term Administration of Ethyl Icosapentate (MND-21) In Hyperlipaemic Patients,” J. Clin Therapeutic & Medicines, 7: 1801-16 (1991).
Mattson MP. Modification of ion homeostasis by lipid peroxidation: roles in neuronal degeneration and adaptive plasticity. Trends Neurosci. Feb. 1998;21(2):53-57.
Mayatepek, E., et al., The Lancet, vol. 352, Leukotriene C4-synthesis deficiency: a new inborn error of metabolism linked to a fatal developmental syndrome, pp. 1514-1517 (Nov. 7, 1998).
Mayo Clinic at http://www.mayoclinic.org.diseases-conditions/high-blood-cholesterol/in-depth/cholesterol (2014)(5 pages).
Mayo Clinic, Diabetes Diagnosis and Treatment, 1998, http://www.mayoclinic.org/diseases-conditions/diabetes/diagnosis-treatment/drc-20371451 (1998-2018).
McCabe, John B. “Literature of Resuscitation”, Resuscitation, Elsevier, IE, vol. 19, No. 3 (Jun. 1, 1990), vol. 19, pp. 303-319, DOI: 10.1016/0300-9572 (90)90109-R.
McElroy, S.L., et al., “Clozapine in the Treatment of Psychotic Mood Disorders, Schizoaffective Disorder, and Schizophrenia”, Journal of Clinical Psychiatry, vol. 52, No. 10, pp. 411-414 (Oct. 1991).
McIntyre M, Hamilton CA, Rees DD, Reid JL, Dominiczak AF. Sex differences in the abundance of endothelial nitric oxide in a model of genetic hypertension. Hypertension. Dec. 1997;30:1517-1524.
McKenney et al., “Prescription omega-3 fatty acids for the treatment of hypertriglyceridemia,” Am. J. Health Syst. Pharm., 64(6):595-605 (Mar. 15, 2007).
McKenney et al., CMRO, “Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin and pravastatin in achieving lipid goals: results from the Stellar trial”, 689-98 (2003).
McKenney, J., “Niacin for dyslipidemia: considerations in product selection”, Am. J. Health Syst. Pharm., 60:995-1005, (May 15, 2003).
McKenney, J.M. et al. Study of the pharmacokinetic interaction between simvastatin and prescription omega-3-acid ethyl esters. J. Clin. Pharmacol. 46, 785-791 (Jul. 2006).
McKenney, James et al., “Role of prescription omega-3 fatty acids in the treatment of Hypertriglyceridemia,” Pharmacotherapy, LNKD—Pubmed: 17461707, vol. 27, No. 5, pp. 715-728 (May 2007).
McKeone et al., “Alterations in serum phosphatidylcholine fatty acyl species by eicosapentaenoic and docosahexaenoic ethyl esters in patients with severe hypertriglyceridemia.” J. Lipid Res. 38:429-436 (Mar. 1997).
McMurchie, E.J., et al., “Incorporation and effects of dietary eicosapentaenoate (20 : 5(n-3)) on plasma and erythrocyte lipids of the marmoset following dietary supplementation with differing levels of linoleic acid.” Biochimica et Biophysics Acta, 1045:164-173 (Jul. 16, 1990).
McNamara JR, et al., Remnant-like particle (RLP) Cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study, Atherosclerosis, vol. 154(1), pp. 229-236 (Jan. 2001).
MedlinePlus. “Coronary heart disease,” Available at: https://medlineplus.gov/ency/article/007115.htm (review date Jul. 14, 2015)(accessed Sep. 2, 2016)(5 pages).
Menuet, R. et al., “Importance and management of dyslipidemia in the metabolic syndrome,” American Journal of the Medical Sciences 200512 US, vol. 33, No. 6, pp. 295-302 (2005).
Merched, A.J., et al., “Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators.” FASEB J. 22:3595-3606 (Oct. 2008/epub Jun. 17, 2008).
Merkl et al., “Antisense Oligonucleotide Directed to Human Apolipoprotein B-100 Reduces Lipoprotein(a) Levels and Oxidized Phospholipids On Human Apolipoprotein B-100 Particles in Lipoprotein(a) Transgenic Mice,” Circulation, vol. 118, pp. 743-753 (epub Jul. 28, 2008).
Mesa, M., “Effects of oils rich in Eicosapentaenoic and docosahexaenoic acids on the oxidizability and thrombogenicity of low-density lipoprotein,” Artherosclerosis 175, pp. 333-343 (Aug. 2004).
Metcalf, R.G. et al., “Effect of dietary n-3 polyunsaturated fatty acids on the inducibility of ventricular tachycardia in patients with ischemic cardiomyopathy.” Am J Cardiol 101:758-761 (Mar. 15, 2008/epub Jan. 14, 2008).
Metcalf, R.G., et al., “Effects of fish-oil supplementation on myocardial fatty acids in humans.” Am J Clin Nutr 85:1222-28 (May 2007).
Meyer et al., “Comparison of Seal Oil to Tuna Oil on Plasma Lipid Levels and Blood Pressure in Hypertiglyceridaemic Subjects,” Lipids, 44:827-835 (Sep. 2009).
Meyer, et al., “Dose-Dependent Effects of Docosahexaenoic Acid Supplementation on Blood Lipids in Statin-Treated Hyperlipidaemic Subjects.” Lipids, 42:109-115 (Mar. 2007/epub Feb. 8, 2007).
Meyers, et al., “Nicotinic acid induces secretion of prostaglandin D2 in human macrophages: An in vitro model of the niacin-flush”, Atherosclerosis, 192:253-258, (Jun. 2007/ epub Sep. 1, 2006).
Micheletta F, Natoli S, Misuraca M, Sbarigia E, Diczfalusy U, Iuliano L. Vitamin E supplementation in patients with carotid atherosclerosis: Reversal of altered oxidative stress in plasma but not in plaque. Arterioscler. Thromb. Vasc. Biol. Jan. 2004 (epub Dec. 16, 2006); 24:136-140.
Michos et al., “Niacin and Statin Combination Therapy for Atherosclerosis Regression and Prevention of Cardiovascular Disease Events,” Journ. Amer. Coll. Cardiol., vol. 59, No. 23:2058-2064 (Jun. 5, 2012)(epub Apr. 18, 2012).
Mii, S., et al., “Perioperative use of eicosapentaenoic acid and patency of infrainguinal vein bypass: a retrospective chart review.” Curr Ther Res Clin Exp. 68:161-174 (May 2007).
Miles, et al., “Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin,” Diabetes Care, 25(7):1123-1128 (2002).
Miller AK, DiCicco RA, Freed MI. The effect of ranitidine on the pharmacokinetics of rosiglitazone in healthy adult male volunteers. Clin. Ther. Jul. 2002;24:1062-1071.
Miller AK, Inglis AM, Culkin KT, Jorkasky DK, Freed MI. The effect of acarbose on the pharmacokinetics of rosiglitazone. Eur. J. Clin. Pharmacol. May 2001;57:105-109.
Miller M, Cannon CP, Murphy SA, et al. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the Prove IT-TIMI 22 trial. J Am Coll Cardiol 51:724-730, Feb. 19, 2008.
Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. May 24, 2011 (epub Apr. 18, 2011); 123:2292-2333.
Miller M. Current perspectives on the management of hypertriglyceridemia. Am Heart J 140:232-40, 2000.
Miller, M., et al., “Impact of lowering triglycerides on raising HDL-C in hypertriglyceridemic and non-hypertriglyceridemic subjects.” International Journal of Cardiology 119:192-195 (Jul. 10, 2007)(epub Oct. 18, 2006).
Minihane, A.M., et al., “ApoE polymorphism and fish oil supplementation in subjects with an atherogenic lipoprotein phenotype.” Arterioscler. Thromb. Vasc. Biol. 20:1990-1997 (Aug. 2000).
Mishra, A., et al., “Oxidized omega-3 fatty acids inhibit NF-κB activation via a PPARα-Dependent Pathway.” Arterioscler Thromb Vasc Biol. 24:1621-1627 (Sep. 2004)(epub Jul. 1, 2004).
Missouri DUReport, Statin Therapy (Oct./Nov. 2003) Drug Use Review Newsletter 8(6):1-9.
Mita, T. et al., Eicosapentaenoic acid reduces the progression of carotid intima-media thickness in patients with type 2 diabetes, Atherosclerosis 191:162-167 (Mar. 2007)(epub Apr. 17, 2006).
Mizota M, Katsuki Y, Mizuguchi K, Endo S, Miyata H, Kojima M, Kanehiro H et al. “Pharmacological studies of eicosapentaenoic acid ethylester (EPA E) on high cholesterol diet-fed rabbits,” Nippon Yakurigaku Zasshi, 91:255-66 (Apr. 1988) (with English abstract).
Mizota M, Katsuki Y, Mizuguchi K, Endo S, Miyata H, Kojima M, Kanehiro H et al. “The effects of eicosapentaenoic acid ethylester (EPA E) on arterial thrombosis in rabbits and vascular lesions in rats,” Nippon Yakurigaku Zasshi, 91:81-9 (Feb. 1988)(with English abstract).
Mizuguchi K, Yano T, Kojima M, Tanaka Y, Ishibashi M, Masada A, Sato M et al. “Hypolipidemic effect of ethyl all-cis-5,8,11,14,17-eicosapentaenoate (EPA-E) in rats,” Jpn J Pharmacol., 59(3):307-12 (Jul. 1992).
Mizuguchi, K., et al., “Ethyl all-cis-5,8,11,14,17-icosapentaenoate modifies the biochemical properties of rat very low-density lipoprotein.” European Journal of Pharmacology, 231:221-227 (Apr. 28, 1993).
Mizuguchi, K., et al., “Mechanism of the lipid-lowering effect of ethyl all-cis-5,8,11,14,17-icosapentaenoate.” European Journal of Pharmacology, 231:121-127 (Jan. 1993).
Mochida Press Release, Pharmaceutical Col., Ltd.: Conclusion of Distributorship Agreement Concerning Switch-OTC Drug for Hyperlipidemia Treatment, Epadel, (Apr. 30, 2009)(1 page).
Mochida, Announcement, “Mochida Announces Completion of “JELIS” Major Clinical Trial for Epadel,” Mar. 22, 2005 (2 pages).
Mochida's Epadel Reduces Risk of Stroke Recurrence—New Results of JELIS Major Clinical Trial, JCNNetwork Newswire Nov. 13, 2006 (2 pages).
Mora, S., et al., “LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA).” Atherosclerosis.;192:211-217 (May 2007).
Mori et al., “Differential Effects of Eicosapentaenoic Acid and Docosahexaenoic Acid on Vascular Reactivity of the Forearm Microcirculation in Hyperlipidemic, Overweight Men,” Circulation, 102:1264-1269 (Sep. 12, 2000).
Mori TA, Woodman RJ. “The independent effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors in humans,” Curr Opin Clin Nutr Metab Care 2006; 9:95-104 (Mar. 2006).
Mori TA. Omega-3 fatty acids and blood pressure. Cell Mol Biol. Feb. 25, 2010;56(1):83-92.
Mori, et al., “Purified Eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men,” Am J Clin Nutr 71:1085-1094 (May 2000).
Mori, T. et al., Effect of Eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects, Free Radical Biology & Medicine, vol. 35, No. 7, pp. 772-781 (Oct. 1, 2003).
Mori, Trevor A., et al., “Docosahexaenoic Acid but Not Eicosapentaenoic Acid Lowers Ambulatory Blood Pressure and Heart Rate in Humans”, Hypertension, 34(2):253-60 (Aug. 1999).
Morita, I., et al., “Effects of purified eicosapentaenoic acid on arachidonic acid metabolism in cultured murine aortic smooth muscle cells, vessel walls and platelets.” Lipids 18:42-490 (Jan. 1983).
Morris M, Sacks F, Rosner B. Does fish oil lower blood pressure? A meta-analysis of controlled trials. Circ., Aug. 1993;88:523-533.
Morrow, JD, “Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid”, Prostaglandins, 38:263-274, (Aug. 1989).
Morton, R.E., “Specificity of lipid transfer protein for molecular species of cholesteryl ester.” J Lipid Res., 27:523-529 (May 1986).
Mosher LR et al., “Nicotinic Acid Side Effects and Toxicity: A review,” Am J Psychiat., 126: 1290-1296 (Mar. 1970).
Mostad et al., “Effects of Marine N-3 Fatty Acid Supplementation on Lipoprotein Subclasses Measured by Nuclear Magnetic Resonance in Subjects with Type II Diabetes,” European Journ. Clin. Nutr., 62(3):419-429 (Mar. 2008/epub Feb. 27, 2007).
Mostad, I.L, et al., “Effects of n-3 fatty acids in subjects with type 2 diabetes: reduction of insulin sensitivity and time-dependent alteration from carbohydrate to fat oxidation.” Am J Clin Nutr 84:540-50 (Sep. 2006).
Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, et al.; on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2016 update: a report from the American Heart Association [published online ahead of print Dec. 16, 2015], Circulation, doi: 10.1161/CIR.0000000000000350.
Mozaffarian D, Geelen A, Brouwer I, Geleijnse J, Zock P, Katan M. Effect of Fish Oil on Heart Rate in Humans A Meta-Analysis of Randomized Controlled Trials. Circ.Sep. 27, 2005/ epub Sep. 19, 2005; 112:1945-1952.
Mozaffarian D, Marchioli R, Macchia A, et al. Fish Oil and Postoperative Atrial Fibrillation The Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) Randomized Trial. JAMA. Nov. 21, 2012;308(19):2001-11.
Mozaffarian D, Psaty B, Rimm E, Lemaitre R, Burke G, Lyles M, Lefkowitz D, Siscovick D. Fish Intake and Risk of Incident Atrial Fibrillation. Circ., Jul. 27, 2004/epub Jul. 19, 2004; 110:368-373.
Mozaffarian et al., “Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways and clinical events,” J. Am. Coll. Cardiol. (Nov. 8, 2011) 58(2):2047-2067.
Mozaffarian, “JELIS, fish oil, and cardiac events,” www.thelancet.com vol. 369, pp. 1062-1063 (Mar. 31, 2007).
Mozaffarian, D., “Fish and n-3 fatty acids for the prevention of fatal coronary heart disease and sudden cardiac death.” Am J Clin Nutr, 87:1991S-6S (Jun. 2008).
Mozaffarian, D., et al., “Dietary fish and ω-3 fatty acid consumption and heart rate variability in US adults.” Circulation, 117:1130-1137 (Mar. 4, 2008/ epub Feb. 19, 2008).
Murck et al., “Ethyl-EPA in Huntington disease—Potentially relevant mechanism of action,” Brain Research Bulletin, 72:159-164 (2007) (available online Nov. 15, 2006).
Murphy SA, Cannon CP, Blazing MA, et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post-acute coronary syndrome. J Am Coll Cardiol. 67(4):353-361 (publication date Feb. 2, 2016; epublication date Jan. 25, 2016).
Naba, H., et al., “Improving effect of ethyl eicosapentanoate on statin-induced rhabdomyolysis in Eisai hyperbilirubinemic rats.” Biochemical and Biophysical Research Communications, 340:215-220 (Feb. 2006/epub Dec. 9, 2005).
Nagakawa et al., Effect of [EPA] on the Platelet Aggregation and Composition of Fatty Acid in Man: A Double Blind Study, Atherosclerosis 47(1):71-75 (Apr. 1983).
Naik H, Wu JT, Palmer R, McLean L. The effects of febuxostat on the pharmacokinetic parameters of rosiglitazone, a CYP2C8 substrate. Br. J. Clin. Pharmacol. Jan. 13, 2012;74:327-335.
Nakamura et al., Remnant lipoproteinemia is a risk factor for endothelial vasomotor dysfuction and coronary artery disease in metabolic syndrome, Atherosclerosis, vol. 181(2), pp. 321-327 (Aug. 2005/epub Feb. 16, 2005).
Nakamura, et al., “Effects of Eicosapentaenoic Acids on Remnant-like Particles, Cholesterol Concentrations and Plasma Fatty Acid Composition in Patients with Diabetes Mellitus.” in vivo 12: 311-314 (May/Jun. 1998).
Nakamura, H., et al., “Evaluation of ethyl icosapentate in the treatment of hypercholesterolemia in kidney transplant recipients.” Transplantation Proceedings, 30:3047-3048 (Nov. 1998).
Nakamura, N. et al., “Joint effects of HMG-CoA reductase inhibitors and eicosapentaenoic acids on serum lipid profile and plasma fatty acid concentrations in patients with hyperlipidemia,” International Journal of Clinical and Laboratory Research, Springer, Berlin, DE LNKD-DOI: 10.1007/S005990050057, vol. 29, No. 1, pp. 22-25 (1999).
Nambi V, Bhatt DL. Primary prevention of atherosclerosis: Time to take a selfie? J Am Coll Cardiol 2017;70(24):2992-4 (publication date Dec. 19, 2017; epublication date Dec. 11, 2017).
Nambi, V., et al., “Combination therapy with statins and omega-3 fatty acids.” Am J Cardiol 98:34i-38i (Aug. 21, 2006/epub May 30, 2006).
Nasa, et al., “Long-Term Supplementation With Eicosapentaenoic Acid Salvages Cardiomyocytes From Hypoxia/Reoxygenation-Induced Injury in Rats Fed With Fish-Oil-Deprived Diet,” Jpn. J. Pharmacol. 77, 137-146 (Jun. 1998).
National Kidney Foundation, “Glomerular Filtration Rate (GFR),” Jan. 30, 2017 (Jan. 30, 2017), retrieved on Jul. 30, 2018 from https://web/archive.org/web/20170130183218/https://www.kidney.org/atoz/content/gfr; entire document, especially p. 1 paragraph 1 and p. 3, paragraph 2.
National Kidney Foundation, “The Heart and Kidney Connection,” Apr. 17, 2017 (Apr. 17, 2017), retrieved on Jul. 30, 2018 from https://web.archive.org/web/2017041700416/https://www.kidney.org/atoz/content/heart-and-kidney-connection; entire document, especially p. 2, paragraph 1.
Natsuno et al., “Clinical Effects of Eicosapentaenoic Acid on Type-2 Diabetes Effects on Serum Lipids, Pulse Wave Speed, and Ankle-Brachial Blood Pressure Index,” Diagnosis and Treatment 93(12):133-137 (2005)(16 pages).
Nattel, S., et al., “Atrial remodeling and atrial fibrillation: Mechanisms and implications.” Circ Arrhythmia Electrophysiol, 1:62-73 (Apr. 2008).
Needleman P, Raz A, Minkes MS, Ferrendelli JA, Sprecher H. Triene prostaglandins: prostacyclin and thromboxane biosynthesis and unique biological properties. Proc Natl Acad Sci USA. Feb. 1979;76:944-948.
Negre-Salvayre, A., et al., “Advanced lipid peroxidation end products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for the inhibitors.” British Journal of Pharmacology 153:6-20 (Jan. 2008/epub Jul. 23, 2007).
Nelson et al. “Icosapent Ethyl for Treatment of Elevated Triglyceide Levels,” Annals of Pharmacotheraphy, 47(11):1517-1523 (Nov. 2013/epub Nov. 5, 2013).
Nelson JR, Wani O, May HT, Budoff M. Potential benefits of eicosapentaenoic acid on atherosclerotic plaques. Vascul Pharmacol. 91:1-9 (publication date Apr. 2017; epublication date Mar. 2, 2017).
Nelson, G.J., et al., “The Effect of Dietary Docosahexaenoic Acid on Plasma Lipoproteins and Tissue Fatty Acid Composition in Humans”, Lipids, 32(11):1137-1146, (Nov. 1997).
Nemets, Boris, M.D., “Addition of Omega-3 Fatty Acid to Maintenance Medication Treatment for Recurrent Unipolar Depressive Disorder”, Am. J. Psychiatry, 159(3):477-479, (Mar. 2002).
Nemoto et al., “Ethyl-eicosapentaenoic Acid Reduces Liver Lipids and Lowers Plasma Levels of Lipids in Mice Fed a High-Fat Diet, in vivo,” 23:685-690 (Sep./Oct. 2009).
Nenseter, MS et al., “Effect of dietary supplementation with n-3 polyunsaturated fatty acids on physical properties and metabolism of low density lipoprotein in humans,” Arterioscler. Thromb. Vasc. Biol., 12;369-379 (Mar. 1992).
Nestel, et al., “The n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid increase systemic arterial compliance in humans,” Am J Clin Nutr., 76:326-30 (Aug. 2002).
Nestel, P.J., “Effects of N-3 fatty acids on lipid metabolism.” Ann Rev Nutr., 10:149-167 (1990).
Nichols GA, Philip S, Reynolds K, Granowitz CB, Fazio S. Increased cardiovascular risk in hypertriglyceridemic patients with statin-controlled LDL cholesterol. J Clin Endocrinol Metab 103(8):3019-27 (publication date Aug. 1, 2018; epublication date May 29, 2018).
Nichols GA, Philip S, Reynolds K, Granowitz CB, Fazio S. Increased residual cardiovascular risk in patients with diabetes and high vs. normal triglycerides despite statin-controlled LDL Cholesterol. Diabetes Obes Metab (publication date Sep. 17, 2018; epublication date Sep. 17, 2018).
Niemi M, Backman JT, Grantors M, Laitila J, Neuvonen M, Neuvonen PJ. Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. Diabetologia. Oct. 2003/ Jul. 29, 2003); 46: 1319-1323.
Niemi M, Backman JT, Neuvonen PJ. Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. Clin. Pharmacol. Ther., Sep. 2004;76:239-249.
Nigon F, Lesnik P, Rouis M, Chapman MJ. Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor. J. Lipid Res., Nov. 1991;32(11):1741-1753.
Nippon Rinsho, Metabolic Syndrome 2nd Edition—Basics and New Clinical Findings, Jan. 20, 2011, Special Issue 1 (vol. 69), pp. 503-506 (with English translation).
Nishikawa M. et al., “Effects of Eicosapentaenoic acid (EPA) on prostacyclin production in diabetics. GC/MS analysis of PG12 and PG13 levels” Methods Find Exp Clin Pharmacol. 19(6):429-33 (Jul./Aug. 1997).
Nobukata, H., et al., “Age-related changes in coagulation, fibrinolysis, and platelet aggregation in male WBN/Kob rats.” Thrombosis Research 98: 507-516 (Jun. 15, 2000).
Nobukata, H., et al., “Long-term administration of highly purified eicosapentaenoic acid ethyl ester improves the dysfunction of vascular endothelial and smooth muscle cells in male WBN/Kob rats.” Metabolism, 49(12): 1588-1591 (Dec. 2000).
Nobukata, H., et al., “Long-term administration of highly purified eicosapentaenoic acid ethyl ester prevents diabetes and abnormalities of blood coagulation in male WBN/Kob rats.” Metabolism, 49(12): 912-919 (Jul. 2000).
Noguchi et al., “Chemoprevention of DMBA-induced mammary carcinogenesis in rats by low-dose EPA and DHA.” Br. J. Cancer 75(3): 348-353 (1997).
Nomura et al., “The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients.” Platelets, 20(1):16-22 (Feb. 2009).
Nomura S, Shouzu A, Omoto S, et al. Effects of eicosapentaenoic acid on endothelial cell-derived microparticles, angiopoietins and adiponectin in patients with type 2 diabetes. J Atheroscler Throm., Apr. 2009;16:83-90.
Nourooz-Zadeh, J., et al., “Urinary 8-epi-PGF2α and its endogenous β-oxidation products (2,3-dinor and 2,3-dinor-5,6-dihydro) as biomarkers of total body oxidative stress.” Biochemical and Biophysical Research Communications 330:731-736 (May 13, 2005).
Nozaki S. et al., “Effects of purified Eicosapentaenoic acid ethyl ester on plasma lipoproteins in primary hypercholesterolemia” Int J Vitam Nutr Res. 62(3):256-260 (1992).
Obata, et al., “Eicosapentaenoic acid inhibits prostaglandin D2 generation by inhibiting cyclo-oxygenase in cultured human mast cells”, Clin. & Experimental Allergy, 29:1129-1135, (Aug. 1999).
O'Donnell, C.J., et al., “Leukocyte telomere length and carotid artery intimal medial thickness—the Framingham heart study.” Arteriosclerosis, Thrombosis, and Vascular Biology.28:1165-1171 (Jun. 2008/epub Apr. 3, 2008).
Oemar BS, Tschudi MR, Godoy N, Brovkovich V, Malinski T, Luscher TF. Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis. Circulation., Jun. 30, 1998;97:2494-2498.
Oh, Robert C et al., Management of Hypertriglyceridemia, American Family Physician, LNKD-PUBMED: 17508532, vol. 75, No. 9, pp. 1365-1371 (May 1, 2007).
Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J. Clin. Invest. Jun. 1993;91:2546-2551.
Ohashi, Journal of Clinical and Experimental Medicine, Feb. 14, 2009, vol. 228, No. 7, pp. 795-805 (with English translation).
Okuda, Y. et al., Eicosapentaenoic acid enhances nitric oxide production by cultured human endothelial cells. Biochem. Biophys. Res. Commun. 232: 487-491 (Mar. 17, 1997).
Okuda, Y., et al., “Long-term effects of eicosapentaenoic acid on diabetic peripheral neuropathy and serum lipids in patients with type II diabetes mellitus.” Journal of Diabetes and Its Complications 10:280-287 (Sep./Oct. 1996).
Okumura, T., et al., “Eicosapentaenoic acid improves endothelial function in hypertriglyceridemic subjects despite increased lipid oxidizability.” Am J Med Sci 324(5):247-253 (Nov. 2002).
Oliw, E.H., et al., “Biosynthesis of prostaglandins from 17(18)epoxy-eicosatetraenoic acid, a cytochrome P-450 metabolite of eicosapentaenoic acid.” Biochimica el Biophysica Acta, 1126, 261-268 (Jun. 26, 1992).
Olofsson et al., “Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis” Journal of Internal Medicine, 258: 395-410 (Nov. 2005).
Omacor Summary of Product Characteristics, Pronova BioPharma Norge AS. Lysaker, Norway, Mar. 2015.
Omacor® Prescribing Information (Omega-3-acid ethyl esters, capsules) (2004). (9 pages).
Omacor®, Physicians' Desk Reference 2735 (60th ed. 2006)(3 pages).
Ona, V.O., et al., Nature, vol. 399, Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease, pp. 263-267 (May 20, 1999).
Ooi EM, “Apolipoprotein C-III: Understanding an emerging cardiovascular risk factor”, Clin.Sci. (London), vol. 114, pp. 611-624 (May 2008).
Opalinska et al., “Increasing Level of Prostate-Specific Antigen and Prostate Cancer Risk Factors Among 193 Men Examined in Screening Procedure,” Ann. Univ. Curie Sklowoska Med., 58(2):57-63 (Abstract Only)(2003)(2 pages).
ORIGIN Trial Investigators (The), n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med Jul. 6, 2012/epub Jun. 11, 2012; 367:309-318.
O'Riordan, “DHA and EPA have differential effects on LDL-cholsterol,” May 24, 2011 [online][Retrieved on Aug. 21, 2015] Retrieved from website: http://www.medscape.com/viewarticle/743305 (2 pages).
Osher et al., “Omega-3 Eicosapentaenoic Acid in Bipolar Depression: Report of a Small Open-Label Study,” J. Clin. Psych. 66:726-729 (Jun. 2005).
Otvos et al., “Clinical Implications of Discordance Between LDL Cholesterol and LDL Particle Number,” J. Clin. Lipidol, 5(2):105-113 (Mar.-Apr. 2011)(available online Mar. 1, 2011).
Ou Z, Ou J, Ackerman AW, Oldham KT, Pritchard KA, Jr. L-4f, an apolipoprotein a-1 mimetic, restores nitric oxide and superoxide anion balance in low-density lipoprotein-treated endothelial cells. Circulation. Mar. 25, 2003;107:1520-1524.
Ozaki M, Kawashima S, Yamashita T, Hirase T, Namiki M, Inoue N, Hirata K, Yasui H, Sakurai H, Yoshida Y, Masada M, Yokoyama M. Overexpression of endothelial nitric oxide synthase accelerates atherosclerotic lesion formation in apoe-deficient mice. J. Clin. Invest. Aug. 2002; 110:331-340.
Ozawa, Akio, Nakamura E, Jinbo H. Fujita T, Hirai A, Terano T, Hamazaki T et al., “Determination of higher fatty acids in various lipid fractions of human plasma, platelets, and erythrocyte membrane using thin layer chromatography and gas chromatography,” Bunseki Kagaku, 32:174-8 (1982) (with English abstract).
Padgett et al., “Phylogenetic and immunological definition of four lipoylated proteins from Novosphingobium aromaticivorans, implications for primary biliary cirrhosis,” Journ. Autoimmunity 24:209-219 (May 2005).
Park JH, Park DI, Kim HJ, et al. Metabolic syndrome is associated with erosive esophagitis. World J. Gastroenterol. Sep. 2008 14 (35): 5442-7.
Park JY, Kim KA, Kang MH, Kim SL, Shin JG. Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. Clin. Pharmacol. Ther., Mar. 2004;75:157-162.
Park, Y., et al., “Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance.” J. Lipid Res. 44:455-463 (Mar. 2003).
Pase M, Grima N, Sarris J. Do long-chain n-3 fatty acids reduce arterial stiffness? A meta-analysis of randomized controlled trials.Br J Nutr., Oct. 2011; 106:974-980.
Patel et al., “Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study,” Diabetes, Obesity and Metabolism, vol. 1, pp. 165-172 (May 1999).
Paton, CM, Ntambi, JM., Biochemical and physiological function of stearoyl-CoA desaturase, AM. J. Physiol. Endocrinol. Metab. Jul. 2009/epub Dec. 9, 2008; 297:E28-E37.
PCT/GB00/00164 International Search Report dated Oct. 20, 2000 (8 pages).
PCT/US2011/062247 International Search Report and Written Opinion dated Jun. 14, 2012 (12 pages).
PCT/US2013/020526 International Search Report dated Mar. 29, 2013 (2 pages).
PCT/US2013/048241 International Search Report dated Dec. 13, 2013 (3 pages).
PCT/US2013/048516 International Search Report dated Dec. 20, 2013 (3 pages).
PCT/US2013/048559 International Search Report dated Dec. 13, 2013 (3 pages).
PCT/US2013/068647 International Search Report and Written Opinion dated May 13, 2014 (18 pages).
PCT/US2014/019454 International Search Report and Written Opinion dated Jun. 3, 2014 (12 pages).
Pedersen RS, Damkier P, Brosen K. The effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects. Br. J. Clin. Pharmacol. Dec. 2006/epub Jul. 12, 2006; 62:682-689.
Pedersen, T., et al., “Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastation Survival Study (4S)”, The Lancet, No. 19, vol. 344, 8934, p. 1383-1389 (Nov. 19, 1994).
Peet et al., “A Dose-Ranging Study of the Effects of Ethyl-Eicosapentaenoate in Patients with Ongoing Depression Despite Apparently Adequate Treatment with Standard Drugs”, Arch. Gen. Psychiatry, 59:913-919, (Oct. 2002).
Peet, M., et al., Phospholipid Spectrum Disorder in Psychiatry pp. 1-19, (1999).
Pejic et al., “Hypertriglyceridimia,” Journ. Amer. Board Fam. Med., vol. 19(3):310-316 (May/Jun. 2006).
Pennathur S, Heinecke JW. Mechanisms for oxidative stress in diabetic cardiovascular disease. Antioxid. Redox Signal. Jul. 2007;9(7):955-969.
Pepys, M.B. et al., “C-reactive protein: a critical update”, Journal of Clinical Investigation, e-pub Jun. 15, 2003; Jul. 2003, vol. 111(12), pp. 1805-1812.
Piccini, Monica, et al., Genomics, vol. 47, “FACL4, a new gene encoding long-chain acyl-CoA synthetase 4, is deleted in a family with Alport syndrome, elliptocytosis, and mental retardation,” pp. 350-358 (Feb. 1998).
Piche, “Tumor Necrosis Factor-Alpha, and Fibrinogen to Abdominal Adipose Tissue, Blood Pressure, and Cholesterol and Triglyceride Levels in Healthy Postmenopausal Women”, American Journal of Cardiology, 2005, 96(1), 92-97.
Pike, NB, “Flushing out the role of GPR109A (HM74V) in the clinical efficacy of nicotinic acid”, J. Clin. Invest., 115:3400-3403, (Dec. 2005).
Plusepa® Product brochure “Super Critically Different from Other Omega-3 Fish Oil Supplements for Depression and ADHD,” by Minami Nutrition (Apr. 2009, pp. 1-6).
Poirier, “Obesity and Cardiovascular Disease: Pathophysiology, Evaluation, and Effect of Weight Loss”, Circulation, Feb. 14, 2006;113(6):898-918. Epub Dec. 27, 2005.
Pollin TI, Damcott CM, Shen H, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science. Dec. 12, 2008;322(5908):1702-1705.
Pownall, H.J., et al., “Correlation of serum triglyceride and its reduction by ω-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins.” Atherosclerosis 143:285-297 (Apr. 1999).
Press Release: Amarin Corporation Says Huntington's Diease Drug Failed in Trials, http://www.fiercebiotech.com/node/6607/print (Apr. 24, 2007) (Printed on Aug. 22, 2008)(2 pages).
Pritchard KA, Ackerman AW, Ou J, Curtis M, Smalley DM, Fontana JT, Stemerman MB, Sessa WC. Native low-density lipoprotein induces endothelial nitric oxide synthase dysfunction: Role of heat shock protein 90 and caveolin-1. Free Radic. Biol. Med. Jul. 2002;33:52-62.
Pritchard KA, Jr., Groszek L, Smalley DM, Sessa WC, Wu M, Villalon P, Wolin MS, Stemerman MB. Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ. Res. Sep. 1995;77:510-518.
Puri et al., “Reduction in Cerebral Atrophy Associated with Ethyl-eicosapentaenoic Acid Treatment in Patients with Huntington's Disease,” Journ. Int'l. Med. Research, 36:896-905 (Oct. 1, 2008).
Puri, B., et al., “Eicosapentaenoic Acid in Treatment-Resistant Depression Associated with Symptom Remission, Structural Brain Changes and Reduced Neuronal Phospholipid Turnover,” Int J Clinical Practice, 55:560-563 (Oct. 2001).
Puri, B., et al., Archives of General Psychiatry, No. 55, “Sustained remission of positive and negative symptoms of schizophrenia following treatment with eicosapentaenoic acid,” pp. 188-189, (Feb. 1998).
Puri, B.K., et al., “Ethyl-EPA in Huntington Disease: A Double-Blind, Randomized, Placebo-Controlled Trial”, Neurology, 65:286-292, (Jul. 26, 2005).
Qi, K., et al., “Omega-3 fatty acid containing diets decrease plasma triglyceride concentrations in mice by reducing endogenous triglyceride synthesis and enhancing the blood clearance of triglyceride-rich particles.” Clinical Nutrition 27(8):424-430 (Jun. 2008/epub Mar. 24, 2008).
Rader, Lipid Disorders, in Eric J. Topol (ed.)Textbook of Cardiovascular Medicine pp. 55-75 (2007).
Rahimy M, Hallen B, Narang P. Effect of tolterodine on the anticoagulant actions and pharmacokinetics of single-dose warfarin in healthy volunteers. Arzneimittelforschung 2002 52 (12): 890-5.
Raitt, M.H., et al., “Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators—a randomized controlled trial.” JAMA. 293(23):2884-2891 (Jun. 15, 2005).
Rambjor, Gro S., et al., “Eicosapentaenoic Acid is Primarily Responsible for Hypotrigylceridemic Effect of Fish Oil in Humans”, Fatty Acids and Lipids from Cell Biology to Human Disease: Proceedings of the 2nd international Congress of the ISSFAL (International Society for the Study of Fatty Acids and Lipids, AOCS Press, 31:S-45-S-49, (Mar. 1, 1996).
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study, Lancet. 344: 1383-1389 (1994).
Rao MN, Mullangi R, Katneni K, et al. Lack of effect of sucralfate on the absorption and pharmacokinetics of rosiglitazone. J. Clin. Pharmacol. Jun. 2002;42:670-675.
Rauch B, Rudolf R, Schneider S, et al. Omega, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation. Nov. 23, 2010 (epub Nov. 8, 2010); 122:2152-2159.
Rees DD, Palmer RM, Moncada S. The role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc. Natl. Acad. Sci. USA. May 1989;86:3375-3378.
Reich, “Formulation and physical properties of soft capsules,” Pharmaceutical capsules. (2004) Chapter 11:201-212.
Reiffel, J.A., et al., “Antiarrhythmic effects of omega-3 fatty acids.” Am J Cardiol 98:50i-60i (Aug. 21, 2006/epub May 26, 2006).
Reiner Z, Catapano AL, De BG, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur. Heart J. Jul. 2011 (epub Jun. 28, 2011); 32:1769-1818.
Richter, Werner O. , “Hypertriglyceridamie: Ein klinischer-Leitfaden,” Wissenschaftliche Verlagsgesellschaft mbH Stuttgart, front page to p. V, pp. 2 to 55, 64 to 85, 90 to 97 (2008) (with English Summary).
Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with canakinumab for atherosclerotic disease. N Engl J Med 377(12):1119-31 (publication date Sep. 21, 2017; epublication date Aug. 27, 2017).
Ridker, “C-Reactive Protein : A Simple Test to Help Predict Risk of Heart Attack and Stroke”, Circulation: Journal of the American Heart Association, Sep. 23, 2003, 108, e81-e85.
Riediger, N.D., et al., “A systemic review of the roles of n-3 fatty acids in health and disease.” J Am Diet Assoc. 109:668-679. (Apr. 2009).
Rifai, “High-Sensitivity C-Reactive Protein: A Novel and Promising Marker of Coronary Heart Disease”, Clinical Chemistry, Mar. 2001, 47(3), 403-411.
Risé, P., et al., “Effects of simvastatin on the metabolism of polyunsaturated fatty acids and on glycerolipid, cholesterol, and de novo lipid synthesis in THP-1 cells.” J. Lipid Res. 38:1299-1307 (Jul. 1997).
Risk and Prevention Study Collaborative Group, Roncaglioni MC, Tombesi M, et al. n-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med., May 9, 2013;368(19):1800-8.
Rissanen et al., “Fish Oil-Derived Fatty Acids, Docosahexaenoic Acid and Docosapentaenoic Acid, and the Risk of Acute Coronary Events The Kuopio Ischaemic Heart Disease Risk Factor Study,” Circulation. (Nov. 28, 2000)(102):2677-2679 doi:10.1161/01.CIR.102.22.2677.
Rizzo M, Bemeis K. Low-density lipoprotein size and cardiovascular risk assessment. Q. J. Med. Jan. 2006; 99(1): 1-14.
Roach, P.D., et al., “The effects of dietary fish oil on hepatic high density and low density lipoprotein receptor activities in the rat.” FEBS Lett., 222: 159-162 (Sep. 28, 1987).
Robinson, J.G., et al., “Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart risk.” J Am Coll Cardiol., 53: 316-322 (Jan. 27, 2009).
Roche, H.M., et al., “Effect of long-chain n-3 polyunsaturated fatty acids on fasting and postprandial triacylglycerol metabolism.” Am J Clin Nutr 71:232S-7S (Jan. 2000).
Roche, H.M., et al., “Long-chain n-3 polyunsaturated fatty acids and triacylglycerol metabolism in the postprandial state.” Lipids 34: S259-S265 (1999).
Rodriguez, Y., et al., “Long-chain ω6 polyunsaturated fatty acids in erythrocyte phospholipids are associated with insulin resistance in non-obese type 2 diabetics.” Clinica Chimica Acta 354:195-199 (Apr. 2005).
Roe MT, Armstrong PW, Fox KAA, et al.; Trilogy ACS Investigators. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 367(14):1297-1309 (publication date Oct. 4, 2012; epublication Aug. 25, 2012).
Rogers, P. J., “No effect of n-3 long-chain polyunsaturated fatty acid (EPA and DHA) supplementation on depressed mood and cognitive function: a randomised controlled trial” British Journal of Nutrition, 99:421-431, (Feb. 2008/epub Oct. 24, 2007).
Rost KL, Roots I. Nonlinear kinetics after high-dose omeprazole caused by saturation of genetically variable CYP2C19. Hepatology Jun. 23, 1996 (6): 1491-7.
Rubins, HB, et al., “Distribution of lipids in 8,500 men with coronary artery disease: Department of Veterans Affairs HDL Intervention Trial Study Group,” Am. J. Cardiol, 75:1196-1201, (Jun. 15, 1995).
Rubins, HB, et al., “Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs HDL-C Intervention Trial Study Group”, N. Eng. J. Med., 341:410-418, (Aug. 5, 1999).
Ruiz-Narváez, E.A., et al., “Abdominal obesity and hyperglycemia mask the effect of a common APOC3 haplotype on the risk of myocardial infarction.” Am J Clin Nutr 87:1932-8 (Jun. 2008).
Ruocco MJ, Shipley GG. Interaction of cholesterol with galactocerebroside and galactocerebroside phosphatidylcholine bilayer membranes. Biophys. J. Dec. 1984; 46:695-707.
Rupp, “Omega-3-Fettsauren in der Sekundarpravention nach Myokardinfarkt,” Clin. Res. Cardiol., vol. 95:Suppl. 6, Vi/12/-V1-16 (2006)(with English summary).
Rustan, A.C., et al., “Eicosapentaenoic acid inhibits cholesterol esterification in cultured parenchymal cells and isolated microsomes from rat liver.” J. Bio. Chem. 263(17):8126-32 (Jun. 15, 1988).
Rustan, A.C., et al., “Eicosapentaenoic acid reduces hepatic synthesis and secretion of triacylglycerol by decreasing the activity of acyl-coenzyme A:1,2-diacylglycerol acyltransferase.” J. Lipid Res. 29:1417-1426 (Nov. 1988).
Rustan, A.C., et al., “Postprandial decrease in plasma unesterified fatty acids during n-3 fatty acid feeding is not caused by accumulation of fatty acids in adipose tissue.” Biochimica et Biophysica Acta 1390.245-25 (Feb. 23, 1998).
Ryan, A.M., et al., “Enteral nutrition enriched with eicosapentaenoic acid (EPA) preserves lean body mass following esophageal cancer surgery: results of a double-blinded randomized controlled trial.” Ann Surg 249:355-363 (Mar. 2009).
Ryan, A.S., et al., “Clinical overview of algal-docosahexaenoic acid: effects on triglyceride levels and other cardiovascular risk factors.” Am J Ther., 16:183-192 (Mar./Apr. 2009).
Sacks, Frank M., “The apolipoprotein story,” Atherosclerosis Supplements, 23-27 (Aug. 2006/epub Jul. 5, 2006).
Saito et al., “Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: Sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS),” Atherosclerosis, 200:135-140 (Sep. 2008/epub Jun. 19, 2008).
Saito et al., “Results of Clinical Usage of Improved Formulation (MND-21S) Epadel Capsule 300 with Respect to Hyperlipidemia,” 26(12) Jpn. Pharmacol. Ther. 2047-62 (1998) (with English abstract).
Saito, J., et al., “Mechanisms of enhanced production of PGI2 in cultured rat vascular smooth muscle cells enriched with eicosapentaenoic acid.” Atherosclerosis 131: 219-228 (Jun. 1997).
Sampath H, Ntambi JM., Role of stearoyl-CoA desaturase in human metabolic disease, Future Lipidol. 2008;3:2,163-73.
Sampath H, Ntambi JM., The Role of stearoyl-CoA desaturase in obesity, insulin resistance, and inflammation, Ann. NY. Acad. Sci. Dec. 2011; 1243:4 7-53.
Samuels, Martin A., M. D., et al., “Huntington's Disease”, Office Practice of Neurology, (122):654-655, (1996).
Sanders, A. Hinds and C.C. Pereira, “Influence of n-3 fatty acids on blood lipids in normal subjects” Journal of Internal Medicine. 225:99-104,(1989).
Sanders, et al., “Influence of an algal triacylglycerol containing docosahexaenoic acid (22:6n-3) and docosapentaenoic acid (22:5n-6) on cardiovascular risk factors in healthy men and women,” British Journal of Nutrition, 95, 525-531 (Mar. 2006).
Sanders, T.A., et al., “Effect of varying the ratio of n-6 to n-3 fatty acids by increasing the dietary intake of α-linolenic acid, eicosapentaenoic and docosahexaenoic acid, or both on fibrinogen and clotting factors VII and XII in persons aged 45-70 y: the OPTILIP Study.” Am J Clin Nutr 84:513-22 (Sep. 2006).
Sanders, T.A., et al., “Triglyceride-lowering effect of marine polyunsaturates in patients with hypertriglyceridemia.” Arterioscler. Thromb. Vasc. Biol. 5:459-465 (Sep./Oct. 1985).
Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 115:450-458, Jan. 30, 2007/epub Dec. 26, 2006.
Sasaki J, Miwa T, Odawara M. Administration of highly purified eicosapentaenoic acid to stain-treated diabetic patients further improves vascular function. Endocrine J. Jan. 27, 2012; 59(4):297-304.
Sasaki J, Yokoyama M, Matsuzaki M, et al. Relationship between coronary artery disease and non-HDL-C, and effect of highly purified EPA on the risk of coronary artery disease in hypercholesterolemic patients treated with statins: sub-analysis of the Japan EPA Lipid Intervention Study (JELIS). J. Atheroscler. Thromb. Dec. 17, 2012;19:194-204.
Sasaki, Y.F., et al., “Bio-anticlastogenic effects of unsaturated fatty acids included in fish oil—docosahexaenoic acid, docosapentaenoic acid, and eicosapentaenoic acid—in cultured Chinese hamster cells.” Mutation Research, 320: 9-22 (Jan. 1994).
Sato et al., “General Pharmacological Studies on 5 8 11 14 17 Eicosapentaenoic Acid Ethyl Ester EPA-E”, Folia Pharmacol JPN, 94 (1), 35-47. cited by other (Jul. 1989) (with English abstract).
Sato, “Effects of Highly Purified Ethyl All-cis-5,8,11,14,17-icosapentaenoate (EPA-E) on Rabbit Platelets,” Biol. Pharm. Bull., 16(4)362-367 (Apr. 1993).
Satoh et al., “Highly purified eicosapentaenoic acid reduces cardio-ankle vascular index in association with decreased serum amyloid A-LDL in metabolic syndrome,” Hypertension Research (Nov. 2009/epub Sep. 18, 2009) (32):1004-1008.
Satoh, N., et al., “Purified eicosapentaenoic acid reduces small dense LDL, remnant lipoprotein particles, and C-reactive protein in metabolic syndrome.” Diabetes Care, 30(1): 144-146 (Jan. 2007).
Satoh-Asahara N, Shimatsu A, Sasaki Y, Nakaoka H, Himeno A, Tochiya M, Kono S, Takaya T, Ono K, Wada H, Suganami T, Hasegawa K, Ogawa Y., “Highly purified eicosapentaenoic acid increases interleukia-10 levels of peripheral blood monocytes in obese patients with dyslipidemia.” Diabetes Care. Dec. 2012/epub Aug. 21, 2012; 35(12):2631-2639.
Schaefer, E.J., et al., “Effects of eicosapentaenoic acid, docosahexaenoic acid, and olive oil on cardiovascular disease risk factors [abstract 20007].” Circulation, 122:A20007 (2010) (Abstract only).
Schectman, G. & Hiatt, J., “Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals”, Am. J. Med., 100:197-204, (Feb. 1996).
Schectman, G., et al., “Dietary fish oil decreases low-density-lipoprotein clearance in nonhuman primates.” Am J Clin Nutr., 64:215-221 (Aug. 1996).
Schectman, G., et al., “Heterogeneity of Low Density Lipoprotein Responses to Fish-Oil Supplementation in Hypertriglyceridemic Subjects.” Arterioscler. Thromb. Vasc. Biol. 9:345-354 (May/Jun. 1989).
Schmidt, E.B., et al., “Lipoprotein-associated phospholipase A2 concentrations in plasma are associated with the extent of coronary artery disease and correlate to adipose tissue levels of marine n-3 fatty acids.” Atherosclerosis 196: 420-424 (Jan. 2008).
Schmitz PG, McCloud LK, Reikes ST, et al. Prophylaxis of hemodialysis graft thrombosis with fish oil: double-blind, randomized, prospective trial. J. Am. Soc. Nephrol. Jan. 13, 2002 (1): 184-90.
Schmitz, G., et al., “The opposing effects of n-3 and n-6 fatty acids.” Progress in Lipid Research, 47:147-155 (Mar. 2008/epub Dec. 27, 2007).
Schreiner et al., “Lipoprotein[a] as a Risk Factor for Preclinical Atherosclerosis,” 13 Atherosclerosis, Thrombosis & Vascular Biology 6: 826-833 (1993).
Schuirmann, D.J. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J. Pharmacokinet. Biopharm. 15(6), 657-680 (Dec. 1987).
Schunkert H, König IR, Kathiresan S, et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet. Mar. 6, 2011;43(4):333-8.
Schwartz GG, Bessac L, Berdan LG, et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the Odyssey outcomes trial. Am Heart J 168(5):682-9 (publication date Nov. 2014, epublication date Aug. 7, 2017).
Schwarz, S., et al., “Lycopene inhibits disease progression in patients with benign prostate hyperplasia.” J. Nutr. 138: 49-53 (Jan. 2008).
Schwellenbach et al., “The Triglyceride-Lowering Effects of a Modest Dose of Docosahexaenoic Acid Alone Versus in Combination with Low Dose Eicosapentaenoic Acid in Patients with Coronary Artery Disease and Elevated Triglycerides.” J. Am. Coll. Nutr. 25(6):480-485 (Dec. 2006).
Segrest et al., Structure of Apolipoprotein B-100 in Low Density Lipoproteins, J. Lipid Res. 42(9):1346-1367 (Sep. 2001).
Self-Medlin Y, Byun J, Jacob RF, Mizuno Y, Mason RP. Glucose promotes membrane cholesterol crystalline domain formation by lipid peroxidation. Biochim. Biophys. Acta. Jun. 2009/epub Apr. 17, 2009; 1788(6): 1398-1403.
Serhan C, Chiang N, Van Dyke T. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol. May 2008; 8:3449-361.
Serhan, C.N., et al., “Resolvins: A family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals.” J. Exp. Med. 196:1025-1037 (Oct. 21, 2002).
Sevanian A, Ursini F. Lipid peroxidation in membranes and low-density lipoproteins: similarities and differences. Free Radic. Biol. Med., Aug. 2000;29(3-4):306-311.
Shah, S., et al., “Eicosapentaenoic Acid (EPA) as an Adjunct in the Treatment of Schizophrenia”, Schizophrenia Research, vol. 29, No. 1/02 (1998).
Shan, Z., et al., “A combination study of spin-trapping, LC/ESR and LC/MS on carbon-centred radicals formed from lipoxygenase-catalysed peroxidation of eicosapentaenoic acid.” Free Radical Research, 43(1):13-27 (Jan. 2009).
Shearer et al., “Red Blood Cell Fatty Acid Patters and Acute Coronary Syndrome,” PLoS One 4(5): e5444, publ. May 6, 2009 (doi:10.1371/journal/pone.0005444).
Sherratt SCR, Mason RP. Eicosapentaenoic acid and docosahexaenoic acid have distinct membrane locations and lipid interactions as determined by X-ray diffraction. Chem Phys Lipids 212:73-9 (publication date May 2018, epublication date Jan. 31, 2018).
Shimizu et al., “Effects of Highly Purified Eicosapentaenoic Acid on Erythrocyte Fatty Acid Composition and Leukocyte and Colonic Mucosa Leukotriene B4 Production in Children with Ulcerative Colitis,” J. Pediatr. Gastroenterol. Nutr., vol. 37, No. 5, pp. 581-585 (Nov. 2003).
Shimizu, H., et al., “Long-term effect of eicosapentaenoic acid ethyl (EPA-E) on albuminuria of non-insulin dependent diabetic patients.” Diabetes Research and Clinical Practice 28: 35-40 (Apr. 1995).
Shimokawa H, Flavahan NA, Vanhoutte PM. Loss of endothelial pertussis toxin-sensitive g protein function in atherosclerotic porcine coronary arteries. Circulation. Feb. 1991;83:652-660.
Shinozaki K. et al., “The long-term effect of Eicosapentaenoic acid on serum levels of lipoprotein (a) and lipids in patients with vascular disease” J Atheroscler Thromb. 2(2):207-9 (1996).
Shishehbor MH, Brenna ML, Aviles RJ, Fu X, Penn MS, Sprecher DL, Hazen SL. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation. Jul. 29, 2003;108(4):426-431.
Sicherer et al., “Prevalence of seafood allergy in the United States determined by a randomtelephonesurvey,” J. Allergy Clin. Immunol., 114(1):159-165 (Jul. 2004).
Sierra, S., et al., “Dietary eicosapentaenoic acid and docosahexaenoic acid equally incorporate as decosahexaenoic acid but differ in inflammatory effects.” Nutrition 24: 245-254 (Mar. 2008).
Silvers, Karen M., et al., “Randomised double-blind placebo-controlled trial of fish oil in the treatment of depression”, Prostagandins, Leukotrienes and Essential Fatty Acids, 72:211-218, (Mar. 2005).
Simoens, C.M., et al., “Inclusion of 10% fish oil in mixed medium-chain triacylglycerol-long chain triacylglycerol emulsions increases plasma triacylglycerol clearance and induces rapid eicosapentaenoic acid (20:5n-3) incorporation into blood cell phospholipids.” Am J Clin Nutr 88: 282-8 (Aug. 2008).
Simon, Joel A., et al., “Serum Fatty Acids and the Risk of Coronary Heart Disease”, American Journal of Epidemiology, 142(5):469-476, (Sep. 1, 1995).
Simopolous, The Importance of the Omega-6/Omega-3 Fatty Acid Ratio in Cardiovascular Disease and Other Chronic Diseases, Exp. Biol. Med, 233:674-688 (Jun. 1, 2008)(available online Jun. 1, 2008).
Simopoulos, “Omega-3 fatty acids in health and disease and in growth and development,” Am. J. Clin. Nutr. 54:438-63 (Sep. 1991).
Singer, Peter, “Fluvastatin plus fish oil are more effective on cardiovascular risk factors than fluvastatin alone,” Letter to the Editor, Prostaglandinis, Leukotrienes and Essential Fatty Acids, vol. 72, pp. 379-380 (May 2005).
Singh, R.B., et al., “Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: the Indian experiment of infarct survival-4.” Cardiovascular Drugs and Therapy 11:485-491 (Jul. 1997).
Sirtori, C.R., et al., “One-year treatment with ethyl esters of n-3 fatty acids in patients with hypertriglyceridemia and glucose intolerance—Reduced triglyceridemia, total cholesterol and increased HDL-C.” Atherosclerosis 137: 419-427 (Apr. 1998).
Siscovick et al., “Dietary Intake and Cell Membrane levels of Long-chain N-3 Polyunsaturated Fatty Acids and the Risk of Primary Cardiac Arrest”, JAMA, vol. 274, No. 17, Nov. 1, 1995, pp. 1363-1367, XP008041164.
Skinner JS, Cooper A, & Feder GS and on behalf of the Guideline Development Group. “Secondary prevention for patients following a myocardial infarction; summary of NICE guidance,” Heart, 93:862-864 (Jul. 2007).
Slides for the Oct. 16, 2013 Meeting of the Endocrinologicand Metabolic Drugs Advisory Committee, (158 pages).
Smith et al., Pharmacokinetics and Pharmacodynamics of Epoetin Delta in Two Studies in Health Volunteers and Two Studies in Patients with Chronic Kidney Disease, Clinical Therapeutics/vol. 29, pp. 1368-1380 (Jul. 2007).
Sniderman A, Kwiterovich PO. Update on the detection and treatment of atherogenic low-density lipoproteins. Curr. Opin. Endocrinol. Diabetes Obes. Apr. 20, 2013;20:140-147.
Sohma, R., et al., “Protective effect of n-3 polyunsaturated fatty acid on primary culture of rat hepatocytes without glycemic alterations.” Journal of Gastroenterology and Hepatology 22: 1965-1970 (Nov. 2007).
Spector, A.A., “Arachidonic acid cytochrome P450 epoxygenase pathway.” Journal of Lipid Research, 50: S52-S56 (2009) (published online on Oct. 23, 2008.).
Spector, A.A., et al., “Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function.” Progress in Lipid Research 43: 55-90 (Jan. 2004).
Springer, T.A., “Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm.” Cell, 76: 301-314 (Jan. 28, 1994).
Squires, RW, et al., “Low-dose, time release nicotinic acid: effects in selected patients with low concentrations of high density lipoprotein cholesterol”, Mayo Clinic Proc., 67:855-860, (Sep. 1992).
Srinivas, et al., “Controlled release of lysozyme from succinylated gelatin microspheres,” J. Biomater. Sci., Polymer Ed., vol. 12(2):137-148 (2001).
Stalenhoef, A.F.H., et al., “The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia.” Atherosclerosis 153: 129-138 (Nov. 2000).
Stampfer MJ, Krauss RM, Ma J, et al. A prospective study of triglyceride level, lowdensity lipoprotein particle diameter, and risk of myocardial infarction. JAMA. Sep. 1996;276:882-888.
Stancu et al., “Statins: Mechanism of Action and Effects,” Journal of Cellular and Molecular Medicine (Oct.-Dec. 2001), 5(4), 378-387.
Stark, K.D. & Holub, B.J., Differential eicosapentaenoic acid elevations and altered cardiovascular disease risk factor responses after supplementation with docosahexaenoic acid in postmenopausal women receiving and not receiving hormone replacement therapy, Am. J. Clin. Nutr., vol. 79, pp. 765-773 (May 2004).
Stark, K.D., “The percentage of n-3 highly unsaturated fatty acids in total HUFA as a biomarker for omega-3 fatty acid status in tissues.” Lipids 43:45-53 (Jan. 2008/epub Nov. 6, 2007).
Stark, K.D., et al., “Effect of a fish-oil concentrate on serum lipids in postmenopausal women receiving and not receiving hormone replacement therapy in a placebo-controlled, double-blind trial.” Am J Clin Nutr 72:389-94 (Aug. 2000).
Steg PG, Bhatt DL, Wilson PWF, et al; Reach Registry Investigators. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 297(11):1197-1206 (publication date May 21, 2007).
Stein et al., “Effect of Statin Therapy on Remnant Lipoprotein Cholesterol Levels in Patients with Combined Hyperlipidemia,” Arteriosclerosis, Thrombosis and Vascular Biology, vol. 21, pp. 2026-2031(Dec. 1, 2001).
Steinberg D, Witztum JL. Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis? Circulation. Apr. 30, 2002;105:2107-2111.
Steinberg D. Lewis A. Conner Memorial Lecture: Oxidative modification of LDL and atherogenesis. Circulation. Feb. 18, 1997;95(4):1062-1071.
Stepp DW, Ou J, Ackerman AW, Welak S, Klick D, Pritchard KA, Jr. Native ldl and minimally oxidized ldl differentially regulate superoxide anion in vascular endothelium in situ. Am. J. Physiol. Aug. 2002;283:H750-H759.
Sternbach “The Glasgow Coma Scale.” The Journal of Emergency Medicine, 19(1):67-71 (Feb. 8, 2000).
Stielow et al., “Novel Nox Inhibitor of oxLDL-Induced Reactive Oxygen Species Formation in Human Endothelial Cells,” Biochem. Biophys. Res. Comm., 344:200-205 (May 26, 2006/epub Mar. 26, 2006).
Stiles, FDA approves EPA-only omega-3 PUFA capsule for high TG, Jul. 26, 2012, http://www.medscape.com/viewarticle/791268, accessed Dec. 17, 2014 (1 page).
Stitziel N, Stirrups K, Masca N, et al. Supplement to: Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease. N Engl J Med. DOI: 10.1056/NEJMoa1507652; Mar. 24, 2016/epub Mar. 2, 2016.
Stojancevic et al., “The impact of farnesoid X receptor activation on intestinal permeability in inflammatory bowel disease,” Can. J Gastroenterol. 26(9):631-637 (Sep. 2012).
Stoll, Andrew L. et al., “Omega 3 Fatty Acids in Bipolar Disorder”, Arch. Gen. Psychiatry, 56:407-412, (May 1999).
Stone NJ, Robinson J, Lichtenstein AH, et al. ACC/AHA Prevention Guideline: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. erratum in Circulation. Jun. 24, 2014;129:S46-S48.
Su, Kuan-Pin, et al., “Omega-3 Fatty Acids in Major Depressive Disorder A Preliminary Double-Blind, Placebo-Controlled Trial”, European Neuropsychopharmacology, 13:267-271, (Aug. 2003).
Sugiyama et al., “A Comparison of the Hypotensive Effects of Eicosapentaenoic Acid Ethyl (EPA) on Three Diseases (Occluded Arteriosclerosis, Hyperlipidemia, and These Two Diseases Combined) P2-504 Abstract,” Annual Meeting of the Japanese Society of Pharmaceutical Health Care and Sciences 20:473 (Nov. 2010) (with English translation)(3 pages).
Sugiyama, E., et al., “Eicosapentaenoic acid lowers plasma and liver cholesterol levels in the presence of peroxisome proliferators-activated receptor alpha.” Life Sciences, 83:19-28 (Jul. 4, 2008/epub May 1, 2008).
Superko et al., “Lipid Management to Reduce Cardiovascular Risk: A New Strategy is Required,” Circulation, 117:560-568 (Jan. 29, 2008).
Surette, M.E., et al., “Dependence on dietary cholesterol for n-3 polyunsaturated fatty acid induced changes in plasma cholesterol in the Syrian hamster.” J Lipid Res., 33:263-271 (Feb. 1992).
Surette, M.E., et al., “Evidence for mechanisms of the hypotriglyceridemic effect of n-3 polyunsaturated fatty, acids.” Biochimica et Biophysic Acta, 1126:199-205 (Jun. 22, 1992).
Tagawa H, Shimokawa H, Tagawa T, et al. Long-term treatment with eicosapentaenoic acid augments both nitric oxide-mediated and non-nitric oxide-mediated endothelium-dependent forearm vasodilatation in patients with coronary artery disease. J Cardiovasc Pharmacol 33(4):633-40, Apr. 1999.
Takaki A, Umemoto S, Ono K, Seki K, Ryoke T, Fujii A, Itagaki T, Harada M, Tanaka M, Yonezawa T, Ogawa H, Matsuzaki M. Add-on therapy of epa reduces oxidative stress and inhibits the progression of aortic stiffness in patients with coronary artery disease and statin therapy: A randomized controlled study. J. Atheroscler. Thromb. Jun. 23, 2011;18:857-866.
Takaku et al., Study on the Efficacy and Safety of Ethyl Icosapentate (MND-21) in Treatment of Hyperlipidemia Based on a Long-Term Administration Test, 7 J. Clin. Ther. Med. 191 (1991) (with English Translation)(27 pages).
Talayero BG, Sacks FM. The role of triglycerides in atherosclerosis. Curr. Cardiol. Rep. 2011;13:544-552.
Tamura, et al., “Study of the Clinical Usefulness of Ethyl Icosapentate (MND-21) in Long-Term Treatment of Hyperlipaemic Patients.” J Clin Thera & Medicines, 7:1817-1834 (1991).
Tanaka et al., “Genome-Wide Association Study of Plasma Polyunsaturated Fatty Acids in the InCHIANTI Study.” PLoS Genetics 5(1):1-8 (Jan. 2009).
Tanaka et al., “Suppression of prostaglandin synthesis by arachidonic acid or eicosapentaenoic acid in a macrophage-like cell line, RAW 264.7, treated with LPS,” Biol. Pharm. Bull., 22(10):1057-7 (Oct. 1999).
Tanaka et al., “Administration of high dose eicosapentaenoic acid enhances anti-inflammatory properties of high-density lipoprotein in Japanese patients with dyslipidemia,” Atherosclerosis, 237(2):577-83 (Dec. 2014).
Tanaka et al., “Eicosapentaenoic Acid-Enriched High-Density Lipoproteins Exhibit Anti-Atherogenic Properties,” Circ. J., doi: 10.1253/circj.CJ-17-0294. [Epub ahead of print] (Jun. 23, 2017)(6 pages).
Tanaka, K.T., et al., “Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients—Subanalysis of the JELIS trial.” Stroke, 39(7):2052-8 (Jul. 2008/epub May 1, 2008).
Tatarczyk, et al., “Analysis of long-chain ω-3 fatty acid content in fish-oil supplements,” Wien Klin Wochenschr, 119/13-14: 417-422 (2007).
Tatsuno et al., Efficacy and safety of TAK-085 compared with eicosapentaenoic acid in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: The omega-3 fatty acids randomized double-blind (ORL) study, J. Clin. Lipid; vol. 7(6), pp. 615-625 (Sep. 12, 2013).
Taylor et al., “Fish allergy: fish and products thereof,” Journal Food Science (2004) 69.8 R175-R180.
Taylor, A.J., et al., “Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins”, Circulation, 110:3512-3517, (Dec. 7, 2004/epub Nov. 10, 2004).
Tedgui, A., et al., “Anti-inflammatory mechanisms in the vascular wall.” Circ. Res. 88:877-887 (May 11, 2001).
Teissier E, Nohara A, Chinetti G, Paumelle R, Cariou B, Fruchart JC, Brandes RP, Shah A, Staels B. Peroxisome proliferator-activated receptor alpha induces NADPH oxidase activity in macrophages, leading to the generation of LDL with PPAR-alpha activation properties. Circ. Res. Dec. 10, 2004/epub Nov. 11, 2004;95(12):1174-1182.
Teramoto T, Sasaki J, Ishibashi S, et al. Diagnosis of atherosclerosis. Executive Summary of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan—2012 Version. J Atheroscler Thromb. 2014;21(4):296-8. Electronic publication Dec. 10, 2013.
Terano, et al., “Effect of Oral Administration of Highly Purified Eicosapentaenoic Acid on Platelet Function, Blood Viscosity and Red Cell Deformability in Healthy Human Subjects,” Atherosclerosis, 46, 321-331 (Mar. 1983).
The TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. Jul. 3, 2014/epub Jun. 18, 2014; 371(1):22-31.
Theilla, M., et al., “A diet enriched in eicosapentaenoic acid, gamma-linolenic acid and antioxidants in the prevention of new pressure ulcer formation in critically ill patients with acute lung injury: A randomized, prospective, controlled study.” Clinical Nutrition 26: 752-757 (Dec. 2007/epub Oct. 22, 2007).
Theobald et al., “LDL Cholesterol-Raising Effect of Low-Dose Docosahexaenoic Acid in Middle-Aged Men and Women,” Am. J. Clin. Nutr. 79:558-63 (Apr. 2004).
Thies, F., et al., “Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial.” Lancet 361: 477-85 (Feb. 8, 2003).
Thies, F., et al., “Dietary supplementation with eicosapentaenoic acid, but not with other long-chain n-3 or n-6 polyunsaturated fatty acids, decreases natural killer cell activity in healthy subjects aged >55 y.” Am J Clin Nutr 73:539-48 (Mar. 2001).
Third Report of the National Cholesterol Education Program (NCEPP) Expert Panel on Detection, Evaluation, and Treatment of High blood Cholesterol in Adults (Adult Treatment Panel III) May 2001, National Institutes of Health, Publication No. 01-3670.
Third Report of the NCEP Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report, NIH Publication No. 02-5215 Sep. 2002 (220 pages in three parts).
Thomas et al., “Renal Failure—Measuring the Glomerular Filtration Rate,” Dtsch Arztebl Int., Dec. 18, 2009, 106(51-52); 849-54.
Thomas II et al., “Prostate Cancer Risk in Men with Baseline History of Coronary Artery Disease: Results from the Reduce Study,” Cancer Epidemiology, Biomarkers and Prevention, 21(4) published online Feb. 7, 2012.
Thorwest M, Balling E, Kristensen SD, et al. Dietary fish oil reduces microvascular thrombosis in a porcine experimental model. Thromb. Res. Jul. 2000, 99(2): 203-8.
Thygesen K., Alpert J., Jaffe A., et al. Third Universal Definition of Myocardial Infarction. J Am Coll Cardiol., Oct. 16, 2012/epub Sep. 5, 2012; 60(16):1581-1598.
Tilg H, Moschen AR. Inflammatory Mechanisms in the Regulation of Insulin Resistance. Mol. Med., Mar./Apr. 2008;14(3-4):222-231.
Tirosh et al., “Changes in Triglyceride Levels and Risk for Coronary Heart Disease in Young Men,” American College of Physicians, pp. 377-385 (Sep. 18, 2007).
Torrejon, C. et al., “n-3 Fatty acids and cardiovascular disease: Actions and molecular mechanisms,” Prostaglandins Leukotrienes & Essent. Fatty Acids, 77(5-6):319-26 Nov./Dec. 2007/epub Dec. 3, 2007. doi:10.1016/j.plefa.2007.10.014 (2007).
Toth PP, Granowitz C, Hull M, Liassou D, Anderson A, Philip S. High Triglycerides are associated with increased cardiovascular events, medical costs, and resource use: A real-world administrative claims analysis of statin-treated patients with high residual cardiovascular risk. Journal of the American Heart Association, 7(15):e008740 (publication date Jul. 25, 2018; epublication Aug. 7, 2018).
Transcript from Oct. 16, 2013 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee, 76 pages.
TREND-HD Investigators, Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study, Arch Neurol., vol. 65(12): 1582-9 (Dec. 2008).
Tribble DL, Holl LG, Wood PD, Krauss RM. Variations in oxidative susceptibility among six low density lipoprotein subtractions of differing density and particle size. Atherosclerosis. Apr. 1992;93(3):189-199.
Tribble DL, Rizzo M, Chait A, Lewis DM, Blanche PJ, Krauss RM. Enhanced oxidative susceptibility and reduced antioxidant content of metabolic precursors of small, dense low-density lipoproteins. Am. J. Med. Feb. 1, 2001;110(2):103-110.
Trilipix Package Insert (Sep. 2010)(10 pages).
Tsimikas S, Witztum JL, Miller ER, Sasiela WJ, Szarek M, Olsson AG, Schwartz GG. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-1 00 in patients with acute coronary syndromes in the MIRACL trial. Circulation., Sep. 14, 2004/epub Sep. 7, 2004; 110(11):1406-1412.
Tsuruta K., et al.,“Effects of purified eicosapentaenoate ethyl ester on fibriolytic capacity in patients with stable coronary artery disease and lower extremity ischaemia” Coron Artery Dis. 7(11):837-42 (Nov. 1996).
Tulenko TN, Chen M, Mason PE, Mason RP. Physical effects of cholesterol on arterial smooth muscle membranes: Evidence of immiscible cholesterol domains and alterations in bilayer width C during atherogenesis. J. Lipid Res. May 1998;39:947-956.
Tungsiripat, et al., “Dyslipidemia in HIV patients,” Cleveland Clinic Journal of Medicine, v. 72, No. 12 (Dec. 2005).
Turini et al., “Short-term fish oil supplementation improved innate immunity, but increased ex vivo oxidation of LDL in man—a pilot study.” Eur. J. Nutr. 40:56-65 (Apr. 2001).
U.S. Appl. No. 14/245,499, filed Apr. 4, 2014 (now abandoned) (43 pages).
U.S. Food and Drug Administration and Dept of Health and Human Services. Substances affirmed as generally recognized as safe: Menhaden Oil. Fed Register, 62:30751-30757 (Jun. 5, 1997).
Ullian, M.E., “Fatty acid inhibition of angiotensin II-stimulated inositol phosphates in smooth muscle cells.” Am J Physiol Heart Circ Physiol., 264 (2 Pt 2):H595-603 (Feb. 1993).
Urakaze, Masaharu, et al., “Infusion of emulsified trieicosapentaenoylglycerol into rabbits. The effects on platelet aggregation, polymorphonuclear leukocyte adhesion, and fatty acid composition in plasma and platelet phospholipids”, Thromb. Res., 44(5):673-682 (Dec. 1986).
Urquhart et al., “Profile of eicosanoids produced by human saphenous vein endothelial cells and the effect of dietary fatty acids,” Prostaglandins Leukot. Essent. Fatty Acid, 65(1):15-22 (Jul. 2001).
Vaagenes et al., “The Hypolipidaemic Effect of EPA is Potentiated by 2- and 3-Methylation.” In P. Quant & S. Eaton (eds.) Current Views of Fatty Acid Oxidation and Ketogenesis from Organelles to Point Mutations; Advances in Experimental Medicine and Biology, vol. 466 , pp. 221-226 (1999).
Vaddadi, K.S., et al., “A Randomised, Placebo-Controlled, Double-Blind Study of Treatment of Huntington's Disease with Unsaturated Fatty Acids”, Clinical Neuroscience and Neuropathology, 13(1):29-33, (Jan. 2002).
Vaduganathan M, Venkataramani AS, Bhatt DL. Moving toward global primordial prevention in cardiovascular disease: The heart of the matter. J Am Coll Cardiol Oct. 6, 2015;66(14):1535-7.
Van der Steeg, W.A., et al., “High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: Significance for cardiovascular risk—the Ideal and Epic-Norfolk studies.” J. Am. Coll. Cardiol. 51;634-642 (Feb. 12, 2008).
Van Do et al., “Allergy to fish parvalbumins: Studies on the cross-reactivity of allergens from 9 commonly consumed fish,” Journ. Allergy & Clin. Immunol., 16(6):1314-1320 (Dec. 1, 2005).
Van Wijk et al. Rosiglitazone improves postprandial triglyceride and free fatty acid metabolism in type 2 diabetes. Diabetes Care, vol. 28, No. 4, (Apr. 2005) pp. 844-849.
Varbo A, Benn M, Tybjærg-Hansen A, Nordestgaard BG. Reply to letters regarding article, “Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation”. Circulation. Jun. 17, 2014; 129(24):e656.
Varbo et al., Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease, J. Am. Coll. Cardiol., vol. 61(4), pp. 427-436 (Jan. 29, 2013/epub Dec. 19, 2012).
Varbo et al., Remnant cholesterol as a cause of ischemic heart disease: Evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment, Pharmacol. Ther., vol 141(3), pp. 358-367 (Mar. 2014/epub Nov. 26, 2013).
Vascepa [package insert], Bedminster, NJ: Amarin Pharma Inc.; Jul. 2012. (12 pages).
Vascepa [package insert]. Bedminster, NJ: Amarin Pharma Inc.; Nov. 2013. (11 pages).
Vasudevan et al., “Effective Use of Combination Lipid Therapy”, Curr. Atheroscl. Rep., vol. 8, pp. 76-84 (Jan. 2006).
Vedin, I., et al., “Effects of docosahexaenoic acid-rich n-3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study.” Am J Clin Nutr 87:1616-22 (Jun. 2008).
Velliquette et al., “Regulation of human stearoyl-CoA desaturase by omega-3 and omega-6 fatty acids: Implications for the dietary management of elevated serum triglycerides,” Journal of Clinical Lipdology. (Aug. 2009/epub Jun. 21, 2009) 3:281-288.
Vergnani L, Hatrik S, Ricci F, Passaro A, Manzoli N, Zuliani G, Brovkovych V, Fellin R, Malinski T. Effect of native and oxidized low-density lipoprotein on endothelial nitric oxide and superoxide production : Key role of 1-arginine availability. Circulation. Mar. 21, 2000; 101:1261-1266.
Verma S, Leiter LA, Bhatt DL. CANTOS ushers in a new calculus of inflammasome targeting for vascular protection-and maybe more. Cell Metab 26(5):703-5 (publication date Nov. 7, 2017; epublication date Oct. 19, 2017).
Vidal F, Colome C, Martinez-Gonzalez J, Badimon L. Atherogenic concentrations of native low density lipoproteins down-regulate nitric-oxide-synthase mma and protein levels in endothelial cells. Eur. J. Biochem. Mar. 15, 1998; 252:378-384.
Vidgren, H.M., et al., “Incorporation of n-3 fatty acids into plasma lipid fractions, and erythrocyte membranes and platelets during dietary supplementation with fish, fish oil, and docosahexaenoic acid-rich oil among healthy young men.” Lipids 32: 697-705 (Jul. 1997).
Virani et al., “The Role of Lipoprotein-associated Phospholipase A2 as a marker for atherosclerosis” Curr. Atheroscler. Rep. 9[2): 97-103 (Aug. 2007).
Volcik, K.A., et al., “Peroxisome proliferator-activated receptor agenetic variation interacts with n-6 and long-chain n-3 fatty acid intake to affect total cholesterol and LDL-cholesterol concentrations in the Atherosclerosis Risk in Communities Study.” Am J Clin Nutr 87:1926-31 (Jun. 2008).
Von Schacky C, Baumann K, Angerer P. The effect of n-3 fatty acids on coronary atherosclerosis: results from SCIMO, an angiographic study, background and implications. Lipids 2001 36 Suppl: S99-102.
Von Schacky, C., “A review of omega-3 ethyl esters for cardiovascular prevention and treatment of increased blood triglyceride levels.” Vascular Health and Risk Management 2(3): 251-262 (2006).
Von Schacky, C., et al., “The Effect of Dietary ω-3 Fatty Acids on Cornoray Atherosclerosis: A Randomized, Double-Blind, Placebo-Controlled Trial”, American College of Physicians—American Society of Internal Medicine, 130(7):554-562, (Apr. 6, 1999).
Wada, M., et al., “Enzymes and receptors of prostaglandin pathways with arachidonic acid-derived versus eicosapentaenoic acid-derived substrates and products.” J. Biol. Chem. 282(31): 22254-22266 (Aug. 3, 2007/epub May 22, 2007).
Wagner AH, Kohler T, Ruckschloss U, Just I, Hecker M. Improvement of nitric oxidedependent vasodilation by hmg-coa reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler. Thromb. Vasc. Biol., Jan. 2000;20:61-69.
Walker G, Mandagere A, Dufton C, et al. The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers. Br. J. Clin. Pharmacol. May 2009/epub Feb. 4, 2009; 67 (5): 527-34.
Wall R, Ross RP, Fitzgerald G, Stanton C. Fatty acids from fish: the anti-inflammatory potential of long-chain omega-3 fatty acids. Nutr Rev. May 2010; 68:280-289.
Walldius, G., et al., “Editorial: Rationale for using apolipoprotein B and apolipoprotein A-I as indicators of cardiac risk and as targets for lipid-lowering therapy.” European Heart Journal 26, 210-212 (Feb. 2005/epub Dec. 15, 2004).
Walter MF, Jacob RF, Bjork RE, Jeffers B, Buch J, Mizuno Y, Mason RP. Circulating lipid hydroperoxides predict cardiovascular events in patients with stable coronary artery disease: the Prevent study. J. Am. Coll. Cardiol., Mar. 25, 2008;51(12):1196-1202.
Walter MF, Jacob RF, Jeffers B, Ghadanfar MM, Preston GM, Buch J, Mason RP. Serum levels of thiobarbituric acid reactive substances predict cardiovascular events in patients with stable coronary artery disease: A longitudinal analysis of the Prevent study. J. Am. Coll. Cardiol. Nov. 16, 2004; 44(10):1996-2002.
Wander, R.C., et al., “Influence of long.chain polyunsaturated fatty acids on oxidation of low density lipoprotein.” Prostaglandins, Leukotrienes and Essential Fatty Acids 59(2):143-151 (Aug. 1998).
Wang Q, Liang X, Wang L, Lu X, Huang J, Cao J, Li H, Gu D. Effect of omega-3 fatty acids supplementation on endothelial function: A meta-analysis of randomized controlled trials. Atherosc. Apr. 2012/epub Jan. 20, 2012; 221:563-543.
Wang, C., et al., “n-3 Fatty acids from fish or fish-oil supplements, but not α-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review.” Am J Clin Nutr 84:5-17 (Jan. 2006).
Wang, L., et al., “Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation.” J. Lipid Res. 50:204-213 (Feb. 2009/epub Sep. 23, 2008).
Warren, Stephen T., “The Expanding World of Trinucleotide Repeats”, Science, 271:1374-1375, (Mar. 8, 1996).
Wassmann S, Laufs U, Muller K, Konkol C, Ahlbory K, Baumer AT, Linz W, Bohm M, Nickenig G. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol. Feb. 1, 2002; 22:300-305.
Watanabe et al., “Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c,” J Clin Invest. 113(10): 1408-1418 (May 2004).
Watanabe T, Ando K, Daidoji H, et al. A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins. J Cardiol 70(6):537-44 (publication date Dec. 2017; epublication date Aug. 31, 2017).
Watanabe, Ikuyoshi, et al., “Usefulness of EPA-E (eicosapentaenoic acid ethyl ester) in preventing neointimal formation after vascular injury”, Kokyu to Junkan, 42(7):673-677 (1994) (with English summary).
Weaver, K.L., et al., “Effect of Dietary Fatty Acids on Inflammatory Gene Expression in Healthy Humans.” J. Biol. Chem., 284(23): 15400-15407 (2009) (published online Apr. 9, 2009).
Webcast Information for the Oct. 16, 2013 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee, (1 page).
Weber, P., “Triglyceride-lowering effect of n-3 long chain polyunsaturated fatty acid: eicosapentaenoic acid vs. docosahexaenoic acid.” Lipids 34: S269 (1999).
Wei et al., Effects of [EPA] Versus [DHA] on Serum Lipids: A Systematic Review and Meta-Analysis, 13 Current Atherosclerosis Rep. 13(6):474-483 (Dec. 2011).
Wei LJ, Lin DY, Weissfeld L. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. J Am Stat Assoc. 84(408):1065-1073 (publication date Dec. 1989).
Westerveld H.T. et al., “Effects of low-dose EPA-Eon glycemic control, lipid profile, lipoprotein(a), platelet aggretation, viscosity, and platelet and vessel wall interaction in NIDDM” Diabetes Care 16(5):683-8 (May 1993).
Westphal, S., et al., “Postprandial chylomicrons and VLDLs in severe hypertriacylglycerolemia are lowered more effectively than are chylomicron remnants after treatment with n23 fatty acids.” Am J Clin Nutr 71:914-20 (Apr. 2000).
Whelan, J., et al., “Evidence that dietary arachidonic acid increases circulating triglycerides.” Lipids 30, 425-429 (May 1995).
Wierzbicki, A.S., “Editorial: Newer, lower, better? Lipid drugs and cardiovascular disease—the continuing story.” Int J Clin Pract, 61 (7):1064-1067 (Jul. 2007).
Wierzbicki, A.S., “Editorial: Raising HDL-C: back to the future?” Int J Clin Pract, 61(7):1069-1071 (Jul. 2007).
Wikipedia, “Diabetes mellitus,” Dec. 12, 2016 (Dec. 12, 2016), retrieved on Jul. 30, 2018 from https://en.wikipedia.org/w/index.php?title=Diabetes_mellitus&oldid=754431573; entire document, especially p. 1, paragraph 1.
Wikipedia, “Ethyl eicosapentaenoic acid,” Apr. 1, 2016 (Apr. 1, 2016); retrieved on Jul. 27, 2018 from https://en.wikipedia.org/w/index.php?title=Ehtyl_eicosapentaenoic_acid&oldid=713086755; entire document, especially p. 1, col. 2 and p. 3, paragraph 2.
Williams et al., “NADPH Oxidase Inhibitors New Antihypertensive Agents?” J. Cardiovasc Pharmacol 50(1):9-16 (Jul. 1, 2007).
Willumsen, N. et al., Biochimica et Biophysica Acta. vol. 1369, “On the effect of 2-deuterium- and 2-methyl-eicosapentaenoic acid derivatives on triglycerides, peroxisomal beta-oxidation and platelet aggregation in rats,” pp. 193-203, (Mar. 2, 1998).
Willumsen, N., et al., “Eicosapentaenoic acid, but not docosahexaenoic acid, increased, mitochondrial fatty acid oxidation and upregulates 2,3-dienoyl-CoA reductase gene expression in rats.” Lipids, 31:579-592 (Jun. 1996).
Wilson Omega 3 fish oil: EPA versus DHA (Dietivity.com, 1-16) (2006).
Wilt, VM & Gumm, JG, “Isolated low high-density lipoprotein cholesterol”, Ann. Pharmacol., 31:89-97, (Jan. 1997).
Wink, J., et al., “Effect of very-low-dose niacin on high-density lipoprotein in patients undergoing long-term statin therapy”, Am. Heart J., 143:514-518, (Mar. 2002).
Wittrup HH, Tybjrg-Hansen A, Nordestgaard BG. Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease: a meta-analysis. Circulation., Jun. 8, 1999;99:2901-2907.
Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet, Sep. 17, 1994;344(8925):793-795.
Wojczynski et al., “High-fat meal effect on LDL, HDL and VLDL particle size and number in the Genetics of Lipid-Lowering Drugs and Diet Network (GOLDN): an interventional study,” Lipids in Health and Disease 10:181, pp. 1-11 (Oct. 18, 2011).
Wojenski, C.M., et al., “Eicosapentaenoic acid ethyl ester as an antithrombotic agent: comparison to an extract of fish oil.” Biochimica et Biophysica Acta. 1081:33-38 (Jan. 4, 1991).
Wong, S.H., et al., “Effects of eicosapentaenoic and docosahexaenoic acids on Apoprotein B mRNA and secretion of very low density lipoprotein in HepG2 cells.” Arterioscler. Thromb. Vasc. Biol. 9;836-841 (Nov./Dec. 1989).
Wood et al., “Carbohydrate Restriction Alters Lipoprotein Metabolism by Modifying VLDL, LDL and HDL Subraction Distribution and Size in Overweight Men,” Journ. of Nutrition, 136(2):384-9 (Feb. 2006).
Woodman et al., “Effects of Purified Eicosapentaenoic and Docosahexaenoic Acids on Glycemic Control, Blood Pressure, and Serum Lipids in Type 2 Diabetic Patients with Treated Hypertension”, The American Journal of Clinical Nutrition: Official Journal of the American Society for Clinical Nutrition, Inc., 76(5):1007-1015 (Nov. 1, 2002).
Woodman, R.J., et al., “Effects of purified eicosapentaenoic acid and docosahexaenoic acid on platelet, fibrinolytic and vascular function in hypertensive type 2 diabetic patients.” Atherosclerosis 166: 85-93 (Jan. 2003).
Wu et al., “Diabetic dyslipidemia,” Metabolism Clinical and Experimental, 63:1469-1479 (Dec. 2014)(available online Aug. 29, 2014).
Wu, W.H., et al., “Effects of docosahexaenoic acid supplementation on blood lipids, estrogen metabolism, and in vivo oxidative stress in postmenopausal vegetarian women.” Eur J Clin Nutr., 60:386-392 (Mar. 2006).
Xiao, Y.F., et al., “Inhibitory effect of n-3 fish oil fatty acids on cardiac Na+/Ca2+ exchange currents in HEK293t cells.” Biochemical and Biophysical Research Communications 321: 116-123 (Aug. 13, 2004).
Xiao, Y-F., et al., “Blocking effects of polyunsaturated fatty acids on Na+ channels of neonatal rat ventricular myocytes.” Proc. Natl. Acad. Sci. 92: 11000-11004 (Nov. 21, 1995).
Xiao, Y-F., et al., “Fatty acids suppress voltage-gated Na+ currents in HEK293t cells transfected with the a-subunit of the human cardiac Na+ channel.” Proc. Natl. Acad. Sci. 95: 2680-2685 (Mar. 3, 1998).
Xydakis, A M et al., “Combination therapy for combined dyslipidemia,” American Journal of Cardiology, Nov. 20, 2002 US, vol. 90, No. 10 Suppl. 2, p. 21 K-29K (Nov. 20, 2002).
Yacyshyn BR, Thomson AB. The clinical importance of proton pump inhibitor pharmacokinetics. Digestion 2002 66 (2): 67-78.
Yadav D, Pitchumoni CS. Issues in Hyperlipidemic Pancreatitis. J Clin Gastroenterol 236(1):54-62, Jan. 2003.
Yagi K. Assay for blood plasma or serum. Methods Enzymol. 1984;105:328-331.
Yamagishi K, Nettleton J, Folsom A. Plasma fatty acid composition and incident heart failure in middle-aged adults: The Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J., Nov. 2008/epub Aug. 29, 2008; 156:965-974.
Yamakawa K, Shimabukuro M, Higa N, Asahi T, Ohba K, Arasaki O, Higa M, Oshiro Y, Yoshida H, Higa T, Saito T, Ueda S, Masuzaki H, Sata M. Eicosapentaenoic Acid Supplementation Changes Fatty Acid Composition and Corrects Endothelial Dysfunction in Hyperlipidemic Patients. Cardiol Res Practice. Dec. 26, 2012; epub Article ID 754181.
Yamamoto, H. et al., Improvement of coronary vasomotion with Eicosapentaenoic acid does not inhibit acetylcholine-induced coronary vasospasm in patients with variant angina: Jpn Cir J. 59(9):608-16 (Sep. 1995).
Yamamoto, K., et al., “4-Hydroxydocosahexaenoic acid, a potent Peroxisome Proliferator-Activated Receptor C agonist alleviates the symptoms of DSS-induced colitis.” Biochemical and Biophysical Research Communications 367: 566-572 (Mar. 14, 2008/epub Jan. 10, 2008).
Yamano T, Kubo T, Shiono Y, et al. Impact of eicosapentaenoic acid treatment on the fibrous cap thickness in patients with coronary atherosclerotic plaque: an optical coherence tomography study. J Atheroscler Thromb. 2015/epub Aug. 15, 2014;22:52-61.
Yamashita et al., J. Biochem., vol. 122, No. 1, “Acyl-transferases and Transaclyases Involved in Fatty Acid Remodeling of Phospholipids and Metabolism of Bioactive Lipids in Mammalian Cells”, pp. 1-16 (Jul. 1997).
Yamashita, N., et al., “Inhibition of natural killer cell activity of human lymphocytes by eicosapentaenoic acid.” Biochem. Biophys. Res. Comm. 138(3): 1058-1067 (Aug. 25, 1986).
Yamazaki et al., “Changes in fatty acid composition in rat blood and organs after infusion of eicosapentaenoic acid ethyl ester”, Biochim. Biophys. ACTA, 1128(1):35-43, (Sep. 22, 1992).
Yamazaki, et al., “Dissolution tests by RDC method for soft gelatin capsules containing ethyl icosapentate,”, Pharm. Tech. Japan, vol. 15, No. 4, pp. 595-603 Abstract (Apr. 1999) (with English abstract).
Yang, S.P., et al., “Eicosapentaenoic acid attenuates vascular endothelial growth factor-induced proliferation via inhibiting Flk-1 receptor expression in bovine carotid artery endothelial cells.” J. Cell. Physio. 176:342-349 (Aug. 1998).
Yano T, Mizuguchi K, Takasugi K, Tanaka Y, Sato M. “Effects of ethyl all-cis-5,8,11,14,17-icosapentaenoate on low density lipoprotein in rabbits,” Yakugaku Zasshi, 115:843-51 (Oct. 1995).
Yano, T., et al., “Effects of ethyl-all-cis-5,8,11,14,17-icosapentaenoate (EPA-E), pravastatin and their combination on serum lipids and intimal thickening of cuff-sheathed carotid artery in rabbits.” Life Sciences, 61(20):2007-2015 (1997).
Yao et al., “Oxidized high density lipoprotein induces macrophage apoptosis via toll-like receptor 4-dependent CHOIP pathway,” Journ. Lipid Res., 58:164-177 (Jan. 2017)(First published Nov. 28, 2016).
Yates RA, Wong J, Seiberling M, et al. The effect of anastrozole on the single-dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteers. Br. J. Clin. Pharmacol. May 2001 51(5): 429-35.
Yerram, N.R., et al., “Eicosapentaenoic acid metabolism in brain microvessel endothelium: effect on prostaglandin formation.” J. Lipid Res.30:1747-1757 (Nov. 1989).
Yokoyama et al., “Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholeterolemia: Rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS),” Amer. Heart Journal 146(4):613-620 (Oct. 2003).
Yokoyama et al., “Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomized open-label, blinded endpoint analysis”, Lancet, vol. 369, pp. 1090-1098 (Mar. 31, 2007).
Yorioka, N, “Lipid-lowering therapy and coagulation/fibrinolysis parameters in patients on peritoneal dialysis,” The International Journal of Artificial Organs, vol. 23(1):27-32 (Jan. 2000).
Yoshimura et al., “Effects of highly purified eicosapentaenoic acid on plasma beta thromboglobulin level and vascular reactivity to angiotensin II”, Artery, 14(5):295-303 (1987).
Zaima, N., et al., “Trans geometric isomers of EPA decrease LXRa-induced cellular triacylglycerol via suppression of SREBP-1c and PGC-1β,” J. Lipid Res. 47: 2712-2717 (Dec. 2006).
Zalewski et al., Role of Lipoprotein-Associated Phospholipase A2 in Atherosclerosis: Biology, Epidemiology, and Possible Therapeutic Target, Arteriosclerosis, Thrombosis, & Vascular Biology 25(5):923-931 (May 2005/epub Feb. 24, 2005).
Zanarini, et al., “Omega-3 Fatty Acid Treatment of Women with Borderline Personality Disorder: A Double-Blind, Placebo-Controlled Pilot Study,” Am J Psychiatry, 160:167-169 (Jan. 2003).
Zhan, S. et al. “Meta-analysis of the effects of soy protein containing isoflavones on the lipid profile,” Am. J. Clin. Nutr. (Feb. 2005), 81, p. 397-408.
Zhang, M., et al., “Effects of eicosapentaenoic acid on the early stage of type 2 diabetic nephropathy in KKAy/Ta mice: involvement of anti-inflammation and antioxidative stress.” Metabolism Clinical and Experimental 55:1590-1598 (Dec. 2006).
Zhang, Y.W., et al., “Inhibitory effects of eicosapentaenoic acid (EPA) on the hypoxia/reoxygenation-induced tyrosine kinase activation in cultured human umbilical vein endothelial cells.” Prostaglandins, Leukotrienes and Essential FattyAcids 67(4):253-261 (Oct. 2002).
Zhang, Y.W., et al., “Pretreatment with eicosapentaenoic acid prevented hypoxia/reoxygenation-induced abnormality in endothelial gap junctional intercellular communication through inhibiting the tyrosine kinase activity.” Prostaglandins, Leukotrienes and Essential Fatty Acids 61(1): 33-40 (Jul. 1999).
Zhao et al., “Polyunsaturated Fatty Acids are FXR Ligands and Differentially Regulate Expression of FXR Targets,” DNA and Cell Biology, 23(8):519-526 (Aug. 25, 2004).
Zhao, G. et al., “Dietary α-linolenic acid inhibits proinflammatory cytokine production by peripheral blood mononuclear cells in hypercholesterolemic subjects.” Am J Clin Nutr 85:385-91 (Feb. 2007).
Zhao, G., et al., “Dietary α-linolenic acid reduces inflammatory and lipid cardiovascular risk factors in hypercholesterolemic men and women.” J. Nutr. 134: 2991-2997 (Nov. 2004).
Zheng et al., “Function of ω-3 long chain unsaturated fatty acid in metabolic syndrome,” Chinese Journal of Endocrinology and Metabolism, vol. 27, No. 9, pp. 787-790 (Sep. 30, 2011)(with English translation).
Ziegler, D., et al., “Treatment of symptomatic diabetic polyneuropathy with the antioxidant α-lipoic acid: A 7-month multicenter randomized controlled trial (ALADIN III Study).” Diabetes Care 22:1296-1301 (Aug. 1999).
Zimmer et al., “Danger signaling in Atherosclerosis,” Circulation Research, Jan. 16, 2015, vol. 116, pp. 323-340.
Zimmerman JJ, Raible DG, Harper DM, et al. Evaluation of a potential tigecycline-warfarin drug interaction. Pharmacotherapy Jul. 2008 28 (7): 895-905.
Zuijdgeest-van Leeuwen, et al., “N-3 Fatty Acids Administered as Triacylglycerols or as Ethyl Esters Have Different Effects on Serum Lipid Concentrations in Healthy Subjects,” N-3 Fatty Acids, Lipid Metabolism and Cancer, pp. 89-100 (2000).
Zuijdgeest-van Leeuwen, S.D., et al., “Incorporation and washout of orally administered n-3 fatty acid ethyl esters in different plasma lipid fractions.” British Journal of Nutrition 82:481-488 (1999).
Zuijdgeest-van Leeuwen, SD, et al., “Eicosapentaenoic acid inhibits lipolysis in weight-losing cancer patients as well as in healthy volunteers,” Eur J Gastroenterol & Hepatol., 10(12):A67 (1998).
Zvyaga T, Chang SY, Chen C, et al. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19. Drug Metab. Dispos. Sep. 2012 40(9): 1698-711.
Bays HE et al., “AMR101, a Pure Ethyl Eicosapentaenoic Acid Omega-3 Fatty Acid: Effects on Inflammation-Associated End Points from the Marine and Anchor Studies,” Journ. Clin. Lipid., vol. 6 No. 3, p. 279 (May 30, 2012).
Bays HE et al., Effects of prescription omega-3-acid ethyl esters on non-high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin; Mayo Clinic Proc. 85(2):122-128 (Feb. 2010).
Billman et al., “Effects of dietary omega-3 fatty acids on ventricular function in dogs with healed myocardial infarctions: in vivo and in vitro studies.” Am. J. Physiol Heart Circ. Physiol., 298:H1219-H1228 (Jan. 22, 2010).
Gromova, O.A et al, published Jan. 2009, [found online Dec. 11, 2019] (found from Internet: t-patient.ru/articles/6417/) with English Machine Translation, . . . 2009.
Li, X., et al., “Protection against fine particle-induced pulmonary and systemic inflammation by omega-3 polyunsaturated fatty acids.” vol. 1861, No. 3, pp. 577-584 (Dec. 21, 2016).
Lin, Z., et al., “Cardiovascular Benefits of Fish-Oil Supplementation Against Fine Particulate Air Pollution in China.” Apr. 30, 2019; 73(16):2076-2085.
Shen, W., et al., “Influence of Omega-3 Fatty Acids Intake on Human Responsiveness to Ambient Air Pollution Exposure”, Apr. 1, 2017, The FASEB Journal; retrieved from Internet: URL://https://www.fasebj.org/doi/abs/10.1096/fasebj.31.1_supplement.971.2; [retrieved on Jan. 7, 2020].
Signori, S., et al., “Administration of omega-3 fatty acids and Raloxifene to women at high risk of breast cancer: interim feasibility and biomarkers analysis from a clinical trial,” European Journ of Clin. Nutr., 66, 878-884 (published online Jun. 6, 2012).
Tong, H., et al., “Omega-3 fatty acid supplementation appears to attenuate particulate air pollution-induced cardiac effects and lipid changes in healthy middle-aged adults.” Eniron. Health Perspect., Jul. 2012, epub Apr. 19, 2012; 120(7):952-7.
U.S. District Court of Nevada, judgment dated Mar. 30, 2020 in Amarin Pharma, Inc. et al. v. Hikma Pharmaceuticals USA Inc. et al., Case 2:16-cv-02525-MMC-NJK Document 381 Filed Mar. 30, 2020 (70 pages).
Akil et al., Relationships between obesity and cardiovascular diseases in four southern states and colorado, J Health Care Poor Underserved, 2011, 22(4 Suppl): 61-72.
At-a-Glance: Coronary Heart Disease; National Heart, Lung and Blood Institute, NIH Publication, Aug. 2009.
Ballantyne et al., Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on remnant-like particle cholesterol from the marine and anchor studies; Atherosclerosis, Aug. 20, 2016, pp. 81-87.
Bays H.E. et al., Comparison of once-daily, niacin extended-release/lovastatin with standard dosdes of atorvastatin and simvastatin (the advisor versus other cholesterol-modulating agents trial evaluation [Advocate], Am J. Cardiol, Mar. 15, 2003, vol. 91, pp. 667-672.
Brinton et al., Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (epa); Lipids in Health and Disease, 2017, 16:23, DOI 10.1186/x12944-017-0415-8.
Calo et al., N-3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery, J. Amer. Coll. Cardiology, May 17, 2005, vol. 45, No. 10; pp. 1723-1728.
Claudel et al., The Farnesoid x receptor, a molecular link between bile acid and lipid and glucose metabolism; Arterioscler Thromb Vasc Biol; Oct. 1, 2005; 25:2020-2031.
Colihan, Statins lower blood pressure; WebMD, Apr. 11, 2008.
Deuster et al., Dietary Supplements and Military Divers, A synopsis for Undersea Medical Officers, Jan. 2004.
Fontela et al., Estimated glomerular filtration rate in patients with type 2 diabetes mellitus; Rev Assoc Med Bras 2014; 60(6):531-537.
Förstermann et al., “Roles of Vascular Oxidative Stress and Nitric Oxide in the Pathogenesis of Atherosclerosis,” Circ. Res. Feb. 17, 2017; 120(4):713-735 (Accepted Dec. 26, 2016).
Guise, Bone loss and fracture risk associated with cancer therapy, The Oncologist, 2006; 11:1121-1131, available online at www.theoncologist.com.
Hong, Coronary artery calcification and risk factors for atherosclerosis in patients with venous thromboembolism, Atherosclerosis, 2005, vol. 183, pp. 169-174.
Lawrence MJ, Polyoxyethylene Sorbitan Fatty Acid Esters, Handbook of Pharmaceutical Excipients Fifth Edition by Rowe et al., 2006, Pharmaceutical Press, London/Chicago, XP002765740, ISBN: 0853696187, pp. 580-584 (table VIII).
Li et al., Lipid profile and incidence of atrial fibrillation: a prospective cohort study in China; Wiley Clinical Cardiology, Mar. 2018, vol. 41, No. 3, pp. 314-320.
Li, Q, et al., Eicosapentaenoic acid modifies lipid composition in caveolae and induces translocation of endothelial nitric oxide synthase, Biochimie 89 (2007) pp. 169-177 (publ online Nov. 7, 2006).
Lins et al., “Pharmacokinetics of Atorvastatin and its Metabolites After Single and Multiple Dosing in Hypercholesterolaemic Haemodialysis Patients,” Nephrol. Dial. Transplant., May 2003; 18(5):967-76 (Accepted in Revised Form May 12, 2002).
Luo et al., The emerging role of apolipoprotein C-III: beyond effects on triglyceride metabolism; Lipids in Health and Disease, 2016, 15:184, 7 pages.
Martinez et al., “Serum level changes of long chain-polyunsaturated fatty acids in patients undergoing periodontal therapy combined with one year of omega-3 supplementation: a pilot randomized clinical trial;” Journal of Periodontal & Implant Science, Aug. 28, 2014, vol. 44, pp. 169-177.
Morin et al., “Anti-proliferative effects of a new docosapentaenoic acid monoacylglyceride in colorectal carcinoma cells;” Prostaglandins, Leukotrienes and Essential Fatty Acids, Aug. 7, 2013, vol. 89, pp. 203-213.
National Kidney Foundation, Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification; Copyright 2002, 356 pages.
NCBI , Table 6-1 “Factors for Converting International Units of Vitamin Ea to α-Tocopherolb (mg) to Meet Recommended Intake,” taken from Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium and Carotenoids, Institute of Medicine (US) Panel on Dietary Antioxidants and Related Compounds, Washington DC, National Academies Press (US) 2000.
Saito et al., “Effects of Ethyl Eicosapentaenoate (EPA-E), Clopidogrel, and Their Combination on Platelet Aggregation and Bleeding Time;” Japanese Pharmacology & Therapeutics, Feb. 20, 2007 (epub Jan. 2007), vol. 35, No. 2, pp. 179-185 (English abstract only).
Toyoda, Pharmacotherapy for the Secondary Prevention of Stroke, Drugs, 69(6) pp. 633-647 (2009).
Triglyceride vs. Ethyl Ester Forms of Fish Oil Omega-3s, ScienceBased Health, Apr. 18, 2012; URL:https://web.archive.org/web/20120420022941/https://www.sciencebasedhealth.com/Fish-Oil-EE-vs-TGomega-3s-which-is-better-W119.aspx.
Vega et al., Hypercholesterolemia with Cholesterol-Enriched LDL and Normal Levels of LDL-Apolipoprotein B; Arteriosclerosis, Thrombosis and Vascular Biology, Apr. 1996; 16(4):517-22 (Accepted Jan. 3, 1996).
Related Publications (1)
Number Date Country
20200405677 A1 Dec 2020 US
Provisional Applications (1)
Number Date Country
61889315 Oct 2013 US
Continuations (3)
Number Date Country
Parent 16384230 Apr 2019 US
Child 16897663 US
Parent 15411500 Jan 2017 US
Child 16384230 US
Parent 14496429 Sep 2014 US
Child 15411500 US